<SEC-DOCUMENT>0001680367-23-000035.txt : 20230509
<SEC-HEADER>0001680367-23-000035.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509160900
ACCESSION NUMBER:		0001680367-23-000035
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		47
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Shattuck Labs, Inc.
		CENTRAL INDEX KEY:			0001680367
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				812575858
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39593
		FILM NUMBER:		23902025

	BUSINESS ADDRESS:	
		STREET 1:		500 W. 5TH STREET
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78701
		BUSINESS PHONE:		512-900-4690

	MAIL ADDRESS:	
		STREET 1:		500 W. 5TH STREET
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78701
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sttk-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:ce8ca630-3d4e-4325-8fca-ef7176ea5407,g:0c784f84-7059-42e0-96eb-5624e9f8221f,d:ab75d73ad8e54df383e5480fddd6dcb5--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sttk="http://www.shattucklabs.com/20230331" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sttk-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80L2ZyYWc6NTRhZDc4NTAyZDU2NDdjOWExZjQ5YjI4NmQ1YTFhNzUvdGFibGU6ZDAwYTE5OWQ0Yjk5NDMxMjk5Y2VlOTgzNDA4NDgyN2QvdGFibGVyYW5nZTpkMDBhMTk5ZDRiOTk0MzEyOTljZWU5ODM0MDg0ODI3ZF8yLTEtMS0xLTMzNzM2_daf23ab8-a939-4356-b39f-ac1883afae01">0001680367</ix:nonNumeric><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80L2ZyYWc6NTRhZDc4NTAyZDU2NDdjOWExZjQ5YjI4NmQ1YTFhNzUvdGFibGU6ZDAwYTE5OWQ0Yjk5NDMxMjk5Y2VlOTgzNDA4NDgyN2QvdGFibGVyYW5nZTpkMDBhMTk5ZDRiOTk0MzEyOTljZWU5ODM0MDg0ODI3ZF80LTEtMS0xLTMzNzM2_af813626-7ce8-4222-8e6c-1dc339d56e98">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80L2ZyYWc6NTRhZDc4NTAyZDU2NDdjOWExZjQ5YjI4NmQ1YTFhNzUvdGFibGU6ZDAwYTE5OWQ0Yjk5NDMxMjk5Y2VlOTgzNDA4NDgyN2QvdGFibGVyYW5nZTpkMDBhMTk5ZDRiOTk0MzEyOTljZWU5ODM0MDg0ODI3ZF81LTEtMS0xLTMzNzM2_93c2c480-d7c3-4a14-a388-f8d1585adf5c">2023</ix:nonNumeric><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80L2ZyYWc6NTRhZDc4NTAyZDU2NDdjOWExZjQ5YjI4NmQ1YTFhNzUvdGFibGU6ZDAwYTE5OWQ0Yjk5NDMxMjk5Y2VlOTgzNDA4NDgyN2QvdGFibGVyYW5nZTpkMDBhMTk5ZDRiOTk0MzEyOTljZWU5ODM0MDg0ODI3ZF82LTEtMS0xLTMzNzM2_d21be800-0fcf-4a76-af9d-5c279eff646a">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80L2ZyYWc6NTRhZDc4NTAyZDU2NDdjOWExZjQ5YjI4NmQ1YTFhNzUvdGFibGU6ZDAwYTE5OWQ0Yjk5NDMxMjk5Y2VlOTgzNDA4NDgyN2QvdGFibGVyYW5nZTpkMDBhMTk5ZDRiOTk0MzEyOTljZWU5ODM0MDg0ODI3ZF83LTEtMS0xLTMzNzM2_99ac74af-d9af-4bbe-9ea0-7cc2105694b1">December 31</ix:nonNumeric><ix:nonNumeric contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMi0wLTEtMS0zMzczNg_0dbd2c13-8918-4b63-bdf2-300920a2fc2e">http://fasb.org/us-gaap/2022#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMi0wLTEtMS0zMzczNg_b87d8af4-7cf2-4221-895b-3d002e7a2319">http://fasb.org/us-gaap/2022#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="i991dfc7ff32043179c7e3f86c543184b_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE4MDA_cc775207-fe02-4c9b-8e4e-2107d58e985d">P4Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sttk-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0da03d1a066047c19888f60d1a23d25e_I20230501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic79fdedfe69a4831bd0c813659e24620_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6329837530214020b3ca9fff657cea9b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic22a2288c5fa4a87bdc2dc2f63c68bee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i237ffce164a14b11b3d4a56d948a6d2d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib31390f36c5a45249b07c710d4824091_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e92a7048fc84c1aa85deddf715d1c18_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70b47fdbe5a84c6e8cf8ce134ab56bdb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id186272227244ec3b82b3b87eabc97f9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b3ef141d1cc4f10aa5bcdaa504aa1a2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7da54cb1c2b04054814e3dfed37c7947_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i104d8a78724041988c7e63d9c8bd9624_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i465bbee7d341453dbf57ff22cf4c2c7f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf15edfb0127444c8297ddfefadc5003_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbe46f015ce244558ede3196621fd998_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6675d59e3920448683346ca6b09615ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a0210c92623410b817e1521f5ad2f4b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9126dbe3941542e6958b2493b197a481_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i070803840450402f8ea63b2237086a3e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i321f3e6305f148e49074f9fc1dca1b0c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64ca7813e54547a1b035602b2d224a95_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5137177e56c046f79cf0cea692f9f5bf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88a5936fb32b4acfa2716e68e93e1c09_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc6431ddab1f47ae881d4c7214c8921b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8199b2a3360472d9aaf8cec50d6e134_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie23479f9e8944779858f19140c19a37f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8acaafaf90b4af786b67f9282de530a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="candidate"><xbrli:measure>sttk:candidate</xbrli:measure></xbrli:unit><xbrli:context id="ia5a069be2f114474a16ab65a58e0073c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sttk:OperatingAccountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb23ff2081e748fd9ff374eb3980514e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24b4d1c38b1242aca9f89fabfca382b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sttk:OperatingAccountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5862eb6343f4314b9960014696b7d5e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66202690cd934e39a5b02adc401092ec_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c8063b21bdd42d6a8b2bd6b8a659fe6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1634b5c2ee444f55945905fb30149f97_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64b931a9bad34aaf9918cffa88232c5e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f7e7bca8d6041f39e4dc1a03ecdaf39_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56b2909098264559bde53509e6f16d96_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0fe0931d7fd474e9944465230cae621_D20221102-20221102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-02</xbrli:startDate><xbrli:endDate>2022-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c388e0f89f34e2c831691fb79c15cb8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ifdcd40cea1904365b4a1a01161642a02_D20230101-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fb1051978f94abc950815f2d8001c2f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i991dfc7ff32043179c7e3f86c543184b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="tranch"><xbrli:measure>sttk:tranch</xbrli:measure></xbrli:unit><xbrli:context id="i0e6401db080843d78c401499533d1dc2_I20201014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb1b33d499ae4e9d975505ddf2b6a145_D20201014-20201014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-14</xbrli:startDate><xbrli:endDate>2020-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76febd49246745a9a7bb5f9df44806a6_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a2cffc815b14f15ba52b9eacfa7e4a7_D20230101-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cbaef79f5984155995efe7d1dfec7e6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic07dbdc8b50c460b91220dd5d8950518_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f423208f22d42beb3d0027d59f5a13a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i553413b499654651890bbd3c2a30bad5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0696e705fa644b0eb1e32b0abcf24c9a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26ed59b30fb3417b8f0372f4e8d87f2a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24d5ba980a4546dd9c94c7d3d055e5dc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b0c733727b44be5a7356b37de831391_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i428ae4dc142344e4867b47e344b894fe_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf0a0042588b4fd2ac8a83479b491708_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d4b4c0ce8c04ddbaf55caff9825c696_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3286ad000a74fb2b534f75b6f23f669_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c88b5d9b1e14fc3b353ec2bed09c97d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3ea58e597ec4bc9b179b6cbe88d9b32_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:MonteCarloOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafe592e811e24849a2a391b482b2fa73_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:MonteCarloOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4634c39261264b90ac1a96707bd46a0b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58eae8a702644e09b9d6eafabc8fd6fd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001680367</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:115%">WASHINGTON, DC 20549 </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.365%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:700;line-height:115%">FORM <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDgz_ba6286c8-9cc5-41ef-b880-670dff0e2e6c">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.365%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"></td><td style="width:13.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6NTYxNTk3ZjZiMzAzNDUxOTg1NWI2ZDc4YWQ1ZTQ4ZmUvdGFibGVyYW5nZTo1NjE1OTdmNmIzMDM0NTE5ODU1YjZkNzhhZDVlNDhmZV8wLTAtMS0xLTMzNzM2_38ca031a-8509-451a-be16-49ee48b333ed">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8xMzg_f9602d2d-72ae-4a52-b563-408c058e8f3e">March 31, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"></td><td style="width:16.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6OGU2MWI3YTdiNWIyNDRlN2I3MDA0Mjg4OTM0NjQ2NzEvdGFibGVyYW5nZTo4ZTYxYjdhN2I1YjI0NGU3YjcwMDQyODg5MzQ2NDY3MV8wLTAtMS0xLTMzNzM2_bcd0a883-ea99-41a6-873a-babb8490c7d0">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">For the transition period from      to      </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:85%">Commission File Number: <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDc2_87b1a1c1-f5ae-4909-b802-e16ab2b35c2f">001-39593</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.198%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20.5pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDgw_fac88c47-ba3b-40ca-be02-56b16d631cf1">Shattuck Labs, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:49.198%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.352%"><tr><td style="width:1.0%"></td><td style="width:34.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.168%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.170%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6ZTk5ZjEyMjRhMmRhNGE5NzlmMDEwZTY2MGE4ZDhkNzYvdGFibGVyYW5nZTplOTlmMTIyNGEyZGE0YTk3OWYwMTBlNjYwYThkOGQ3Nl8wLTAtMS0xLTMzNzM2_92ed7a6e-0f0e-465f-844d-0c14e12a2bac">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6ZTk5ZjEyMjRhMmRhNGE5NzlmMDEwZTY2MGE4ZDhkNzYvdGFibGVyYW5nZTplOTlmMTIyNGEyZGE0YTk3OWYwMTBlNjYwYThkOGQ3Nl8wLTItMS0xLTMzNzM2_f877dcd2-a54c-4d55-9489-2ddee07e566d">81-2575858</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Identification Number)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDgx_4dec615c-a3e1-4c63-90c1-680de111c8bf">500 W. 5th Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDg0_0eccfd53-0edc-40c8-87bf-985a9543da4d">Suite 1200</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDg1_933be8fe-c49e-4d45-a8c4-7b0922dac176">Austin</ix:nonNumeric>, <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDkx_68f7d333-d3df-4b87-b213-2f391af27dbe">TX</ix:nonNumeric> <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDky_b9b6d233-7e03-43af-a12c-2ad5805073d0">78701</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(<ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDc4_ec1ad4e0-d967-478a-b091-a13c7979d66a">512</ix:nonNumeric>) <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDg2_d6e6c12d-0438-41ab-8e73-b95409b35f1f">900-4690</ix:nonNumeric> </span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.673%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Address of principal executive offices including zip code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:85%">Former name, former address and former fiscal year, if changed since last report: N/A</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.429%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:85%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:85%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.946%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:85%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:85%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:85%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:85%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6ZjFiM2E4ZjcwNjBiNDgyNGIyY2QyY2ZiZTdjOTU0ODUvdGFibGVyYW5nZTpmMWIzYThmNzA2MGI0ODI0YjJjZDJjZmJlN2M5NTQ4NV8xLTAtMS0xLTMzNzM2_9bddd521-e8d7-4a75-9db9-8505b3f1064f">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:85%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6ZjFiM2E4ZjcwNjBiNDgyNGIyY2QyY2ZiZTdjOTU0ODUvdGFibGVyYW5nZTpmMWIzYThmNzA2MGI0ODI0YjJjZDJjZmJlN2M5NTQ4NV8xLTEtMS0xLTMzNzM2_d880a605-7d79-4370-ae9d-6e8a92ed8205">STTK</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:85%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6ZjFiM2E4ZjcwNjBiNDgyNGIyY2QyY2ZiZTdjOTU0ODUvdGFibGVyYW5nZTpmMWIzYThmNzA2MGI0ODI0YjJjZDJjZmJlN2M5NTQ4NV8xLTItMS0xLTMzNzM2_c1e09fb9-a4df-4020-a9bf-69986162c0e1">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:85%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDgy_f807e69c-ce6d-4e13-8900-faf792680d8d">Yes</ix:nonNumeric>  &#9746;    No &#9744;</span></div><div style="margin-top:3pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:85%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDg3_56fea583-d659-46ea-8f81-294cc05ef79f">Yes</ix:nonNumeric>  &#9746;    No  &#9744;</span></div><div style="margin-top:3pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:85%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:18.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.370%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Large accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6M2Y2Zjc4ZTk5NWYwNGMyZjgyNGRhODgyNDc5OTJiYTgvdGFibGVyYW5nZTozZjZmNzhlOTk1ZjA0YzJmODI0ZGE4ODI0Nzk5MmJhOF8xLTAtMS0xLTMzNzM2_261f55d7-3261-4ca9-9e3e-c4bbd70a57b6">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#9746;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6M2Y2Zjc4ZTk5NWYwNGMyZjgyNGRhODgyNDc5OTJiYTgvdGFibGVyYW5nZTozZjZmNzhlOTk1ZjA0YzJmODI0ZGE4ODI0Nzk5MmJhOF8xLTMtMS0xLTMzNzM2_02e11d7b-49cc-445e-a8a2-6fde42c89d4b">&#9746;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6M2Y2Zjc4ZTk5NWYwNGMyZjgyNGRhODgyNDc5OTJiYTgvdGFibGVyYW5nZTozZjZmNzhlOTk1ZjA0YzJmODI0ZGE4ODI0Nzk5MmJhOF8yLTMtMS0xLTMzNzM2_347377fd-d174-4024-aed5-d1252e5ecca8">&#9746;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:85%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDc5_81c3672f-d5e9-4642-993c-4189f27bf9c0">&#9744;</ix:nonNumeric> </span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:85%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDg4_48fa6a13-0583-46aa-812c-e2b5888a7238">&#9744;</ix:nonNumeric>    No  &#9746;</span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May 1, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="i0da03d1a066047c19888f60d1a23d25e_I20230501" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDA2_c9350fc6-09bb-4307-8fc7-750238a6959c">42,471,288</ix:nonFraction> shares of common stock, $0.0001 par value per share, outstanding.</span></div><div style="margin-top:3pt;text-align:center;text-indent:24.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:1pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PART I</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_16">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 1.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_16">Condensed Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_16">Condensed Balance Sheets as of March 31, 2023 and December 31, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_19">Condensed Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_22">Condensed Statements of Changes in Stockholders&#8217; Equity for the Three Months Ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_28">Condensed Statements of Cash Flows for the Three Months Ended March 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_31">Notes to the Unaudited Interim Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_55">Item 2</a>.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_55">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_88">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_91">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PART II</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_94">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_97">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_100">Item 1</a>A.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_100">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_103">Item </a>2.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_103">Unregistered Sales of Equity Securities and Use of Proceeds </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_106">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_109">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_112">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_115">Item&#160;</a>6.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_115">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:none" href="#iab75d73ad8e54df383e5480fddd6dcb5_118">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans or intentions relating to products and markets, and business trends and other information referred to under the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;objective,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;design,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;plan,&#8221; or the negative of these terms, and similar expressions intended to identify forward-looking statements. Forward-looking statements are not historical facts and reflect our current views with respect to future events. Given the significant uncertainties, you should not place undue reliance on these forward-looking statements. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this Quarterly Report on Form 10-Q. Such risks, uncertainties and other factors include, among others, the following: </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the timing of the initiation, progress, and expected results of our nonclinical studies, our clinical trials, and our research and development programs;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to enroll patients in our clinical trials;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs related to our nonclinical studies, our clinical trials and our research and development programs, and the impact of inflationary pressures on such costs;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to retain the continued service of our key executives and to identify, hire, and retain additional qualified professionals; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to advance product candidates into, and successfully complete, nonclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the timing or likelihood of regulatory filings and approvals; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the commercialization of our product candidates, if approved; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the pricing, coverage, and reimbursement of our product candidates, if approved; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the implementation of our business model, strategic plans for our business, and product candidates; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platforms, including our ARC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and GADLEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product candidates and other product candidates, and the defense of such intellectual property rights;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our potential need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated;</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to enter into strategic arrangements and/or collaborations and to realize the potential benefits of such arrangements; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our estimates regarding the market opportunity for our product candidates, if approved; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our estimates regarding expenses, capital requirements, and needs for additional financing and our ability to obtain additional capital; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">our financial performance; and</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">developments relating to our competitors and our industry, including competing product candidates and therapies.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be other factors that may cause our actual results to differ materially from the forward-looking statements expressed or implied in this Quarterly Report on Form 10-Q, including factors disclosed in &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; You should evaluate all forward-looking statements made in this Quarterly Report on Form 10-Q in the context of these risks and uncertainties. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We caution you that the risks, uncertainties, and other factors referred to above and elsewhere in this Quarterly Report on Form 10-Q may not contain all of the risks, uncertainties and other factors that may affect our future results and operations. Moreover, new risks will emerge from time to time. It is not possible for our management to predict all risks. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any forward-looking statements contained in this Quarterly Report on Form 10-Q speak only as of the date hereof and not of any future date, and we expressly disclaim any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_13"></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_16"></div><hr style="page-break-after:always"/><div style="min-height:22.5pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Condensed Financial Statements</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfNC0xLTEtMS0zMzczNg_761763c5-b3f8-4f30-a735-97c36923c702">66,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfNC0zLTEtMS0zMzczNg_ea542767-99aa-4173-966b-abb5c31b96c9">47,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfNS0xLTEtMS0zMzczNg_20706c58-f46d-4b79-af44-28d0ba73bb66">69,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfNS0zLTEtMS0zMzczNg_1bf1707e-b5f0-46b2-8cd1-8df5b48dca29">113,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfNi0xLTEtMS0zMzczNg_87ca0e84-a5f0-49fe-961e-1cc9b8f16740">22,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfNi0zLTEtMS0zMzczNg_bb5081fe-0d6d-42b3-8a57-4dcf19d8fec4">23,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfNy0xLTEtMS0zMzczNg_1cc2543e-ddf5-48db-bd81-bf9caa94a755">157,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfNy0zLTEtMS0zMzczNg_c51b5a7e-d5b4-4f33-ad6b-f8dee6e8b833">184,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfOC0xLTEtMS0zMzczNg_2a81b2e7-711a-4b05-ac8d-f2a4ab22f1fb">16,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfOC0zLTEtMS0zMzczNg_c4037c96-8a55-4673-8a33-ee32e570b9e4">17,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfOS0xLTEtMS0zMzczNg_ee5cda7d-038b-4113-9960-b7ed868eb95b">2,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfOS0zLTEtMS0zMzczNg_0039a3b4-d1e3-4909-a121-d290b172995e">3,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTAtMS0xLTEtMzM3MzY_ca258f9a-a669-4f46-9ca0-c63e1383ec17">177,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTAtMy0xLTEtMzM3MzY_ff43bf6a-7374-4a27-a582-4dbb5f9dd99d">205,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTQtMS0xLTEtMzM3MzY_b03bab96-b3c6-458f-b48a-fd614a41efbb">5,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTQtMy0xLTEtMzM3MzY_b6cf2a02-e79a-4078-ab02-84bdaff8ff34">7,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTUtMS0xLTEtMzM3MzY_b175cec7-2c79-4fd5-aebb-15373bcb3228">10,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTUtMy0xLTEtMzM3MzY_0a4e1e89-9511-45f3-ab98-b844be682fa9">17,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTYtMS0xLTEtMzM3MzY_d7e1ed6e-469f-4ad9-8f34-2a89e7313c96">16,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTYtMy0xLTEtMzM3MzY_0972ded4-45d2-4a5e-bc99-b9839d09ebb7">24,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTctMS0xLTEtMzM3MzY_484ce57e-0c62-4398-a08c-d6dd94e16d7c">4,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTctMy0xLTEtMzM3MzY_e43ebdd1-d2d5-4fd3-b234-9cd0ab8f9abb">4,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTktMS0xLTEtMzM3MzY_3648d50a-c9af-46ec-9360-b4d4b31b62d6">20,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTktMy0xLTEtMzM3MzY_afdaa043-5d47-43e0-83da-e2ba2c3f7393">29,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjAtMS0xLTEtMzM3MzY_ec3b6e68-283c-49d3-8f24-0826041cdb67"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjAtMy0xLTEtMzM3MzY_8cc17813-75c3-4ff6-94d5-bd310f4efc79"></ix:nonFraction></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMC0xLTEtMzM3MzYvdGV4dHJlZ2lvbjo5OWRmOTM0NGU3NzQ0ZDc5YWIxYTliZjRmZGFhNGQxM18xOQ_3bca0351-96bb-453b-9564-d80a3cfc2ac4"><ix:nonFraction unitRef="usdPerShare" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMC0xLTEtMzM3MzYvdGV4dHJlZ2lvbjo5OWRmOTM0NGU3NzQ0ZDc5YWIxYTliZjRmZGFhNGQxM18xOQ_45dcab6c-9980-47d8-9ea7-a53569171752">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="shares" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMC0xLTEtMzM3MzYvdGV4dHJlZ2lvbjo5OWRmOTM0NGU3NzQ0ZDc5YWIxYTliZjRmZGFhNGQxM18zMw_5fafc705-1198-4bc4-aa78-e81ca9ca9a8d"><ix:nonFraction unitRef="shares" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMC0xLTEtMzM3MzYvdGV4dHJlZ2lvbjo5OWRmOTM0NGU3NzQ0ZDc5YWIxYTliZjRmZGFhNGQxM18zMw_a5c00b2d-0821-401d-8f3d-e80c8263d220">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMC0xLTEtMzM3MzYvdGV4dHJlZ2lvbjo5OWRmOTM0NGU3NzQ0ZDc5YWIxYTliZjRmZGFhNGQxM181NQ_9f844b9f-c871-4dd9-b690-d54a521694ce"><ix:nonFraction unitRef="shares" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMC0xLTEtMzM3MzYvdGV4dHJlZ2lvbjo5OWRmOTM0NGU3NzQ0ZDc5YWIxYTliZjRmZGFhNGQxM181NQ_b6902f65-505e-4a73-a470-1f744140cd79">42,460,258</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2023 and <ix:nonFraction unitRef="shares" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMC0xLTEtMzM3MzYvdGV4dHJlZ2lvbjo5OWRmOTM0NGU3NzQ0ZDc5YWIxYTliZjRmZGFhNGQxM185OA_2a2c2970-abdd-4d13-83cc-e6b990e8f2ca"><ix:nonFraction unitRef="shares" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMC0xLTEtMzM3MzYvdGV4dHJlZ2lvbjo5OWRmOTM0NGU3NzQ0ZDc5YWIxYTliZjRmZGFhNGQxM185OA_7af6b9ff-6bd5-44e5-8d90-a380bddf78ed">42,390,586</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMS0xLTEtMzM3MzY_16cfeb55-6b91-4ed0-afb3-694542685a36">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMy0xLTEtMzM3MzY_f08e9d9e-e825-4299-a7b9-166b211bdb68">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjMtMS0xLTEtMzM3MzY_3ed59645-a525-4fc4-a7b4-2bc297c00483">397,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjMtMy0xLTEtMzM3MzY_a9edc6dc-c0c4-49d3-9934-c7a52a5cb779">396,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjQtMS0xLTEtMzM3MzY_8ca53fd0-be84-4592-8513-68f67e2f82c7">339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjQtMy0xLTEtMzM3MzY_0da4dab3-1649-4bc8-be4c-90adab2b2170">877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjUtMS0xLTEtMzM3MzY_b09d679c-6f70-4248-81ad-0e12c15ab712">239,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjUtMy0xLTEtMzM3MzY_8eaf2be9-c518-4d21-b924-287c8b946a67">219,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjYtMS0xLTEtMzM3MzY_c18950c5-3879-4a55-887d-031f00152b96">157,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjYtMy0xLTEtMzM3MzY_55f2b5a4-8cde-42c4-9ace-a88da2593c53">176,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjctMS0xLTEtMzM3MzY_3e2ff8d6-1fa0-43d0-9afb-3ace42aa1f43">177,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjctMy0xLTEtMzM3MzY_8b0a2614-d8b7-48ef-b082-42c269fe867a">205,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited interim condensed financial statements</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited) </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts) </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMi0wLTEtMS0zMzczNg_0dbd2c13-8918-4b63-bdf2-300920a2fc2e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMi0wLTEtMS0zMzczNg_b87d8af4-7cf2-4221-895b-3d002e7a2319">Collaboration revenue</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMi0yLTEtMS0zMzczNg_f257f7e5-abd1-4af1-b3f6-0389cba8b07f">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMi00LTEtMS0zMzczNg_b14c9079-cd0f-4742-a3fe-74b8b5faf39c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfNC0yLTEtMS0zMzczNg_2f96e42d-04f5-4775-a44f-60151c9e1ed1">16,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfNC00LTEtMS0zMzczNg_460e56b3-2711-419a-a8ba-d924d038c7b6">19,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfNS0yLTEtMS0zMzczNg_08fbf16d-2328-404f-9cd5-134547ca84d7">5,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfNS00LTEtMS0zMzczNg_f1a74708-cd7f-4518-9598-fc82c9c33b7c">4,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expense from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfNi0yLTEtMS0zMzczNg_23fc5e54-79cb-4f06-a902-51b6d2f4df8f">21,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfNi00LTEtMS0zMzczNg_77a73cc3-2a81-4ae2-a37d-0f0039b825f9">24,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfNy0yLTEtMS0zMzczNg_2e2953f8-30b6-4000-95ca-736cf4e02e5f">21,661</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfNy00LTEtMS0zMzczNg_134f54d8-020a-43b1-8036-03e02aa4b29d">24,166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTAtMi0xLTEtMzM3MzY_f7913632-8e41-43c1-aa6d-540fb5879dab">937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTAtNC0xLTEtMzM3MzY_11ec1123-0a88-4f1e-a9b5-2ecc54992625">362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTEtMi0xLTEtMzM3MzY_b20b6f10-33cc-4fd0-b7c0-f2d8a202d8c6">20,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTEtNC0xLTEtMzM3MzY_f280e7ca-0a50-4fcf-92d1-98deafa4bdc3">24,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTItMi0xLTEtMzM3MzY_1927a08a-cba4-46ab-b2e0-b21271d50133">538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTItNC0xLTEtMzM3MzY_34dd05c8-a87f-4c4e-8a5a-c7de306da53b">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTMtMi0xLTEtMzM3MzY_b4da82e2-e014-4d56-88d0-2a23afc506b1">20,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTMtNC0xLTEtMzM3MzY_6495abd7-d6ff-420c-b3fc-40c82947b02f">24,495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share &#8211; basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTUtMi0xLTEtMzM3MzY_4483fe48-7a08-4149-ab27-62fe4a6969c6"><ix:nonFraction unitRef="usdPerShare" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTUtMi0xLTEtMzM3MzY_b012c392-99f5-4a1b-953b-b3be28bca6c6">0.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTUtNC0xLTEtMzM3MzY_5b5cd1a1-d5f4-43ec-b891-ab9a53f8b559"><ix:nonFraction unitRef="usdPerShare" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTUtNC0xLTEtMzM3MzY_cfb04c5d-2544-499f-97b0-76ddb8a70229">0.58</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding &#8211; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTYtMi0xLTEtMzM3MzY_4e7622c2-a8af-456c-b189-409a97baca7d"><ix:nonFraction unitRef="shares" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTYtMi0xLTEtMzM3MzY_6061c39d-c80b-4489-9032-a679050ccca8">42,439,204</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTYtNC0xLTEtMzM3MzY_15bccd75-727f-449b-a31c-12de28141796"><ix:nonFraction unitRef="shares" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTYtNC0xLTEtMzM3MzY_40108573-1a8c-4d30-ae38-dba4e60437a9">42,357,625</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited interim condensed financial statements</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Gain (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic79fdedfe69a4831bd0c813659e24620_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfMy0xLTEtMS0zMzczNg_1073fd58-12f8-4abb-a74e-09ed897af650">42,390,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ic79fdedfe69a4831bd0c813659e24620_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfMy0zLTEtMS0zMzczNg_c83479eb-e669-4787-9801-faa3257cd2f7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i6329837530214020b3ca9fff657cea9b_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfMy01LTEtMS0zMzczNg_8ad9201f-78b0-48fe-bd10-80bdf2de62cc">396,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic22a2288c5fa4a87bdc2dc2f63c68bee_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfMy03LTEtMS0zMzczNg_7933a245-8cbb-45e4-8227-968eec1ba190">877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i237ffce164a14b11b3d4a56d948a6d2d_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfMy05LTEtMS0zMzczNg_36b256e2-b128-4099-938f-f642e5f33ab0">219,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfMy0xMS0xLTEtMzM3MzY_40978487-dd02-47e4-838e-9d28116bde07">176,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise of stock options and purchases pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib31390f36c5a45249b07c710d4824091_D20230101-20230331" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNC0xLTEtMS0zMzczNg_c092920b-cdb4-4735-9c6c-16b8dedb9896">11,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e92a7048fc84c1aa85deddf715d1c18_D20230101-20230331" decimals="-3" name="sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNC01LTEtMS0zMzczNg_99e9d24b-11c2-49b9-b9c4-f4e437833a02">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNC0xMS0xLTEtMzM3MzY_68829bd0-2d5f-4feb-9c78-3f8c6c144bbd">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock upon settlement of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib31390f36c5a45249b07c710d4824091_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNS0xLTEtMS0zMzkyMg_8ff78dcd-8085-410d-aaea-5a8972204e55">73,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Shares withheld related to net share settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNi0xLTEtMS01MDAxMQ_9a80c4d9-53aa-40b7-97af-08921bd38300">16,153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i2e92a7048fc84c1aa85deddf715d1c18_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNi01LTEtMS01MDAxMQ_c055ee79-0af7-469d-82f3-c434243ba38f">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNi0xMS0xLTEtNTAwMTE_ab9d0e19-8a37-4b59-8ce3-ea5b8933ba3e">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i2e92a7048fc84c1aa85deddf715d1c18_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNS01LTEtMS0zMzczNg_ecbc8fba-f8ca-46b4-8d23-5e2f4996fd6c">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNS0xMS0xLTEtMzM3MzY_12653934-1fe1-4f2b-8195-bb457d28cdc1">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i70b47fdbe5a84c6e8cf8ce134ab56bdb_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNi03LTEtMS0zMzczNg_bd122c86-e90c-49c6-a75a-6122982427dd">538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNi0xMS0xLTEtMzM3MzY_e02c0030-a4f4-4966-b428-d3d48005c286">538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="id186272227244ec3b82b3b87eabc97f9_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNy05LTEtMS0zMzczNg_fc0675b7-9ab1-48a0-a8d9-bc56d05dd57c">20,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNy0xMS0xLTEtMzM3MzY_380ecf61-5a9a-45a3-bce2-9bee77701c8f">20,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance at Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i9b3ef141d1cc4f10aa5bcdaa504aa1a2_I20230331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfOC0xLTEtMS0zMzczNg_d1e2e4cb-cdc4-48ef-83f2-8080565a736b">42,460,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9b3ef141d1cc4f10aa5bcdaa504aa1a2_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfOC0zLTEtMS0zMzczNg_7d68f6bd-66cf-4fd8-933f-9fd07b5db8be">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i7da54cb1c2b04054814e3dfed37c7947_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfOC01LTEtMS0zMzczNg_a80ece90-b4f2-4bb0-beea-ff3194c7288c">397,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i104d8a78724041988c7e63d9c8bd9624_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfOC03LTEtMS0zMzczNg_9738d55c-0378-4434-8853-962c80949414">339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i465bbee7d341453dbf57ff22cf4c2c7f_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfOC05LTEtMS0zMzczNg_4beee9ba-c46f-4e37-840f-6245ccc42654">239,736</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfOC0xMS0xLTEtMzM3MzY_55e6b349-be03-40c7-87f4-90b501527ffa">157,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:29pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2022</span></div></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Gain (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Stockholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibf15edfb0127444c8297ddfefadc5003_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfMy0xLTEtMS00OTY4NQ_88e45f94-c0c8-425a-8cdf-fa584e50b2fb">42,338,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ibf15edfb0127444c8297ddfefadc5003_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfMy0zLTEtMS00OTY4NQ_aa09f6da-717a-4411-a218-b16512c05976">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="icbe46f015ce244558ede3196621fd998_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfMy01LTEtMS00OTY4NQ_19ca5281-124c-4aa1-92e1-5c611938716d">389,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i6675d59e3920448683346ca6b09615ee_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfMy03LTEtMS00OTY4NQ_177315c5-3993-49e8-a95e-8d6a00e5bcea">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i8a0210c92623410b817e1521f5ad2f4b_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfMy05LTEtMS00OTY4NQ_e7e9f585-448b-4194-925a-b04c1848105a">117,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9126dbe3941542e6958b2493b197a481_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfMy0xMS0xLTEtNDk2ODU_595baa56-cc55-4aeb-85ce-ca7e59e29525">271,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise of stock options and purchases pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i070803840450402f8ea63b2237086a3e_D20220101-20220331" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNC0xLTEtMS00OTY4NQ_8cff6e82-e2ac-4efe-a5f5-9d4360ab880d">39,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i321f3e6305f148e49074f9fc1dca1b0c_D20220101-20220331" decimals="-3" name="sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNC01LTEtMS00OTY4NQ_037014e3-19e9-40e0-9565-876f56233b68">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNC0xMS0xLTEtNDk2ODU_cd434fe7-4157-467a-af9a-2c8017e9b017">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i321f3e6305f148e49074f9fc1dca1b0c_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNS01LTEtMS00OTY4NQ_bd8f30c7-d722-4fd3-a7fd-832cb0ada995">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNS0xMS0xLTEtNDk2ODU_01db15d2-fb2a-442b-b008-ec43d12cc359">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i64ca7813e54547a1b035602b2d224a95_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNi03LTEtMS00OTY4NQ_3401a02f-b0bd-41d6-a8d0-bc248af42682">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNi0xMS0xLTEtNDk2ODU_af567561-a10c-42ea-8204-96e89aaf5351">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5137177e56c046f79cf0cea692f9f5bf_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNy05LTEtMS00OTY4NQ_b9b35ad8-2c27-4cbf-b7ed-ff58f639492b">24,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNy0xMS0xLTEtNDk2ODU_d557400f-0c92-4c3d-b034-9eb4e4190d5d">24,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance at March&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i88a5936fb32b4acfa2716e68e93e1c09_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfOC0xLTEtMS00OTY4NQ_bfe3b15a-12b8-429e-a655-bef0a12e8c61">42,378,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88a5936fb32b4acfa2716e68e93e1c09_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfOC0zLTEtMS00OTY4NQ_23f7286e-7f98-408c-800b-901da6aacdc3">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="idc6431ddab1f47ae881d4c7214c8921b_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfOC01LTEtMS00OTY4NQ_3b7af036-7ed2-46d7-ab8f-ee8f4ca42bda">391,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ic8199b2a3360472d9aaf8cec50d6e134_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfOC03LTEtMS00OTY4NQ_4b55af49-a112-4cb5-b040-a60de235d569">527</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ie23479f9e8944779858f19140c19a37f_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfOC05LTEtMS00OTY4NQ_aa2f5bbe-5215-460f-b56b-c05c88b290d7">141,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib8acaafaf90b4af786b67f9282de530a_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfOC0xMS0xLTEtNDk2ODU_a322def6-8433-4dda-9bba-7ab2569f72d9">248,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited interim condensed financial statements</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_28"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.479%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMy0xLTEtMS0zMzczNg_b20b6f10-33cc-4fd0-b7c0-f2d8a202d8c6">20,724</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMy0zLTEtMS0zMzczNg_f280e7ca-0a50-4fcf-92d1-98deafa4bdc3">24,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to net cash used in operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfNS0xLTEtMS0zMzczNg_f2e11829-75a5-4eec-b74e-2178549f27fe">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfNS0zLTEtMS0zMzczNg_84c52ed6-b909-4522-bf90-34c1f2e3de76">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfNi0xLTEtMS00ODkwMA_0059c574-992d-45f5-94cf-0de08fa0a55d">1,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfNi0zLTEtMS00ODkwMA_ac5ec480-4350-43e3-96a5-92dcb1843195">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfOC0xLTEtMS0zMzczNg_b06c3a23-3b5c-46be-b185-a712ee7963ea">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfOC0zLTEtMS0zMzczNg_8b8d7b44-0922-4e09-9f20-aa4655f719b8">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net amortization (accretion) of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfOS0xLTEtMS01MDI2NA_73687801-690b-4794-813f-03a65cc85638">213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfOS0zLTEtMS01MDI2NA_bfea9a1d-c9da-42c3-8ee1-5a96dace8b47">981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTAtMS0xLTEtMzM3MzY_466868e0-0c01-4e2f-a841-33149de6f3dd">1,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTAtMy0xLTEtMzM3MzY_9f30c1e0-1a05-442f-b67c-6b4758516957">3,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTEtMS0xLTEtMzM3MzY_d096bd08-977f-4e49-8288-1e21e5c377c9">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTEtMy0xLTEtMzM3MzY_555bad36-0e22-40b8-ac13-67091ed568f1">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTItMS0xLTEtMzM3MzY_0e5a2f1e-f2db-4d55-af2a-567126f2a08f">2,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTItMy0xLTEtMzM3MzY_45acc39e-9ffb-48f6-aed7-95920971225b">7,738</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTMtMS0xLTEtMzM3MzY_7d1728c1-6105-42fd-b9b2-71f4ef1d1aec">7,356</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTMtMy0xLTEtMzM3MzY_124f5e54-7aa6-4f84-a678-605eb994d557">601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTQtMS0xLTEtMzM3MzY_b550b8db-9a9f-4f63-a80b-7f0cd0939fc2">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTQtMy0xLTEtMzM3MzY_63349e5f-6767-426a-bd17-cf1f658d187a">165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTYtMS0xLTEtMzM3MzY_1196d528-3207-4af2-92bf-f1a3e496bd9e">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTYtMy0xLTEtMzM3MzY_17d07f02-160b-4f14-af43-b7fcac0ada1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTctMS0xLTEtMzM3MzY_dbab6682-c95d-42fa-a766-7d5ab440f4c1">26,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTctMy0xLTEtMzM3MzY_094adf4d-86f0-4023-a4f7-587bf0f5330f">26,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjAtMS0xLTEtMzM3MzY_086e000d-e320-4a39-b92f-1fabd7354ebe">75</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjAtMy0xLTEtMzM3MzY_b7f3ea90-bb54-4206-9cd4-0764929af7eb">2,488</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net change in investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjEtMS0xLTEtMzM3MzY_08e13fa8-231e-4271-a81e-c3843bedf1d9">45,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjEtMy0xLTEtMzM3MzY_d71d473c-3a38-4ee9-a27e-55d60977f4df">12,894</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjItMS0xLTEtMzM3MzY_2f293142-80d9-46c1-9ed3-ad651d26f5b6">45,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjItMy0xLTEtMzM3MzY_560e22f9-4c61-4102-9f87-ac8e1a4eab46">15,382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the exercises of stock options and purchases pursuant to employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjUtMS0xLTEtMzM3MzY_bce3b2f6-5a7f-4108-8ee5-7a2aae6df4b8">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjUtMy0xLTEtMzM3MzY_8941b29b-a9ab-49d5-ba17-a3be5f26a949">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjUtMS0xLTEtNTAxNjU_8ee80395-8848-4d52-883e-4e1fd7e3aa55">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjUtMy0xLTEtNTAxNTg_6ddafbc9-bd7a-465c-9b15-74a2ec01ff71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjYtMS0xLTEtMzM3MzY_9d0dab1c-ac4b-4e89-8562-84c07f35b977">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjYtMy0xLTEtMzM3MzY_7c1160b9-63a5-43f5-8eee-6b6c5b556818">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjctMS0xLTEtMzM3MzY_3e04f10e-6dfb-49c6-b4fb-de27af6feabf">18,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjctMy0xLTEtMzM3MzY_d484976b-590a-4273-bed2-4b3c9ef63845">41,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjgtMS0xLTEtMzM3MzY_494db93a-977b-4970-bb94-546e7956a3ab">47,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9126dbe3941542e6958b2493b197a481_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjgtMy0xLTEtMzM3MzY_42630e59-6cbd-4405-8b98-dcdc0226bc23">92,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjktMS0xLTEtMzM3MzY_bc2b6ae6-d3d7-40eb-a206-b26887f5ed8e">66,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ib8acaafaf90b4af786b67f9282de530a_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjktMy0xLTEtMzM3MzY_8beaecfd-ab0f-494d-bafb-85a05fcbcbe3">50,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental disclosures of non-cash financial activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities recognized for operating right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="sttk:OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMzItMS0xLTEtMzM3MzY_65986f17-0a3f-494f-b39f-8e1b0026c13d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="sttk:OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMzItMy0xLTEtMzM3MzY_a77a2783-a48a-41f6-87bd-5483eb71e385">5,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating right-of-use assets exchanged for operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMzMtMS0xLTEtMzM3MzY_2971d8fe-c772-4bd6-92cb-94d40844fac1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMzMtMy0xLTEtMzM3MzY_4917e305-c89e-4919-9bbf-d561bdadd945">2,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue billed but not received</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="sttk:RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMzQtMS0xLTEtNTA2MzA_294a02da-12c2-4719-982d-2ffd67093f4c">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="sttk:RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMzQtMy0xLTEtNTA2MjM_31ab2efd-5aaf-41b6-a844-a84ffea3c069">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unpaid amounts related to purchases of property and equipment</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMzUtMS0xLTEtMzM3MzY_ef87995f-4dd9-41c6-97d3-eb3491a958e1">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMzUtMy0xLTEtMzM3MzY_c406b206-61b3-40ac-b8c3-c397226b74d8">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited interim condensed financial statements</span></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHATTUCK LABS, INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS</span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_34"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNC9mcmFnOjEyZWQ5YzM2ZmUxNTQyZTRhYTkwMGEzYmE2ODZmYTQyL3RleHRyZWdpb246MTJlZDljMzZmZTE1NDJlNGFhOTAwYTNiYTY4NmZhNDJfMzE5Mg_f9746e4e-5e0d-41a9-a5b5-6f0695f1404b" continuedAt="i00350c765cdf4027a0c5fe984db2a748" escape="true">Organization and Description of Business </ix:nonNumeric></span></div><ix:continuation id="i00350c765cdf4027a0c5fe984db2a748"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shattuck Labs, Inc. (the &#8220;Company&#8221;) was incorporated in 2016 in the State of Delaware and is a clinical-stage biopharmaceutical company developing dual-sided fusion proteins, including its Agonist Redirected Checkpoint (&#8220;ARC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and gamma delta T cell engager (&#8220;GADLEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) platforms, as novel classes of biologic medicines capable of multifunctional activity with potential applications in oncology and inflammatory diseases. Using its proprietary technology, the Company is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic malignancies. The Company has <ix:nonFraction unitRef="candidate" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="INF" name="sttk:NumberOfClinicalStageProductCandidates" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNC9mcmFnOjEyZWQ5YzM2ZmUxNTQyZTRhYTkwMGEzYmE2ODZmYTQyL3RleHRyZWdpb246MTJlZDljMzZmZTE1NDJlNGFhOTAwYTNiYTY4NmZhNDJfMjc0ODc3OTA3NjY1Nw_35b96464-3c60-4434-bac8-e7e4c534986c">one</ix:nonFraction> clinical-stage product candidate, SL-172154, and has several compounds in preclinical development. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNC9mcmFnOjEyZWQ5YzM2ZmUxNTQyZTRhYTkwMGEzYmE2ODZmYTQyL3RleHRyZWdpb246MTJlZDljMzZmZTE1NDJlNGFhOTAwYTNiYTY4NmZhNDJfOTA4_8782d07e-dfc3-409f-9b9e-cfef9e05bc0f">239.7</ix:nonFraction> million as of March&#160;31, 2023. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company&#8217;s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company&#8217;s cash and cash equivalents and investments of $<ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNC9mcmFnOjEyZWQ5YzM2ZmUxNTQyZTRhYTkwMGEzYmE2ODZmYTQyL3RleHRyZWdpb246MTJlZDljMzZmZTE1NDJlNGFhOTAwYTNiYTY4NmZhNDJfMTc0Mw_b605bea7-7f9e-4fbe-a714-e085617d8960">135.5</ix:nonFraction> million as of March&#160;31, 2023 are sufficient to fund projected operations of the Company for at least the next twelve months. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Economic Considerations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine and other political tensions, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on our future operations.</span></div></ix:continuation><div id="iab75d73ad8e54df383e5480fddd6dcb5_37"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMjc_82317780-c497-4cdd-901b-d06db6fd98bb" continuedAt="icc4d9b61eb4f47ca931b7fd930c8d763" escape="true">Basis of Presentation and Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="icc4d9b61eb4f47ca931b7fd930c8d763" continuedAt="ie8bcc261593a427587709a79d36a358a"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMTc_990544fc-5d5c-4453-9f2d-0522d6ced590" continuedAt="i8722e436a40449ba98e1d154bdfd9938" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Financial Statements </span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8722e436a40449ba98e1d154bdfd9938">In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position, its results of operations, statements of changes in stockholders&#8217; equity and cash flows for the interim periods presented. Operating results for interim periods presented are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023. The interim financial statements presented herein do not contain all required disclosures under GAAP for annual financial statements. The accompanying unaudited interim condensed financial statements should be read in conjunction with the annual audited financial statements and related notes in our Annual Report on Form 10-K for the year ended December&#160;31, 2022.</ix:continuation> </span></div><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMTg_f9fa89d1-3ac6-4488-86bb-855c1977bad9" continuedAt="ib16ae73bdf00438386fef513fbf66ef7" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ie8bcc261593a427587709a79d36a358a" continuedAt="ib8ba8cb1e23d4156b600e10691181454"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib16ae73bdf00438386fef513fbf66ef7">the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#8217;s estimates.</ix:continuation></span></div><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjc0ODc3OTExMTE1Mg_375fa0dd-dda2-4a3d-b286-cd0aae9fe66f" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMzM_51849944-3b01-424c-b6cf-9f1d758016b2" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including investments and accounts payable, approximate fair value due to the short-term nature of those instruments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMTk_38aca953-201a-4fab-8d6f-71532026e1c4" continuedAt="ie7c3432e612e4f91adef54a173cd6e23" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. While the Company has not experienced any losses, the recent failure of Silicon Valley Bank (&#8220;SVB&#8221;), at which the Company held cash, exposed the Company to significant credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors. The Company is in the process of transferring its cash to an alternate depository institution, the financial position of which management believes does not expose the Company to significant credit risk. Where possible, the Company will also continue to hold its excess cash in investments and money market accounts to further limit exposure. The Company does not believe that it is subject to other unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only U.S. Treasury securities that management believes protects the Company from risk of default and impairment of value.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract manufacturing organizations (&#8220;CMOs&#8221;) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ib8ba8cb1e23d4156b600e10691181454" continuedAt="i556c228caed645adae02a960bf434992"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie7c3432e612e4f91adef54a173cd6e23">The Company is highly dependent on a limited number of contract research organizations (&#8220;CROs&#8221;) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.</ix:continuation> </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMzk_4e070a5d-0580-4435-9a6a-f51c68cd660f" continuedAt="i8eee0acb044b4d27a52327be1c6354a9" escape="true">Cash and Cash Equivalents </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8eee0acb044b4d27a52327be1c6354a9">The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents.</ix:continuation> Cash and cash equivalents consisted of $<ix:nonFraction unitRef="usd" contextRef="ia5a069be2f114474a16ab65a58e0073c_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfNTQ4Mg_74dcb47f-af83-459b-a573-4d218ddff916">0.8</ix:nonFraction> million held in operating accounts and $<ix:nonFraction unitRef="usd" contextRef="idb23ff2081e748fd9ff374eb3980514e_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfNTUxNg_82a11ae0-4708-4270-a98b-a214e96e4bda">65.2</ix:nonFraction> million held in money market funds as of March&#160;31, 2023, and $<ix:nonFraction unitRef="usd" contextRef="i24b4d1c38b1242aca9f89fabfca382b8_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfNTU2MA_3ea15295-b299-49bd-9589-93d97c3d58cf">3.5</ix:nonFraction> million held in operating accounts and $<ix:nonFraction unitRef="usd" contextRef="ia5862eb6343f4314b9960014696b7d5e_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfNTU5NA_46a79009-2728-439c-a17f-6207ff5fe931">43.9</ix:nonFraction> million held in money market funds as of December&#160;31, 2022. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMjg_43537574-0b3c-4fca-b32e-172b7a32b323" continuedAt="i9a076f1b36314e0ebd2d0b15fdf9fbce" escape="true">Investments </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9a076f1b36314e0ebd2d0b15fdf9fbce">The Company&#8217;s investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter.</ix:continuation> As of March&#160;31, 2023 and December 31, 2022, there were no impairments related to credit losses of investments. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjc0ODc3OTEwNTAxNQ_07477853-a45a-4697-a2c2-27caa1aedcfd" continuedAt="id13bc28cb7e048cb915cdd9e798552ab" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id13bc28cb7e048cb915cdd9e798552ab">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-5" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjc0ODc3OTEwNTY2NA_79a55d43-c18f-4a69-bfbd-ff0a68a40836"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-5" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjc0ODc3OTEwNTY2NA_a6543420-3124-4f82-88b5-37bf021dd72d">no</ix:nonFraction></ix:nonFraction> impairments of long-lived assets for the three months ended March 31, 2023 and 2022.</span></div><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMjE_aafbb9ed-569c-4fec-9501-c29ffca3e517" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The classification of the Company&#8217;s leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirement of Accounting Standards Codification (&#8220;ASC&#8221;) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Financial Accounting Standards Board (&#8220;FASB&#8221;) to leases with a term of 12 months or less for all classes of assets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjc0ODc3OTEwNTAzMg_7c98c7a4-d863-4977-8b8c-1483f93dad99" continuedAt="i46ebbb4230ed4bf6acb8dea8b5515f51" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments and Contingencies</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 450-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the FASB to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i556c228caed645adae02a960bf434992" continuedAt="i72208114dd7148b995e9d401adc9bb4a"><ix:continuation id="i46ebbb4230ed4bf6acb8dea8b5515f51"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#8217;s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</span></div></ix:continuation><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMjQ_64f8515f-5aac-4bf6-97bf-eca904b80cb2" continuedAt="i45f339e55a8349b79c46a57fd3585e0c" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">identify the contract(s) with a customer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">identify the performance obligations in the contract; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">determine the transaction price; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">allocate the transaction price to the performance obligations within the contract; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements may consist of a license of, or options to license, the Company&#8217;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i72208114dd7148b995e9d401adc9bb4a" continuedAt="i3f610522479d4a2caf10e7ad364de453"><ix:continuation id="i45f339e55a8349b79c46a57fd3585e0c" continuedAt="i951872c4ef2e4002b6b23c94fb051973"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s collaboration revenue arrangements may include the following: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will </span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i3f610522479d4a2caf10e7ad364de453" continuedAt="i0152fb39677e49b88663bdff95f90b71"><ix:continuation id="i951872c4ef2e4002b6b23c94fb051973" continuedAt="i24e2cce725a64d00af48d7541791a5a0"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. </span></div></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><ix:continuation id="i24e2cce725a64d00af48d7541791a5a0" continuedAt="i37e30c0fc2b04a5084c1bdfa99f1d0f2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company considered the guidance in ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i37e30c0fc2b04a5084c1bdfa99f1d0f2"> and will recognize the payments received from these agreements as revenue when the related costs are incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMjU_8509accc-5877-4a6b-821a-1c88a4a7ddad" continuedAt="i65210604f11e4a59850b653b7b51a489" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i65210604f11e4a59850b653b7b51a489">A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including CROs and CMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO or outside service provider, the payments will be recorded as a prepaid asset, which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#8217;s accruals that could materially affect the Company&#8217;s results of operations.</ix:continuation> </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMjY_e8962ee7-3a35-41e5-a52f-b2c517d35bc7" continuedAt="i399e4efc60ee41069db8f360a942cd53" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i399e4efc60ee41069db8f360a942cd53">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock or convertible notes, if any, stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</ix:continuation> </span></div><div style="margin-top:6pt;text-indent:27pt"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMjI_1c88a304-043c-4844-b655-a9870cb4fe24" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as of March&#160;31, 2023 and 2022, as they would be anti-dilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.484%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i66202690cd934e39a5b02adc401092ec_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RhYmxlOmFiMDBhZDZmOTQwNjRkZmM4ODM2MzA1Njk0OTU0ZmUyL3RhYmxlcmFuZ2U6YWIwMGFkNmY5NDA2NGRmYzg4MzYzMDU2OTQ5NTRmZTJfMi01LTEtMS0zMzczNg_2947016e-eec6-4f9c-bd02-cdc88834eb43">5,261,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2c8063b21bdd42d6a8b2bd6b8a659fe6_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RhYmxlOmFiMDBhZDZmOTQwNjRkZmM4ODM2MzA1Njk0OTU0ZmUyL3RhYmxlcmFuZ2U6YWIwMGFkNmY5NDA2NGRmYzg4MzYzMDU2OTQ5NTRmZTJfMi03LTEtMS0zMzczNg_39108d47-e3b7-4db2-8436-75b337cc7782">3,460,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i1634b5c2ee444f55945905fb30149f97_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RhYmxlOmFiMDBhZDZmOTQwNjRkZmM4ODM2MzA1Njk0OTU0ZmUyL3RhYmxlcmFuZ2U6YWIwMGFkNmY5NDA2NGRmYzg4MzYzMDU2OTQ5NTRmZTJfMy01LTEtMS0zMzczNg_8979cadf-fecc-463c-bb58-77b671256214">652,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i64b931a9bad34aaf9918cffa88232c5e_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RhYmxlOmFiMDBhZDZmOTQwNjRkZmM4ODM2MzA1Njk0OTU0ZmUyL3RhYmxlcmFuZ2U6YWIwMGFkNmY5NDA2NGRmYzg4MzYzMDU2OTQ5NTRmZTJfMy03LTEtMS0zMzczNg_ea5fb3f8-157e-447d-9848-43fc179543c1">313,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RhYmxlOmFiMDBhZDZmOTQwNjRkZmM4ODM2MzA1Njk0OTU0ZmUyL3RhYmxlcmFuZ2U6YWIwMGFkNmY5NDA2NGRmYzg4MzYzMDU2OTQ5NTRmZTJfNC01LTEtMS0zMzczNg_2a63b7b7-d3c5-408c-9f9a-9922b81e02e3">5,914,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RhYmxlOmFiMDBhZDZmOTQwNjRkZmM4ODM2MzA1Njk0OTU0ZmUyL3RhYmxlcmFuZ2U6YWIwMGFkNmY5NDA2NGRmYzg4MzYzMDU2OTQ5NTRmZTJfNC03LTEtMS0zMzczNg_f3657787-5446-4e49-a83a-bd881ab88959">3,774,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:1pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwNDU_2a38f860-ef16-4b89-8dd0-387eedfc9277" continuedAt="i21d33eaeb35d4cbfab9b05a222190b14" escape="true">Other Comprehensive Income (Loss) </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i21d33eaeb35d4cbfab9b05a222190b14">Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on investments.</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i0152fb39677e49b88663bdff95f90b71"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwNDY_e53b8023-658d-4cd2-bf41-a43f3a6cc1f1" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div></ix:nonNumeric></ix:continuation><div id="iab75d73ad8e54df383e5480fddd6dcb5_40"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RleHRyZWdpb246MjIzNmJiNmI2N2RlNDBmM2JmYmNmMDlhYmZkMDg4NWJfNDk3_17b35726-b5c9-4f21-a5dd-b3453764c319" continuedAt="i26c8f5285fcf4f9caf97251856278c58" escape="true">Investments </ix:nonNumeric></span></div><ix:continuation id="i26c8f5285fcf4f9caf97251856278c58"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RleHRyZWdpb246MjIzNmJiNmI2N2RlNDBmM2JmYmNmMDlhYmZkMDg4NWJfNDk4_7f5788a6-554b-4af4-af91-bec75fd89e6c" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s available for sale investments by major security type (amounts in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1f7e7bca8d6041f39e4dc1a03ecdaf39_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjdlNWE2NzEyMDgxZjQxZTFhY2VmNzEzNTQyNDdlYTNmL3RhYmxlcmFuZ2U6N2U1YTY3MTIwODFmNDFlMWFjZWY3MTM1NDI0N2VhM2ZfNC0xLTEtMS0zMzczNg_4357d1d5-a9ed-4d33-9535-dde0f612dded">69,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i1f7e7bca8d6041f39e4dc1a03ecdaf39_I20230331" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjdlNWE2NzEyMDgxZjQxZTFhY2VmNzEzNTQyNDdlYTNmL3RhYmxlcmFuZ2U6N2U1YTY3MTIwODFmNDFlMWFjZWY3MTM1NDI0N2VhM2ZfNC0zLTEtMS0zMzczNg_514c553c-4304-48ba-a6d5-fd1b36c5106d">339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i1f7e7bca8d6041f39e4dc1a03ecdaf39_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjdlNWE2NzEyMDgxZjQxZTFhY2VmNzEzNTQyNDdlYTNmL3RhYmxlcmFuZ2U6N2U1YTY3MTIwODFmNDFlMWFjZWY3MTM1NDI0N2VhM2ZfNC01LTEtMS0zMzczNg_1a6f2092-c313-4d69-a484-3f46d68bdef0">69,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjdlNWE2NzEyMDgxZjQxZTFhY2VmNzEzNTQyNDdlYTNmL3RhYmxlcmFuZ2U6N2U1YTY3MTIwODFmNDFlMWFjZWY3MTM1NDI0N2VhM2ZfNS0xLTEtMS0zMzczNg_3217f0e8-f721-4454-945d-7ffb8c6c357e">69,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjdlNWE2NzEyMDgxZjQxZTFhY2VmNzEzNTQyNDdlYTNmL3RhYmxlcmFuZ2U6N2U1YTY3MTIwODFmNDFlMWFjZWY3MTM1NDI0N2VhM2ZfNS0zLTEtMS0zMzczNg_33bfbcf0-d3c4-4f82-82f8-9aa25c555e25">339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjdlNWE2NzEyMDgxZjQxZTFhY2VmNzEzNTQyNDdlYTNmL3RhYmxlcmFuZ2U6N2U1YTY3MTIwODFmNDFlMWFjZWY3MTM1NDI0N2VhM2ZfNS01LTEtMS0zMzczNg_09c58aed-494e-4281-a024-dbe3811bce3e">69,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56b2909098264559bde53509e6f16d96_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjljOWFjNGI3OGNjODQwNGNhYzE0ODcxZDYxNmI3OTg0L3RhYmxlcmFuZ2U6OWM5YWM0Yjc4Y2M4NDA0Y2FjMTQ4NzFkNjE2Yjc5ODRfNC0xLTEtMS0zMzczNg_8a7a4ebd-6d81-446e-b4eb-585bd7e2d14d">114,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i56b2909098264559bde53509e6f16d96_I20221231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjljOWFjNGI3OGNjODQwNGNhYzE0ODcxZDYxNmI3OTg0L3RhYmxlcmFuZ2U6OWM5YWM0Yjc4Y2M4NDA0Y2FjMTQ4NzFkNjE2Yjc5ODRfNC0zLTEtMS0zMzczNg_3f8a87df-45d4-49b1-aa82-96390a3bd2d6">877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i56b2909098264559bde53509e6f16d96_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjljOWFjNGI3OGNjODQwNGNhYzE0ODcxZDYxNmI3OTg0L3RhYmxlcmFuZ2U6OWM5YWM0Yjc4Y2M4NDA0Y2FjMTQ4NzFkNjE2Yjc5ODRfNC01LTEtMS0zMzczNg_37a50f25-839b-482f-8510-360d0a75d72c">113,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjljOWFjNGI3OGNjODQwNGNhYzE0ODcxZDYxNmI3OTg0L3RhYmxlcmFuZ2U6OWM5YWM0Yjc4Y2M4NDA0Y2FjMTQ4NzFkNjE2Yjc5ODRfNS0xLTEtMS0zMzczNg_84abe972-f127-4ead-be92-7f86b019bbe5">114,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjljOWFjNGI3OGNjODQwNGNhYzE0ODcxZDYxNmI3OTg0L3RhYmxlcmFuZ2U6OWM5YWM0Yjc4Y2M4NDA0Y2FjMTQ4NzFkNjE2Yjc5ODRfNS0zLTEtMS0zMzczNg_2461beef-8e65-41fc-bac9-44d488d69ea6">877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjljOWFjNGI3OGNjODQwNGNhYzE0ODcxZDYxNmI3OTg0L3RhYmxlcmFuZ2U6OWM5YWM0Yjc4Y2M4NDA0Y2FjMTQ4NzFkNjE2Yjc5ODRfNS01LTEtMS0zMzczNg_9f1d16b2-4dbc-416a-a060-da221d63c5b2">113,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:1pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment instruments and cash and cash equivalents are classified using Level&#160;1 inputs within the fair value hierarchy and are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Debt securities have a weighted-average maturity of <ix:nonNumeric contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RleHRyZWdpb246MjIzNmJiNmI2N2RlNDBmM2JmYmNmMDlhYmZkMDg4NWJfNDc5_66c255bd-320e-4951-bdf3-a297cbecb4d2">0.24</ix:nonNumeric> years as of March&#160;31, 2023.</span></div></ix:continuation><div id="iab75d73ad8e54df383e5480fddd6dcb5_43"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RleHRyZWdpb246N2JmOTllODE3Y2JjNDY0Yjg5ZGNiM2EwY2JmZGJkMmNfOTQ_a02d0939-b640-46b6-805e-7ec18c947090" continuedAt="i7869d30644554a55910f59b93652e335" escape="true">Accrued Expenses and Other Current Liabilities</ix:nonNumeric></span></div><ix:continuation id="i7869d30644554a55910f59b93652e335"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RleHRyZWdpb246N2JmOTllODE3Y2JjNDY0Yjg5ZGNiM2EwY2JmZGJkMmNfOTY_db9bd4de-621a-4138-ac9b-24af38e3d853" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (amounts in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development contract costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="sttk:AccruedResearchAndContractCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfMS0xLTEtMS0zMzczNg_5346ffe6-6a29-44d7-a572-785c80c413de">6,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="sttk:AccruedResearchAndContractCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfMS0zLTEtMS0zMzczNg_12c6208c-39e0-44ba-b6c3-88aee6b03f23">11,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfMy0xLTEtMS01MDMwOQ_71d3887c-fc6c-449c-b290-55616e55560f">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfMy0zLTEtMS01MDMwOQ_1098c51d-9ef3-489f-be29-f706d35cdc57">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfMi0xLTEtMS0zMzczNg_6c60ff0e-d60c-4842-879c-0f29282e0d9e">1,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfMi0zLTEtMS0zMzczNg_b5e9ae87-4087-4bcd-8041-ff3e8a2794dd">3,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfNS0xLTEtMS01MDQ1Mg_d8b9e738-486f-48e8-bdb5-9698549da6c9">1,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfNS0zLTEtMS01MDQ1Mg_d36dc6c9-29a7-4e99-8b41-a24f056d497c">1,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-3" name="sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfNC0xLTEtMS0zMzczNg_599fa443-4d4e-4096-ae18-2f37105bac08">10,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="-3" name="sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfNC0zLTEtMS0zMzczNg_73bdcfd2-daa1-40aa-add7-d27d2f460ff6">17,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iab75d73ad8e54df383e5480fddd6dcb5_46"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80Ni9mcmFnOmM3MTAxNzMyZTk5MDRhYWViNzEzMzVmMWRkYjRjZGZmL3RleHRyZWdpb246YzcxMDE3MzJlOTkwNGFhZWI3MTMzNWYxZGRiNGNkZmZfNDI0MA_5490f315-7e3f-4dfa-8dbf-2910de2e81f9" continuedAt="ia566b04e7a7540caab2a1f2dc0d805f5" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="ia566b04e7a7540caab2a1f2dc0d805f5" continuedAt="i4903f5346b0c465b8ced583224636d6a"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space, laboratory facilities, and equipment. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has operating leases. There have been no material changes in our operating leases as compared to operating leases disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i4903f5346b0c465b8ced583224636d6a" continuedAt="ib255454714c54cbe9af42600595924ea"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nighthawk Biosciences, Inc. License Agreement </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a license agreement with Nighthawk Biosciences, Inc. (&#8220;Nighthawk&#8221;), the Company is required to make payments of up to $<ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-5" name="sttk:LicenseAgreementRoyaltyPaymentsMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80Ni9mcmFnOmM3MTAxNzMyZTk5MDRhYWViNzEzMzVmMWRkYjRjZGZmL3RleHRyZWdpb246YzcxMDE3MzJlOTkwNGFhZWI3MTMzNWYxZGRiNGNkZmZfMTcwMA_019f9805-af27-4b87-ad37-2041637d55b7">20.6</ix:nonFraction>&#160;million in aggregate for the achievement of specified development, regulatory and commercial sales milestones for certain licensed products. The Company paid $<ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsForRoyalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80Ni9mcmFnOmM3MTAxNzMyZTk5MDRhYWViNzEzMzVmMWRkYjRjZGZmL3RleHRyZWdpb246YzcxMDE3MzJlOTkwNGFhZWI3MTMzNWYxZGRiNGNkZmZfMjc0ODc3OTA4MzAzOQ_65ed027d-5e12-46ba-b8a5-eb0a67177535">0.1</ix:nonFraction>&#160;million to Nighthawk in the three months ended March 31, 2023 as a milestone payment for the Company&#8217;s completion of a Phase 1 clinical trial for SL-172154.&#160;The Company is required to pay Nighthawk a percentage of upfront fees or other non-royalty payments not tied to milestone events that it receives in connection with certain sublicenses of the licensed patents.&#160;The Company is also required to pay Nighthawk a royalty on all of its worldwide net sales, those of its affiliates, and sublicenses of certain licensed patents in the low single digits. The Company has <ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="INF" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80Ni9mcmFnOmM3MTAxNzMyZTk5MDRhYWViNzEzMzVmMWRkYjRjZGZmL3RleHRyZWdpb246YzcxMDE3MzJlOTkwNGFhZWI3MTMzNWYxZGRiNGNkZmZfMjIzOA_9d0b93c4-494e-4995-b874-cd109ad41a8f">no</ix:nonFraction>t recorded a liability for the aforementioned payments given the achievement of specified development, regulatory and commercial sales milestones for certain licensed products is not probable as of the balance sheet date.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. On January 31, 2022 and February 11, 2022, putative class action lawsuits were filed in the U.S. District Court for the Eastern District of New York against us and certain of the Company&#8217;s officers and directors. The cases were consolidated on June 2, 2022, and the plaintiffs filed an amended complaint on July 1, 2022. The amended complaint cites the volatility in the Company&#8217;s common stock and alleges that the defendants made or are responsible for misleading omissions regarding the Company&#8217;s clinical trial results and the collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company, Ltd. The parties reached a settlement in principle of the plaintiffs&#8217; claims in the amount of $<ix:nonFraction unitRef="usd" contextRef="ie0fe0931d7fd474e9944465230cae621_D20221102-20221102" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80Ni9mcmFnOmM3MTAxNzMyZTk5MDRhYWViNzEzMzVmMWRkYjRjZGZmL3RleHRyZWdpb246YzcxMDE3MzJlOTkwNGFhZWI3MTMzNWYxZGRiNGNkZmZfMjc0ODc3OTA4MjY0OA_793e9a20-c2b0-4a7d-8f3c-7659a62a3e98">1.4</ix:nonFraction>&#160;million on November 2, 2022. The settlement is subject to a definitive settlement agreement, notice to stockholders and court approval. The parties filed their motion for preliminary approval of the settlement agreement with the court on December 14, 2022, and, as of May 8, 2023, that motion is pending. The Company has accrued the settlement amount in accrued expenses and other current liabilities as of March 31, 2023.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations </span></div></ix:continuation><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib255454714c54cbe9af42600595924ea">Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which the Company cannot reasonably predict future payment. The Company&#8217;s contractual obligations result primarily from obligations for various CMOs and CROs, which include potential payments that may be required under its agreements. The contracts also contain variable costs and milestones that are hard to predict, as they are based on such things as patients enrolled and clinical trial sites. The timing of payments and actual amounts paid under CMO and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Such agreements are cancellable upon written notice by the Company and, therefore, are not long-term liabilities.</ix:continuation> </span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_374"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNzQvZnJhZzphYWEwNmRmZGJlMWQ0NGQyODA4MzA4NzQzNTNkMmU3ZS90ZXh0cmVnaW9uOmFhYTA2ZGZkYmUxZDQ0ZDI4MDgzMDg3NDM1M2QyZTdlXzI3NDg3NzkwNzI2MDk_e7788f84-fbbc-46db-bc8c-967903b78a24" continuedAt="ie30523a44a2f43cebf2ef479a2ca4387" escape="true">Equity</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie30523a44a2f43cebf2ef479a2ca4387">The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNzQvZnJhZzphYWEwNmRmZGJlMWQ0NGQyODA4MzA4NzQzNTNkMmU3ZS90ZXh0cmVnaW9uOmFhYTA2ZGZkYmUxZDQ0ZDI4MDgzMDg3NDM1M2QyZTdlXzI3NDg3NzkwNzI1MDM_1dbbb9a4-33b3-42f0-b621-ef7c74f52902">300,000,000</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNzQvZnJhZzphYWEwNmRmZGJlMWQ0NGQyODA4MzA4NzQzNTNkMmU3ZS90ZXh0cmVnaW9uOmFhYTA2ZGZkYmUxZDQ0ZDI4MDgzMDg3NDM1M2QyZTdlXzI3NDg3NzkwNzI1MTY_b3be3495-8d3b-4ce3-ad57-dd4551955196">10,000,000</ix:nonFraction> shares of preferred stock, all with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNzQvZnJhZzphYWEwNmRmZGJlMWQ0NGQyODA4MzA4NzQzNTNkMmU3ZS90ZXh0cmVnaW9uOmFhYTA2ZGZkYmUxZDQ0ZDI4MDgzMDg3NDM1M2QyZTdlXzI3NDg3NzkwNzI1Mjg_b619f618-012d-42db-8a04-a30a444f9b6e"><ix:nonFraction unitRef="usdPerShare" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNzQvZnJhZzphYWEwNmRmZGJlMWQ0NGQyODA4MzA4NzQzNTNkMmU3ZS90ZXh0cmVnaW9uOmFhYTA2ZGZkYmUxZDQ0ZDI4MDgzMDg3NDM1M2QyZTdlXzI3NDg3NzkwNzI1Mjg_ea1deb87-b4e7-41ad-bdd6-8a4daf90b514">0.0001</ix:nonFraction></ix:nonFraction> per share. The holders of the Company&#8217;s common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. The Company&#8217;s common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of the Company&#8217;s common stock will receive ratably any dividends declared by the Company&#8217;s board of directors (&#8220;Board&#8221;) out of funds legally available. In the event of the Company&#8217;s liquidation, dissolution or winding-up, the holders of the Company&#8217;s common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. As of the periods presented, no common stock dividends had been declared by the Board. At March 31, 2023, <ix:nonFraction unitRef="shares" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNzQvZnJhZzphYWEwNmRmZGJlMWQ0NGQyODA4MzA4NzQzNTNkMmU3ZS90ZXh0cmVnaW9uOmFhYTA2ZGZkYmUxZDQ0ZDI4MDgzMDg3NDM1M2QyZTdlXzI3NDg3NzkwNzI1NTI_83caf03b-dc11-4346-8eb0-26760c3ffed9">none</ix:nonFraction> of the <ix:nonFraction unitRef="shares" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNzQvZnJhZzphYWEwNmRmZGJlMWQ0NGQyODA4MzA4NzQzNTNkMmU3ZS90ZXh0cmVnaW9uOmFhYTA2ZGZkYmUxZDQ0ZDI4MDgzMDg3NDM1M2QyZTdlXzM4NDgyOTA3MDA1MDc_61209e55-b65d-4d68-b288-481f2664677a">10,000,000</ix:nonFraction> shares of preferred stock were outstanding, and the Company has no present plans to issue any shares of preferred stock.</ix:continuation></span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_365"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE1OTQ_d400abba-cdce-458f-8763-1512abbedb8e" continuedAt="ife877637fb7f46d0954597bdfe7f4167" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ife877637fb7f46d0954597bdfe7f4167" continuedAt="id82cee6f4a9049af85e751fcc5914283"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) which, as of the adoption date, replaced the 2016 Stock Incentive Plan. Under the 2020 Plan, the share reserve automatically </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="id82cee6f4a9049af85e751fcc5914283" continuedAt="i84cdfae73c8e41fdb863702c525013b0"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increases on January 1st of each year beginning in 2021 and ending with a final increase on January 1, 2030 in an amount equal to <ix:nonFraction unitRef="number" contextRef="i5c388e0f89f34e2c831691fb79c15cb8_I20200930" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE1OTY_574c653f-d905-442f-a2d8-27000cca54f2">4</ix:nonFraction>% of the Company&#8217;s outstanding common shares on December 31st of the preceding calendar year. The Board may provide that there will be no increase in the share reserve for any such year or that the increase in the share reserve may be smaller than would otherwise occur. On January 1, 2023, the share reserve automatically increased by <ix:nonFraction unitRef="shares" contextRef="ifdcd40cea1904365b4a1a01161642a02_D20230101-20230101" decimals="INF" name="sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2MDA_e61adc77-6d7c-4659-b1b7-567b3f8615d9">1,695,623</ix:nonFraction> shares. As of March&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="i6fb1051978f94abc950815f2d8001c2f_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDYzNzU_f44cc9b1-05fa-476a-a52b-6613b76f0e09">3,739,124</ix:nonFraction> shares available for future grants. The 2020 Plan permits the granting of options, stock appreciation rights, restricted stock units (&#8220;RSUs&#8221;), performance stock and performance cash awards. The terms of the agreements under the 2020 Plan are determined by the Board. The Company&#8217;s awards generally vest over <ix:nonNumeric contextRef="i991dfc7ff32043179c7e3f86c543184b_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3Njg_babba7e2-6704-4e85-8573-dbf207e53bbc">four years</ix:nonNumeric> and have a term of <ix:nonNumeric contextRef="i991dfc7ff32043179c7e3f86c543184b_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3ODc_47ab6ba8-72a8-4934-bad4-29b5345c41c3">10</ix:nonNumeric> years. In 2023, the Company granted <ix:nonFraction unitRef="shares" contextRef="i991dfc7ff32043179c7e3f86c543184b_D20230101-20230331" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2MTE_e9c8905f-d33d-4399-a91f-0c023e85c5ab">165,050</ix:nonFraction> awards that vest in <ix:nonFraction unitRef="tranch" contextRef="i6fb1051978f94abc950815f2d8001c2f_I20230331" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTIwMzI_6b659843-1d23-4db6-97d3-d432c0cfab34">three</ix:nonFraction> equal tranches based on the Company achieving a certain closing share price for each tranche for <ix:nonNumeric contextRef="i991dfc7ff32043179c7e3f86c543184b_D20230101-20230331" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2NDE_5c1d3df8-0cdd-4b9a-bdaa-33ad91be2689">30</ix:nonNumeric> consecutive trading days on or before the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE4MDA_cc775207-fe02-4c9b-8e4e-2107d58e985d">four</span>th anniversary of the grant date.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (&#8220;2020 ESPP&#8221;) became effective in October 2020. A total of <ix:nonFraction unitRef="shares" contextRef="i0e6401db080843d78c401499533d1dc2_I20201014" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2NDk_6d046ce5-3904-4ab7-8444-23b6b73a9841">395,795</ix:nonFraction> shares of common stock were reserved for issuance under the 2020 ESPP. Eligible employees may purchase shares of common stock under the 2020 ESPP at <ix:nonFraction unitRef="number" contextRef="ieb1b33d499ae4e9d975505ddf2b6a145_D20201014-20201014" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2NTg_51155463-7f4a-4bbd-ac5c-8c70d239ef0a">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock as of the first or the last day of each offering period. Employees are limited to contributing <ix:nonFraction unitRef="number" contextRef="i0e6401db080843d78c401499533d1dc2_I20201014" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2NzY_048d311a-c2f4-4eed-a3dd-52eb054b1d24">15</ix:nonFraction>% of the employee&#8217;s eligible compensation and may not purchase more than $<ix:nonFraction unitRef="usd" contextRef="ieb1b33d499ae4e9d975505ddf2b6a145_D20201014-20201014" decimals="-3" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2NjM_fe983e5e-19d7-4217-a076-48f10f38a862">25,000</ix:nonFraction> of stock during any calendar year or more than <ix:nonFraction unitRef="shares" contextRef="ieb1b33d499ae4e9d975505ddf2b6a145_D20201014-20201014" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2ODE_77c9c76e-4674-4fdb-bd7a-de20ebb256c3">600</ix:nonFraction> shares during any one purchase period. The 2020 ESPP share reserve automatically increases on January 1st of each calendar year, for <ix:nonNumeric contextRef="i76febd49246745a9a7bb5f9df44806a6_D20210101-20210101" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3NDg_4ce2c134-8283-4fc3-bc1e-aa234a385957">ten years</ix:nonNumeric>, commencing on January 1, 2021, in an amount equal to <ix:nonFraction unitRef="number" contextRef="i0e6401db080843d78c401499533d1dc2_I20201014" decimals="INF" name="sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2NzI_08f5d8a1-9d26-44db-94b4-792257441005">1</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Board may act prior to January 1st of a given year to provide that there will be no January 1st increase of the share reserve for such year or that the increase in the share reserve for such year will be a smaller number of shares of common stock than would otherwise occur pursuant to the preceding sentence. On January 1, 2023, the share reserve increased by <ix:nonFraction unitRef="shares" contextRef="i9a2cffc815b14f15ba52b9eacfa7e4a7_D20230101-20230101" decimals="INF" name="sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2ODY_16364e67-5623-4452-b366-93d112331654">423,905</ix:nonFraction> shares. As of March&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="i9cbaef79f5984155995efe7d1dfec7e6_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDcyNjY_1410bebe-4955-4ef6-a018-6f4e1b56a22e">1,216,723</ix:nonFraction> shares available for future grants. During the three months ended March 31, 2023 and 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="ic07dbdc8b50c460b91220dd5d8950518_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY2ODY_fafd05b7-4151-4f24-a1df-fcdef1e2a1f0">11,171</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9f423208f22d42beb3d0027d59f5a13a_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3NDI_86698d15-4db0-474b-bd63-cd3765f8c885">5,227</ix:nonFraction> shares of common stock for aggregate cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic07dbdc8b50c460b91220dd5d8950518_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2OTU_e0a7e1d4-dae8-43c1-bf6a-57dba8a1cf49">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9f423208f22d42beb3d0027d59f5a13a_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3MDk_c91f9956-db07-4bc8-8a2f-9f853c919f25">0.1</ix:nonFraction>&#160;million, respectively.</span></div><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3MjI_dd0df584-106f-43c8-bd0a-e26f89c8d22b" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying unaudited interim condensed statements of operations and comprehensive loss (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.269%"><tr><td style="width:1.0%"></td><td style="width:70.205%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.648%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i553413b499654651890bbd3c2a30bad5_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZGZlODhkODhkOWQ0YjM0ODMyNGViNjgzODlhMzAxMy90YWJsZXJhbmdlOjdkZmU4OGQ4OGQ5ZDRiMzQ4MzI0ZWI2ODM4OWEzMDEzXzItMS0xLTEtNTA5MTU_aea4c0b2-45d9-41df-9ec6-120b6227cba6">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i0696e705fa644b0eb1e32b0abcf24c9a_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZGZlODhkODhkOWQ0YjM0ODMyNGViNjgzODlhMzAxMy90YWJsZXJhbmdlOjdkZmU4OGQ4OGQ5ZDRiMzQ4MzI0ZWI2ODM4OWEzMDEzXzItMy0xLTEtNTA5MTU_41858434-2c50-4b32-8909-c0a499463718">827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i26ed59b30fb3417b8f0372f4e8d87f2a_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZGZlODhkODhkOWQ0YjM0ODMyNGViNjgzODlhMzAxMy90YWJsZXJhbmdlOjdkZmU4OGQ4OGQ5ZDRiMzQ4MzI0ZWI2ODM4OWEzMDEzXzMtMS0xLTEtNTA5MTU_974b48fe-3a68-4103-9530-2b53cf834baa">869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i24d5ba980a4546dd9c94c7d3d055e5dc_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZGZlODhkODhkOWQ0YjM0ODMyNGViNjgzODlhMzAxMy90YWJsZXJhbmdlOjdkZmU4OGQ4OGQ5ZDRiMzQ4MzI0ZWI2ODM4OWEzMDEzXzMtMy0xLTEtNTA5MTU_164e55ab-9a10-4dd4-8cb7-4485dae86b7c">686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZGZlODhkODhkOWQ0YjM0ODMyNGViNjgzODlhMzAxMy90YWJsZXJhbmdlOjdkZmU4OGQ4OGQ5ZDRiMzQ4MzI0ZWI2ODM4OWEzMDEzXzQtMS0xLTEtNTA5MTU_dd321e00-3c04-4ebb-b27a-0e3dd6e7845e">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZGZlODhkODhkOWQ0YjM0ODMyNGViNjgzODlhMzAxMy90YWJsZXJhbmdlOjdkZmU4OGQ4OGQ5ZDRiMzQ4MzI0ZWI2ODM4OWEzMDEzXzQtMy0xLTEtNTA5MTU_1510930e-8b55-42a0-acc4-ca498937a897">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3MjM_e624f59b-e267-459e-9ee1-9434922ba21c" escape="true"><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the 2020 Plan:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:48.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.886%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.023%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining&#160;Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzEtMS0xLTEtNTA5MTU_d45c03f1-7e8d-4387-bc20-f2f438f24d7a">4,209,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzEtMy0xLTEtNTA5MTU_0d1dee9c-762f-4cf8-91a4-e865cca21b6a">8.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2b0c733727b44be5a7356b37de831391_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzEtNS0xLTEtNTA5MTU_ad76bb28-90fe-4eba-b368-4a4cc3cb974f">8.07</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzItMS0xLTEtNTA5MTU_a77478c8-e2d3-425b-9171-75be8cc35878">1,181,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzItMy0xLTEtNTA5MTU_38f9f7f1-fa9b-4e1a-bf02-8eb3fc4817f6">3.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzMtMS0xLTEtNTA5MTU_cdf2e14d-034a-4aef-8cff-51e8f00796d7">717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzMtMy0xLTEtNTA5MTU_689a6faa-fe67-44d3-9786-76a601d22ee9">2.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzQtMS0xLTEtNTA5MTU_d65dbd9a-3e7b-4559-b42e-2fb296230aae">128,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzQtMy0xLTEtNTA5MTU_4c52f847-fa4a-4659-8312-075bee605354">7.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzUtMS0xLTEtNTA5MTU_fd562a4a-9236-49bd-89e7-4a911eedee8f">5,261,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzUtMy0xLTEtNTA5MTU_5a4e14c8-a7ec-445c-8c82-8c13d0f3fdfc">7.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzUtNS0xLTEtNTA5MTU_c93b6554-ba43-44a9-844a-7efd14b76bb9">8.07</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzYtMS0xLTEtNTA5MTU_3de45eac-fd6b-45bd-8995-076862c5a042">5,174,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzYtMy0xLTEtNTA5MTU_82f440d7-fb32-41f6-8a3e-528a9e6c283b">7.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzYtNS0xLTEtNTA5MTU_f8441e3c-212b-43ff-bf03-1637028f0f51">8.05</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at the end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzctMS0xLTEtNTA5MTU_2cb08b35-58d3-422b-b015-540e051cb9e1">2,122,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzctMy0xLTEtNTA5MTU_2343a1cc-7b94-4328-9d0f-5cecb6c1b9ee">8.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzctNS0xLTEtNTA5MTU_61c3b53f-25c5-4720-9b79-8731d5227c6b">6.55</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the three months ended March 31, 2023 and 2022 had weighted-average grant-date fair values of $<ix:nonFraction unitRef="usdPerShare" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY4MDU_c407f881-c575-4acf-b987-1492a0e5c443">2.46</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3MjU_0bd588f1-60f8-4221-96b8-fe851f9b50b1">5.13</ix:nonFraction> per share, respectively. As of March 31, 2023, the unrecognized compensation cost for options issued was $<ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY4MzI_af14a00e-fce8-4168-b3e4-7d331f3c77e5">14.1</ix:nonFraction> million and will be recognized over an estimated weighted-average amortization period of <ix:nonNumeric contextRef="i428ae4dc142344e4867b47e344b894fe_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY4NDc_7f3f88ee-a3b1-48e1-a7b5-b5243aef7ce1">2.49</ix:nonNumeric> years. The total intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i84cdfae73c8e41fdb863702c525013b0" continuedAt="i54e58223da9b40e380d5f916991a5741"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $<ix:nonFraction unitRef="usd" contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY4OTA_4f4709e9-d786-4298-9c55-0cb8c342fdc3">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY4OTU_4bd039a7-dd58-44e1-8be9-70999632e393">0.1</ix:nonFraction> million, respectively. The aggregate intrinsic value of options outstanding and exercisable as of March 31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY5MjQ_41f1c547-c261-47bf-83c2-49263bfc0fa8"><ix:nonFraction unitRef="usd" contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY5MjQ_87468520-b504-4628-8b78-c662b09b2533">0.2</ix:nonFraction></ix:nonFraction> million.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3MzE_4d2008ca-8b7c-4ab6-bf7e-40011dc9d405" escape="true"><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes employee RSU activity for the three months ended March 31, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.455%"><tr><td style="width:1.0%"></td><td style="width:67.780%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested RSUs as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="iaf0a0042588b4fd2ac8a83479b491708_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzEtMS0xLTEtNTExOTQ_93e5ed28-8383-402c-a597-e2960dcbafe7">309,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="iaf0a0042588b4fd2ac8a83479b491708_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzEtMy0xLTEtNTEyMDE_cafedfbe-2507-41c7-a9a0-a94705524998">7.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzItMS0xLTEtNTExOTQ_b951dfd9-aab1-40d3-9ea0-bfe482cd67c0">445,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzItMy0xLTEtNTEyMDE_deebc632-9162-4c09-a94d-ea939303d6fa">3.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzMtMS0xLTEtNTExOTQ_cb3464ff-2562-4123-89cb-bd38b9c8c3f6">73,937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzMtMy0xLTEtNTEyMDE_ba5cdf02-8b4e-46af-9df6-b8ed6f9ccbba">7.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzQtMS0xLTEtNTExOTQ_2bf3bf50-0552-443e-a95f-65594843f4cb">27,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzQtMy0xLTEtNTEyMDE_44c66440-30f4-4f2f-a118-9204de9e7080">4.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i4d4b4c0ce8c04ddbaf55caff9825c696_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzUtMS0xLTEtNTE2NDg_98dcc731-175b-4b84-b974-b805e0942315">652,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4d4b4c0ce8c04ddbaf55caff9825c696_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzUtMy0xLTEtNTEyMDc_60205d22-f300-462a-8f84-a400f24223b0">4.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY5Nzc_720b7f66-8c02-4e41-b929-e5d41927113a">0.2</ix:nonFraction> million of stock-based compensation related to RSUs as of March 31, 2023. As of March 31, 2023, the unrecognized compensation cost for RSUs issued was $<ix:nonFraction unitRef="usd" contextRef="i4d4b4c0ce8c04ddbaf55caff9825c696_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDcwMjY_3a4780f4-83c0-44ab-9c9c-03738b82a8f3">3.1</ix:nonFraction> million and will be recognized over an estimated weighted-average amortization period of <ix:nonNumeric contextRef="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDcwMzk_3d18bc6d-b506-4d90-b4d1-938b4766239e">3.47</ix:nonNumeric> years. The fair values of RSUs are based on the fair value of the Company&#8217;s common stock on the date of the grant.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Stock Options and Shares Issued</span></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation by measuring and recognizing as compensation expense the fair value of all share-based payment awards made to employees, including employee stock options and restricted stock awards. The Company uses the Black-Scholes option pricing model to estimate the fair value of employee stock options that only have service or performance conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The inputs to both pricing models require a number of management estimates such as the expected term, volatility, risk-free interest rate and dividend yield. The fair value of stock options was determined using the methods and assumptions discussed below.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected term of employee stock options with service-based vesting is determined using the &#8220;simplified&#8221; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#8217;s lack of sufficient historical data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected stock price volatility assumption is based on the historical volatilities of the common stock of a peer group of publicly traded companies as well as the historical volatility of the Company&#8217;s common stock since the Company began trading subsequent to the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in October 2020 over the period corresponding to the expected life as of the grant date. The historical volatility data was computed using the daily closing prices during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of the Company&#8217;s stock price becomes available, or until circumstances change, such that the identified entities are no longer comparable companies. In the latter case, other suitable, similar entities whose share prices are publicly available would be utilized in the calculation.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected dividend yield is <ix:nonFraction unitRef="number" contextRef="i428ae4dc142344e4867b47e344b894fe_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3MzM_599cb1d3-6c66-4569-8b3b-84e376e9a091">0</ix:nonFraction>% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay dividends on its common stock. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Prior to the Company&#8217;s IPO, the Board periodically estimated the fair value of the Company&#8217;s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. Subsequent to the Company&#8217;s IPO, options are issued with a strike price no less than the market price on date of grant.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i54e58223da9b40e380d5f916991a5741"><ix:nonNumeric contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3NDA_b843a776-b9eb-4528-b2f8-638c6a64a82e" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company&#8217;s 2020 Plan were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"></td><td style="width:68.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia3286ad000a74fb2b534f75b6f23f669_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NGQ1ZjU5OWJkODM0MGI5YTQwMThiYzc0MWM3MWVmYS90YWJsZXJhbmdlOjY0ZDVmNTk5YmQ4MzQwYjlhNDAxOGJjNzQxYzcxZWZhXzMtMS0xLTEtNTEzMDQ_f0b604bd-0f71-4980-9927-9ccb5ada0ab4">6.08</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i8c88b5d9b1e14fc3b353ec2bed09c97d_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NGQ1ZjU5OWJkODM0MGI5YTQwMThiYzc0MWM3MWVmYS90YWJsZXJhbmdlOjY0ZDVmNTk5YmQ4MzQwYjlhNDAxOGJjNzQxYzcxZWZhXzMtMy0xLTEtNTEzMTE_a2a02fcc-0bce-4918-b6dc-deba3de06aa9">6.08</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia3286ad000a74fb2b534f75b6f23f669_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NGQ1ZjU5OWJkODM0MGI5YTQwMThiYzc0MWM3MWVmYS90YWJsZXJhbmdlOjY0ZDVmNTk5YmQ4MzQwYjlhNDAxOGJjNzQxYzcxZWZhXzQtMS0xLTEtNTEzMDQ_329bdd4f-6762-4e18-9462-a5e326ec34dd">84.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8c88b5d9b1e14fc3b353ec2bed09c97d_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NGQ1ZjU5OWJkODM0MGI5YTQwMThiYzc0MWM3MWVmYS90YWJsZXJhbmdlOjY0ZDVmNTk5YmQ4MzQwYjlhNDAxOGJjNzQxYzcxZWZhXzQtMy0xLTEtNTEzMTE_296e1e77-126f-47e1-8125-f97e976c0c9f">81.9</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia3286ad000a74fb2b534f75b6f23f669_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NGQ1ZjU5OWJkODM0MGI5YTQwMThiYzc0MWM3MWVmYS90YWJsZXJhbmdlOjY0ZDVmNTk5YmQ4MzQwYjlhNDAxOGJjNzQxYzcxZWZhXzUtMS0xLTEtNTEzMDQ_bdb27af3-b222-45a3-9e4c-60bdb0a0bc44">3.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8c88b5d9b1e14fc3b353ec2bed09c97d_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NGQ1ZjU5OWJkODM0MGI5YTQwMThiYzc0MWM3MWVmYS90YWJsZXJhbmdlOjY0ZDVmNTk5YmQ4MzQwYjlhNDAxOGJjNzQxYzcxZWZhXzUtMy0xLTEtNTEzMTE_82e9dc0a-6937-4348-a1f6-d2dbc9e20ee0">1.6</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia3286ad000a74fb2b534f75b6f23f669_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NGQ1ZjU5OWJkODM0MGI5YTQwMThiYzc0MWM3MWVmYS90YWJsZXJhbmdlOjY0ZDVmNTk5YmQ4MzQwYjlhNDAxOGJjNzQxYzcxZWZhXzYtMS0xLTEtNTEzMDQ_bd0a029b-0caf-4a19-81b0-b1f7c1b0459f">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i8c88b5d9b1e14fc3b353ec2bed09c97d_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NGQ1ZjU5OWJkODM0MGI5YTQwMThiYzc0MWM3MWVmYS90YWJsZXJhbmdlOjY0ZDVmNTk5YmQ4MzQwYjlhNDAxOGJjNzQxYzcxZWZhXzYtMy0xLTEtNTEzMTE_602199d4-15ad-4948-880b-0003b819e055">&#8212;</ix:nonFraction></span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Monte Carlo option pricing model granted under the Company&#8217;s 2020 Plan were estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"></td><td style="width:68.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie3ea58e597ec4bc9b179b6cbe88d9b32_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTphY2I3MWE5M2U3YTQ0M2VmYjk4NmIxYWQ4N2U1MzMwOC90YWJsZXJhbmdlOmFjYjcxYTkzZTdhNDQzZWZiOTg2YjFhZDg3ZTUzMzA4XzMtMS0xLTEtNTE2NDA_eb2ddc12-5864-4c93-9c7a-809e97fbb9c6">4.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="iafe592e811e24849a2a391b482b2fa73_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTphY2I3MWE5M2U3YTQ0M2VmYjk4NmIxYWQ4N2U1MzMwOC90YWJsZXJhbmdlOmFjYjcxYTkzZTdhNDQzZWZiOTg2YjFhZDg3ZTUzMzA4XzMtMy0xLTEtNTE2NDM_80a50385-374b-4d00-a5f5-bc71ad159af3">4.00</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie3ea58e597ec4bc9b179b6cbe88d9b32_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTphY2I3MWE5M2U3YTQ0M2VmYjk4NmIxYWQ4N2U1MzMwOC90YWJsZXJhbmdlOmFjYjcxYTkzZTdhNDQzZWZiOTg2YjFhZDg3ZTUzMzA4XzQtMS0xLTEtNTE2NDA_0d36b5c2-7e93-4ac2-8535-aeb97f3252ee">80.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="iafe592e811e24849a2a391b482b2fa73_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTphY2I3MWE5M2U3YTQ0M2VmYjk4NmIxYWQ4N2U1MzMwOC90YWJsZXJhbmdlOmFjYjcxYTkzZTdhNDQzZWZiOTg2YjFhZDg3ZTUzMzA4XzQtMy0xLTEtNTE2NDM_bcc9e5e4-70e8-4be5-9f66-1da47d139c22">80.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie3ea58e597ec4bc9b179b6cbe88d9b32_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTphY2I3MWE5M2U3YTQ0M2VmYjk4NmIxYWQ4N2U1MzMwOC90YWJsZXJhbmdlOmFjYjcxYTkzZTdhNDQzZWZiOTg2YjFhZDg3ZTUzMzA4XzUtMS0xLTEtNTE2NDA_7e17376e-f306-4080-8f86-09f082ae1925">3.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="iafe592e811e24849a2a391b482b2fa73_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTphY2I3MWE5M2U3YTQ0M2VmYjk4NmIxYWQ4N2U1MzMwOC90YWJsZXJhbmdlOmFjYjcxYTkzZTdhNDQzZWZiOTg2YjFhZDg3ZTUzMzA4XzUtMy0xLTEtNTE2NDM_f73c351a-575e-4d9a-9e64-099a989c1058">1.4</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie3ea58e597ec4bc9b179b6cbe88d9b32_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTphY2I3MWE5M2U3YTQ0M2VmYjk4NmIxYWQ4N2U1MzMwOC90YWJsZXJhbmdlOmFjYjcxYTkzZTdhNDQzZWZiOTg2YjFhZDg3ZTUzMzA4XzYtMS0xLTEtNTE2NDA_be3df753-653b-48f7-98bc-7cc8970a59ea">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="iafe592e811e24849a2a391b482b2fa73_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTphY2I3MWE5M2U3YTQ0M2VmYjk4NmIxYWQ4N2U1MzMwOC90YWJsZXJhbmdlOmFjYjcxYTkzZTdhNDQzZWZiOTg2YjFhZDg3ZTUzMzA4XzYtMy0xLTEtNTE2NDM_b8a09ad0-6e67-4161-bad8-603560091dd5">&#8212;</ix:nonFraction></span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company&#8217;s 2020 ESPP were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"></td><td style="width:68.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 ESPP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4634c39261264b90ac1a96707bd46a0b_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NTg1M2I0NGM4ODg0ZjQ5ODI3Nzc4ZjM4NzJhZGE3MC90YWJsZXJhbmdlOjY1ODUzYjQ0Yzg4ODRmNDk4Mjc3NzhmMzg3MmFkYTcwXzMtMS0xLTEtNTEzMTg_02d8dacc-4b28-4d72-a2a6-acebf2c797ec">0.49</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i58eae8a702644e09b9d6eafabc8fd6fd_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NTg1M2I0NGM4ODg0ZjQ5ODI3Nzc4ZjM4NzJhZGE3MC90YWJsZXJhbmdlOjY1ODUzYjQ0Yzg4ODRmNDk4Mjc3NzhmMzg3MmFkYTcwXzMtMy0xLTEtNTEzMjU_19b569fd-4618-4424-b470-f4e494fc8c9f">0.49</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i4634c39261264b90ac1a96707bd46a0b_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NTg1M2I0NGM4ODg0ZjQ5ODI3Nzc4ZjM4NzJhZGE3MC90YWJsZXJhbmdlOjY1ODUzYjQ0Yzg4ODRmNDk4Mjc3NzhmMzg3MmFkYTcwXzQtMS0xLTEtNTEzMTg_95bfbe35-4f98-4315-8da7-a6000459d780">84.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i58eae8a702644e09b9d6eafabc8fd6fd_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NTg1M2I0NGM4ODg0ZjQ5ODI3Nzc4ZjM4NzJhZGE3MC90YWJsZXJhbmdlOjY1ODUzYjQ0Yzg4ODRmNDk4Mjc3NzhmMzg3MmFkYTcwXzQtMy0xLTEtNTEzMjU_cc630217-5967-4115-95ac-a5e369363eda">81.8</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i4634c39261264b90ac1a96707bd46a0b_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NTg1M2I0NGM4ODg0ZjQ5ODI3Nzc4ZjM4NzJhZGE3MC90YWJsZXJhbmdlOjY1ODUzYjQ0Yzg4ODRmNDk4Mjc3NzhmMzg3MmFkYTcwXzUtMS0xLTEtNTEzMTg_782aef07-7d96-471f-93e6-75bc01bedde7">3.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i58eae8a702644e09b9d6eafabc8fd6fd_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NTg1M2I0NGM4ODg0ZjQ5ODI3Nzc4ZjM4NzJhZGE3MC90YWJsZXJhbmdlOjY1ODUzYjQ0Yzg4ODRmNDk4Mjc3NzhmMzg3MmFkYTcwXzUtMy0xLTEtNTEzMjU_ac44d9fd-8843-4a75-a1a8-638e598a54a3">2.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i4634c39261264b90ac1a96707bd46a0b_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NTg1M2I0NGM4ODg0ZjQ5ODI3Nzc4ZjM4NzJhZGE3MC90YWJsZXJhbmdlOjY1ODUzYjQ0Yzg4ODRmNDk4Mjc3NzhmMzg3MmFkYTcwXzYtMS0xLTEtNTEzMTg_3b4c2f49-5d89-45f7-a02f-a1d3bbf4d7e0">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i58eae8a702644e09b9d6eafabc8fd6fd_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NTg1M2I0NGM4ODg0ZjQ5ODI3Nzc4ZjM4NzJhZGE3MC90YWJsZXJhbmdlOjY1ODUzYjQ0Yzg4ODRmNDk4Mjc3NzhmMzg3MmFkYTcwXzYtMy0xLTEtNTEzMjU_a73b1a6d-a488-4642-a123-64f7ee1df906">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed financial statements and related notes appearing in this Quarterly Report on Form 10-Q, as well as the audited financial statements, notes and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2022. This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the &#8220;Risk Factors&#8221; section of our Annual Report on Form 10-K. You should carefully read the &#8220;Cautionary Note About Forward-Looking Statements&#8221; of this Quarterly Report on Form 10-Q and the &#8220;Risk Factors&#8221; section of our Annual Report on Form 10-K to gain an understanding of the important factors that could cause actual results to differ materially from the results described below. </span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_58"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are an innovative clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. We have created a novel approach to immune modulation by designing biologics with structural characteristics that may not be achievable by existing therapeutic modalities, including monoclonal or bispecific antibodies. Compounds derived from our proprietary Agonist Redirected Checkpoint, or ARC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic.</span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRP&#945; macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. Coupling CD40 activation with CD47 inhibition differentiates SL-172154 from all other clinical-stage CD47/SIRP&#945; inhibitors in development, and in our published preclinical studies, SL-172154 resulted in superior antitumor immunity as compared to certain CD47/SIRP&#945; inhibitors. We are pursuing a broad clinical development strategy in both solid and hematologic tumors, with multiple ongoing clinical trials. SL-172154 is in an ongoing Phase 1 clinical trial for the treatment of patients with ovarian cancer. W</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e are also evaluating SL-172154 in an ongoing Phase 1 clinical trial for the treatment of patients with certa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in hematologic malignancies, including acute myeloid leukemia, or AML, and higher-risk myelodysplastic syndromes, or HR-MDS. We believe our clinical development plan may provide both first-in-class and best-in-class development opportunities for SL-172154.</span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that data shared to date in human cancer patients have demonstrated that the unique protein engineering and physical properties of the ARC platform have led to a differentiated profile in terms of safety and on-target immune activation, demonstrated by unique pharmacodynamic findings, as compared to monoclonal or bispecific antibodies. </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our clinical-stage ARC product candidate, we possess a deep pipeline of potential product candidates in preclinical development. As an example, SL-9258, an ARC compound in preclinical development, is designed to inhibit the TIGIT/PVR checkpoint interaction while simultaneously activating HVEM and LT&#946; costimulatory receptors. </span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our expertise in dual-sided fusion proteins has led to the development of a second novel platform technology. We call this our gamma delta T cell engager, or GADLEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, platform. The most advanced compounds from this platform are a CD20-directed GADLEN and a B7-H3-directed GADLEN.</span></div><div style="margin-top:6pt;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Longer-term, we are pursuing additional disease areas, including autoimmune diseases, where our dual-sided fusion protein platforms may provide advantages over current treatment modalities.</span></div><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview of Operations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2016, we have devoted substantially all of our resources to conducting research and development activities, including undertaking nonclinical studies of our product candidates, conducting clinical trials of our most advanced product candidates, manufacturing our product candidates, developing and perfecting our intellectual property rights, organizing and staffing our company, business planning and raising capital. We do not have any products approved for sale, and we have not generated any revenue from product sales. We have </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">funded our operations as of the filing date of this Quarterly Report on Form 10-Q through the net proceeds from our initial public offering, or IPO, of approximately $213.5 million, the sale of redeemable convertible preferred stock for approximately $152.9&#160;million, the issuance of convertible notes for approximately $10.5&#160;million and payments received pursuant to our collaboration agreements for approximately $82.7&#160;million. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, our net loss was $20.7&#160;million and $24.5&#160;million, respectively. We have not been profitable since inception, and as of March&#160;31, 2023, we had an accumulated deficit of $239.7&#160;million and $135.5&#160;million in cash and cash equivalents and investments. We expect to continue to incur significant expenses and operating losses in the near term in connection with our ongoing activities, as we: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">continue to advance the nonclinical and clinical development of our clinical-stage product candidate, SL-172154; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">initiate nonclinical studies and clinical trials for additional product candidates that we may identify in the future; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">manufacture sufficient quantities of bulk drug substance and drug product to support our ongoing and planned nonclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">continue our process development efforts for our current and future product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">maintain our operational, financial, and management systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">retain key personnel and infrastructure to support our clinical development, research and manufacturing efforts; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">utilize our in-house process development and manufacturing capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">continue to develop, perfect, and defend our intellectual property portfolio; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">incur additional legal, accounting, or other expenses in operating our business, including the additional costs associated with operating as a public company and expenses incurred in connection with ongoing and future litigation, if any.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate significant product revenue unless and until we successfully complete development and obtain regulatory and marketing approval of, and begin to sell, one or more of our product candidates, if ever, which we expect will take several years. We expect to spend a significant amount in development and marketing costs prior to such time. We may never succeed in achieving regulatory and marketing approval for our product candidates. We may obtain unexpected results from our nonclinical studies and clinical trials. We may elect to discontinue, delay, or modify nonclinical studies and clinical trials of our product candidates. We may be adversely affected by inflationary pressures and the macroeconomic environment, which are beyond our control. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. Accordingly, until such time as we can generate significant product revenue, if ever, we expect to continue to seek private or public equity and debt financing, and/or additional collaborations with third-parties, to meet our capital requirements. There can be no assurance that such funding may be available to us on acceptable terms, or at all, or that we will be able to commercialize our product candidates. In addition, we may not be profitable even if we commercialize any of our product candidates.</span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_61"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Global Economic Considerations </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine and other political tensions, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on our future operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of our Results of Operation </span></div><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale, and we have not generated any revenue from commercial product sales. Our total revenue to date has been generated from our collaboration and research agreements with various third parties, including a clinical trial collaboration agreement with ImmunoGen, Inc., or ImmunoGen, under which we expect to recognize up to $2.0 million of revenue, beginning in 2023 and continuing into or through 2024.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to explore other potential collaborations and expect that collaboration revenue we may generate, if any, will fluctuate from period to period.</span></div><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expense </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses consist primarily of costs incurred in connection with the discovery and development of our current and potential future product candidates. These expenses include: </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expenses incurred to conduct our nonclinical studies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">costs of manufacturing nonclinical study and clinical trial materials, including the costs of raw materials required for manufacturing; </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">process development activities to optimize manufacturing processes;</span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">employee-related expenses, including salaries, benefits, and stock-based compensation; </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">laboratory materials and supplies used to support our research activities;</span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">fees paid to third parties who assist with research and development activities; </span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">expenses relating to regulatory activities, including filing fees paid to regulatory agencies; and</span></div><div style="margin-top:6pt;padding-left:24.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">allocated expenses for facility-related costs.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our research and development expenses by product candidate: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SL-172154</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other pipeline compounds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal costs, including personnel related benefits, facilities and depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,667&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,187&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials, including increased demand for clinical trial material. We expect to incur significant research and development expenses throughout 2023. While it is difficult for us to predict with certainty, we expect increasing year-over-year operating expense over the next several years in the event that we conduct additional nonclinical studies and clinical trials (beyond our currently planned clinical trials), including later-stage clinical trials, for our current and future product candidates, pursue regulatory approval of our product candidates, or advance our preclinical pipeline.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of conducting the necessary nonclinical and clinical research to obtain regulatory approval is costly and time consuming. The actual probability of success for our product candidates may be affected by a variety of factors including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the safety and efficacy of our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">early clinical data for our product candidates; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">investment in our clinical programs; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">competition; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">manufacturing capability; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">commercial viability. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may never succeed in achieving regulatory approval for any of our product candidates due to the uncertainties discussed above. We are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates, if ever. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense consists primarily of personnel expenses, including salaries, benefits, and stock-based compensation expense, for employees and consultants in executive, finance, accounting, legal, information technology, business development and human resource functions. General and administrative expense also includes corporate facility costs, including rent, utilities, depreciation, and maintenance, not otherwise included in research and development expense, as well as legal fees related to intellectual property, corporate, and litigation matters and fees for accounting and tax services. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expense may increase in the future to support our ongoing research and development activities and as a result of the costs of operating as a public company. These increases may include increased costs related to the retention of personnel and fees paid to outside consultants, lawyers, and accountants, among other expenses. Additionally, we anticipate that we will continue to incur significant costs associated with being a public company, including expenses related to services associated with maintaining compliance with the requirements of Nasdaq and the Securities and Exchange Commission, or SEC, insurance, and investor relations costs. If any of our current or future product candidates advances to later-stage clinical development or obtains regulatory approval, we expect that we would incur significantly increased expenses associated with building the appropriate general and administrative support for our increased research and development activities, or building a sales and marketing team, respectively.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income consists of interest earned on our cash, cash equivalents and investments, which consists of amounts held in a money market fund and at various times in government obligations as well as investment fees and realized gain or losses on investments (if any).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have not recorded any income tax benefits for the net operating losses, or NOLs, we have incurred or for our research and development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our NOLs and tax credits will not be realized. Our NOLs and tax credit carryforwards will begin to expire in 2024. We have recorded a full valuation allowance against our deferred tax assets at each balance sheet date.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March 31, 2023 and 2022</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our results of operations for the three months ended March&#160;31, 2023 and 2022. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.993%"><tr><td style="width:1.0%"></td><td style="width:46.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.923%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Dollar</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,520)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21,661)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,166)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">358.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20,724)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,528)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,804&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:1pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue increased by $0.1&#160;million, or 100.0%, to $0.1&#160;million for the three months ended March&#160;31, 2023 from none&#160;for the three months ended March&#160;31, 2022. The increase in revenue was attributable to an increase in clinical activity associated with our clinical trial collaboration agreement with ImmunoGen, under which we expect to recognize up to $2.0 million of revenue through 2024.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses decreased by $2.5&#160;million, or (13.1)%, to $16.7&#160;million for the three months ended March&#160;31, 2023 from $19.2&#160;million for the three months ended March&#160;31, 2022. The decrease in research and development cost was primarily a result of a decrease in the good manufacturing practice manufacture of clinical trial material of $7.0 million offset by increases in costs associated with the conduct of clinical trials for SL-172154 of $1.6 million, employee compensation and benefits of $1.0 million, facility and depreciation costs related to the 2022 expansion of our in-house manufacturing and development capabilities of $1.0 million and research and development costs related to other pipeline candidates of $0.8 million.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses remained relatively unchanged for the three months ended March&#160;31, 2023 as compared to the three months ended March&#160;31, 2022.</span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_73"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, our primary sources of liquidity have been generated by sales of our preferred stock and common stock, including our IPO, and through our collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company, Ltd., or Takeda.</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had an accumulated deficit of $239.7&#160;million and $135.5&#160;million of cash and cash equivalents and investments. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we entered into a sales agreement, or the Sales Agreement, with SVB Securities LLC, or the Sales Agent, pursuant to which we may offer and sell up to $75.0 million of shares of our common stock from time to time in the ATM Facility. The Sales Agent is generally entitled to compensation at a commission equal to 3.0% of the aggregate gross sales price per share sold under the Sales Agreement. As of March 31, 2023, there were no sales pursuant to the ATM Facility.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Resources and Funding Requirements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash and cash equivalents and investments are to fund our operations, which consist primarily of research and development expenditures related to our programs, product development costs, research expenses, administrative support, capital expenditures related to bringing in-house certain process development and manufacturing capabilities and working capital requirements. We anticipate incurring additional net losses and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">negative cash flows from operations in the near future until such time, if ever, that we can generate significant sales of our product candidates currently in development. Our future funding requirements will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the scope, timing, progress and results of discovery, nonclinical development, laboratory testing, and clinical trials for our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs of process development and scale up of a commercially ready manufacturing process to support registrational clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs of manufacturing our product candidates for clinical trials and in preparation for marketing approval and commercialization;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the extent to which we enter into collaborations or other arrangements with additional third parties in order to further develop our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending other intellectual property-related claims; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs and fees associated with the discovery, acquisition or in-license of additional product candidates or technologies; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">the costs of future commercialization activities, if any, including establishing sales, marketing, manufacturing, distribution and storage capabilities, for any of our product candidates for which we receive marketing approval; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until we obtain regulatory approval to market our product candidates, if ever, we cannot generate revenues from sales of our products. Even if we are able to sell our products, we may not generate a sufficient amount of product revenues to finance our cash requirements. Accordingly, it will be necessary for us to seek to raise additional capital through equity offerings and/or debt financings or from other potential sources of liquidity, which may include new collaborations, licensing or other commercial agreements for one or more of our development programs or patent portfolios. There can be no assurance that such funding may be available to us on acceptable terms, or at all. The issuance of equity securities may result in dilution to stockholders and the issuance of debt securities may have rights, preferences and privileges senior to those of our common stock and the terms of any such debt securities could impose significant restrictions on our operations. The failure to raise funds as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies. Additionally, if additional funding is not secured when required, we may need to delay or curtail our operations until such funding is received, which would have a material and adverse impact on our business prospects and results of operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash and cash equivalents and investments as of March&#160;31, 2023 are sufficient to fund projected operations through year-end 2024.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the periods indicated: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.561%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,461)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,277)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,664&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(41,525)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Operating Activities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, net cash used in operating activities was $26.5&#160;million and primarily reflected our net loss of $20.7&#160;million and a $8.3&#160;million net change in our operating assets and liabilities, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">offset by noncash charges of $1.7&#160;million in stock-based compensation, and $0.8&#160;million in depreciation expense, accretion of investments and non-cash operating lease expense. We expect to continue to use cash in our operating activities as we conduct our clinical trials and nonclinical studies, incur costs of manufacturing clinical trial and nonclinical study materials and continue process development activities to optimize our manufacturing processes.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, net cash used in operating activities was $26.3&#160;million and primarily reflected our net loss of $24.5 million and a $4.8&#160;million net change in our operating assets and liabilities, offset by noncash charges of $1.5 million in stock-based compensation and $1.5 million in depreciation expense, amortization of investments and non-cash operating lease expense.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by (Used in) Investing Activities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, net cash provided by investing activities was $45.1&#160;million, of which $45.2 million represents the net change in investments and $0.1 million was used to purchase property and equipment, primarily attributable to our continued efforts to bring in-house certain process development, manufacturing and laboratory capabilities.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, net cash used in investing activities was $15.4&#160;million, of which $12.9&#160;million represents the net change in investments and $2.5&#160;million was used to purchase property and equipment.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing Activities </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, net cash provided by financing activities was $0.1&#160;million and was primarily from the exercise of stock options and purchases pursuant to our employee stock purchase plan.</span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_76"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Other Commitments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 5 to our financial statements found elsewhere in this Quarterly Report on Form 10-Q for additional disclosures. There have been no other material changes from the Contractual Obligations and Other Commitments disclosed in Note 6 and 7 of our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_79"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the United States of America, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, the accrual for research and development expenses, and the valuation of stock-based awards. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our financial statements. We believe that the assumptions and estimates associated with our most critical accounting policies are those relating to revenue, accrued research and development costs and stock-based compensation.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_82"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to our financial statements found elsewhere in this Quarterly Report on Form 10-Q for a description of recent accounting pronouncements applicable to our financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company and Smaller Reporting Company Status</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company as defined in the JOBS Act. Under the JOBS Act, an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards and delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from complying with new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have evaluated the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an emerging growth company, we may rely on certain of these exemptions, including without limitation exemptions to the requirements for (1)&#160;providing an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act and (2)&#160;complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an emerging growth company until the earlier of (a)&#160;the last day of the fiscal year (i)&#160;following the fifth anniversary of the completion of our IPO, (ii)&#160;in which we have total annual gross revenues of at least $1.235&#160;billion or (iii)&#160;in which we are deemed to be a &#8220;large accelerated filer&#8221; under the rules of the SEC, which means the market value of our common stock that is held by non-affiliates exceeds $700.0&#160;million as of the prior June&#160;30th, or (b)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt during the prior three-year period. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company&#8221; as defined under the Securities and Exchange Act of 1934, as amended, or the Exchange Act. We may continue to be a smaller reporting company if either (i)&#160;the market value of our stock held by non-affiliates is less than $250.0&#160;million or (ii)&#160;our annual revenue is less than $100.0&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_88"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company, as defined by Rule 12b-2 under the Exchange Act and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.</span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_91"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures. Based on this evaluation of our disclosure controls and procedures as of March&#160;31, 2023, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the first quarter of the year ending December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_94"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_97"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as discussed in Note 5 to our financial statements found elsewhere in this Quarterly Report on Form 10-Q, we are not presently a party to any other legal proceedings that, in the opinion of our management and if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition or cash flows.</span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_100"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes from the risk factors disclosed in Item 1A of our Annual Report on Form 10-K.</span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_103"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_106"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_109"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_112"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_115"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth below.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.003%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description of Exhibit</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520269417/d72237dex31.htm">Amended and Restated Certificate of Incorporation of Shattuck Labs, Inc. (incorporated by reference from Exhibit 3.1 to Shattuck&#8217;s Current Report on Form 8-K filed on October 14, 2020 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520269417/d72237dex32.htm">Amended and Restated Bylaws of Shattuck Labs, Inc. (incorporated by reference from Exhibit 3.2 to Shattuck&#8217;s Current Report on Form 8-K filed on October 14, 2020 (Commission File No. 001-39593))</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520263321/d69956dex41.htm">Form of common stock certificate of Shattuck (incorporated by reference from Exhibit 4.1 of Shattuck&#8217;s Amendment No. 2 to Registration Statement on Form S-1 filed on October 8, 2020 (Commission File No. 333-248918))</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1680367/000119312520249204/d69956dex42.htm">Second Amended and Restated Investors&#8217; Rights Agreement, dated as of June 12, 2020, by and among Shattuck Labs, Inc. and certain of its stockholders (incorporated by reference from Exhibit 4.2 of Shattuck&#8217;s Amendment No. 2 to Registration Statement on Form S-1 filed on October 8, 2020 (Commission File No. 333-248918))</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="sub-certxsection302xceoxq1.htm">Certification of the principal executive officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="sub-certxsection302xcfoxq1.htm">Certification of the principal financial officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">32.1* (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="sub-certxsection906ofthesa.htm">Certification of the principal executive officer and principal financial officer pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(b) under the Securities Exchange Act of 1934</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inline XBRL Instance Document </span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The cover page for this report, formatted in Inline XBRL (included in Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">______________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The certifications on Exhibit 32 hereto are deemed not &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="iab75d73ad8e54df383e5480fddd6dcb5_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shattuck Labs, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May 9, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Dr. Taylor Schreiber</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr.&#160;Taylor Schreiber</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chief Executive Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(principal executive officer)</span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May 9, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Andrew R. Neill</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">Andrew R. Neill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:104%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(principal financial and accounting officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>sub-certxsection302xceoxq1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7a953487caf841a9ada6a4444d9b3076_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:167%">Exhibit 31.1</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO </font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Taylor Schreiber, certify that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">I have reviewed this Quarterly Report on Form&#160;10-Q of Shattuck Labs, Inc.&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">c.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">d.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.074%"><tr><td style="width:1.0%"></td><td style="width:62.801%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.054%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.845%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; May 9, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Dr. Taylor Schreiber</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Dr.&#160;Taylor Schreiber</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">Chief Executive Officer</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:125%">(principal executive officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>sub-certxsection302xcfoxq1.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1c9719e6892f4d6b8ae4ca446f34839d_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:167%">Exhibit 31.2</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES</font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO </font></div><div style="margin-bottom:0.08pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Andrew R. Neill, certify that&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.000%"><tr><td style="width:1.0%"></td><td style="width:3.298%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">I have reviewed this Quarterly Report on Form&#160;10-Q of Shattuck Labs, Inc.&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">c.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">d.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">a.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.461%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">b.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.305%"><tr><td style="width:1.0%"></td><td style="width:62.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.769%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; May 9, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Andrew R. Neill</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:104%">Andrew R. Neill</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:104%">Chief Financial Officer</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(principal financial and accounting officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>sub-certxsection906ofthesa.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5616ecc347a04c358a0e12b31620b717_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:167%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:7pt;margin-top:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Shattuck Labs, Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:3.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:3.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.162%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:35.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.037%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.162%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; May 9, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Dr. Taylor Schreiber</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Dr. Taylor Schreiber</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Chief Executive Officer</font></div><div style="margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">(principal executive officer)</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt"><font><br></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; May 9, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Andrew R. Neill</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Andrew R. Neill</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Chief Financial Officer</font></div><div style="margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:139%">(principal financial and accounting officer)</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt"><font><br></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167;1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note&#58; A signed original of this written statement required by &#167;906 has been provided to Shattuck Labs, Inc. and will be retained by Shattuck Labs, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>sttk-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:ce8ca630-3d4e-4325-8fca-ef7176ea5407,g:0c784f84-7059-42e0-96eb-5624e9f8221f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sttk="http://www.shattucklabs.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.shattucklabs.com/20230331">
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sttk-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sttk-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sttk-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sttk-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="COVER" roleURI="http://www.shattucklabs.com/role/COVER">
        <link:definition>0000001 - Document - COVER</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETS" roleURI="http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETSParenthetical" roleURI="http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONDENSED BALANCE SHEETS - Parenthetical</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>0000005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>0000007 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.shattucklabs.com/role/Investments">
        <link:definition>0000009 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>0000010 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.shattucklabs.com/role/CommitmentsandContingencies">
        <link:definition>0000011 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.shattucklabs.com/role/Equity">
        <link:definition>0000012 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.shattucklabs.com/role/StockBasedCompensation">
        <link:definition>0000013 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000014 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000015 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.shattucklabs.com/role/InvestmentsTables">
        <link:definition>0000016 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>0000017 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationTables">
        <link:definition>0000018 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusinessDetails" roleURI="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails">
        <link:definition>0000019 - Disclosure - Organization and Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000020 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails">
        <link:definition>0000021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofavailableforsaleinvestmentsDetails" roleURI="http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails">
        <link:definition>0000022 - Disclosure - Investments - Schedule of available for sale investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.shattucklabs.com/role/InvestmentsNarrativeDetails">
        <link:definition>0000023 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails" roleURI="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails">
        <link:definition>0000024 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of accrued expenses and other current liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>0000025 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetails" roleURI="http://www.shattucklabs.com/role/EquityDetails">
        <link:definition>0000026 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>0000027 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails">
        <link:definition>0000028 - Disclosure - Stock-Based Compensation - Schedule of stock-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofoptionactivityDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails">
        <link:definition>0000029 - Disclosure - Stock-Based Compensation - Schedule of option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofrestrictedstockactivityDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails">
        <link:definition>0000030 - Disclosure - Stock-Based Compensation - Schedule of restricted stock activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofvaluationassumptionsDetails" roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails">
        <link:definition>0000031 - Disclosure - Stock-Based Compensation - Schedule of valuation assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived" abstract="false" name="RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" abstract="false" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sttk_LicenseAgreementRoyaltyPaymentsMaximum" abstract="false" name="LicenseAgreementRoyaltyPaymentsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" abstract="false" name="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sttk_OperatingAccountMember" abstract="true" name="OperatingAccountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" abstract="false" name="OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_AccruedResearchAndContractCostsCurrent" abstract="false" name="AccruedResearchAndContractCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_MonteCarloOptionPricingModelMember" abstract="true" name="MonteCarloOptionPricingModelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_BlackScholesOptionPricingModelMember" abstract="true" name="BlackScholesOptionPricingModelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_A2020StockIncentivePlanMember" abstract="true" name="A2020StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_A2020EmployeeStockPurchasePlanMember" abstract="true" name="A2020EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sttk_NumberOfClinicalStageProductCandidates" abstract="false" name="NumberOfClinicalStageProductCandidates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" abstract="false" name="StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>sttk-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:ce8ca630-3d4e-4325-8fca-ef7176ea5407,g:0c784f84-7059-42e0-96eb-5624e9f8221f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="sttk-20230331.xsd#CONDENSEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0e041c6e-de4d-4b55-9f4f-ec4439f8c84f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_667b9987-d37b-41dd-b643-bfff4b9bce15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0e041c6e-de4d-4b55-9f4f-ec4439f8c84f" xlink:to="loc_us-gaap_LiabilitiesCurrent_667b9987-d37b-41dd-b643-bfff4b9bce15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8bd47118-e13a-47e2-aec2-90216095eafc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_0e041c6e-de4d-4b55-9f4f-ec4439f8c84f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8bd47118-e13a-47e2-aec2-90216095eafc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b1bfff2c-0096-4294-a8b2-24e5a434b677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ad320a31-1208-42e4-98fa-7d80d504f52f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b1bfff2c-0096-4294-a8b2-24e5a434b677" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ad320a31-1208-42e4-98fa-7d80d504f52f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_acedf715-8a22-43b6-b3ef-670f0c82da79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b1bfff2c-0096-4294-a8b2-24e5a434b677" xlink:to="loc_us-gaap_AdditionalPaidInCapital_acedf715-8a22-43b6-b3ef-670f0c82da79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b1382066-373a-4dd1-9888-1cd2939e77f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b1bfff2c-0096-4294-a8b2-24e5a434b677" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b1382066-373a-4dd1-9888-1cd2939e77f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_82ac5b33-f836-4d87-be72-552b1ba97089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b1bfff2c-0096-4294-a8b2-24e5a434b677" xlink:to="loc_us-gaap_CommonStockValue_82ac5b33-f836-4d87-be72-552b1ba97089" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bf6d2524-a880-4ea7-8b30-dc9adeb2a1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_88e51e2f-786c-443c-9e34-0d5f52256416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bf6d2524-a880-4ea7-8b30-dc9adeb2a1f4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_88e51e2f-786c-443c-9e34-0d5f52256416" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f3c9d2-0dff-4dea-8ae8-ec11d1da7c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bf6d2524-a880-4ea7-8b30-dc9adeb2a1f4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f3c9d2-0dff-4dea-8ae8-ec11d1da7c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ea203b86-7bd4-42ac-9eb4-bef6d48cfa0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bf6d2524-a880-4ea7-8b30-dc9adeb2a1f4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ea203b86-7bd4-42ac-9eb4-bef6d48cfa0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3c02969c-6f6d-494e-baa2-4b1c537c5d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_314328d7-df4a-4b83-b84e-76ddbc68cf4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c02969c-6f6d-494e-baa2-4b1c537c5d7b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_314328d7-df4a-4b83-b84e-76ddbc68cf4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1ed11b40-3fab-4b0a-a60e-c39037c27583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c02969c-6f6d-494e-baa2-4b1c537c5d7b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1ed11b40-3fab-4b0a-a60e-c39037c27583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_eb79c45a-5c79-49d2-bf09-ed7d4864459c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_3c02969c-6f6d-494e-baa2-4b1c537c5d7b" xlink:to="loc_us-gaap_AssetsCurrent_eb79c45a-5c79-49d2-bf09-ed7d4864459c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2c7e6c11-204c-4788-985f-c0f9a9fd1b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_afc3d6f4-3edf-4764-9577-658059e14603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2c7e6c11-204c-4788-985f-c0f9a9fd1b6a" xlink:to="loc_us-gaap_AccountsPayableCurrent_afc3d6f4-3edf-4764-9577-658059e14603" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_b6dd526e-e3c2-45f9-aea3-261fd966ffd7" xlink:href="sttk-20230331.xsd#sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2c7e6c11-204c-4788-985f-c0f9a9fd1b6a" xlink:to="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_b6dd526e-e3c2-45f9-aea3-261fd966ffd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9672b3a9-3a05-4789-bf2c-8d01bc96233d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9c570006-9fd2-4ce8-be5b-f11e3603b209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9672b3a9-3a05-4789-bf2c-8d01bc96233d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9c570006-9fd2-4ce8-be5b-f11e3603b209" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4956d1da-a602-4b9d-b187-312b96fc7721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9672b3a9-3a05-4789-bf2c-8d01bc96233d" xlink:to="loc_us-gaap_Liabilities_4956d1da-a602-4b9d-b187-312b96fc7721" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d2916bf3-d6dd-412b-871f-84ba520e95cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9672b3a9-3a05-4789-bf2c-8d01bc96233d" xlink:to="loc_us-gaap_StockholdersEquity_d2916bf3-d6dd-412b-871f-84ba520e95cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sttk-20230331.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1a94e217-b2a8-45fd-90ca-a5c853873e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_31d04cfc-56b1-48d3-9df1-455b4550d544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1a94e217-b2a8-45fd-90ca-a5c853873e77" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_31d04cfc-56b1-48d3-9df1-455b4550d544" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f6d4b726-194c-4223-8b02-bce216a91e46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1a94e217-b2a8-45fd-90ca-a5c853873e77" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f6d4b726-194c-4223-8b02-bce216a91e46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6b22941a-ac8d-4e9e-9a75-de91093e2d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_024cc132-64e1-4197-8336-37d1de491fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6b22941a-ac8d-4e9e-9a75-de91093e2d5f" xlink:to="loc_us-gaap_NetIncomeLoss_024cc132-64e1-4197-8336-37d1de491fc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_cc515fac-7141-4c9c-ba7d-8382580647a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6b22941a-ac8d-4e9e-9a75-de91093e2d5f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_cc515fac-7141-4c9c-ba7d-8382580647a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_177742f7-d757-4412-b6c3-c89a35efb538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_784ff9b4-2691-45c1-9785-66542bd918f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_177742f7-d757-4412-b6c3-c89a35efb538" xlink:to="loc_us-gaap_OperatingExpenses_784ff9b4-2691-45c1-9785-66542bd918f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_be428b47-2c06-4f7b-97f2-639c45abc431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_177742f7-d757-4412-b6c3-c89a35efb538" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_be428b47-2c06-4f7b-97f2-639c45abc431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1316cd4a-c1a8-4631-9266-b17bdf6a70f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_36e8f8cc-a752-49d8-a6d7-b5a2a1fdc8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1316cd4a-c1a8-4631-9266-b17bdf6a70f9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_36e8f8cc-a752-49d8-a6d7-b5a2a1fdc8fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ace49a90-f3d3-4fce-817a-8389036bce44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1316cd4a-c1a8-4631-9266-b17bdf6a70f9" xlink:to="loc_us-gaap_OperatingIncomeLoss_ace49a90-f3d3-4fce-817a-8389036bce44" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sttk-20230331.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_778e4e28-37d9-423d-8c43-8ac4475f6e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eb7620d3-b1e1-47e6-8c26-00e3bd48ae3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_778e4e28-37d9-423d-8c43-8ac4475f6e4a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_eb7620d3-b1e1-47e6-8c26-00e3bd48ae3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_904b43f0-71c7-4497-bbeb-83ac5d5226aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_778e4e28-37d9-423d-8c43-8ac4475f6e4a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_904b43f0-71c7-4497-bbeb-83ac5d5226aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d4181ad-169d-40fe-b459-1eeb9c4d2394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_778e4e28-37d9-423d-8c43-8ac4475f6e4a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d4181ad-169d-40fe-b459-1eeb9c4d2394" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0fc02b9-409d-4be5-b786-f1d101e13879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm_1d284200-cffd-4a2e-9be1-cd77f804a649" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0fc02b9-409d-4be5-b786-f1d101e13879" xlink:to="loc_us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm_1d284200-cffd-4a2e-9be1-cd77f804a649" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ba9d660a-81dd-4d57-8d96-03be78c2da9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0fc02b9-409d-4be5-b786-f1d101e13879" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ba9d660a-81dd-4d57-8d96-03be78c2da9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ad55442-b3ee-4800-8908-52aebcf9d734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8e6d4f71-346d-4676-9ee4-8990d61fc8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ad55442-b3ee-4800-8908-52aebcf9d734" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_8e6d4f71-346d-4676-9ee4-8990d61fc8b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_46cd8eaf-6ff9-4e97-9b22-97936abc70c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ad55442-b3ee-4800-8908-52aebcf9d734" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_46cd8eaf-6ff9-4e97-9b22-97936abc70c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ab070c80-80da-42a4-a717-3c37a03511de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ad55442-b3ee-4800-8908-52aebcf9d734" xlink:to="loc_us-gaap_Depreciation_ab070c80-80da-42a4-a717-3c37a03511de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cab5bb19-c35b-49cd-adf5-253e40b5c7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ad55442-b3ee-4800-8908-52aebcf9d734" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cab5bb19-c35b-49cd-adf5-253e40b5c7cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5487b7e4-33d9-4749-8da3-dc0fa04c66aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ad55442-b3ee-4800-8908-52aebcf9d734" xlink:to="loc_us-gaap_NetIncomeLoss_5487b7e4-33d9-4749-8da3-dc0fa04c66aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_be3e99cb-7706-4e28-b4e5-7401099aca3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ad55442-b3ee-4800-8908-52aebcf9d734" xlink:to="loc_us-gaap_ShareBasedCompensation_be3e99cb-7706-4e28-b4e5-7401099aca3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c7bc53dd-c5c1-4c15-928b-c8659d53f4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ad55442-b3ee-4800-8908-52aebcf9d734" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c7bc53dd-c5c1-4c15-928b-c8659d53f4a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_ff9c4f86-9c2a-47c1-b948-5bf7141eece0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ad55442-b3ee-4800-8908-52aebcf9d734" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_ff9c4f86-9c2a-47c1-b948-5bf7141eece0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2c4a1ad2-f908-488e-85f8-566b9fbb3118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ad55442-b3ee-4800-8908-52aebcf9d734" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2c4a1ad2-f908-488e-85f8-566b9fbb3118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4ea6d3eb-131c-4e4d-ba4a-791aa8ed81b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ad55442-b3ee-4800-8908-52aebcf9d734" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4ea6d3eb-131c-4e4d-ba4a-791aa8ed81b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_57affa23-519f-4b00-b1b3-9513febad523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ad55442-b3ee-4800-8908-52aebcf9d734" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_57affa23-519f-4b00-b1b3-9513febad523" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2a631b0-96ec-4813-b3fb-8228439b5a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_588b62d8-1df3-4e5e-ad57-fd488a8b6fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2a631b0-96ec-4813-b3fb-8228439b5a8c" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_588b62d8-1df3-4e5e-ad57-fd488a8b6fc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_bf3d2d3b-06ba-4265-8c62-c53bf3f1324a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2a631b0-96ec-4813-b3fb-8228439b5a8c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_bf3d2d3b-06ba-4265-8c62-c53bf3f1324a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#InvestmentsScheduleofavailableforsaleinvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9021da7a-1179-4c65-9f3a-18c351acc564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ef023a31-54a5-434b-afcc-71ef0160e402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9021da7a-1179-4c65-9f3a-18c351acc564" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ef023a31-54a5-434b-afcc-71ef0160e402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_615dd59d-d5a7-4ca8-af5f-b70fa6302a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9021da7a-1179-4c65-9f3a-18c351acc564" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_615dd59d-d5a7-4ca8-af5f-b70fa6302a77" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_d7eb67cb-d666-4b04-a21d-f52f3dfc1659" xlink:href="sttk-20230331.xsd#sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_56579bf6-8b22-4570-a26d-c62ab24b3653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_d7eb67cb-d666-4b04-a21d-f52f3dfc1659" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_56579bf6-8b22-4570-a26d-c62ab24b3653" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedResearchAndContractCostsCurrent_51999c55-8d42-4cf7-84b8-cda92ccce7f2" xlink:href="sttk-20230331.xsd#sttk_AccruedResearchAndContractCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_d7eb67cb-d666-4b04-a21d-f52f3dfc1659" xlink:to="loc_sttk_AccruedResearchAndContractCostsCurrent_51999c55-8d42-4cf7-84b8-cda92ccce7f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_395e31ac-a0d3-4370-92f1-959b47db0e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_d7eb67cb-d666-4b04-a21d-f52f3dfc1659" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_395e31ac-a0d3-4370-92f1-959b47db0e32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_d66dc355-e771-4079-bc85-9031161a272e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_d7eb67cb-d666-4b04-a21d-f52f3dfc1659" xlink:to="loc_us-gaap_LitigationReserveCurrent_d66dc355-e771-4079-bc85-9031161a272e" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>sttk-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:ce8ca630-3d4e-4325-8fca-ef7176ea5407,g:0c784f84-7059-42e0-96eb-5624e9f8221f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sttk-20230331.xsd#CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="i6acc6166b0374c78a8a834f2c42f015a_CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1a79a40a-751c-4718-8262-1a425854574b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1a79a40a-751c-4718-8262-1a425854574b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a4109176-a088-409e-ac8c-be4a47825499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_SharesOutstanding_a4109176-a088-409e-ac8c-be4a47825499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_60bcb954-c157-4d4d-ae58-c6dee2747871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_StockholdersEquity_60bcb954-c157-4d4d-ae58-c6dee2747871" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_0f8f5cf2-341d-4d29-8116-757e5e744cc2" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_0f8f5cf2-341d-4d29-8116-757e5e744cc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_c4c8e7d2-3f95-4dbc-b293-f21a21f868d9" xlink:href="sttk-20230331.xsd#sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_c4c8e7d2-3f95-4dbc-b293-f21a21f868d9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0b8ecb21-83b8-4d84-93e2-f5ad3fa609a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0b8ecb21-83b8-4d84-93e2-f5ad3fa609a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_b5396bf2-ffab-486e-93a9-1332ea652707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_b5396bf2-ffab-486e-93a9-1332ea652707" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1cc10a64-a654-433f-ac4e-1f044bc73c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1cc10a64-a654-433f-ac4e-1f044bc73c9a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_bc8749ce-18af-47eb-8bb8-032a7de677b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_bc8749ce-18af-47eb-8bb8-032a7de677b8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0ec9f995-90b2-4c4e-8f40-bf698e7f86e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0ec9f995-90b2-4c4e-8f40-bf698e7f86e6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_42a6f176-0a79-4c05-8536-71ad07a951c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_NetIncomeLoss_42a6f176-0a79-4c05-8536-71ad07a951c5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_dcc65a81-b0cd-4803-b762-b6e9db0936d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f34fa36e-b5d5-404e-be39-d722977d6aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_99f5769c-f5ec-456f-9a7d-8b86fe75fefb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1a79a40a-751c-4718-8262-1a425854574b" xlink:to="loc_us-gaap_StatementTable_99f5769c-f5ec-456f-9a7d-8b86fe75fefb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7ebcb0fb-5ab3-40e2-90f2-152e60e8733a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_99f5769c-f5ec-456f-9a7d-8b86fe75fefb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7ebcb0fb-5ab3-40e2-90f2-152e60e8733a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7ebcb0fb-5ab3-40e2-90f2-152e60e8733a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7ebcb0fb-5ab3-40e2-90f2-152e60e8733a" xlink:to="loc_us-gaap_EquityComponentDomain_7ebcb0fb-5ab3-40e2-90f2-152e60e8733a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_339044a5-1719-47af-ac17-b7f498a0a58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7ebcb0fb-5ab3-40e2-90f2-152e60e8733a" xlink:to="loc_us-gaap_EquityComponentDomain_339044a5-1719-47af-ac17-b7f498a0a58f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b3fa8a22-e824-4517-b3bc-1e8a154470bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_339044a5-1719-47af-ac17-b7f498a0a58f" xlink:to="loc_us-gaap_CommonStockMember_b3fa8a22-e824-4517-b3bc-1e8a154470bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fe72b95b-30e0-44fb-a4a5-28a3013b6f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_339044a5-1719-47af-ac17-b7f498a0a58f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fe72b95b-30e0-44fb-a4a5-28a3013b6f27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a4ae2912-0b90-4ec2-bdb5-a153180191b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_339044a5-1719-47af-ac17-b7f498a0a58f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a4ae2912-0b90-4ec2-bdb5-a153180191b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_77585f0e-43c7-4cdd-be0c-57ed99695ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_339044a5-1719-47af-ac17-b7f498a0a58f" xlink:to="loc_us-gaap_RetainedEarningsMember_77585f0e-43c7-4cdd-be0c-57ed99695ce1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="ia1fd05ab70854f519d411d509ebbb829_BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_8310d917-7d5e-4a04-ab9c-e8080a7d7126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b9acfc0-3d48-4b3b-a8c5-65f2f061fa26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_8310d917-7d5e-4a04-ab9c-e8080a7d7126" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b9acfc0-3d48-4b3b-a8c5-65f2f061fa26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_4abb23f4-65c4-4dec-bb7f-2555765ce833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_8310d917-7d5e-4a04-ab9c-e8080a7d7126" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_4abb23f4-65c4-4dec-bb7f-2555765ce833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a2c23fc4-021a-40e9-b17d-2e70fed470ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_8310d917-7d5e-4a04-ab9c-e8080a7d7126" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a2c23fc4-021a-40e9-b17d-2e70fed470ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_f998d2c4-ee2c-4592-a680-e3de6c58bd97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a2c23fc4-021a-40e9-b17d-2e70fed470ab" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_f998d2c4-ee2c-4592-a680-e3de6c58bd97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f998d2c4-ee2c-4592-a680-e3de6c58bd97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f998d2c4-ee2c-4592-a680-e3de6c58bd97" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f998d2c4-ee2c-4592-a680-e3de6c58bd97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_edea96c9-935e-47bc-971c-7d01fab8159c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f998d2c4-ee2c-4592-a680-e3de6c58bd97" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_edea96c9-935e-47bc-971c-7d01fab8159c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OperatingAccountMember_90b58dec-a654-4fd4-afbd-f3a043b3a0f4" xlink:href="sttk-20230331.xsd#sttk_OperatingAccountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_edea96c9-935e-47bc-971c-7d01fab8159c" xlink:to="loc_sttk_OperatingAccountMember_90b58dec-a654-4fd4-afbd-f3a043b3a0f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_438f295f-d928-455f-81cc-0e44811c309a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_edea96c9-935e-47bc-971c-7d01fab8159c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_438f295f-d928-455f-81cc-0e44811c309a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" xlink:type="extended" id="i2456fb46e0ee4edc8aba875acc9f1091_BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_525704b9-b8c2-4399-98b7-aad6bd80fa08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_106a24ff-56e9-466a-ba73-7ae95d1fcebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_525704b9-b8c2-4399-98b7-aad6bd80fa08" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_106a24ff-56e9-466a-ba73-7ae95d1fcebb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d07fafc8-5299-4905-bbce-727bdee5f72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_525704b9-b8c2-4399-98b7-aad6bd80fa08" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d07fafc8-5299-4905-bbce-727bdee5f72f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a7a188d2-cd8f-46cc-a5d0-ac571e667341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d07fafc8-5299-4905-bbce-727bdee5f72f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a7a188d2-cd8f-46cc-a5d0-ac571e667341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7a188d2-cd8f-46cc-a5d0-ac571e667341_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a7a188d2-cd8f-46cc-a5d0-ac571e667341" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a7a188d2-cd8f-46cc-a5d0-ac571e667341_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c4f74b-15ce-4bca-9bd8-8c43c97211f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a7a188d2-cd8f-46cc-a5d0-ac571e667341" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c4f74b-15ce-4bca-9bd8-8c43c97211f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d7449870-9d56-4ae2-9616-0bb3e639b574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c4f74b-15ce-4bca-9bd8-8c43c97211f3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d7449870-9d56-4ae2-9616-0bb3e639b574" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_197a5bee-6082-4861-85ca-d4871c4a63ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c4f74b-15ce-4bca-9bd8-8c43c97211f3" xlink:to="loc_us-gaap_RestrictedStockMember_197a5bee-6082-4861-85ca-d4871c4a63ea" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#InvestmentsScheduleofavailableforsaleinvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" xlink:type="extended" id="iaacd416d6c9f46c9a9cb1aa35e7b717d_InvestmentsScheduleofavailableforsaleinvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b69b5429-7264-4e84-b284-8b67d5f1aee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract_bd64a894-d283-4999-a4e6-52fd18569800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b69b5429-7264-4e84-b284-8b67d5f1aee4" xlink:to="loc_us-gaap_DebtSecuritiesAbstract_bd64a894-d283-4999-a4e6-52fd18569800" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e12a3ce2-58e7-487e-8795-26c7a6598108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_bd64a894-d283-4999-a4e6-52fd18569800" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e12a3ce2-58e7-487e-8795-26c7a6598108" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_5a0523fb-2b57-40ba-9653-8140e946fb39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_bd64a894-d283-4999-a4e6-52fd18569800" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_5a0523fb-2b57-40ba-9653-8140e946fb39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2b9daf69-94f3-40e8-9913-ecaee5965207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_bd64a894-d283-4999-a4e6-52fd18569800" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2b9daf69-94f3-40e8-9913-ecaee5965207" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3b646ad5-464b-431c-bd8f-d4b93e99b1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b69b5429-7264-4e84-b284-8b67d5f1aee4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3b646ad5-464b-431c-bd8f-d4b93e99b1df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_73b9b16d-441a-494b-b56a-6e5e84eb39d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3b646ad5-464b-431c-bd8f-d4b93e99b1df" xlink:to="loc_us-gaap_FinancialInstrumentAxis_73b9b16d-441a-494b-b56a-6e5e84eb39d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_73b9b16d-441a-494b-b56a-6e5e84eb39d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_73b9b16d-441a-494b-b56a-6e5e84eb39d6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_73b9b16d-441a-494b-b56a-6e5e84eb39d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bdc41e84-5b48-429d-90ed-c6cad6cae3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_73b9b16d-441a-494b-b56a-6e5e84eb39d6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bdc41e84-5b48-429d-90ed-c6cad6cae3ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7ef94de1-dadd-4395-8f7f-ccbf0433fb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bdc41e84-5b48-429d-90ed-c6cad6cae3ba" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7ef94de1-dadd-4395-8f7f-ccbf0433fb3d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i7d8b4478b87d4610afe079de5dbaaf2d_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_1a6d77c9-5413-449f-8ce0-58328ce3badb" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_1a6d77c9-5413-449f-8ce0-58328ce3badb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_eb7f8258-4a54-46ad-b02f-468d7361f35f" xlink:href="sttk-20230331.xsd#sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_eb7f8258-4a54-46ad-b02f-468d7361f35f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9a2196af-2a8d-4122-bfa9-87727d6c2e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9a2196af-2a8d-4122-bfa9-87727d6c2e00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5e65c2c3-b41c-47b3-8008-8e657e229870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5e65c2c3-b41c-47b3-8008-8e657e229870" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_01b5286f-abea-4339-ae8d-707f4ca02ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_01b5286f-abea-4339-ae8d-707f4ca02ffc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod_d79f21b1-9244-4d28-b5c2-601a34b9820c" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod_d79f21b1-9244-4d28-b5c2-601a34b9820c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches_f7449ab8-aa5f-40b4-9972-c895a4609e1e" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches_f7449ab8-aa5f-40b4-9972-c895a4609e1e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays_b1dbbcd9-2850-4e00-8266-799457c00d12" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays_b1dbbcd9-2850-4e00-8266-799457c00d12" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_9d4c269c-349a-4200-acf4-d4d6814eb1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_9d4c269c-349a-4200-acf4-d4d6814eb1b8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f468a9dd-c626-452d-8125-b9b1e35696f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f468a9dd-c626-452d-8125-b9b1e35696f2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_779ab185-0ee5-447f-b438-73a308c0daef" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_779ab185-0ee5-447f-b438-73a308c0daef" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_8359e1f9-f16e-4180-9fa9-e1ac4e3c64d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_8359e1f9-f16e-4180-9fa9-e1ac4e3c64d3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_f7e9b224-7fe2-466e-8184-f7c9ac577bed" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_f7e9b224-7fe2-466e-8184-f7c9ac577bed" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6f5cc7c1-1aac-4dcd-90d0-60721df08d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6f5cc7c1-1aac-4dcd-90d0-60721df08d2c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_bb311342-caa2-4863-9ea0-1b6a1d8e20f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ProceedsFromStockPlans_bb311342-caa2-4863-9ea0-1b6a1d8e20f9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5e5b28d2-61cb-4e02-8232-2d4c92a9da1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5e5b28d2-61cb-4e02-8232-2d4c92a9da1f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e8a40641-a276-4c35-b9d1-f56ee5c39588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e8a40641-a276-4c35-b9d1-f56ee5c39588" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ae1a4e16-4825-4432-93dc-2ddfecf2cfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ae1a4e16-4825-4432-93dc-2ddfecf2cfe1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8a224cfd-df8a-4415-80ae-c0ea5e2d505c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8a224cfd-df8a-4415-80ae-c0ea5e2d505c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b3471eee-08fa-4e9a-8f30-d62e1937f5df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b3471eee-08fa-4e9a-8f30-d62e1937f5df" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d0a2590d-38b8-4cb0-8c26-35e670a31814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d0a2590d-38b8-4cb0-8c26-35e670a31814" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3dabca22-f922-4875-a8b1-c5db654c7a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3dabca22-f922-4875-a8b1-c5db654c7a3b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d63f9dd0-15dc-41fe-a1e6-a4df0792b72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d63f9dd0-15dc-41fe-a1e6-a4df0792b72f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_80333a6c-840b-4c2d-8bfc-8f92d1b6ecaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_80333a6c-840b-4c2d-8bfc-8f92d1b6ecaa" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2955cbd4-aa3a-478b-a8eb-a15c33bc75ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2955cbd4-aa3a-478b-a8eb-a15c33bc75ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_49ed6034-14e9-4224-a789-793b5810d221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2955cbd4-aa3a-478b-a8eb-a15c33bc75ad" xlink:to="loc_us-gaap_PlanNameAxis_49ed6034-14e9-4224-a789-793b5810d221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_49ed6034-14e9-4224-a789-793b5810d221_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_49ed6034-14e9-4224-a789-793b5810d221" xlink:to="loc_us-gaap_PlanNameDomain_49ed6034-14e9-4224-a789-793b5810d221_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3ceae33d-0896-4117-8535-4c7bdbdd78b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_49ed6034-14e9-4224-a789-793b5810d221" xlink:to="loc_us-gaap_PlanNameDomain_3ceae33d-0896-4117-8535-4c7bdbdd78b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_58fe277f-6d62-40cb-9fc6-f7cb5fe5545c" xlink:href="sttk-20230331.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3ceae33d-0896-4117-8535-4c7bdbdd78b4" xlink:to="loc_sttk_A2020StockIncentivePlanMember_58fe277f-6d62-40cb-9fc6-f7cb5fe5545c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_a2b1ad1c-e86a-447f-b8c7-3f805708fb76" xlink:href="sttk-20230331.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3ceae33d-0896-4117-8535-4c7bdbdd78b4" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_a2b1ad1c-e86a-447f-b8c7-3f805708fb76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_32575bff-c719-4f91-b90c-5853295b97c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2955cbd4-aa3a-478b-a8eb-a15c33bc75ad" xlink:to="loc_us-gaap_AwardTypeAxis_32575bff-c719-4f91-b90c-5853295b97c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32575bff-c719-4f91-b90c-5853295b97c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_32575bff-c719-4f91-b90c-5853295b97c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32575bff-c719-4f91-b90c-5853295b97c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5065b02b-d812-408e-965e-f454a64ecb80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_32575bff-c719-4f91-b90c-5853295b97c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5065b02b-d812-408e-965e-f454a64ecb80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fc44725d-8710-4e34-96ed-07a9f9da6a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5065b02b-d812-408e-965e-f454a64ecb80" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fc44725d-8710-4e34-96ed-07a9f9da6a0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_559262e1-db4b-44d4-a821-db2a7f315740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5065b02b-d812-408e-965e-f454a64ecb80" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_559262e1-db4b-44d4-a821-db2a7f315740" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" xlink:type="extended" id="i49d9a6ad97bf46fc988523ffb33210b1_StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_53e54a46-78e1-492a-98b0-d41664492edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b82034b5-6a01-4538-ab3f-9a24fce550eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_53e54a46-78e1-492a-98b0-d41664492edd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b82034b5-6a01-4538-ab3f-9a24fce550eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e513f8ed-73ab-421b-b7fb-bacaf757ef33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_53e54a46-78e1-492a-98b0-d41664492edd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e513f8ed-73ab-421b-b7fb-bacaf757ef33" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_38b9c334-a141-437d-94f5-cdc684a98d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e513f8ed-73ab-421b-b7fb-bacaf757ef33" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_38b9c334-a141-437d-94f5-cdc684a98d38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_38b9c334-a141-437d-94f5-cdc684a98d38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_38b9c334-a141-437d-94f5-cdc684a98d38" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_38b9c334-a141-437d-94f5-cdc684a98d38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_48888085-93f9-4be5-9ca6-d5d05003b385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_38b9c334-a141-437d-94f5-cdc684a98d38" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_48888085-93f9-4be5-9ca6-d5d05003b385" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e616f5b2-179e-4b75-a7d1-742055606a16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_48888085-93f9-4be5-9ca6-d5d05003b385" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e616f5b2-179e-4b75-a7d1-742055606a16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_75ebc6d2-3d06-4910-afd0-33b9900e6cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_48888085-93f9-4be5-9ca6-d5d05003b385" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_75ebc6d2-3d06-4910-afd0-33b9900e6cf3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#StockBasedCompensationScheduleofrestrictedstockactivityDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" xlink:type="extended" id="i89ad44f8c8b44e688842c31d66a72a85_StockBasedCompensationScheduleofrestrictedstockactivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d569954b-dbfc-4407-870b-31c7e76bfd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2eaeb801-b604-447a-8023-52ec884b3f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d569954b-dbfc-4407-870b-31c7e76bfd9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2eaeb801-b604-447a-8023-52ec884b3f13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1079e46d-35ec-4670-80df-0b694863a537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2eaeb801-b604-447a-8023-52ec884b3f13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1079e46d-35ec-4670-80df-0b694863a537" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6f3ad6fa-3253-4395-876c-596cb5e21b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2eaeb801-b604-447a-8023-52ec884b3f13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6f3ad6fa-3253-4395-876c-596cb5e21b95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9d3a0ec2-206c-44d4-8e05-3dfe0eb780ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2eaeb801-b604-447a-8023-52ec884b3f13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9d3a0ec2-206c-44d4-8e05-3dfe0eb780ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fbe14a3f-3fd8-45f1-809d-95994c2ee321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2eaeb801-b604-447a-8023-52ec884b3f13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fbe14a3f-3fd8-45f1-809d-95994c2ee321" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4a5d0a00-4cbb-491f-8cf9-9418da0fb3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b56dae8f-a450-432e-be65-d6cc2eba4832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d569954b-dbfc-4407-870b-31c7e76bfd9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b56dae8f-a450-432e-be65-d6cc2eba4832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e49c2360-2d36-4b18-9ff9-4898e10b4e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b56dae8f-a450-432e-be65-d6cc2eba4832" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e49c2360-2d36-4b18-9ff9-4898e10b4e3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8290e568-250b-4e26-9200-d05493a5a77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b56dae8f-a450-432e-be65-d6cc2eba4832" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8290e568-250b-4e26-9200-d05493a5a77c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c2dc917d-612c-4b9e-8801-2d5af43ad33b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b56dae8f-a450-432e-be65-d6cc2eba4832" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c2dc917d-612c-4b9e-8801-2d5af43ad33b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fb8be4fc-1111-4efd-a391-fa01acc4bfce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b56dae8f-a450-432e-be65-d6cc2eba4832" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fb8be4fc-1111-4efd-a391-fa01acc4bfce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_75ab8599-903c-43a5-a82d-d67d8b8706f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad98ddfe-2fcd-4bbe-aa6f-b35e33d2ac3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d569954b-dbfc-4407-870b-31c7e76bfd9b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad98ddfe-2fcd-4bbe-aa6f-b35e33d2ac3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_13ce8018-fe73-4549-b2df-962aee58e7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad98ddfe-2fcd-4bbe-aa6f-b35e33d2ac3c" xlink:to="loc_us-gaap_AwardTypeAxis_13ce8018-fe73-4549-b2df-962aee58e7f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13ce8018-fe73-4549-b2df-962aee58e7f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_13ce8018-fe73-4549-b2df-962aee58e7f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_13ce8018-fe73-4549-b2df-962aee58e7f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d6b9123-a022-44a0-b54c-4f0b88f008d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_13ce8018-fe73-4549-b2df-962aee58e7f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d6b9123-a022-44a0-b54c-4f0b88f008d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3326a97c-f15c-453a-aead-c8148276b149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d6b9123-a022-44a0-b54c-4f0b88f008d1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3326a97c-f15c-453a-aead-c8148276b149" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#StockBasedCompensationScheduleofvaluationassumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" xlink:type="extended" id="i87e86ebf906544bf8e320bfe39d83cee_StockBasedCompensationScheduleofvaluationassumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22374bfd-e201-4acd-8e2f-1b686cb9f8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b5b8e820-c070-4f9b-88e1-e5ba2609e781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22374bfd-e201-4acd-8e2f-1b686cb9f8e1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b5b8e820-c070-4f9b-88e1-e5ba2609e781" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3d45979d-be8a-463a-9788-e9e4707d797a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22374bfd-e201-4acd-8e2f-1b686cb9f8e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3d45979d-be8a-463a-9788-e9e4707d797a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_244be0d2-6b9b-450d-983d-18fd54854e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22374bfd-e201-4acd-8e2f-1b686cb9f8e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_244be0d2-6b9b-450d-983d-18fd54854e68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_feda7f7f-3c55-4dea-bed0-62b2bc9316ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22374bfd-e201-4acd-8e2f-1b686cb9f8e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_feda7f7f-3c55-4dea-bed0-62b2bc9316ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e22422de-865c-4c43-a417-c7d040ff2bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22374bfd-e201-4acd-8e2f-1b686cb9f8e1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e22422de-865c-4c43-a417-c7d040ff2bd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_865106c5-b239-49ed-8ceb-7010ad45ebfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e22422de-865c-4c43-a417-c7d040ff2bd3" xlink:to="loc_us-gaap_AwardTypeAxis_865106c5-b239-49ed-8ceb-7010ad45ebfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_865106c5-b239-49ed-8ceb-7010ad45ebfd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_865106c5-b239-49ed-8ceb-7010ad45ebfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_865106c5-b239-49ed-8ceb-7010ad45ebfd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7ff8ae4-f8d9-4c28-b7e8-8e345ad3335d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_865106c5-b239-49ed-8ceb-7010ad45ebfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7ff8ae4-f8d9-4c28-b7e8-8e345ad3335d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_712cfcaa-c570-464d-b995-2500efb9ce1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7ff8ae4-f8d9-4c28-b7e8-8e345ad3335d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_712cfcaa-c570-464d-b995-2500efb9ce1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_02ea73cc-ce3c-4aeb-9b72-e35fcf175d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7ff8ae4-f8d9-4c28-b7e8-8e345ad3335d" xlink:to="loc_us-gaap_EmployeeStockMember_02ea73cc-ce3c-4aeb-9b72-e35fcf175d32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b66205f8-c39f-4f25-b73e-527908d2b3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e22422de-865c-4c43-a417-c7d040ff2bd3" xlink:to="loc_us-gaap_PlanNameAxis_b66205f8-c39f-4f25-b73e-527908d2b3ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b66205f8-c39f-4f25-b73e-527908d2b3ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b66205f8-c39f-4f25-b73e-527908d2b3ec" xlink:to="loc_us-gaap_PlanNameDomain_b66205f8-c39f-4f25-b73e-527908d2b3ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_52b12b4c-27e2-49e2-8b28-00e349e770bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b66205f8-c39f-4f25-b73e-527908d2b3ec" xlink:to="loc_us-gaap_PlanNameDomain_52b12b4c-27e2-49e2-8b28-00e349e770bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_6477e1bd-4381-4e65-9c75-8d3ff302eb76" xlink:href="sttk-20230331.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_52b12b4c-27e2-49e2-8b28-00e349e770bd" xlink:to="loc_sttk_A2020StockIncentivePlanMember_6477e1bd-4381-4e65-9c75-8d3ff302eb76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_24e1ed8d-449d-4dd4-bbc4-70ba88918a60" xlink:href="sttk-20230331.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_52b12b4c-27e2-49e2-8b28-00e349e770bd" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_24e1ed8d-449d-4dd4-bbc4-70ba88918a60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_35528d4c-6386-49c7-8ada-72e353d6460d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e22422de-865c-4c43-a417-c7d040ff2bd3" xlink:to="loc_us-gaap_ValuationTechniqueAxis_35528d4c-6386-49c7-8ada-72e353d6460d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_35528d4c-6386-49c7-8ada-72e353d6460d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_35528d4c-6386-49c7-8ada-72e353d6460d" xlink:to="loc_us-gaap_ValuationTechniqueDomain_35528d4c-6386-49c7-8ada-72e353d6460d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_91eef13f-b9d7-4df8-a14f-d3b30a4e2e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_35528d4c-6386-49c7-8ada-72e353d6460d" xlink:to="loc_us-gaap_ValuationTechniqueDomain_91eef13f-b9d7-4df8-a14f-d3b30a4e2e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_BlackScholesOptionPricingModelMember_2be43dcf-e770-45e0-9464-56a9bcaba524" xlink:href="sttk-20230331.xsd#sttk_BlackScholesOptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_91eef13f-b9d7-4df8-a14f-d3b30a4e2e89" xlink:to="loc_sttk_BlackScholesOptionPricingModelMember_2be43dcf-e770-45e0-9464-56a9bcaba524" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_MonteCarloOptionPricingModelMember_8a6c99ba-b236-45f2-aa7b-67bcf7d7954a" xlink:href="sttk-20230331.xsd#sttk_MonteCarloOptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_91eef13f-b9d7-4df8-a14f-d3b30a4e2e89" xlink:to="loc_sttk_MonteCarloOptionPricingModelMember_8a6c99ba-b236-45f2-aa7b-67bcf7d7954a" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>sttk-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:ce8ca630-3d4e-4325-8fca-ef7176ea5407,g:0c784f84-7059-42e0-96eb-5624e9f8221f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_sttk_OperatingAccountMember_56698ab5-c503-4d1a-9316-fa554c3d8775_terseLabel_en-US" xlink:label="lab_sttk_OperatingAccountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Account</link:label>
    <link:label id="lab_sttk_OperatingAccountMember_label_en-US" xlink:label="lab_sttk_OperatingAccountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Account [Member]</link:label>
    <link:label id="lab_sttk_OperatingAccountMember_documentation_en-US" xlink:label="lab_sttk_OperatingAccountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OperatingAccountMember" xlink:href="sttk-20230331.xsd#sttk_OperatingAccountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_OperatingAccountMember" xlink:to="lab_sttk_OperatingAccountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1b532c1d-8125-4257-8b96-33cd813527b6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76f8eed4-44df-4f96-abb2-56a7a2236588_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_350e53a5-9dcc-4d37-a1d9-614f51ce1a45_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_8c0d3aeb-0388-4970-9db9-77437568ee18_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares authorized, percentage of capital stock outstanding</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1999916f-0c6c-4303-bab7-e0cbff9247df_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_fe27cfd0-9079-42c6-abe2-4c24a3944461_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_51164cdb-6941-4f08-b149-2eb1f4103c75_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a7df4022-af8a-439a-8f49-f3980f7514d3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b7c90972-d686-42b2-87a1-0f9fe2655974_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_A2020EmployeeStockPurchasePlanMember_d3af388a-b163-4251-ad14-9032a1f0f926_terseLabel_en-US" xlink:label="lab_sttk_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_sttk_A2020EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_sttk_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_sttk_A2020EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_sttk_A2020EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember" xlink:href="sttk-20230331.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_A2020EmployeeStockPurchasePlanMember" xlink:to="lab_sttk_A2020EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_c6f42022-4a02-4327-b5a0-66446194ec5f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_a292ea02-705c-451c-b1d5-4407345e328d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3c83f756-f04b-43d6-a65a-31e4381dd0f8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_a9409259-c205-45eb-93d7-3ddce18dea3b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_83610a10-5c07-491b-be8e-b2015d0beaaf_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ed0075a6-9621-4932-ba29-60a92c22adb2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term - years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_0efd09b0-dd8a-48f7-81f8-33ba06c48339_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares per employee during any one purchase period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_86a52620-2b3f-4084-9461-b10cf36a2959_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_d578b6c4-ea88-4a82-9e50-daea864de60e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible List]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ecc574d7-5a57-4dd0-b416-e567b68ca7bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_76bcad47-7612-43b6-866f-61562d5ee19e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value: 300,000,000 shares authorized; 42,460,258 shares issued and outstanding at March&#160;31, 2023 and 42,390,586 shares issued and outstanding at December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_56a508fe-802b-4980-957e-4d3323b9ae0a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_89b6a6b0-a2da-4fb2-a995-e648596da5a0_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9a8cc7f3-d880-4287-89df-6dabe614e193_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_b8fa523d-477b-4e59-ac9d-11ab8507182d_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2fdec732-6c60-4c70-a910-3d908e68b938_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4b84f758-5361-4d0e-8507-4eb6c9e9c700_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of antidilutive securities excluded from computation of net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_292ac361-3906-4ea7-87fa-2ea1e30dc9d5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets_cf0aec86-76f1-4801-bca9-16c9cdada3e9_terseLabel_en-US" xlink:label="lab_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities recognized for operating right-of-use assets</link:label>
    <link:label id="lab_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities Recognized For Operating Lease Right-of-Use Assets</link:label>
    <link:label id="lab_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liabilities Recognized For Operating Lease Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" xlink:href="sttk-20230331.xsd#sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" xlink:to="lab_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_cac4a14e-0083-467a-81a3-1abc28b2401e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_de6083d4-6c5e-4fb7-8e4a-8025408fa131_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_AccruedResearchAndContractCostsCurrent_e73e0627-8ab1-4152-a19c-1dd523e38134_terseLabel_en-US" xlink:label="lab_sttk_AccruedResearchAndContractCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development contract costs</link:label>
    <link:label id="lab_sttk_AccruedResearchAndContractCostsCurrent_label_en-US" xlink:label="lab_sttk_AccruedResearchAndContractCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Contract Costs, Current</link:label>
    <link:label id="lab_sttk_AccruedResearchAndContractCostsCurrent_documentation_en-US" xlink:label="lab_sttk_AccruedResearchAndContractCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Contract Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedResearchAndContractCostsCurrent" xlink:href="sttk-20230331.xsd#sttk_AccruedResearchAndContractCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_AccruedResearchAndContractCostsCurrent" xlink:to="lab_sttk_AccruedResearchAndContractCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_56d22634-9224-412d-be99-51c698612f8f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_61fc3a0a-472b-47f4-92ef-87548ea46826_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c76085e-fc68-40a7-acf5-80b1593b8b62_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_2f37bd5f-53a9-4fcf-aa58-a3df52d6313f_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Exercises And ESPP Purchases in Period</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Exercised And ESPP Purchased in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a60695fd-53e4-4bae-8755-a8279cd94ebe_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_90697b9f-2842-4c0c-abb6-dc333299c66d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_bb559183-2cde-4469-b954-269b7886f9e5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_37e241ae-2f18-4655-8daa-81ad8ad6e882_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;average remaining contract life, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f2c3779f-f420-43cb-b2b7-077affde8758_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e12b402a-595f-40ac-9f0c-c7d21c6bb5cc_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_6cf79b3b-35a9-4f18-bde9-620e641734bd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_88cbeb5a-e280-489e-a4a1-51e1f9290e7e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_967f7157-1a55-4b8a-b52e-90386d8ecf32_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid amounts related to purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c0baf6d2-8b54-4f61-9d09-fe7886fadd42_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod_1c81348f-3755-4d42-8b02-0cd126c59efd_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment award, grants in period (in shares)</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_a3297425-1684-4bbb-94a6-c6695b14c162_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2c6e63e3-eb88-4e07-9185-c8a78d263e88_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_64992554-1cda-4e91-ae03-d63ab1599327_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_ed7d5263-47ba-450a-80a9-2d7afd504b58_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_bbeba7d5-882f-4a5f-9340-f493e3ecf398_terseLabel_en-US" xlink:label="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and purchases pursuant to employee stock purchase plan</link:label>
    <link:label id="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_label_en-US" xlink:label="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased</link:label>
    <link:label id="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_documentation_en-US" xlink:label="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:href="sttk-20230331.xsd#sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:to="lab_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b2f09917-cd0a-41a5-8771-d0f879ef7067_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_900163d5-f78a-4b60-b980-985053dad3ef_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalty</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_5371464d-e5b0-413e-b375-ec4737d7e40b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_232fce93-5142-48b0-84a4-504e8610f16f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercises of stock options and purchases pursuant to employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_7862aef9-c693-4f24-8ac3-b7849e8b470f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_6112d268-6782-4b14-8abd-b2cd2ba6357a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_63768304-7737-42a3-a7ec-1583f8beea62_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_89cb8ee7-8ed4-4ec3-857e-9557da0a68b4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_88b0ae5c-88b5-4d02-b1d4-9524ecadb692_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3f05becb-ac78-4e97-8902-b5abbaf4e949_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d76d7f20-22c2-4f1b-885b-9661535768ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_02d9b4ca-3c18-462d-92e8-a44536c24ac3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash financial activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9de9eb3a-cf15-42f7-853a-89ac6e4d3520_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_2c50c74e-e720-41a5-990a-8adc4f6b9580_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7ef0c647-6e10-4034-bd72-c9b4eb554054_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock in percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_764c553c-dd7a-48be-ab0a-b9293e8f8d98_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost for RSU</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_85a0f84e-b2d3-45d9-9d76-07beed4a1539_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6a9000e4-e4a8-4b89-a77e-e20eda9e2d7e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_aa8d9076-d814-4bbe-b4a5-efeef49b7418_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued under ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_e96e72ff-b92f-4f3d-b398-f8640b67c23b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8dc1842f-36eb-4f2d-9238-dfa2ce393103_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;average remaining contract life, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_A2020StockIncentivePlanMember_a3e9f136-45d7-4845-8ee1-b9cecaf4b3c7_terseLabel_en-US" xlink:label="lab_sttk_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Incentive Plan</link:label>
    <link:label id="lab_sttk_A2020StockIncentivePlanMember_label_en-US" xlink:label="lab_sttk_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_sttk_A2020StockIncentivePlanMember_documentation_en-US" xlink:label="lab_sttk_A2020StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember" xlink:href="sttk-20230331.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_A2020StockIncentivePlanMember" xlink:to="lab_sttk_A2020StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cdff79fc-2f61-4ee4-baf6-94bb78c683da_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a67f2fcd-50e8-45a0-9516-28f36a77159b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_3855ea1a-fa99-454c-9de9-d6d6f6d8c71e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_fac9fed8-b568-491e-8e4b-021179e7bf74_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_efc884bc-0540-46e5-bc95-ee2afcf0c1a0_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0521dde4-5fdf-467a-9e7a-cf7688e73ee3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b69945b3-670e-4b71-b968-4789c9e9d366_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_dd6f8a2e-8b62-408f-8910-e983a5e8c200_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Unaudited Interim Condensed Financial Statements</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8ab12eb7-28cb-4c36-a861-13f347378650_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_6f4ea89d-8ae6-4e24-9df7-aef2555f245f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAbstract_642d8dd3-987c-4b73-9d66-cfb9de7cd946_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments:</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1e2f8be1-d16f-4ce6-ac40-77ec36d05db7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1f3ae862-ebb1-4862-a03f-1933e98d2635_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_393109a7-d27f-43a0-b53e-3b9da6ea6788_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9f11200f-97cf-4e1e-94c0-7c83cb58acd1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_cba5590c-c780-4ad9-a49b-787b9e93927c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ef2ff9a7-bb91-4fa3-af8b-88f98b0e2b52_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2baabdaa-e645-4ae0-8fde-40ede2ce7fc0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum_aa83522a-f4bf-43ab-8e2e-df481000380b_terseLabel_en-US" xlink:label="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, maximum payment</link:label>
    <link:label id="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum_label_en-US" xlink:label="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payments, Maximum</link:label>
    <link:label id="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum_documentation_en-US" xlink:label="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payments, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:href="sttk-20230331.xsd#sttk_LicenseAgreementRoyaltyPaymentsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:to="lab_sttk_LicenseAgreementRoyaltyPaymentsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_191ef8d6-325a-448d-8ca7-4b191439b166_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d3c5a6a9-4798-41eb-ac3e-83e494a0d2af_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29126bd5-282b-4610-899a-89624f6cdaca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_0fcd3351-e823-484c-ab04-c202520aed62_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense from operations</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a0cbc807-0eac-4d22-a61f-eab7c9336160_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_807fc65c-e8f8-46fa-b397-16e647e4215a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_238c6e26-c9a3-4e00-9b0d-ccf912c9b358_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_fc9ca454-49d3-472f-a77a-3021101e324a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b5157ffb-61d4-48bb-8825-3ed24734220b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b0be1090-d2f9-485c-9282-9289c0b95c32_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_9ed67b55-fc76-4df0-b64a-8da5acf00f0f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_21559413-9e5a-4f6a-bb2f-0c75d654279f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_46a55148-3146-4995-b178-0f25a64143be_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_efacc768-bf3a-4909-99c4-368dac158610_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_ea76a0fb-dfc8-4a8e-bb77-cbbdb82a0501_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6669600a-a6d3-475f-9e72-f392461d10ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_8c0d210f-e11a-4bae-ae85-08e2c3df7462_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_be2f2a3b-e625-42e9-88ad-635b3a1c7fc7_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_f4e287ef-f9db-453b-8af2-3c80258ea5a5_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in number of shares authorized, term</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b24fa105-c500-40b1-acce-784c029011e2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_26ef06e2-ff18-4e79-8dab-ebf33ba42707_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_cb8276a4-a4db-4d93-a9a9-c0e8d3c131da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, average maturity term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a3116f32-e424-4c1e-b057-845252933f5e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a6bf8552-0764-4cd4-b805-76f2fed93091_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_4ed1773f-5d8a-4b59-ad63-9c05626e5e86_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_1d70dd37-2be1-4a20-ac85-a687b879645c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a6a1539b-2d66-4704-9f3d-fde4cdcb1e8c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_ef947678-5a97-41db-86cf-917a56768741_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1ddd05be-4e6c-4e86-9400-78735aac6753_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_edb40dc5-40ae-4d45-87d5-fe44e81aac5d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0dbf4501-913f-47e3-8c6d-333e53d7192b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_NumberOfClinicalStageProductCandidates_625b1742-4aaa-4bc1-9fce-ab6aa4799821_terseLabel_en-US" xlink:label="lab_sttk_NumberOfClinicalStageProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of clinical-stage product candidate</link:label>
    <link:label id="lab_sttk_NumberOfClinicalStageProductCandidates_label_en-US" xlink:label="lab_sttk_NumberOfClinicalStageProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical-stage Product Candidates</link:label>
    <link:label id="lab_sttk_NumberOfClinicalStageProductCandidates_documentation_en-US" xlink:label="lab_sttk_NumberOfClinicalStageProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical-stage Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_NumberOfClinicalStageProductCandidates" xlink:href="sttk-20230331.xsd#sttk_NumberOfClinicalStageProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_NumberOfClinicalStageProductCandidates" xlink:to="lab_sttk_NumberOfClinicalStageProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_877a0c41-9673-4235-8a60-af390c4a78dc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm_6062cdb3-a74d-40fd-b0df-fb7ff9ef4345_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in investments</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Available-for-Sale Securities, Short-Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm" xlink:to="lab_us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches_a8a58766-f79d-49a3-a7db-c0c494d8e7e2_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number Of Tranches</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_da6e8835-84ae-4750-9bc0-f721616fe1d8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_afa30a66-9d48-467a-bdbf-51ca8347662a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d4900e6f-f6f1-4e5d-9918-26f889d22206_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amortization (accretion) of investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_70f89b6d-f5d1-4d41-b774-23a7b6c3dd27_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2b8ae7a7-278d-4283-995b-eddeda6b7b82_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea52b811-4ac2-450b-a0a0-5e9753858ae3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_a4d93688-7261-4317-838f-30b9c6312df4_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_140edbbb-02e8-4edc-b695-6ee23af89021_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f9162d31-a5fc-491b-b102-25586fccbb1a_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ba12cca6-775b-4435-a866-babecd5cf983_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_4ef7093c-c8ee-4c3c-8f20-914b22261aee_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ae835ca9-1a77-48a2-a332-9b20f004f19b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_eef52777-fd91-441a-8424-8dd663b82e09_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_94a27054-a43f-4ced-ac38-0c91e0b8fd32_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3eb22b42-5594-42c5-a6b6-f29ee6f843f2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_06bfa527-1024-493c-80da-50a455d4905c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c844ae56-b063-4537-ace0-93f17f91a2d6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_c602df08-f2de-47cf-a1bf-bd28ee0e2196_terseLabel_en-US" xlink:label="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_f632d13f-cf1c-4c27-8e4d-737cbaec430f_totalLabel_en-US" xlink:label="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities, Current</link:label>
    <link:label id="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_documentation_en-US" xlink:label="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:href="sttk-20230331.xsd#sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="lab_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_24c729c2-6181-4d68-b811-fd1d3efa5297_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of valuation assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_e92cc82b-fe1d-420c-bdd8-a23f695cddf7_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_86a81d4a-b0d5-4729-901c-aa40f49264d6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_abdf0f19-61be-410e-a16b-9519a0d359c1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_13893cc5-e0eb-4dfe-8c3c-b2517a9839b1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c5a642a-d074-4961-80ae-3ea4d3f4b356_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8a8802ce-fb70-433e-a5f7-058a12eb5eb0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average amortization period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_eb48afee-bbd9-4b6b-ba4c-0fc778aaacb0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;average remaining contract life, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_786c7b78-5749-48a5-a0db-ab1d42e6a899_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_59bc0df0-91cf-40c8-8f7b-b3c9c143b031_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_bb26f3a9-f87f-449b-ae9a-4f7da00a89a9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 5)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_bc70b529-eb90-4f08-af7e-a4cc0a7eae47_terseLabel_en-US" xlink:label="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, additional capital shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_documentation_en-US" xlink:label="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:href="sttk-20230331.xsd#sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:to="lab_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_dfd7b39f-4c38-4a03-9697-87a0fe4d5293_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e588a10b-e13f-4aa8-acb7-841dc83ef637_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_371594a8-dae6-4d99-a458-ec095a9550ef_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5911afec-b3fd-49dd-b55f-ab087c171bb7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_MonteCarloOptionPricingModelMember_8a68f97c-5b39-4b2f-9803-2368f0ae1cdc_terseLabel_en-US" xlink:label="lab_sttk_MonteCarloOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monte Carlo Option Pricing Model</link:label>
    <link:label id="lab_sttk_MonteCarloOptionPricingModelMember_label_en-US" xlink:label="lab_sttk_MonteCarloOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monte Carlo Option Pricing Model [Member]</link:label>
    <link:label id="lab_sttk_MonteCarloOptionPricingModelMember_documentation_en-US" xlink:label="lab_sttk_MonteCarloOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monte Carlo Option Pricing Model</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_MonteCarloOptionPricingModelMember" xlink:href="sttk-20230331.xsd#sttk_MonteCarloOptionPricingModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_MonteCarloOptionPricingModelMember" xlink:to="lab_sttk_MonteCarloOptionPricingModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7fb67e17-20bb-413c-9a47-14ea85f26e22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividends</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_4cb40dc7-131c-4e9d-97f0-42524e6a44f1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_d60d63cc-96c7-4311-888f-7c80f941b748_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ed0cd738-09cb-4366-b222-71043072c9a5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_340ed8b1-8be6-4d2b-9a78-eec489aff3ee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_c52b793d-cc32-4f15-9cb0-49474bb8b40c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_321a7cc9-70c6-4e21-bfe9-b7d07cdffee5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_4f759213-4061-4803-b1f1-e93b6eb59ec2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_af0a7530-a66b-4f34-887f-5736bc337023_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4e5f3c4e-b3af-4a46-8ad3-88d1d709d100_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_dac17760-625f-4fa0-9fca-df804abfc3fb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5c1377a6-44a8-4c01-aa9e-ad7c0b5fdd8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_BlackScholesOptionPricingModelMember_64a33fca-1b25-4af4-9065-69ca64f04367_terseLabel_en-US" xlink:label="lab_sttk_BlackScholesOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Scholes Option Pricing Model</link:label>
    <link:label id="lab_sttk_BlackScholesOptionPricingModelMember_label_en-US" xlink:label="lab_sttk_BlackScholesOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Scholes Option Pricing Model [Member]</link:label>
    <link:label id="lab_sttk_BlackScholesOptionPricingModelMember_documentation_en-US" xlink:label="lab_sttk_BlackScholesOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Scholes Option Pricing Model</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_BlackScholesOptionPricingModelMember" xlink:href="sttk-20230331.xsd#sttk_BlackScholesOptionPricingModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_BlackScholesOptionPricingModelMember" xlink:to="lab_sttk_BlackScholesOptionPricingModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1dc90a32-6491-4421-888a-55114fe73048_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_38b8c1fc-062c-4bdf-9a39-d8e1031c5786_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_dce62ea6-6cbc-454d-bd9b-2c6c0a7fd655_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4c82f516-b436-4744-80f9-94e551e029a3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ad022b87-e0c7-4460-8e7d-d595474a0599_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_07426c13-93c5-49ef-93dd-74adc80ac74d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b92fa9dd-14d3-42ab-bf3e-65516dd249f8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_66b44be2-0d53-4d82-b391-c784938a5f0f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_05717581-0e78-4da9-9edf-3704c61becbe_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a11aa58a-3d4d-4727-9402-0624dd252774_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share &#8211; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0d80f2de-ca6a-401b-bbda-47458a6d1877_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_ac81bd51-8a3e-4ac5-833c-2731423c6a47_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ae70f881-7b1c-4fbe-8d0d-8392123f1533_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation, vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_5d2349bd-518e-4013-b6ab-5eb12a6f33ff_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_6594946c-c5cd-443f-a6f5-fb597ff98500_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_59f9bfde-7491-453b-a9bc-d59525f6c24a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_00c2b6e3-54c0-4360-a598-fd903fc12b63_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_16f67c48-83ec-4cac-a7a1-44d77fc5bae5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_e1f14ed0-7137-461b-b0e4-ec2fcea8533d_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum value of shares per employee during any calendar year</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_fd69342e-4cec-42a5-adf3-b05e2a722efa_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_d1d29461-aac1-42f4-8268-b3c024acbb13_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share &#8211; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a5d32eb4-97fa-4d89-98be-55d691be9c4c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_642be77c-05ed-4031-ac3d-3f2eb63f2eb3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3dafacf6-2ba8-4b27-b9ef-adf26b8cbff6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a3524bd6-53ea-410f-8de7-20fd4782f3f6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ef75dcd7-a719-403f-b584-e3de60c9f65a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_aeceffa0-9974-46c9-9eac-d6f14e629d8a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0fd993f6-4df0-4f21-b13d-7e018be71231_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_e2aff6e1-1f15-425d-b5a6-dc2aa6a4ed95_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for royalties</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_565bda12-6753-48e4-9e68-0a2cc5bb06c9_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived_313f6645-8ea8-416c-9a76-504a37501579_terseLabel_en-US" xlink:label="lab_sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue billed but not received</link:label>
    <link:label id="lab_sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived_label_en-US" xlink:label="lab_sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Deferred Revenue Billed Not Received</link:label>
    <link:label id="lab_sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived_documentation_en-US" xlink:label="lab_sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Deferred Revenue Billed Not Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived" xlink:href="sttk-20230331.xsd#sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived" xlink:to="lab_sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9920b732-b36c-4062-8d52-737f46f81903_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_08f10260-f125-4352-ac10-7bdd6fcec6c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_b684ad02-bfc0-468f-88f4-dd5d37c29c12_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_51ab7834-6a8e-4d30-ae92-b6f38f8d6c93_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d035f233-bd3d-4b7a-91cd-0606a834a868_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3c0f97dd-e10a-4133-8e48-ca29a7e1c6c8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c7735ee8-495a-4162-944c-1f37bb22f917_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon settlement of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_38f9321b-8bbc-43eb-90d3-e10366472d0a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards, vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_155d411c-c5eb-40eb-9bca-af01e7801e32_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_94553121-da58-4928-8ef7-eff782fe701c_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7969172f-4a58-4bbb-b2de-90761cd6214c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_d41e02df-4ff4-41f3-9e35-dcbf191b405e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution limit in percentage of employee's eligible compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0da29b3f-838f-4b43-a09f-330c75afc6e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3570da91-59c1-4e03-a172-7d03fff3ae4a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_3904b18c-2a5b-41d6-b2b3-46e6178655c1_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_db420d03-c5fd-4fe1-88db-e0cb018df1d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_70ccc11e-8906-4f27-b63f-6838778df0d6_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_8883d753-6f0c-4ac1-9e16-6e0430a3e7c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld related to net share settlement (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_1a38f359-a7b1-41fe-b090-147b52cb2ba2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c34e4c9d-0dc8-4124-861d-f5eeaa2177cb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_374c64d9-9df8-43d3-b02f-4afef69d4792_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_65716039-d3d2-455e-82fb-72fe90077e65_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_cc5703b1-6dbd-4c27-b668-84103a97c52e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_3a2fe6c1-0ceb-4425-9fc3-acfbfb4b4833_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8fa083ca-1d90-47c0-9c06-aca6326f1e25_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_43c02743-2d7d-4722-af73-ac83fc0e893e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3e5d0a22-9c3b-4032-8c0a-d787d8feb01e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_667a4e6b-e857-4033-8713-bafaa6ce531a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b786f61-c9ec-4d01-b42b-94b06b74f944_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays_79abc663-7f49-4805-8667-a9efd0708c42_terseLabel_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" xlink:to="lab_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_964f558b-47c2-41e5-92c6-bc8e1d9957e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld related to net share settlement</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1e911abc-6d42-4707-93e6-b4863c948268_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_579faaec-c496-4dae-8803-3ef1db80cb3a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_49760abf-523e-47e7-ba39-dfd450fc69f9_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_ab2d9fa0-5ffb-4f87-95ba-53a8a54740c6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_f9029012-8739-4e75-9263-944a6e355ae7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2f618601-265b-4e86-8da5-cc0a7392e31a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_75dbc96b-ed09-4a33-941a-0694c330aea2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_07f85193-83d4-4f03-be6f-53c3549f99e2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8af3f55b-910e-4b19-9faf-7f64fde0f09a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_458f12ab-ee95-4914-8f25-2f2f677c048b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_61ba879f-5101-4b9d-8387-e88d0b4f1cf6_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a169b389-eef4-455f-aa7e-b0fabbbb06dc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5717cbe0-32d2-4742-a005-25455b1f9e9c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b43a351f-3cd7-4b3e-a34e-16641fad3ccb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_890ce162-15b9-44da-ac8c-4f5d1068913e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_61cb8d10-36a9-4322-975f-8fd176146f49_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_4fe74562-067e-4ad5-afaa-b6c5ad732171_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_fc9583cc-ac1a-4a08-aec1-57097fba7237_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_37fab3bf-1367-4c8a-a2a8-7382148a7e26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a74d1fe3-660d-4fcf-90fc-8731bd05c69e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_79fc9273-af93-4dee-b320-138ce2c552e8_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bee52639-b528-4c78-a995-f239a62ceffd_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b2255caf-ba6a-47e4-95d1-858109718a62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_bf8db651-4b96-47ff-9406-3d66ddfd48ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2393cef8-c8e9-40bc-9d32-e8e66dca2d7a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_9004e6fd-ea18-44aa-8991-71551709cdf7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_395f23f7-b8da-44d3-9e3b-32b0cab7b5b4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c32dc099-2c21-4548-a438-91aa9e6fd6cb_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating right-of-use assets exchanged for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_08ebb15f-ff42-4a49-b1d7-b8223298c0e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_03fc9af3-6f78-4e68-adc6-fa39d22b1333_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>sttk-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:ce8ca630-3d4e-4325-8fca-ef7176ea5407,g:0c784f84-7059-42e0-96eb-5624e9f8221f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.shattucklabs.com/role/COVER" xlink:type="simple" xlink:href="sttk-20230331.xsd#COVER"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/COVER" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_06d1ba13-1250-4b6a-9aaa-d196da78d7a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_DocumentType_06d1ba13-1250-4b6a-9aaa-d196da78d7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_bc0c28e5-da2e-4b5b-a4ac-fdccebbf1c26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_DocumentQuarterlyReport_bc0c28e5-da2e-4b5b-a4ac-fdccebbf1c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5011a4dd-da80-4ff3-836d-aea818cdacb3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_DocumentPeriodEndDate_5011a4dd-da80-4ff3-836d-aea818cdacb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_783c9768-2855-4950-b826-a5da6bd00286" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_DocumentTransitionReport_783c9768-2855-4950-b826-a5da6bd00286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7509ef6e-b836-41b8-addf-1e707048b414" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityFileNumber_7509ef6e-b836-41b8-addf-1e707048b414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_0fa13368-e173-4ace-9f3b-3afcda0b4085" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityRegistrantName_0fa13368-e173-4ace-9f3b-3afcda0b4085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bbe21f95-73e7-4951-83d6-198a19863d2e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bbe21f95-73e7-4951-83d6-198a19863d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_aee6a306-5027-4435-9a6f-17513fc96c40" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityTaxIdentificationNumber_aee6a306-5027-4435-9a6f-17513fc96c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_b3a00a8f-4b74-465c-a1b9-667c8ec0dc22" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityAddressAddressLine1_b3a00a8f-4b74-465c-a1b9-667c8ec0dc22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_d472bff2-2c6a-4750-b845-8db3d02aebb0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityAddressAddressLine2_d472bff2-2c6a-4750-b845-8db3d02aebb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_20766f16-ed06-4e08-8421-7f05cfc4da8f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityAddressCityOrTown_20766f16-ed06-4e08-8421-7f05cfc4da8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f3e7b492-e53d-4ee1-b7cf-383457084cfd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityAddressStateOrProvince_f3e7b492-e53d-4ee1-b7cf-383457084cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f52c6e7c-0e1d-4c57-8164-ce1ddc8b1124" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityAddressPostalZipCode_f52c6e7c-0e1d-4c57-8164-ce1ddc8b1124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_09aee332-b8bb-42ba-a208-c68e3dc138ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_CityAreaCode_09aee332-b8bb-42ba-a208-c68e3dc138ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d9a1a3b5-306b-4dfa-8783-7be06a89962f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_LocalPhoneNumber_d9a1a3b5-306b-4dfa-8783-7be06a89962f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_55c2ac92-9658-4707-b370-22c4effc72da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_Security12bTitle_55c2ac92-9658-4707-b370-22c4effc72da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_34fe1f4f-d7c2-4047-9c73-2d0938b480a3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_TradingSymbol_34fe1f4f-d7c2-4047-9c73-2d0938b480a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a7abcec3-3470-44b3-89ff-1f757e3fd9d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_SecurityExchangeName_a7abcec3-3470-44b3-89ff-1f757e3fd9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_74219a79-dfe2-464b-a415-4dd9fae32995" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityCurrentReportingStatus_74219a79-dfe2-464b-a415-4dd9fae32995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_55c07e38-3156-4429-b644-5cf06fc18336" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityInteractiveDataCurrent_55c07e38-3156-4429-b644-5cf06fc18336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_5903c1ac-b720-4bc5-945a-93e152cd98c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityFilerCategory_5903c1ac-b720-4bc5-945a-93e152cd98c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_17d3aae5-b404-468b-a92f-e3a84e581f05" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntitySmallBusiness_17d3aae5-b404-468b-a92f-e3a84e581f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_90a287f6-292d-444d-b1ea-675e6842d01d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityEmergingGrowthCompany_90a287f6-292d-444d-b1ea-675e6842d01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_6a595c51-9d7a-4c64-a4e4-a6adafc57f8f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityExTransitionPeriod_6a595c51-9d7a-4c64-a4e4-a6adafc57f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_c36ca3fa-1d7a-4ad4-9fa1-efa261e4fc69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityShellCompany_c36ca3fa-1d7a-4ad4-9fa1-efa261e4fc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_de7199d3-9a9d-4450-a27a-896544a1a2fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_de7199d3-9a9d-4450-a27a-896544a1a2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c83bcf76-3a8e-4edc-ab85-af7c6fadf62d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_EntityCentralIndexKey_c83bcf76-3a8e-4edc-ab85-af7c6fadf62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2e8dd774-cd32-45bd-8c9f-8ed55ad6fa95" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_AmendmentFlag_2e8dd774-cd32-45bd-8c9f-8ed55ad6fa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3e61dad3-1b03-4534-9ee5-446056782e28" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_DocumentFiscalYearFocus_3e61dad3-1b03-4534-9ee5-446056782e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e4f75b4e-77a3-44db-894b-643e736f3d0a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e4f75b4e-77a3-44db-894b-643e736f3d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f26865d4-7f27-44cc-a4f8-e42b7d0a790a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_16ffed31-b8e1-4595-ae33-5502812bdc64" xlink:to="loc_dei_CurrentFiscalYearEndDate_f26865d4-7f27-44cc-a4f8-e42b7d0a790a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="sttk-20230331.xsd#CONDENSEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5f94288d-f627-485c-8c75-deea1f903fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_df4acf2e-0197-4de8-a58b-1dce9f210d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5f94288d-f627-485c-8c75-deea1f903fdf" xlink:to="loc_us-gaap_AssetsAbstract_df4acf2e-0197-4de8-a58b-1dce9f210d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_054e6f92-e633-4e5b-92cc-f6b21c8d3ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_df4acf2e-0197-4de8-a58b-1dce9f210d04" xlink:to="loc_us-gaap_AssetsCurrentAbstract_054e6f92-e633-4e5b-92cc-f6b21c8d3ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e82d54ab-08bb-4acb-bcfc-41ab74f9abca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_054e6f92-e633-4e5b-92cc-f6b21c8d3ff6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e82d54ab-08bb-4acb-bcfc-41ab74f9abca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e747968c-88f3-4379-b9aa-55e5137796b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_054e6f92-e633-4e5b-92cc-f6b21c8d3ff6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e747968c-88f3-4379-b9aa-55e5137796b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_762e8b63-31c1-4a4e-8dfc-144b66cabfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_054e6f92-e633-4e5b-92cc-f6b21c8d3ff6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_762e8b63-31c1-4a4e-8dfc-144b66cabfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a29b4804-761f-42d4-902a-1af2e68f0945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_054e6f92-e633-4e5b-92cc-f6b21c8d3ff6" xlink:to="loc_us-gaap_AssetsCurrent_a29b4804-761f-42d4-902a-1af2e68f0945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_78981f93-3143-40a9-a2d6-46dc1018e9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_df4acf2e-0197-4de8-a58b-1dce9f210d04" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_78981f93-3143-40a9-a2d6-46dc1018e9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9d212698-70ac-4a4b-ab24-265a54deb026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_df4acf2e-0197-4de8-a58b-1dce9f210d04" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9d212698-70ac-4a4b-ab24-265a54deb026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_96d459b4-2a62-4ddf-b606-8e61a988329a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_df4acf2e-0197-4de8-a58b-1dce9f210d04" xlink:to="loc_us-gaap_Assets_96d459b4-2a62-4ddf-b606-8e61a988329a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_002ef2ae-58dd-4721-98f3-765d730556a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5f94288d-f627-485c-8c75-deea1f903fdf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_002ef2ae-58dd-4721-98f3-765d730556a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_bc8b2262-facf-4131-b75c-a655ae656755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_002ef2ae-58dd-4721-98f3-765d730556a7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_bc8b2262-facf-4131-b75c-a655ae656755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1e8b3619-ead4-4109-bbad-2e1a1017f360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc8b2262-facf-4131-b75c-a655ae656755" xlink:to="loc_us-gaap_AccountsPayableCurrent_1e8b3619-ead4-4109-bbad-2e1a1017f360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_647eb218-6c60-43ff-82d3-34b15b53b0bc" xlink:href="sttk-20230331.xsd#sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc8b2262-facf-4131-b75c-a655ae656755" xlink:to="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_647eb218-6c60-43ff-82d3-34b15b53b0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_37c98a92-0a9e-499a-9458-58f3c3ba1f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc8b2262-facf-4131-b75c-a655ae656755" xlink:to="loc_us-gaap_LiabilitiesCurrent_37c98a92-0a9e-499a-9458-58f3c3ba1f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_786679e8-8cc0-4172-86a4-a7489b5b3e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_002ef2ae-58dd-4721-98f3-765d730556a7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_786679e8-8cc0-4172-86a4-a7489b5b3e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_42005ee8-4bda-44d3-bab6-74d1d24a5d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_002ef2ae-58dd-4721-98f3-765d730556a7" xlink:to="loc_us-gaap_Liabilities_42005ee8-4bda-44d3-bab6-74d1d24a5d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_661bb2be-d608-4c5b-9b6c-0b3deb0ddce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_002ef2ae-58dd-4721-98f3-765d730556a7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_661bb2be-d608-4c5b-9b6c-0b3deb0ddce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_16f4d06a-a66e-44f0-98eb-8b0327d37306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_002ef2ae-58dd-4721-98f3-765d730556a7" xlink:to="loc_us-gaap_StockholdersEquityAbstract_16f4d06a-a66e-44f0-98eb-8b0327d37306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_634424e8-3964-4174-bdca-2413328bbb82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_16f4d06a-a66e-44f0-98eb-8b0327d37306" xlink:to="loc_us-gaap_CommonStockValue_634424e8-3964-4174-bdca-2413328bbb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ca7c5970-ef12-46ff-96ec-6282a3b50a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_16f4d06a-a66e-44f0-98eb-8b0327d37306" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ca7c5970-ef12-46ff-96ec-6282a3b50a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_802f01da-8d9c-4da4-9c4c-669cb4b69d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_16f4d06a-a66e-44f0-98eb-8b0327d37306" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_802f01da-8d9c-4da4-9c4c-669cb4b69d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cbd0e8bb-5b5e-4e2f-9d54-64e890814ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_16f4d06a-a66e-44f0-98eb-8b0327d37306" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_cbd0e8bb-5b5e-4e2f-9d54-64e890814ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_51655c62-37ce-4386-8d89-6a8be56a923c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_16f4d06a-a66e-44f0-98eb-8b0327d37306" xlink:to="loc_us-gaap_StockholdersEquity_51655c62-37ce-4386-8d89-6a8be56a923c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_11ac2a7d-4dd5-42bf-9808-ee19e20729c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_002ef2ae-58dd-4721-98f3-765d730556a7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_11ac2a7d-4dd5-42bf-9808-ee19e20729c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sttk-20230331.xsd#CONDENSEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_330c4e8a-2e9a-41b9-9790-3fe3a332ec1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f778b41a-6ac2-4b39-a6c0-06bb212c9829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_330c4e8a-2e9a-41b9-9790-3fe3a332ec1a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f778b41a-6ac2-4b39-a6c0-06bb212c9829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_cb43c6de-f3c6-44b7-b37b-72242cd9e507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_330c4e8a-2e9a-41b9-9790-3fe3a332ec1a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_cb43c6de-f3c6-44b7-b37b-72242cd9e507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ada05f98-1da8-42a0-b8e8-3f9e75496823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_330c4e8a-2e9a-41b9-9790-3fe3a332ec1a" xlink:to="loc_us-gaap_CommonStockSharesIssued_ada05f98-1da8-42a0-b8e8-3f9e75496823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ebc5f636-fdf5-470b-954f-1fe9ee8e4b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_330c4e8a-2e9a-41b9-9790-3fe3a332ec1a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ebc5f636-fdf5-470b-954f-1fe9ee8e4b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sttk-20230331.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2f028f19-5a0a-4230-97e7-13ccf57a44df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_bc055316-0705-4389-a2e2-1a7a888b0b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2f028f19-5a0a-4230-97e7-13ccf57a44df" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_bc055316-0705-4389-a2e2-1a7a888b0b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a8489a3-2682-4dce-9a42-88a453f419a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2f028f19-5a0a-4230-97e7-13ccf57a44df" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a8489a3-2682-4dce-9a42-88a453f419a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7dacce59-5224-4f04-ba52-f8354e9a77a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2f028f19-5a0a-4230-97e7-13ccf57a44df" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7dacce59-5224-4f04-ba52-f8354e9a77a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_88c3a633-4efd-4cfa-8325-563c248f385d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dacce59-5224-4f04-ba52-f8354e9a77a6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_88c3a633-4efd-4cfa-8325-563c248f385d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_de34706a-9e9d-47a1-867d-7f431bd67d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dacce59-5224-4f04-ba52-f8354e9a77a6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_de34706a-9e9d-47a1-867d-7f431bd67d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_646b3d11-fbe2-45c2-a888-a3465d84e4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7dacce59-5224-4f04-ba52-f8354e9a77a6" xlink:to="loc_us-gaap_OperatingExpenses_646b3d11-fbe2-45c2-a888-a3465d84e4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b594dd95-eed5-468f-b306-7a8ddc0103d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2f028f19-5a0a-4230-97e7-13ccf57a44df" xlink:to="loc_us-gaap_OperatingIncomeLoss_b594dd95-eed5-468f-b306-7a8ddc0103d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7f513068-500f-4775-9303-58936ac5dcf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2f028f19-5a0a-4230-97e7-13ccf57a44df" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7f513068-500f-4775-9303-58936ac5dcf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c4685553-9053-463e-87fc-a89e5d5656f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2f028f19-5a0a-4230-97e7-13ccf57a44df" xlink:to="loc_us-gaap_NetIncomeLoss_c4685553-9053-463e-87fc-a89e5d5656f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_bd1a5d01-0737-43c2-9147-69c62e0c1985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2f028f19-5a0a-4230-97e7-13ccf57a44df" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_bd1a5d01-0737-43c2-9147-69c62e0c1985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fb0ea623-0442-40ae-88bb-c33d5a4f23ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2f028f19-5a0a-4230-97e7-13ccf57a44df" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_fb0ea623-0442-40ae-88bb-c33d5a4f23ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7113e2ba-3862-43f6-b2cf-0cdee66744b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2f028f19-5a0a-4230-97e7-13ccf57a44df" xlink:to="loc_us-gaap_EarningsPerShareBasic_7113e2ba-3862-43f6-b2cf-0cdee66744b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4122dfef-5012-4b74-9e6e-a690f0702d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2f028f19-5a0a-4230-97e7-13ccf57a44df" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4122dfef-5012-4b74-9e6e-a690f0702d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a084127c-1f96-4fa8-bb1d-236dd30ccd39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2f028f19-5a0a-4230-97e7-13ccf57a44df" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a084127c-1f96-4fa8-bb1d-236dd30ccd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e0c40fb6-67c9-4e55-9d58-2fae7232bb32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2f028f19-5a0a-4230-97e7-13ccf57a44df" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e0c40fb6-67c9-4e55-9d58-2fae7232bb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sttk-20230331.xsd#CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4b935567-c5e8-44e5-a4e6-520c0c14a903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_99f5769c-f5ec-456f-9a7d-8b86fe75fefb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4b935567-c5e8-44e5-a4e6-520c0c14a903" xlink:to="loc_us-gaap_StatementTable_99f5769c-f5ec-456f-9a7d-8b86fe75fefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7ebcb0fb-5ab3-40e2-90f2-152e60e8733a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_99f5769c-f5ec-456f-9a7d-8b86fe75fefb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7ebcb0fb-5ab3-40e2-90f2-152e60e8733a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_339044a5-1719-47af-ac17-b7f498a0a58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7ebcb0fb-5ab3-40e2-90f2-152e60e8733a" xlink:to="loc_us-gaap_EquityComponentDomain_339044a5-1719-47af-ac17-b7f498a0a58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b3fa8a22-e824-4517-b3bc-1e8a154470bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_339044a5-1719-47af-ac17-b7f498a0a58f" xlink:to="loc_us-gaap_CommonStockMember_b3fa8a22-e824-4517-b3bc-1e8a154470bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fe72b95b-30e0-44fb-a4a5-28a3013b6f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_339044a5-1719-47af-ac17-b7f498a0a58f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fe72b95b-30e0-44fb-a4a5-28a3013b6f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a4ae2912-0b90-4ec2-bdb5-a153180191b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_339044a5-1719-47af-ac17-b7f498a0a58f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a4ae2912-0b90-4ec2-bdb5-a153180191b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_77585f0e-43c7-4cdd-be0c-57ed99695ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_339044a5-1719-47af-ac17-b7f498a0a58f" xlink:to="loc_us-gaap_RetainedEarningsMember_77585f0e-43c7-4cdd-be0c-57ed99695ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1a79a40a-751c-4718-8262-1a425854574b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_99f5769c-f5ec-456f-9a7d-8b86fe75fefb" xlink:to="loc_us-gaap_StatementLineItems_1a79a40a-751c-4718-8262-1a425854574b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1a79a40a-751c-4718-8262-1a425854574b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a4109176-a088-409e-ac8c-be4a47825499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_SharesOutstanding_a4109176-a088-409e-ac8c-be4a47825499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_60bcb954-c157-4d4d-ae58-c6dee2747871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_StockholdersEquity_60bcb954-c157-4d4d-ae58-c6dee2747871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_0f8f5cf2-341d-4d29-8116-757e5e744cc2" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod_0f8f5cf2-341d-4d29-8116-757e5e744cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_c4c8e7d2-3f95-4dbc-b293-f21a21f868d9" xlink:href="sttk-20230331.xsd#sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased_c4c8e7d2-3f95-4dbc-b293-f21a21f868d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0b8ecb21-83b8-4d84-93e2-f5ad3fa609a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0b8ecb21-83b8-4d84-93e2-f5ad3fa609a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_b5396bf2-ffab-486e-93a9-1332ea652707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_b5396bf2-ffab-486e-93a9-1332ea652707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1cc10a64-a654-433f-ac4e-1f044bc73c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1cc10a64-a654-433f-ac4e-1f044bc73c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_bc8749ce-18af-47eb-8bb8-032a7de677b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_bc8749ce-18af-47eb-8bb8-032a7de677b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0ec9f995-90b2-4c4e-8f40-bf698e7f86e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_0ec9f995-90b2-4c4e-8f40-bf698e7f86e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_42a6f176-0a79-4c05-8536-71ad07a951c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_NetIncomeLoss_42a6f176-0a79-4c05-8536-71ad07a951c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_dcc65a81-b0cd-4803-b762-b6e9db0936d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_SharesOutstanding_dcc65a81-b0cd-4803-b762-b6e9db0936d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f34fa36e-b5d5-404e-be39-d722977d6aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9b23786-ed7d-4727-9a41-c523ffced4e2" xlink:to="loc_us-gaap_StockholdersEquity_f34fa36e-b5d5-404e-be39-d722977d6aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sttk-20230331.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_61a51ffe-291b-4de5-b110-0949a25bc9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_655d85bb-7b34-4c64-9cdc-2d243c89d92d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_61a51ffe-291b-4de5-b110-0949a25bc9e7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_655d85bb-7b34-4c64-9cdc-2d243c89d92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4271a6fc-9c5b-47da-a311-cb2f3b58894a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_655d85bb-7b34-4c64-9cdc-2d243c89d92d" xlink:to="loc_us-gaap_NetIncomeLoss_4271a6fc-9c5b-47da-a311-cb2f3b58894a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f5e09da-d81e-4568-9b78-02d0663e5766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_655d85bb-7b34-4c64-9cdc-2d243c89d92d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f5e09da-d81e-4568-9b78-02d0663e5766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5ad108fd-3f3a-427e-b5b5-534eb0c18841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f5e09da-d81e-4568-9b78-02d0663e5766" xlink:to="loc_us-gaap_ShareBasedCompensation_5ad108fd-3f3a-427e-b5b5-534eb0c18841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_0f9caf3f-9fd9-4f4f-9be9-9e14091d560c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f5e09da-d81e-4568-9b78-02d0663e5766" xlink:to="loc_us-gaap_Depreciation_0f9caf3f-9fd9-4f4f-9be9-9e14091d560c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f4c4247f-38b5-427b-9d8e-15b968eaaa18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f5e09da-d81e-4568-9b78-02d0663e5766" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f4c4247f-38b5-427b-9d8e-15b968eaaa18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c5e2511a-d1e3-4c06-adbe-1194f1bf3914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f5e09da-d81e-4568-9b78-02d0663e5766" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c5e2511a-d1e3-4c06-adbe-1194f1bf3914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1fdd399a-201e-4083-be42-dbab76f27c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2f5e09da-d81e-4568-9b78-02d0663e5766" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1fdd399a-201e-4083-be42-dbab76f27c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1223f097-cd98-4ffd-aa52-6b87e2c725a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1fdd399a-201e-4083-be42-dbab76f27c9f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1223f097-cd98-4ffd-aa52-6b87e2c725a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_59e09b24-16d8-404a-a457-d64123693041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1fdd399a-201e-4083-be42-dbab76f27c9f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_59e09b24-16d8-404a-a457-d64123693041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_baece36e-6b06-470f-8af2-2f1292c12772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1fdd399a-201e-4083-be42-dbab76f27c9f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_baece36e-6b06-470f-8af2-2f1292c12772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_89d08a7e-fb9f-4ce8-baff-96fce0518022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1fdd399a-201e-4083-be42-dbab76f27c9f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_89d08a7e-fb9f-4ce8-baff-96fce0518022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a376086b-5dc7-43f7-bea4-2129e0eb036a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1fdd399a-201e-4083-be42-dbab76f27c9f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_a376086b-5dc7-43f7-bea4-2129e0eb036a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b63d600c-9b42-4766-812d-f393ac5e08c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1fdd399a-201e-4083-be42-dbab76f27c9f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b63d600c-9b42-4766-812d-f393ac5e08c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f272f9ce-8b7d-429f-b592-b9396a9352ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1fdd399a-201e-4083-be42-dbab76f27c9f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f272f9ce-8b7d-429f-b592-b9396a9352ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9ec3e85-e8bd-43a8-97d0-c6bef574f212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_61a51ffe-291b-4de5-b110-0949a25bc9e7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9ec3e85-e8bd-43a8-97d0-c6bef574f212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_83a2a3eb-421d-412f-a1ad-e8d94549b635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9ec3e85-e8bd-43a8-97d0-c6bef574f212" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_83a2a3eb-421d-412f-a1ad-e8d94549b635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm_f32623d2-4d63-4e20-9127-a77b9f963058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9ec3e85-e8bd-43a8-97d0-c6bef574f212" xlink:to="loc_us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm_f32623d2-4d63-4e20-9127-a77b9f963058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee206129-74e2-459d-bbd0-3fea05b86cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b9ec3e85-e8bd-43a8-97d0-c6bef574f212" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee206129-74e2-459d-bbd0-3fea05b86cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e27d56e1-60ce-471e-8d64-7e021aea34db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_61a51ffe-291b-4de5-b110-0949a25bc9e7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e27d56e1-60ce-471e-8d64-7e021aea34db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_a8074298-6809-407c-a820-24207a15778c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e27d56e1-60ce-471e-8d64-7e021aea34db" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_a8074298-6809-407c-a820-24207a15778c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ded4b0e4-37b3-47fe-864f-09323e481568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e27d56e1-60ce-471e-8d64-7e021aea34db" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ded4b0e4-37b3-47fe-864f-09323e481568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_627ee2be-f142-4507-9198-16540a9f36ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e27d56e1-60ce-471e-8d64-7e021aea34db" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_627ee2be-f142-4507-9198-16540a9f36ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3b8f1a8a-c660-436e-a8d5-f5ef126d3625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_61a51ffe-291b-4de5-b110-0949a25bc9e7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3b8f1a8a-c660-436e-a8d5-f5ef126d3625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_831f272d-ba35-4cd3-942d-b14fb151d8df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_61a51ffe-291b-4de5-b110-0949a25bc9e7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_831f272d-ba35-4cd3-942d-b14fb151d8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ea466b5d-1bd2-46c8-b82e-65a2fe47fdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_61a51ffe-291b-4de5-b110-0949a25bc9e7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ea466b5d-1bd2-46c8-b82e-65a2fe47fdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_da672aa5-84cf-4960-af3e-5e456060eb19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_61a51ffe-291b-4de5-b110-0949a25bc9e7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_da672aa5-84cf-4960-af3e-5e456060eb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets_c15435ab-4534-4358-ac5f-3050aa6f27e7" xlink:href="sttk-20230331.xsd#sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_da672aa5-84cf-4960-af3e-5e456060eb19" xlink:to="loc_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets_c15435ab-4534-4358-ac5f-3050aa6f27e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1ee67767-a01b-4357-85e1-20f55e0518c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_da672aa5-84cf-4960-af3e-5e456060eb19" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1ee67767-a01b-4357-85e1-20f55e0518c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived_1f6055a9-9962-4ca7-95ac-ad5473eedd7b" xlink:href="sttk-20230331.xsd#sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_da672aa5-84cf-4960-af3e-5e456060eb19" xlink:to="loc_sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived_1f6055a9-9962-4ca7-95ac-ad5473eedd7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_503d7e6c-0411-4088-abe5-28861d023b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_da672aa5-84cf-4960-af3e-5e456060eb19" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_503d7e6c-0411-4088-abe5-28861d023b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="sttk-20230331.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b4b950b4-374a-4944-8c18-cd289569a32c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_80e364b9-3f3c-471d-a8bc-8076dec36652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b4b950b4-374a-4944-8c18-cd289569a32c" xlink:to="loc_us-gaap_NatureOfOperations_80e364b9-3f3c-471d-a8bc-8076dec36652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="sttk-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_02b0c97c-a4f0-441b-9175-94da8da05bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_46e6f9a9-2068-4bc7-bb2f-7b67228912c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_02b0c97c-a4f0-441b-9175-94da8da05bfd" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_46e6f9a9-2068-4bc7-bb2f-7b67228912c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/Investments" xlink:type="simple" xlink:href="sttk-20230331.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8fc88654-abea-42c5-8f5f-ce0466a4f4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_302bbeb6-5586-4c69-b9f2-38ec83907277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8fc88654-abea-42c5-8f5f-ce0466a4f4ee" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_302bbeb6-5586-4c69-b9f2-38ec83907277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="simple" xlink:href="sttk-20230331.xsd#AccruedExpensesandOtherCurrentLiabilities"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c1dbd138-bbdc-403a-af5e-05972de1a8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d7c0be9b-ead2-4808-8a29-9d000388931a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c1dbd138-bbdc-403a-af5e-05972de1a8d3" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d7c0be9b-ead2-4808-8a29-9d000388931a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sttk-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8afc085e-8a80-48ce-88e4-e32531796c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f3b5b65c-6c5e-4f06-90ed-3cda060e591a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8afc085e-8a80-48ce-88e4-e32531796c99" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f3b5b65c-6c5e-4f06-90ed-3cda060e591a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/Equity" xlink:type="simple" xlink:href="sttk-20230331.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4237441d-2d5e-482f-8653-d58a99adbebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b55bd6d2-9031-4ab4-a62a-cd0c0de12700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4237441d-2d5e-482f-8653-d58a99adbebd" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b55bd6d2-9031-4ab4-a62a-cd0c0de12700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="sttk-20230331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd081e3a-ddd7-45b3-b20c-6c6451e513a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7a86744f-2742-46a3-84ef-7663561b0937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fd081e3a-ddd7-45b3-b20c-6c6451e513a0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7a86744f-2742-46a3-84ef-7663561b0937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sttk-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bd2e954-e5de-4b8e-8871-9a6f10386352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f1b66b38-9461-4ffb-955e-b236b1515f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bd2e954-e5de-4b8e-8871-9a6f10386352" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f1b66b38-9461-4ffb-955e-b236b1515f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_25010956-f156-4800-b199-11eb338f4d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bd2e954-e5de-4b8e-8871-9a6f10386352" xlink:to="loc_us-gaap_UseOfEstimates_25010956-f156-4800-b199-11eb338f4d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_422ef7c0-cd75-4705-bd4c-60a500b027ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bd2e954-e5de-4b8e-8871-9a6f10386352" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_422ef7c0-cd75-4705-bd4c-60a500b027ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_b2370463-afc8-4b56-853e-e8b60038d933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bd2e954-e5de-4b8e-8871-9a6f10386352" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_b2370463-afc8-4b56-853e-e8b60038d933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_84f53686-756b-4bfb-9031-3474bb74d299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bd2e954-e5de-4b8e-8871-9a6f10386352" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_84f53686-756b-4bfb-9031-3474bb74d299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_9406958f-26e6-4da6-afb0-308aca4f1a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bd2e954-e5de-4b8e-8871-9a6f10386352" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_9406958f-26e6-4da6-afb0-308aca4f1a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_5073f1d2-e179-4d7e-a977-12f2f62923d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bd2e954-e5de-4b8e-8871-9a6f10386352" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_5073f1d2-e179-4d7e-a977-12f2f62923d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_3b45235c-c478-4940-9ece-7fb5e136dee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bd2e954-e5de-4b8e-8871-9a6f10386352" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_3b45235c-c478-4940-9ece-7fb5e136dee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_30cf3867-d5a6-4f95-bb9e-2e1c7e403835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bd2e954-e5de-4b8e-8871-9a6f10386352" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_30cf3867-d5a6-4f95-bb9e-2e1c7e403835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_074b01d0-cf03-4dff-8f47-4c2a01321aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bd2e954-e5de-4b8e-8871-9a6f10386352" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_074b01d0-cf03-4dff-8f47-4c2a01321aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7d2a323a-b9d9-4147-86dc-6b20804f5c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bd2e954-e5de-4b8e-8871-9a6f10386352" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7d2a323a-b9d9-4147-86dc-6b20804f5c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_aa1b0961-0df7-4ccd-b1a4-b7b194a1fd73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bd2e954-e5de-4b8e-8871-9a6f10386352" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_aa1b0961-0df7-4ccd-b1a4-b7b194a1fd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_123e590c-e3a4-4a5b-8603-97627b51a028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bd2e954-e5de-4b8e-8871-9a6f10386352" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_123e590c-e3a4-4a5b-8603-97627b51a028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_d7d8963c-a6f8-4610-a227-ee30fe765c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bd2e954-e5de-4b8e-8871-9a6f10386352" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_d7d8963c-a6f8-4610-a227-ee30fe765c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_04dc748b-a2b8-4257-9228-7abeffba89e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8bd2e954-e5de-4b8e-8871-9a6f10386352" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_04dc748b-a2b8-4257-9228-7abeffba89e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="sttk-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3ad029c8-faf2-491a-a797-0352c377cc40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_626790fb-f65c-405e-b625-581b894086dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3ad029c8-faf2-491a-a797-0352c377cc40" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_626790fb-f65c-405e-b625-581b894086dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/InvestmentsTables" xlink:type="simple" xlink:href="sttk-20230331.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5d1e9c13-9e75-4970-973d-e6aa241cdbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_527d2554-6609-4b9c-82fd-efe8d7da6688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5d1e9c13-9e75-4970-973d-e6aa241cdbb3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_527d2554-6609-4b9c-82fd-efe8d7da6688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="sttk-20230331.xsd#AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_f2c37a33-c00a-4e01-84f5-f15d7d1dc37a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_daac2b17-d4c0-44a2-95c9-7ac8f3a2354f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f2c37a33-c00a-4e01-84f5-f15d7d1dc37a" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_daac2b17-d4c0-44a2-95c9-7ac8f3a2354f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="sttk-20230331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1b4eca4f-f052-4451-bc63-3528be08d507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_19248269-5515-45ea-baef-149c5500825a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1b4eca4f-f052-4451-bc63-3528be08d507" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_19248269-5515-45ea-baef-149c5500825a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4d5e86f9-8532-4495-82b6-e06c2327bd05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1b4eca4f-f052-4451-bc63-3528be08d507" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_4d5e86f9-8532-4495-82b6-e06c2327bd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_73a33a15-1942-46d8-bb5e-c4c91a4e20e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1b4eca4f-f052-4451-bc63-3528be08d507" xlink:to="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_73a33a15-1942-46d8-bb5e-c4c91a4e20e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_036e846b-8ef7-4f3e-bf34-98ea3523b7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1b4eca4f-f052-4451-bc63-3528be08d507" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_036e846b-8ef7-4f3e-bf34-98ea3523b7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#OrganizationandDescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_999d1b40-5419-4de8-90c1-f77cafba44f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_NumberOfClinicalStageProductCandidates_5d6ccaa6-7284-4d78-b354-46c16649d9e7" xlink:href="sttk-20230331.xsd#sttk_NumberOfClinicalStageProductCandidates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_999d1b40-5419-4de8-90c1-f77cafba44f4" xlink:to="loc_sttk_NumberOfClinicalStageProductCandidates_5d6ccaa6-7284-4d78-b354-46c16649d9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a9460ff8-68b0-442a-aee9-9c84bc91d9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_999d1b40-5419-4de8-90c1-f77cafba44f4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a9460ff8-68b0-442a-aee9-9c84bc91d9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0d9e9760-753a-490e-a458-71dedbb34ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_999d1b40-5419-4de8-90c1-f77cafba44f4" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0d9e9760-753a-490e-a458-71dedbb34ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a075e4cc-40cd-4f55-86cf-2ef6ebba509a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a2c23fc4-021a-40e9-b17d-2e70fed470ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a075e4cc-40cd-4f55-86cf-2ef6ebba509a" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a2c23fc4-021a-40e9-b17d-2e70fed470ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_f998d2c4-ee2c-4592-a680-e3de6c58bd97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a2c23fc4-021a-40e9-b17d-2e70fed470ab" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_f998d2c4-ee2c-4592-a680-e3de6c58bd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_edea96c9-935e-47bc-971c-7d01fab8159c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_f998d2c4-ee2c-4592-a680-e3de6c58bd97" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_edea96c9-935e-47bc-971c-7d01fab8159c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_OperatingAccountMember_90b58dec-a654-4fd4-afbd-f3a043b3a0f4" xlink:href="sttk-20230331.xsd#sttk_OperatingAccountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_edea96c9-935e-47bc-971c-7d01fab8159c" xlink:to="loc_sttk_OperatingAccountMember_90b58dec-a654-4fd4-afbd-f3a043b3a0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_438f295f-d928-455f-81cc-0e44811c309a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_edea96c9-935e-47bc-971c-7d01fab8159c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_438f295f-d928-455f-81cc-0e44811c309a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_8310d917-7d5e-4a04-ab9c-e8080a7d7126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_a2c23fc4-021a-40e9-b17d-2e70fed470ab" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_8310d917-7d5e-4a04-ab9c-e8080a7d7126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b9acfc0-3d48-4b3b-a8c5-65f2f061fa26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_8310d917-7d5e-4a04-ab9c-e8080a7d7126" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6b9acfc0-3d48-4b3b-a8c5-65f2f061fa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_4abb23f4-65c4-4dec-bb7f-2555765ce833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_8310d917-7d5e-4a04-ab9c-e8080a7d7126" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_4abb23f4-65c4-4dec-bb7f-2555765ce833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6db22af-2ea3-4acc-bfc4-d8b17870960a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d07fafc8-5299-4905-bbce-727bdee5f72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f6db22af-2ea3-4acc-bfc4-d8b17870960a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d07fafc8-5299-4905-bbce-727bdee5f72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a7a188d2-cd8f-46cc-a5d0-ac571e667341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d07fafc8-5299-4905-bbce-727bdee5f72f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a7a188d2-cd8f-46cc-a5d0-ac571e667341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c4f74b-15ce-4bca-9bd8-8c43c97211f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a7a188d2-cd8f-46cc-a5d0-ac571e667341" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c4f74b-15ce-4bca-9bd8-8c43c97211f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d7449870-9d56-4ae2-9616-0bb3e639b574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c4f74b-15ce-4bca-9bd8-8c43c97211f3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d7449870-9d56-4ae2-9616-0bb3e639b574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_197a5bee-6082-4861-85ca-d4871c4a63ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a8c4f74b-15ce-4bca-9bd8-8c43c97211f3" xlink:to="loc_us-gaap_RestrictedStockMember_197a5bee-6082-4861-85ca-d4871c4a63ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_525704b9-b8c2-4399-98b7-aad6bd80fa08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d07fafc8-5299-4905-bbce-727bdee5f72f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_525704b9-b8c2-4399-98b7-aad6bd80fa08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_106a24ff-56e9-466a-ba73-7ae95d1fcebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_525704b9-b8c2-4399-98b7-aad6bd80fa08" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_106a24ff-56e9-466a-ba73-7ae95d1fcebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#InvestmentsScheduleofavailableforsaleinvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_628b7dd1-3445-44ce-9231-051877317bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3b646ad5-464b-431c-bd8f-d4b93e99b1df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_628b7dd1-3445-44ce-9231-051877317bb5" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3b646ad5-464b-431c-bd8f-d4b93e99b1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_73b9b16d-441a-494b-b56a-6e5e84eb39d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3b646ad5-464b-431c-bd8f-d4b93e99b1df" xlink:to="loc_us-gaap_FinancialInstrumentAxis_73b9b16d-441a-494b-b56a-6e5e84eb39d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bdc41e84-5b48-429d-90ed-c6cad6cae3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_73b9b16d-441a-494b-b56a-6e5e84eb39d6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bdc41e84-5b48-429d-90ed-c6cad6cae3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7ef94de1-dadd-4395-8f7f-ccbf0433fb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bdc41e84-5b48-429d-90ed-c6cad6cae3ba" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7ef94de1-dadd-4395-8f7f-ccbf0433fb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b69b5429-7264-4e84-b284-8b67d5f1aee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_3b646ad5-464b-431c-bd8f-d4b93e99b1df" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b69b5429-7264-4e84-b284-8b67d5f1aee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAbstract_bd64a894-d283-4999-a4e6-52fd18569800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_b69b5429-7264-4e84-b284-8b67d5f1aee4" xlink:to="loc_us-gaap_DebtSecuritiesAbstract_bd64a894-d283-4999-a4e6-52fd18569800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e12a3ce2-58e7-487e-8795-26c7a6598108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_bd64a894-d283-4999-a4e6-52fd18569800" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e12a3ce2-58e7-487e-8795-26c7a6598108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_5a0523fb-2b57-40ba-9653-8140e946fb39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_bd64a894-d283-4999-a4e6-52fd18569800" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_5a0523fb-2b57-40ba-9653-8140e946fb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2b9daf69-94f3-40e8-9913-ecaee5965207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAbstract_bd64a894-d283-4999-a4e6-52fd18569800" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2b9daf69-94f3-40e8-9913-ecaee5965207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c7efd156-6f8e-4e70-97d3-466e765c947f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_7b755909-1bf4-45d2-9bb9-035011c991b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c7efd156-6f8e-4e70-97d3-466e765c947f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_7b755909-1bf4-45d2-9bb9-035011c991b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d3689b5d-66fc-4c58-9955-70ace411bfbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedResearchAndContractCostsCurrent_9188dc30-58b3-43e9-ab01-87ba5aae685f" xlink:href="sttk-20230331.xsd#sttk_AccruedResearchAndContractCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d3689b5d-66fc-4c58-9955-70ace411bfbd" xlink:to="loc_sttk_AccruedResearchAndContractCostsCurrent_9188dc30-58b3-43e9-ab01-87ba5aae685f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_82dc2cb2-3df0-45cd-aa8d-c6c01281152a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d3689b5d-66fc-4c58-9955-70ace411bfbd" xlink:to="loc_us-gaap_LitigationReserveCurrent_82dc2cb2-3df0-45cd-aa8d-c6c01281152a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b727b2d7-a1ab-4169-a556-07ce7058e964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d3689b5d-66fc-4c58-9955-70ace411bfbd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b727b2d7-a1ab-4169-a556-07ce7058e964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_77eb5933-0e11-4986-818d-d8d5a46bd280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d3689b5d-66fc-4c58-9955-70ace411bfbd" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_77eb5933-0e11-4986-818d-d8d5a46bd280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_c3bdee60-b743-416d-a79f-798635c49664" xlink:href="sttk-20230331.xsd#sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d3689b5d-66fc-4c58-9955-70ace411bfbd" xlink:to="loc_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent_c3bdee60-b743-416d-a79f-798635c49664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8aada687-5a7d-4982-8ec0-167496ee73db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_LicenseAgreementRoyaltyPaymentsMaximum_ff662916-1726-42cd-bc1a-7955f70938a0" xlink:href="sttk-20230331.xsd#sttk_LicenseAgreementRoyaltyPaymentsMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8aada687-5a7d-4982-8ec0-167496ee73db" xlink:to="loc_sttk_LicenseAgreementRoyaltyPaymentsMaximum_ff662916-1726-42cd-bc1a-7955f70938a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_4a01a1ad-4579-44bc-8919-73a5d4a7d150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8aada687-5a7d-4982-8ec0-167496ee73db" xlink:to="loc_us-gaap_PaymentsForRoyalties_4a01a1ad-4579-44bc-8919-73a5d4a7d150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_b9a51e74-9d1e-4a81-b5db-0f016d20f3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8aada687-5a7d-4982-8ec0-167496ee73db" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_b9a51e74-9d1e-4a81-b5db-0f016d20f3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_1335d16b-f9ed-4ac2-8df9-c0e438834662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8aada687-5a7d-4982-8ec0-167496ee73db" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_1335d16b-f9ed-4ac2-8df9-c0e438834662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/EquityDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#EquityDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/EquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_191a95b7-71f4-4696-9f79-ecc28603f2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0e416b7e-2c67-4799-9cf2-42efbaa97080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_191a95b7-71f4-4696-9f79-ecc28603f2d9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0e416b7e-2c67-4799-9cf2-42efbaa97080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4d91390b-0572-4f69-8ea4-4cb7642ff850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_191a95b7-71f4-4696-9f79-ecc28603f2d9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4d91390b-0572-4f69-8ea4-4cb7642ff850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_53e1ce03-6b86-42a4-9de1-45fcfb5b8a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_191a95b7-71f4-4696-9f79-ecc28603f2d9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_53e1ce03-6b86-42a4-9de1-45fcfb5b8a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_edd87bd9-7d6b-4a31-94c8-e5f9c13b9e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_191a95b7-71f4-4696-9f79-ecc28603f2d9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_edd87bd9-7d6b-4a31-94c8-e5f9c13b9e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_014558ec-896d-4546-8693-ff8c161a2f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_191a95b7-71f4-4696-9f79-ecc28603f2d9" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_014558ec-896d-4546-8693-ff8c161a2f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_170a2d80-7dd5-48b8-8c7c-0d698d3bfd50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2955cbd4-aa3a-478b-a8eb-a15c33bc75ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_170a2d80-7dd5-48b8-8c7c-0d698d3bfd50" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2955cbd4-aa3a-478b-a8eb-a15c33bc75ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_49ed6034-14e9-4224-a789-793b5810d221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2955cbd4-aa3a-478b-a8eb-a15c33bc75ad" xlink:to="loc_us-gaap_PlanNameAxis_49ed6034-14e9-4224-a789-793b5810d221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3ceae33d-0896-4117-8535-4c7bdbdd78b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_49ed6034-14e9-4224-a789-793b5810d221" xlink:to="loc_us-gaap_PlanNameDomain_3ceae33d-0896-4117-8535-4c7bdbdd78b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_58fe277f-6d62-40cb-9fc6-f7cb5fe5545c" xlink:href="sttk-20230331.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3ceae33d-0896-4117-8535-4c7bdbdd78b4" xlink:to="loc_sttk_A2020StockIncentivePlanMember_58fe277f-6d62-40cb-9fc6-f7cb5fe5545c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_a2b1ad1c-e86a-447f-b8c7-3f805708fb76" xlink:href="sttk-20230331.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3ceae33d-0896-4117-8535-4c7bdbdd78b4" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_a2b1ad1c-e86a-447f-b8c7-3f805708fb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_32575bff-c719-4f91-b90c-5853295b97c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2955cbd4-aa3a-478b-a8eb-a15c33bc75ad" xlink:to="loc_us-gaap_AwardTypeAxis_32575bff-c719-4f91-b90c-5853295b97c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5065b02b-d812-408e-965e-f454a64ecb80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_32575bff-c719-4f91-b90c-5853295b97c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5065b02b-d812-408e-965e-f454a64ecb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fc44725d-8710-4e34-96ed-07a9f9da6a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5065b02b-d812-408e-965e-f454a64ecb80" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fc44725d-8710-4e34-96ed-07a9f9da6a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_559262e1-db4b-44d4-a821-db2a7f315740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5065b02b-d812-408e-965e-f454a64ecb80" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_559262e1-db4b-44d4-a821-db2a7f315740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2955cbd4-aa3a-478b-a8eb-a15c33bc75ad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_1a6d77c9-5413-449f-8ce0-58328ce3badb" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage_1a6d77c9-5413-449f-8ce0-58328ce3badb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_eb7f8258-4a54-46ad-b02f-468d7361f35f" xlink:href="sttk-20230331.xsd#sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_eb7f8258-4a54-46ad-b02f-468d7361f35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9a2196af-2a8d-4122-bfa9-87727d6c2e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9a2196af-2a8d-4122-bfa9-87727d6c2e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5e65c2c3-b41c-47b3-8008-8e657e229870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5e65c2c3-b41c-47b3-8008-8e657e229870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_01b5286f-abea-4339-ae8d-707f4ca02ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_01b5286f-abea-4339-ae8d-707f4ca02ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod_d79f21b1-9244-4d28-b5c2-601a34b9820c" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod_d79f21b1-9244-4d28-b5c2-601a34b9820c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches_f7449ab8-aa5f-40b4-9972-c895a4609e1e" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches_f7449ab8-aa5f-40b4-9972-c895a4609e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays_b1dbbcd9-2850-4e00-8266-799457c00d12" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays_b1dbbcd9-2850-4e00-8266-799457c00d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_9d4c269c-349a-4200-acf4-d4d6814eb1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_9d4c269c-349a-4200-acf4-d4d6814eb1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f468a9dd-c626-452d-8125-b9b1e35696f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f468a9dd-c626-452d-8125-b9b1e35696f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_779ab185-0ee5-447f-b438-73a308c0daef" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue_779ab185-0ee5-447f-b438-73a308c0daef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_8359e1f9-f16e-4180-9fa9-e1ac4e3c64d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_8359e1f9-f16e-4180-9fa9-e1ac4e3c64d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_f7e9b224-7fe2-466e-8184-f7c9ac577bed" xlink:href="sttk-20230331.xsd#sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm_f7e9b224-7fe2-466e-8184-f7c9ac577bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6f5cc7c1-1aac-4dcd-90d0-60721df08d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6f5cc7c1-1aac-4dcd-90d0-60721df08d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_bb311342-caa2-4863-9ea0-1b6a1d8e20f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ProceedsFromStockPlans_bb311342-caa2-4863-9ea0-1b6a1d8e20f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5e5b28d2-61cb-4e02-8232-2d4c92a9da1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5e5b28d2-61cb-4e02-8232-2d4c92a9da1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e8a40641-a276-4c35-b9d1-f56ee5c39588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e8a40641-a276-4c35-b9d1-f56ee5c39588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ae1a4e16-4825-4432-93dc-2ddfecf2cfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ae1a4e16-4825-4432-93dc-2ddfecf2cfe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8a224cfd-df8a-4415-80ae-c0ea5e2d505c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8a224cfd-df8a-4415-80ae-c0ea5e2d505c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b3471eee-08fa-4e9a-8f30-d62e1937f5df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b3471eee-08fa-4e9a-8f30-d62e1937f5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d0a2590d-38b8-4cb0-8c26-35e670a31814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d0a2590d-38b8-4cb0-8c26-35e670a31814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3dabca22-f922-4875-a8b1-c5db654c7a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3dabca22-f922-4875-a8b1-c5db654c7a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d63f9dd0-15dc-41fe-a1e6-a4df0792b72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d63f9dd0-15dc-41fe-a1e6-a4df0792b72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_80333a6c-840b-4c2d-8bfc-8f92d1b6ecaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_83e311d7-84aa-497b-bc4a-eef702727680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_80333a6c-840b-4c2d-8bfc-8f92d1b6ecaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_57bac291-7969-4ba8-ae59-552392f7c68c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e513f8ed-73ab-421b-b7fb-bacaf757ef33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_57bac291-7969-4ba8-ae59-552392f7c68c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e513f8ed-73ab-421b-b7fb-bacaf757ef33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_38b9c334-a141-437d-94f5-cdc684a98d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e513f8ed-73ab-421b-b7fb-bacaf757ef33" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_38b9c334-a141-437d-94f5-cdc684a98d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_48888085-93f9-4be5-9ca6-d5d05003b385" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_38b9c334-a141-437d-94f5-cdc684a98d38" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_48888085-93f9-4be5-9ca6-d5d05003b385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e616f5b2-179e-4b75-a7d1-742055606a16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_48888085-93f9-4be5-9ca6-d5d05003b385" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e616f5b2-179e-4b75-a7d1-742055606a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_75ebc6d2-3d06-4910-afd0-33b9900e6cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_48888085-93f9-4be5-9ca6-d5d05003b385" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_75ebc6d2-3d06-4910-afd0-33b9900e6cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_53e54a46-78e1-492a-98b0-d41664492edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e513f8ed-73ab-421b-b7fb-bacaf757ef33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_53e54a46-78e1-492a-98b0-d41664492edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b82034b5-6a01-4538-ab3f-9a24fce550eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_53e54a46-78e1-492a-98b0-d41664492edd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b82034b5-6a01-4538-ab3f-9a24fce550eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#StockBasedCompensationScheduleofoptionactivityDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1ba66aa-ff3f-47e3-aa5a-41c5d27f330f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_df03de31-f2db-4273-9603-d3b65640d5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1ba66aa-ff3f-47e3-aa5a-41c5d27f330f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_df03de31-f2db-4273-9603-d3b65640d5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ff21fa90-25a3-47d0-a23a-cc7eb6473a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_df03de31-f2db-4273-9603-d3b65640d5f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ff21fa90-25a3-47d0-a23a-cc7eb6473a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_75e66f89-9cec-4de4-b1e3-7850e95c24d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_df03de31-f2db-4273-9603-d3b65640d5f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_75e66f89-9cec-4de4-b1e3-7850e95c24d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_034348f8-3235-4820-b244-73e51a98d2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_df03de31-f2db-4273-9603-d3b65640d5f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_034348f8-3235-4820-b244-73e51a98d2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_153574e2-64e9-4323-b012-e48d72290f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_df03de31-f2db-4273-9603-d3b65640d5f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_153574e2-64e9-4323-b012-e48d72290f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d9e80d99-7aa9-413e-90bf-b90755e9a57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_df03de31-f2db-4273-9603-d3b65640d5f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d9e80d99-7aa9-413e-90bf-b90755e9a57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e1bcfd33-cf28-4d18-846c-4991a09b8d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_df03de31-f2db-4273-9603-d3b65640d5f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e1bcfd33-cf28-4d18-846c-4991a09b8d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2cc0f51f-9b7c-43ab-b444-6a90b4d16a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_df03de31-f2db-4273-9603-d3b65640d5f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2cc0f51f-9b7c-43ab-b444-6a90b4d16a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d089a4d4-7f9f-426a-9c0e-cf89cba2b859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1ba66aa-ff3f-47e3-aa5a-41c5d27f330f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d089a4d4-7f9f-426a-9c0e-cf89cba2b859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_42508b03-9ad9-4d8e-b56c-d7327a07a225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d089a4d4-7f9f-426a-9c0e-cf89cba2b859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_42508b03-9ad9-4d8e-b56c-d7327a07a225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c32a762e-3a93-4e6e-b8c1-8307c1f8f46f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d089a4d4-7f9f-426a-9c0e-cf89cba2b859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c32a762e-3a93-4e6e-b8c1-8307c1f8f46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_eee2f443-6dfb-43b7-b1b2-83517ce5d642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d089a4d4-7f9f-426a-9c0e-cf89cba2b859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_eee2f443-6dfb-43b7-b1b2-83517ce5d642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b559cb60-a683-491d-886e-0e62ed3e4392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d089a4d4-7f9f-426a-9c0e-cf89cba2b859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b559cb60-a683-491d-886e-0e62ed3e4392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4b7b23f2-41c3-494b-b8a4-01d0c363d3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d089a4d4-7f9f-426a-9c0e-cf89cba2b859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4b7b23f2-41c3-494b-b8a4-01d0c363d3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_80154b9a-90a2-465c-9c59-1cd35168be8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d089a4d4-7f9f-426a-9c0e-cf89cba2b859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_80154b9a-90a2-465c-9c59-1cd35168be8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f22c8fdd-8ae9-4ad3-8809-45e80612416d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d089a4d4-7f9f-426a-9c0e-cf89cba2b859" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_f22c8fdd-8ae9-4ad3-8809-45e80612416d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d12729af-cf53-4cee-a6f5-d1a9ff0021d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1ba66aa-ff3f-47e3-aa5a-41c5d27f330f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d12729af-cf53-4cee-a6f5-d1a9ff0021d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_efaabada-27df-4572-8c2b-e7211271b924" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d12729af-cf53-4cee-a6f5-d1a9ff0021d4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_efaabada-27df-4572-8c2b-e7211271b924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_fcdbc5f1-5ba5-47ae-9b84-df8205c1f5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d12729af-cf53-4cee-a6f5-d1a9ff0021d4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_fcdbc5f1-5ba5-47ae-9b84-df8205c1f5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_15b206bb-2cbe-4ef0-baa1-37d8fcb80703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d12729af-cf53-4cee-a6f5-d1a9ff0021d4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_15b206bb-2cbe-4ef0-baa1-37d8fcb80703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#StockBasedCompensationScheduleofrestrictedstockactivityDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68062991-ed81-48ff-b4be-40800b408369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad98ddfe-2fcd-4bbe-aa6f-b35e33d2ac3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68062991-ed81-48ff-b4be-40800b408369" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad98ddfe-2fcd-4bbe-aa6f-b35e33d2ac3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_13ce8018-fe73-4549-b2df-962aee58e7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad98ddfe-2fcd-4bbe-aa6f-b35e33d2ac3c" xlink:to="loc_us-gaap_AwardTypeAxis_13ce8018-fe73-4549-b2df-962aee58e7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d6b9123-a022-44a0-b54c-4f0b88f008d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_13ce8018-fe73-4549-b2df-962aee58e7f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d6b9123-a022-44a0-b54c-4f0b88f008d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3326a97c-f15c-453a-aead-c8148276b149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d6b9123-a022-44a0-b54c-4f0b88f008d1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3326a97c-f15c-453a-aead-c8148276b149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d569954b-dbfc-4407-870b-31c7e76bfd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ad98ddfe-2fcd-4bbe-aa6f-b35e33d2ac3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d569954b-dbfc-4407-870b-31c7e76bfd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2eaeb801-b604-447a-8023-52ec884b3f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d569954b-dbfc-4407-870b-31c7e76bfd9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2eaeb801-b604-447a-8023-52ec884b3f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1079e46d-35ec-4670-80df-0b694863a537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2eaeb801-b604-447a-8023-52ec884b3f13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1079e46d-35ec-4670-80df-0b694863a537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6f3ad6fa-3253-4395-876c-596cb5e21b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2eaeb801-b604-447a-8023-52ec884b3f13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6f3ad6fa-3253-4395-876c-596cb5e21b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9d3a0ec2-206c-44d4-8e05-3dfe0eb780ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2eaeb801-b604-447a-8023-52ec884b3f13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9d3a0ec2-206c-44d4-8e05-3dfe0eb780ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fbe14a3f-3fd8-45f1-809d-95994c2ee321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2eaeb801-b604-447a-8023-52ec884b3f13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fbe14a3f-3fd8-45f1-809d-95994c2ee321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4a5d0a00-4cbb-491f-8cf9-9418da0fb3a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2eaeb801-b604-447a-8023-52ec884b3f13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4a5d0a00-4cbb-491f-8cf9-9418da0fb3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b56dae8f-a450-432e-be65-d6cc2eba4832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d569954b-dbfc-4407-870b-31c7e76bfd9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b56dae8f-a450-432e-be65-d6cc2eba4832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e49c2360-2d36-4b18-9ff9-4898e10b4e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b56dae8f-a450-432e-be65-d6cc2eba4832" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e49c2360-2d36-4b18-9ff9-4898e10b4e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8290e568-250b-4e26-9200-d05493a5a77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b56dae8f-a450-432e-be65-d6cc2eba4832" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8290e568-250b-4e26-9200-d05493a5a77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c2dc917d-612c-4b9e-8801-2d5af43ad33b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b56dae8f-a450-432e-be65-d6cc2eba4832" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c2dc917d-612c-4b9e-8801-2d5af43ad33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fb8be4fc-1111-4efd-a391-fa01acc4bfce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b56dae8f-a450-432e-be65-d6cc2eba4832" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fb8be4fc-1111-4efd-a391-fa01acc4bfce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_75ab8599-903c-43a5-a82d-d67d8b8706f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b56dae8f-a450-432e-be65-d6cc2eba4832" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_75ab8599-903c-43a5-a82d-d67d8b8706f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" xlink:type="simple" xlink:href="sttk-20230331.xsd#StockBasedCompensationScheduleofvaluationassumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_efa06241-3174-4566-b52f-29750260f3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e22422de-865c-4c43-a417-c7d040ff2bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_efa06241-3174-4566-b52f-29750260f3ef" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e22422de-865c-4c43-a417-c7d040ff2bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_865106c5-b239-49ed-8ceb-7010ad45ebfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e22422de-865c-4c43-a417-c7d040ff2bd3" xlink:to="loc_us-gaap_AwardTypeAxis_865106c5-b239-49ed-8ceb-7010ad45ebfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7ff8ae4-f8d9-4c28-b7e8-8e345ad3335d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_865106c5-b239-49ed-8ceb-7010ad45ebfd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7ff8ae4-f8d9-4c28-b7e8-8e345ad3335d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_712cfcaa-c570-464d-b995-2500efb9ce1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7ff8ae4-f8d9-4c28-b7e8-8e345ad3335d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_712cfcaa-c570-464d-b995-2500efb9ce1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_02ea73cc-ce3c-4aeb-9b72-e35fcf175d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7ff8ae4-f8d9-4c28-b7e8-8e345ad3335d" xlink:to="loc_us-gaap_EmployeeStockMember_02ea73cc-ce3c-4aeb-9b72-e35fcf175d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b66205f8-c39f-4f25-b73e-527908d2b3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e22422de-865c-4c43-a417-c7d040ff2bd3" xlink:to="loc_us-gaap_PlanNameAxis_b66205f8-c39f-4f25-b73e-527908d2b3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_52b12b4c-27e2-49e2-8b28-00e349e770bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b66205f8-c39f-4f25-b73e-527908d2b3ec" xlink:to="loc_us-gaap_PlanNameDomain_52b12b4c-27e2-49e2-8b28-00e349e770bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020StockIncentivePlanMember_6477e1bd-4381-4e65-9c75-8d3ff302eb76" xlink:href="sttk-20230331.xsd#sttk_A2020StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_52b12b4c-27e2-49e2-8b28-00e349e770bd" xlink:to="loc_sttk_A2020StockIncentivePlanMember_6477e1bd-4381-4e65-9c75-8d3ff302eb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_A2020EmployeeStockPurchasePlanMember_24e1ed8d-449d-4dd4-bbc4-70ba88918a60" xlink:href="sttk-20230331.xsd#sttk_A2020EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_52b12b4c-27e2-49e2-8b28-00e349e770bd" xlink:to="loc_sttk_A2020EmployeeStockPurchasePlanMember_24e1ed8d-449d-4dd4-bbc4-70ba88918a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_35528d4c-6386-49c7-8ada-72e353d6460d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e22422de-865c-4c43-a417-c7d040ff2bd3" xlink:to="loc_us-gaap_ValuationTechniqueAxis_35528d4c-6386-49c7-8ada-72e353d6460d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_91eef13f-b9d7-4df8-a14f-d3b30a4e2e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_35528d4c-6386-49c7-8ada-72e353d6460d" xlink:to="loc_us-gaap_ValuationTechniqueDomain_91eef13f-b9d7-4df8-a14f-d3b30a4e2e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_BlackScholesOptionPricingModelMember_2be43dcf-e770-45e0-9464-56a9bcaba524" xlink:href="sttk-20230331.xsd#sttk_BlackScholesOptionPricingModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_91eef13f-b9d7-4df8-a14f-d3b30a4e2e89" xlink:to="loc_sttk_BlackScholesOptionPricingModelMember_2be43dcf-e770-45e0-9464-56a9bcaba524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sttk_MonteCarloOptionPricingModelMember_8a6c99ba-b236-45f2-aa7b-67bcf7d7954a" xlink:href="sttk-20230331.xsd#sttk_MonteCarloOptionPricingModelMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_91eef13f-b9d7-4df8-a14f-d3b30a4e2e89" xlink:to="loc_sttk_MonteCarloOptionPricingModelMember_8a6c99ba-b236-45f2-aa7b-67bcf7d7954a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22374bfd-e201-4acd-8e2f-1b686cb9f8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e22422de-865c-4c43-a417-c7d040ff2bd3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22374bfd-e201-4acd-8e2f-1b686cb9f8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b5b8e820-c070-4f9b-88e1-e5ba2609e781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22374bfd-e201-4acd-8e2f-1b686cb9f8e1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b5b8e820-c070-4f9b-88e1-e5ba2609e781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3d45979d-be8a-463a-9788-e9e4707d797a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22374bfd-e201-4acd-8e2f-1b686cb9f8e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3d45979d-be8a-463a-9788-e9e4707d797a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_244be0d2-6b9b-450d-983d-18fd54854e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22374bfd-e201-4acd-8e2f-1b686cb9f8e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_244be0d2-6b9b-450d-983d-18fd54854e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_feda7f7f-3c55-4dea-bed0-62b2bc9316ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_22374bfd-e201-4acd-8e2f-1b686cb9f8e1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_feda7f7f-3c55-4dea-bed0-62b2bc9316ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292429065952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVER - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Shattuck Labs, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-2575858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 W. 5th Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Austin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">78701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">900-4690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">STTK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,471,288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001680367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292432450640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 66,043<span></span>
</td>
<td class="nump">$ 47,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">69,452<span></span>
</td>
<td class="nump">113,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">22,342<span></span>
</td>
<td class="nump">23,304<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">157,837<span></span>
</td>
<td class="nump">184,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">16,887<span></span>
</td>
<td class="nump">17,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,953<span></span>
</td>
<td class="nump">3,069<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">177,677<span></span>
</td>
<td class="nump">205,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,128<span></span>
</td>
<td class="nump">7,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">10,881<span></span>
</td>
<td class="nump">17,795<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,009<span></span>
</td>
<td class="nump">24,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">4,014<span></span>
</td>
<td class="nump">4,202<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">20,023<span></span>
</td>
<td class="nump">29,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value: 300,000,000 shares authorized; 42,460,258 shares issued and outstanding at March&#160;31, 2023 and 42,390,586 shares issued and outstanding at December&#160;31, 2022</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">397,724<span></span>
</td>
<td class="nump">396,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(339)<span></span>
</td>
<td class="num">(877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(239,736)<span></span>
</td>
<td class="num">(219,012)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">157,654<span></span>
</td>
<td class="nump">176,157<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 177,677<span></span>
</td>
<td class="nump">$ 205,324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities and Other Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292431735984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - Parenthetical - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">42,460,258<span></span>
</td>
<td class="nump">42,390,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">42,460,258<span></span>
</td>
<td class="nump">42,390,586<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292426087984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible List]</a></td>
<td class="text">License [Member]<span></span>
</td>
<td class="text">License [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">16,667<span></span>
</td>
<td class="nump">19,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,051<span></span>
</td>
<td class="nump">4,979<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Expense from operations</a></td>
<td class="nump">21,718<span></span>
</td>
<td class="nump">24,166<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(21,661)<span></span>
</td>
<td class="num">(24,166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">937<span></span>
</td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,724)<span></span>
</td>
<td class="num">(24,528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on investments</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (20,186)<span></span>
</td>
<td class="num">$ (24,495)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share &#8211; basic (in dollars per share)</a></td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share &#8211; diluted (in dollars per share)</a></td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding &#8211; basic (in shares)</a></td>
<td class="nump">42,439,204<span></span>
</td>
<td class="nump">42,357,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">42,439,204<span></span>
</td>
<td class="nump">42,357,625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920602&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292431565952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,338,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 271,786<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 389,408<span></span>
</td>
<td class="num">$ (560)<span></span>
</td>
<td class="num">$ (117,067)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod', window );">Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased', window );">Exercise of stock options and purchases pursuant to employee stock purchase plan</a></td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on investments</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(24,528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,528)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,378,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">248,938<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">391,055<span></span>
</td>
<td class="num">(527)<span></span>
</td>
<td class="num">(141,595)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,390,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">176,157<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">396,041<span></span>
</td>
<td class="num">(877)<span></span>
</td>
<td class="num">(219,012)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod', window );">Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased', window );">Exercise of stock options and purchases pursuant to employee stock purchase plan</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Issuance of common stock upon settlement of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld related to net share settlement (in shares)</a></td>
<td class="num">(16,153)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares withheld related to net share settlement</a></td>
<td class="num">$ (39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on investments</a></td>
<td class="nump">538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,724)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,460,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 157,654<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 397,724<span></span>
</td>
<td class="num">$ (339)<span></span>
</td>
<td class="num">$ (239,736)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Exercised And ESPP Purchased in Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292427114736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,724)<span></span>
</td>
<td class="num">$ (24,528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,683<span></span>
</td>
<td class="nump">1,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,014<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization (accretion) of investments</a></td>
<td class="num">(213)<span></span>
</td>
<td class="nump">981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,462<span></span>
</td>
<td class="nump">3,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,197)<span></span>
</td>
<td class="num">(7,738)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(7,356)<span></span>
</td>
<td class="num">(601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Non-current operating lease liabilities</a></td>
<td class="num">(188)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(57)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(26,461)<span></span>
</td>
<td class="num">(26,277)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(2,488)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm', window );">Net change in investments</a></td>
<td class="nump">45,200<span></span>
</td>
<td class="num">(12,894)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">45,125<span></span>
</td>
<td class="num">(15,382)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from the exercises of stock options and purchases pursuant to employee stock purchase plan</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(39)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">18,664<span></span>
</td>
<td class="num">(41,525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">47,379<span></span>
</td>
<td class="nump">92,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">66,043<span></span>
</td>
<td class="nump">50,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of non-cash financial activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets', window );">Operating lease liabilities recognized for operating right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating right-of-use assets exchanged for operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived', window );">Deferred revenue billed but not received</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid amounts related to purchases of property and equipment</a></td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities Recognized For Operating Lease Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Deferred Revenue Billed Not Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow (inflow) through acquisition (sale) of short-term available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292429990384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Description of Business</a></td>
<td class="text">Organization and Description of Business <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shattuck Labs, Inc. (the &#8220;Company&#8221;) was incorporated in 2016 in the State of Delaware and is a clinical-stage biopharmaceutical company developing dual-sided fusion proteins, including its Agonist Redirected Checkpoint (&#8220;ARC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and gamma delta T cell engager (&#8220;GADLEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) platforms, as novel classes of biologic medicines capable of multifunctional activity with potential applications in oncology and inflammatory diseases. Using its proprietary technology, the Company is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic malignancies. The Company has one clinical-stage product candidate, SL-172154, and has several compounds in preclinical development. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $239.7 million as of March&#160;31, 2023. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company&#8217;s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company&#8217;s cash and cash equivalents and investments of $135.5 million as of March&#160;31, 2023 are sufficient to fund projected operations of the Company for at least the next twelve months. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Economic Considerations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine and other political tensions, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on our future operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292430707680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Financial Statements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position, its results of operations, statements of changes in stockholders&#8217; equity and cash flows for the interim periods presented. Operating results for interim periods presented are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023. The interim financial statements presented herein do not contain all required disclosures under GAAP for annual financial statements. The accompanying unaudited interim condensed financial statements should be read in conjunction with the annual audited financial statements and related notes in our Annual Report on Form 10-K for the year ended December&#160;31, 2022. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#8217;s estimates.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one segment.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including investments and accounts payable, approximate fair value due to the short-term nature of those instruments.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. While the Company has not experienced any losses, the recent failure of Silicon Valley Bank (&#8220;SVB&#8221;), at which the Company held cash, exposed the Company to significant credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors. The Company is in the process of transferring its cash to an alternate depository institution, the financial position of which management believes does not expose the Company to significant credit risk. Where possible, the Company will also continue to hold its excess cash in investments and money market accounts to further limit exposure. The Company does not believe that it is subject to other unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only U.S. Treasury securities that management believes protects the Company from risk of default and impairment of value.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract manufacturing organizations (&#8220;CMOs&#8221;) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract research organizations (&#8220;CROs&#8221;) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents consisted of $0.8 million held in operating accounts and $65.2 million held in money market funds as of March&#160;31, 2023, and $3.5 million held in operating accounts and $43.9 million held in money market funds as of December&#160;31, 2022. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. As of March&#160;31, 2023 and December 31, 2022, there were no impairments related to credit losses of investments. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets. There were no impairments of long-lived assets for the three months ended March 31, 2023 and 2022.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The classification of the Company&#8217;s leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirement of Accounting Standards Codification (&#8220;ASC&#8221;) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Financial Accounting Standards Board (&#8220;FASB&#8221;) to leases with a term of 12 months or less for all classes of assets.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments and Contingencies</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 450-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the FASB to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#8217;s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">identify the contract(s) with a customer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">identify the performance obligations in the contract; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">determine the transaction price; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">allocate the transaction price to the performance obligations within the contract; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements may consist of a license of, or options to license, the Company&#8217;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s collaboration revenue arrangements may include the following: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company considered the guidance in ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and will recognize the payments received from these agreements as revenue when the related costs are incurred. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including CROs and CMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO or outside service provider, the payments will be recorded as a prepaid asset, which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#8217;s accruals that could materially affect the Company&#8217;s results of operations. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock or convertible notes, if any, stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as of March&#160;31, 2023 and 2022, as they would be anti-dilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,261,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,460,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">652,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">313,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,914,037&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,774,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income (Loss) </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on investments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292429971120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s available for sale investments by major security type (amounts in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.215%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(339)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.215%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(877)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment instruments and cash and cash equivalents are classified using Level&#160;1 inputs within the fair value hierarchy and are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Debt securities have a weighted-average maturity of 0.24 years as of March&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292429971120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">Accrued Expenses and Other Current Liabilities<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (amounts in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development contract costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,795&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292431235776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space, laboratory facilities, and equipment. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has operating leases. There have been no material changes in our operating leases as compared to operating leases disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nighthawk Biosciences, Inc. License Agreement </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a license agreement with Nighthawk Biosciences, Inc. (&#8220;Nighthawk&#8221;), the Company is required to make payments of up to $20.6&#160;million in aggregate for the achievement of specified development, regulatory and commercial sales milestones for certain licensed products. The Company paid $0.1&#160;million to Nighthawk in the three months ended March 31, 2023 as a milestone payment for the Company&#8217;s completion of a Phase 1 clinical trial for SL-172154.&#160;The Company is required to pay Nighthawk a percentage of upfront fees or other non-royalty payments not tied to milestone events that it receives in connection with certain sublicenses of the licensed patents.&#160;The Company is also required to pay Nighthawk a royalty on all of its worldwide net sales, those of its affiliates, and sublicenses of certain licensed patents in the low single digits. The Company has not recorded a liability for the aforementioned payments given the achievement of specified development, regulatory and commercial sales milestones for certain licensed products is not probable as of the balance sheet date.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. On January 31, 2022 and February 11, 2022, putative class action lawsuits were filed in the U.S. District Court for the Eastern District of New York against us and certain of the Company&#8217;s officers and directors. The cases were consolidated on June 2, 2022, and the plaintiffs filed an amended complaint on July 1, 2022. The amended complaint cites the volatility in the Company&#8217;s common stock and alleges that the defendants made or are responsible for misleading omissions regarding the Company&#8217;s clinical trial results and the collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company, Ltd. The parties reached a settlement in principle of the plaintiffs&#8217; claims in the amount of $1.4&#160;million on November 2, 2022. The settlement is subject to a definitive settlement agreement, notice to stockholders and court approval. The parties filed their motion for preliminary approval of the settlement agreement with the court on December 14, 2022, and, as of May 8, 2023, that motion is pending. The Company has accrued the settlement amount in accrued expenses and other current liabilities as of March 31, 2023.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations </span></div>Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which the Company cannot reasonably predict future payment. The Company&#8217;s contractual obligations result primarily from obligations for various CMOs and CROs, which include potential payments that may be required under its agreements. The contracts also contain variable costs and milestones that are hard to predict, as they are based on such things as patients enrolled and clinical trial sites. The timing of payments and actual amounts paid under CMO and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Such agreements are cancellable upon written notice by the Company and, therefore, are not long-term liabilities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292431235776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">EquityThe Company is authorized to issue up to 300,000,000 shares of common stock and 10,000,000 shares of preferred stock, all with a par value of $0.0001 per share. The holders of the Company&#8217;s common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. The Company&#8217;s common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of the Company&#8217;s common stock will receive ratably any dividends declared by the Company&#8217;s board of directors (&#8220;Board&#8221;) out of funds legally available. In the event of the Company&#8217;s liquidation, dissolution or winding-up, the holders of the Company&#8217;s common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. As of the periods presented, no common stock dividends had been declared by the Board. At March 31, 2023, none of the 10,000,000 shares of preferred stock were outstanding, and the Company has no present plans to issue any shares of preferred stock.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292431806672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) which, as of the adoption date, replaced the 2016 Stock Incentive Plan. Under the 2020 Plan, the share reserve automatically </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increases on January 1st of each year beginning in 2021 and ending with a final increase on January 1, 2030 in an amount equal to 4% of the Company&#8217;s outstanding common shares on December 31st of the preceding calendar year. The Board may provide that there will be no increase in the share reserve for any such year or that the increase in the share reserve may be smaller than would otherwise occur. On January 1, 2023, the share reserve automatically increased by 1,695,623 shares. As of March&#160;31, 2023, there were 3,739,124 shares available for future grants. The 2020 Plan permits the granting of options, stock appreciation rights, restricted stock units (&#8220;RSUs&#8221;), performance stock and performance cash awards. The terms of the agreements under the 2020 Plan are determined by the Board. The Company&#8217;s awards generally vest over four years and have a term of 10 years. In 2023, the Company granted 165,050 awards that vest in three equal tranches based on the Company achieving a certain closing share price for each tranche for 30 consecutive trading days on or before the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE4MDA_cc775207-fe02-4c9b-8e4e-2107d58e985d">four</span>th anniversary of the grant date.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (&#8220;2020 ESPP&#8221;) became effective in October 2020. A total of 395,795 shares of common stock were reserved for issuance under the 2020 ESPP. Eligible employees may purchase shares of common stock under the 2020 ESPP at 85% of the lower of the fair market value of the Company&#8217;s common stock as of the first or the last day of each offering period. Employees are limited to contributing 15% of the employee&#8217;s eligible compensation and may not purchase more than $25,000 of stock during any calendar year or more than 600 shares during any one purchase period. The 2020 ESPP share reserve automatically increases on January 1st of each calendar year, for ten years, commencing on January 1, 2021, in an amount equal to 1% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Board may act prior to January 1st of a given year to provide that there will be no January 1st increase of the share reserve for such year or that the increase in the share reserve for such year will be a smaller number of shares of common stock than would otherwise occur pursuant to the preceding sentence. On January 1, 2023, the share reserve increased by 423,905 shares. As of March&#160;31, 2023, there were 1,216,723 shares available for future grants. During the three months ended March 31, 2023 and 2022, the Company issued 11,171 and 5,227 shares of common stock for aggregate cash proceeds of $0.1&#160;million and $0.1&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying unaudited interim condensed statements of operations and comprehensive loss (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.269%"><tr><td style="width:1.0%"/><td style="width:70.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.648%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,683&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,513&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the 2020 Plan:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:48.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining&#160;Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,209,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,181,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(717)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(128,186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,261,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,174,691&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.27&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.05</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at the end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,122,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.28&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.55</span></td></tr></table></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the three months ended March 31, 2023 and 2022 had weighted-average grant-date fair values of $2.46 and $5.13 per share, respectively. As of March 31, 2023, the unrecognized compensation cost for options issued was $14.1 million and will be recognized over an estimated weighted-average amortization period of 2.49 years. The total intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 </span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $0.1 million and $0.1 million, respectively. The aggregate intrinsic value of options outstanding and exercisable as of March 31, 2023 was $0.2 million.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes employee RSU activity for the three months ended March 31, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.455%"><tr><td style="width:1.0%"/><td style="width:67.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested RSUs as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">309,477&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">445,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(73,937)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27,967)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">652,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.81&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $0.2 million of stock-based compensation related to RSUs as of March 31, 2023. As of March 31, 2023, the unrecognized compensation cost for RSUs issued was $3.1 million and will be recognized over an estimated weighted-average amortization period of 3.47 years. The fair values of RSUs are based on the fair value of the Company&#8217;s common stock on the date of the grant.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Stock Options and Shares Issued</span></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation by measuring and recognizing as compensation expense the fair value of all share-based payment awards made to employees, including employee stock options and restricted stock awards. The Company uses the Black-Scholes option pricing model to estimate the fair value of employee stock options that only have service or performance conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The inputs to both pricing models require a number of management estimates such as the expected term, volatility, risk-free interest rate and dividend yield. The fair value of stock options was determined using the methods and assumptions discussed below.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected term of employee stock options with service-based vesting is determined using the &#8220;simplified&#8221; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#8217;s lack of sufficient historical data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected stock price volatility assumption is based on the historical volatilities of the common stock of a peer group of publicly traded companies as well as the historical volatility of the Company&#8217;s common stock since the Company began trading subsequent to the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in October 2020 over the period corresponding to the expected life as of the grant date. The historical volatility data was computed using the daily closing prices during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of the Company&#8217;s stock price becomes available, or until circumstances change, such that the identified entities are no longer comparable companies. In the latter case, other suitable, similar entities whose share prices are publicly available would be utilized in the calculation.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay dividends on its common stock. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Prior to the Company&#8217;s IPO, the Board periodically estimated the fair value of the Company&#8217;s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. Subsequent to the Company&#8217;s IPO, options are issued with a strike price no less than the market price on date of grant.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company&#8217;s 2020 Plan were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"/><td style="width:68.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.800%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Monte Carlo option pricing model granted under the Company&#8217;s 2020 Plan were estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"/><td style="width:68.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.800%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company&#8217;s 2020 ESPP were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"/><td style="width:68.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.800%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 ESPP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.49</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292427191312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Unaudited Interim Condensed Financial Statements</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Financial Statements </span></div>In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position, its results of operations, statements of changes in stockholders&#8217; equity and cash flows for the interim periods presented. Operating results for interim periods presented are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023. The interim financial statements presented herein do not contain all required disclosures under GAAP for annual financial statements. The accompanying unaudited interim condensed financial statements should be read in conjunction with the annual audited financial statements and related notes in our Annual Report on Form 10-K for the year ended December&#160;31, 2022.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, </span></div>the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#8217;s estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including investments and accounts payable, approximate fair value due to the short-term nature of those instruments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. While the Company has not experienced any losses, the recent failure of Silicon Valley Bank (&#8220;SVB&#8221;), at which the Company held cash, exposed the Company to significant credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors. The Company is in the process of transferring its cash to an alternate depository institution, the financial position of which management believes does not expose the Company to significant credit risk. Where possible, the Company will also continue to hold its excess cash in investments and money market accounts to further limit exposure. The Company does not believe that it is subject to other unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only U.S. Treasury securities that management believes protects the Company from risk of default and impairment of value.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract manufacturing organizations (&#8220;CMOs&#8221;) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. </span></div>The Company is highly dependent on a limited number of contract research organizations (&#8220;CROs&#8221;) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash Equivalents The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">Investments The Company&#8217;s investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsLong-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. The classification of the Company&#8217;s leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirement of Accounting Standards Codification (&#8220;ASC&#8221;) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Financial Accounting Standards Board (&#8220;FASB&#8221;) to leases with a term of 12 months or less for all classes of assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments and Contingencies</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 450-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the FASB to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#8217;s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">identify the contract(s) with a customer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">identify the performance obligations in the contract; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">determine the transaction price; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">allocate the transaction price to the performance obligations within the contract; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#8217;s arrangements may consist of a license of, or options to license, the Company&#8217;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#8217;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s collaboration revenue arrangements may include the following: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company considered the guidance in ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span> and will recognize the payments received from these agreements as revenue when the related costs are incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. </span></div>A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including CROs and CMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO or outside service provider, the payments will be recorded as a prepaid asset, which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#8217;s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#8217;s accruals that could materially affect the Company&#8217;s results of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock or convertible notes, if any, stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive Income (Loss) Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on investments.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292431227248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of net loss per share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as of March&#160;31, 2023 and 2022, as they would be anti-dilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,261,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,460,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">652,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">313,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,914,037&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,774,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292427196000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of investments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s available for sale investments by major security type (amounts in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.215%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(339)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.215%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(877)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292431365216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (amounts in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development contract costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,795&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292431103376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying unaudited interim condensed statements of operations and comprehensive loss (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.269%"><tr><td style="width:1.0%"/><td style="width:70.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.648%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,683&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,513&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of option activity</a></td>
<td class="text"><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the 2020 Plan:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:48.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining&#160;Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,209,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,181,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(717)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(128,186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,261,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,174,691&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.27&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.05</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at the end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,122,655&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.28&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.55</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of RSU activity</a></td>
<td class="text"><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes employee RSU activity for the three months ended March 31, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.455%"><tr><td style="width:1.0%"/><td style="width:67.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested RSUs as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">309,477&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">445,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(73,937)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27,967)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">652,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.81&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of valuation assumptions</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company&#8217;s 2020 Plan were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"/><td style="width:68.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.800%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Monte Carlo option pricing model granted under the Company&#8217;s 2020 Plan were estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"/><td style="width:68.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.800%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company&#8217;s 2020 ESPP were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"/><td style="width:68.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.800%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 ESPP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.49</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292431422928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Description of Business (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>candidate</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_NumberOfClinicalStageProductCandidates', window );">Number of clinical-stage product candidate | candidate</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 239,736<span></span>
</td>
<td class="nump">$ 219,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">$ 135,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_NumberOfClinicalStageProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Clinical-stage Product Candidates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_NumberOfClinicalStageProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292431793696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 66,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=sttk_OperatingAccountMember', window );">Operating Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 65,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=sttk_OperatingAccountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=sttk_OperatingAccountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292426994832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">5,914,037<span></span>
</td>
<td class="nump">3,774,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">5,261,439<span></span>
</td>
<td class="nump">3,460,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">652,598<span></span>
</td>
<td class="nump">313,390<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292431411232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of available for sale investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 69,791<span></span>
</td>
<td class="nump">$ 114,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(339)<span></span>
</td>
<td class="num">(877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">69,452<span></span>
</td>
<td class="nump">113,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAbstract', window );"><strong>Investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">69,791<span></span>
</td>
<td class="nump">114,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(339)<span></span>
</td>
<td class="num">(877)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total Fair Value</a></td>
<td class="nump">$ 69,452<span></span>
</td>
<td class="nump">$ 113,901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292430816320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Narrative (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Debt securities, average maturity term</a></td>
<td class="text">2 months 26 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292431362224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities - Schedule of accrued expenses and other current liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_AccruedResearchAndContractCostsCurrent', window );">Research and development contract costs</a></td>
<td class="nump">$ 6,650<span></span>
</td>
<td class="nump">$ 11,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Litigation settlement</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">3,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,628<span></span>
</td>
<td class="nump">1,172<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 10,881<span></span>
</td>
<td class="nump">$ 17,795<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities and Other Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_AccruedResearchAndContractCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Contract Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_AccruedResearchAndContractCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292425983280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 02, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_LicenseAgreementRoyaltyPaymentsMaximum', window );">License agreement, maximum payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Payments for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Accrued royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_LicenseAgreementRoyaltyPaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_LicenseAgreementRoyaltyPaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292425985072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292426251616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th">
<div>Oct. 14, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>tranch </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="nump">$ 5.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,683<span></span>
</td>
<td class="nump">$ 1,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost for RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember', window );">2020 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage', window );">Increase in number of shares authorized, percentage of capital stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance', window );">Common stock, additional capital shares reserved for future issuance (in shares) | shares</a></td>
<td class="nump">1,695,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,739,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock-based compensation, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based compensation, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod', window );">Share-based payment award, grants in period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches', window );">Number of tranches | tranch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays', window );">Threshold consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember', window );">2020 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage', window );">Increase in number of shares authorized, percentage of capital stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance', window );">Common stock, additional capital shares reserved for future issuance (in shares) | shares</a></td>
<td class="nump">423,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,795<span></span>
</td>
<td class="nump">1,216,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock in percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Contribution limit in percentage of employee's eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue', window );">Maximum value of shares per employee during any calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares per employee during any one purchase period (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm', window );">Annual increase in number of shares authorized, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock issued under ESPP (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,171<span></span>
</td>
<td class="nump">5,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sttk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292431364176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of stock-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 1,683<span></span>
</td>
<td class="nump">$ 1,513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 869<span></span>
</td>
<td class="nump">$ 686<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292425989808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of option activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, beginning balance (in shares)</a></td>
<td class="nump">4,209,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, granted (in shares)</a></td>
<td class="nump">1,181,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, exercised (in shares)</a></td>
<td class="num">(717)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, forfeited (in shares)</a></td>
<td class="num">(128,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, ending balance (in shares)</a></td>
<td class="nump">5,261,439<span></span>
</td>
<td class="nump">4,209,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, vested and expected to vest (in shares)</a></td>
<td class="nump">5,174,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, exercisable (in shares)</a></td>
<td class="nump">2,122,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 8.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted (in dollars per share)</a></td>
<td class="nump">3.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised (in dollars per share)</a></td>
<td class="nump">2.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, forfeited (in dollars per share)</a></td>
<td class="nump">7.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in dollars per share)</a></td>
<td class="nump">7.25<span></span>
</td>
<td class="nump">$ 8.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and expected to vest (in dollars per share)</a></td>
<td class="nump">7.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">$ 8.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted&#160;average remaining contract life, outstanding</a></td>
<td class="text">8 years 25 days<span></span>
</td>
<td class="text">8 years 25 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted&#160;average remaining contract life, vested and expected to vest</a></td>
<td class="text">8 years 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted&#160;average remaining contract life, exercisable</a></td>
<td class="text">6 years 6 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292431840288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of restricted stock activity (Details) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards, beginning balance (in shares) | shares</a></td>
<td class="nump">309,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">445,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Awards, vested (in shares) | shares</a></td>
<td class="num">(73,937)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(27,967)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Awards, ending balance (in shares) | shares</a></td>
<td class="nump">652,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">3.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">7.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">4.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140292425225088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of valuation assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2020 Stock Incentive Plan | Black-Scholes Option Pricing Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term - years</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">84.80%<span></span>
</td>
<td class="nump">81.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2020 Stock Incentive Plan | Monte Carlo Option Pricing Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term - years</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | 2020 Employee Stock Purchase Plan | Black-Scholes Option Pricing Model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term - years</a></td>
<td class="text">5 months 26 days<span></span>
</td>
<td class="text">5 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">84.80%<span></span>
</td>
<td class="nump">81.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=sttk_BlackScholesOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=sttk_BlackScholesOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=sttk_MonteCarloOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=sttk_MonteCarloOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sttk_A2020EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>sttk-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sttk="http://www.shattucklabs.com/20230331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sttk-20230331.xsd" xlink:type="simple"/>
    <context id="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0da03d1a066047c19888f60d1a23d25e_I20230501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic79fdedfe69a4831bd0c813659e24620_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6329837530214020b3ca9fff657cea9b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic22a2288c5fa4a87bdc2dc2f63c68bee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i237ffce164a14b11b3d4a56d948a6d2d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib31390f36c5a45249b07c710d4824091_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2e92a7048fc84c1aa85deddf715d1c18_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i70b47fdbe5a84c6e8cf8ce134ab56bdb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id186272227244ec3b82b3b87eabc97f9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9b3ef141d1cc4f10aa5bcdaa504aa1a2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7da54cb1c2b04054814e3dfed37c7947_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i104d8a78724041988c7e63d9c8bd9624_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i465bbee7d341453dbf57ff22cf4c2c7f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibf15edfb0127444c8297ddfefadc5003_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icbe46f015ce244558ede3196621fd998_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6675d59e3920448683346ca6b09615ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a0210c92623410b817e1521f5ad2f4b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9126dbe3941542e6958b2493b197a481_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i070803840450402f8ea63b2237086a3e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i321f3e6305f148e49074f9fc1dca1b0c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i64ca7813e54547a1b035602b2d224a95_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5137177e56c046f79cf0cea692f9f5bf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i88a5936fb32b4acfa2716e68e93e1c09_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idc6431ddab1f47ae881d4c7214c8921b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic8199b2a3360472d9aaf8cec50d6e134_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie23479f9e8944779858f19140c19a37f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib8acaafaf90b4af786b67f9282de530a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia5a069be2f114474a16ab65a58e0073c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sttk:OperatingAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idb23ff2081e748fd9ff374eb3980514e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i24b4d1c38b1242aca9f89fabfca382b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sttk:OperatingAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia5862eb6343f4314b9960014696b7d5e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i66202690cd934e39a5b02adc401092ec_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2c8063b21bdd42d6a8b2bd6b8a659fe6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1634b5c2ee444f55945905fb30149f97_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i64b931a9bad34aaf9918cffa88232c5e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1f7e7bca8d6041f39e4dc1a03ecdaf39_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i56b2909098264559bde53509e6f16d96_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie0fe0931d7fd474e9944465230cae621_D20221102-20221102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <startDate>2022-11-02</startDate>
            <endDate>2022-11-02</endDate>
        </period>
    </context>
    <context id="i5c388e0f89f34e2c831691fb79c15cb8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifdcd40cea1904365b4a1a01161642a02_D20230101-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i6fb1051978f94abc950815f2d8001c2f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i991dfc7ff32043179c7e3f86c543184b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0e6401db080843d78c401499533d1dc2_I20201014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-14</instant>
        </period>
    </context>
    <context id="ieb1b33d499ae4e9d975505ddf2b6a145_D20201014-20201014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-14</startDate>
            <endDate>2020-10-14</endDate>
        </period>
    </context>
    <context id="i76febd49246745a9a7bb5f9df44806a6_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i9a2cffc815b14f15ba52b9eacfa7e4a7_D20230101-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i9cbaef79f5984155995efe7d1dfec7e6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic07dbdc8b50c460b91220dd5d8950518_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9f423208f22d42beb3d0027d59f5a13a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i553413b499654651890bbd3c2a30bad5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0696e705fa644b0eb1e32b0abcf24c9a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i26ed59b30fb3417b8f0372f4e8d87f2a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i24d5ba980a4546dd9c94c7d3d055e5dc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2b0c733727b44be5a7356b37de831391_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i428ae4dc142344e4867b47e344b894fe_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaf0a0042588b4fd2ac8a83479b491708_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4d4b4c0ce8c04ddbaf55caff9825c696_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia3286ad000a74fb2b534f75b6f23f669_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8c88b5d9b1e14fc3b353ec2bed09c97d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie3ea58e597ec4bc9b179b6cbe88d9b32_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:MonteCarloOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iafe592e811e24849a2a391b482b2fa73_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:MonteCarloOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4634c39261264b90ac1a96707bd46a0b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i58eae8a702644e09b9d6eafabc8fd6fd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001680367</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sttk:A2020EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">sttk:BlackScholesOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="candidate">
        <measure>sttk:candidate</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="tranch">
        <measure>sttk:tranch</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80L2ZyYWc6NTRhZDc4NTAyZDU2NDdjOWExZjQ5YjI4NmQ1YTFhNzUvdGFibGU6ZDAwYTE5OWQ0Yjk5NDMxMjk5Y2VlOTgzNDA4NDgyN2QvdGFibGVyYW5nZTpkMDBhMTk5ZDRiOTk0MzEyOTljZWU5ODM0MDg0ODI3ZF8yLTEtMS0xLTMzNzM2_daf23ab8-a939-4356-b39f-ac1883afae01">0001680367</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80L2ZyYWc6NTRhZDc4NTAyZDU2NDdjOWExZjQ5YjI4NmQ1YTFhNzUvdGFibGU6ZDAwYTE5OWQ0Yjk5NDMxMjk5Y2VlOTgzNDA4NDgyN2QvdGFibGVyYW5nZTpkMDBhMTk5ZDRiOTk0MzEyOTljZWU5ODM0MDg0ODI3ZF80LTEtMS0xLTMzNzM2_af813626-7ce8-4222-8e6c-1dc339d56e98">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80L2ZyYWc6NTRhZDc4NTAyZDU2NDdjOWExZjQ5YjI4NmQ1YTFhNzUvdGFibGU6ZDAwYTE5OWQ0Yjk5NDMxMjk5Y2VlOTgzNDA4NDgyN2QvdGFibGVyYW5nZTpkMDBhMTk5ZDRiOTk0MzEyOTljZWU5ODM0MDg0ODI3ZF81LTEtMS0xLTMzNzM2_93c2c480-d7c3-4a14-a388-f8d1585adf5c">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80L2ZyYWc6NTRhZDc4NTAyZDU2NDdjOWExZjQ5YjI4NmQ1YTFhNzUvdGFibGU6ZDAwYTE5OWQ0Yjk5NDMxMjk5Y2VlOTgzNDA4NDgyN2QvdGFibGVyYW5nZTpkMDBhMTk5ZDRiOTk0MzEyOTljZWU5ODM0MDg0ODI3ZF82LTEtMS0xLTMzNzM2_d21be800-0fcf-4a76-af9d-5c279eff646a">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80L2ZyYWc6NTRhZDc4NTAyZDU2NDdjOWExZjQ5YjI4NmQ1YTFhNzUvdGFibGU6ZDAwYTE5OWQ0Yjk5NDMxMjk5Y2VlOTgzNDA4NDgyN2QvdGFibGVyYW5nZTpkMDBhMTk5ZDRiOTk0MzEyOTljZWU5ODM0MDg0ODI3ZF83LTEtMS0xLTMzNzM2_99ac74af-d9af-4bbe-9ea0-7cc2105694b1">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMi0wLTEtMS0zMzczNg_0dbd2c13-8918-4b63-bdf2-300920a2fc2e">http://fasb.org/us-gaap/2022#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMi0wLTEtMS0zMzczNg_b87d8af4-7cf2-4221-895b-3d002e7a2319">http://fasb.org/us-gaap/2022#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i991dfc7ff32043179c7e3f86c543184b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE4MDA_cc775207-fe02-4c9b-8e4e-2107d58e985d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDgz_ba6286c8-9cc5-41ef-b880-670dff0e2e6c">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6NTYxNTk3ZjZiMzAzNDUxOTg1NWI2ZDc4YWQ1ZTQ4ZmUvdGFibGVyYW5nZTo1NjE1OTdmNmIzMDM0NTE5ODU1YjZkNzhhZDVlNDhmZV8wLTAtMS0xLTMzNzM2_38ca031a-8509-451a-be16-49ee48b333ed">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8xMzg_f9602d2d-72ae-4a52-b563-408c058e8f3e">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6OGU2MWI3YTdiNWIyNDRlN2I3MDA0Mjg4OTM0NjQ2NzEvdGFibGVyYW5nZTo4ZTYxYjdhN2I1YjI0NGU3YjcwMDQyODg5MzQ2NDY3MV8wLTAtMS0xLTMzNzM2_bcd0a883-ea99-41a6-873a-babb8490c7d0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDc2_87b1a1c1-f5ae-4909-b802-e16ab2b35c2f">001-39593</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDgw_fac88c47-ba3b-40ca-be02-56b16d631cf1">Shattuck Labs, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6ZTk5ZjEyMjRhMmRhNGE5NzlmMDEwZTY2MGE4ZDhkNzYvdGFibGVyYW5nZTplOTlmMTIyNGEyZGE0YTk3OWYwMTBlNjYwYThkOGQ3Nl8wLTAtMS0xLTMzNzM2_92ed7a6e-0f0e-465f-844d-0c14e12a2bac">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6ZTk5ZjEyMjRhMmRhNGE5NzlmMDEwZTY2MGE4ZDhkNzYvdGFibGVyYW5nZTplOTlmMTIyNGEyZGE0YTk3OWYwMTBlNjYwYThkOGQ3Nl8wLTItMS0xLTMzNzM2_f877dcd2-a54c-4d55-9489-2ddee07e566d">81-2575858</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDgx_4dec615c-a3e1-4c63-90c1-680de111c8bf">500 W. 5th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDg0_0eccfd53-0edc-40c8-87bf-985a9543da4d">Suite 1200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDg1_933be8fe-c49e-4d45-a8c4-7b0922dac176">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDkx_68f7d333-d3df-4b87-b213-2f391af27dbe">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDky_b9b6d233-7e03-43af-a12c-2ad5805073d0">78701</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDc4_ec1ad4e0-d967-478a-b091-a13c7979d66a">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDg2_d6e6c12d-0438-41ab-8e73-b95409b35f1f">900-4690</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6ZjFiM2E4ZjcwNjBiNDgyNGIyY2QyY2ZiZTdjOTU0ODUvdGFibGVyYW5nZTpmMWIzYThmNzA2MGI0ODI0YjJjZDJjZmJlN2M5NTQ4NV8xLTAtMS0xLTMzNzM2_9bddd521-e8d7-4a75-9db9-8505b3f1064f">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6ZjFiM2E4ZjcwNjBiNDgyNGIyY2QyY2ZiZTdjOTU0ODUvdGFibGVyYW5nZTpmMWIzYThmNzA2MGI0ODI0YjJjZDJjZmJlN2M5NTQ4NV8xLTEtMS0xLTMzNzM2_d880a605-7d79-4370-ae9d-6e8a92ed8205">STTK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6ZjFiM2E4ZjcwNjBiNDgyNGIyY2QyY2ZiZTdjOTU0ODUvdGFibGVyYW5nZTpmMWIzYThmNzA2MGI0ODI0YjJjZDJjZmJlN2M5NTQ4NV8xLTItMS0xLTMzNzM2_c1e09fb9-a4df-4020-a9bf-69986162c0e1">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDgy_f807e69c-ce6d-4e13-8900-faf792680d8d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDg3_56fea583-d659-46ea-8f81-294cc05ef79f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6M2Y2Zjc4ZTk5NWYwNGMyZjgyNGRhODgyNDc5OTJiYTgvdGFibGVyYW5nZTozZjZmNzhlOTk1ZjA0YzJmODI0ZGE4ODI0Nzk5MmJhOF8xLTAtMS0xLTMzNzM2_261f55d7-3261-4ca9-9e3e-c4bbd70a57b6">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6M2Y2Zjc4ZTk5NWYwNGMyZjgyNGRhODgyNDc5OTJiYTgvdGFibGVyYW5nZTozZjZmNzhlOTk1ZjA0YzJmODI0ZGE4ODI0Nzk5MmJhOF8xLTMtMS0xLTMzNzM2_02e11d7b-49cc-445e-a8a2-6fde42c89d4b">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGFibGU6M2Y2Zjc4ZTk5NWYwNGMyZjgyNGRhODgyNDc5OTJiYTgvdGFibGVyYW5nZTozZjZmNzhlOTk1ZjA0YzJmODI0ZGE4ODI0Nzk5MmJhOF8yLTMtMS0xLTMzNzM2_347377fd-d174-4024-aed5-d1252e5ecca8">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDc5_81c3672f-d5e9-4642-993c-4189f27bf9c0">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDg4_48fa6a13-0583-46aa-812c-e2b5888a7238">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0da03d1a066047c19888f60d1a23d25e_I20230501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xL2ZyYWc6N2JmZjQyOTUyZjcyNDAwMzg3MjBmMDAxMTIxZWQwNzkvdGV4dHJlZ2lvbjo3YmZmNDI5NTJmNzI0MDAzODcyMGYwMDExMjFlZDA3OV8yMDA2_c9350fc6-09bb-4307-8fc7-750238a6959c"
      unitRef="shares">42471288</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfNC0xLTEtMS0zMzczNg_761763c5-b3f8-4f30-a735-97c36923c702"
      unitRef="usd">66043000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfNC0zLTEtMS0zMzczNg_ea542767-99aa-4173-966b-abb5c31b96c9"
      unitRef="usd">47379000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfNS0xLTEtMS0zMzczNg_20706c58-f46d-4b79-af44-28d0ba73bb66"
      unitRef="usd">69452000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfNS0zLTEtMS0zMzczNg_1bf1707e-b5f0-46b2-8cd1-8df5b48dca29"
      unitRef="usd">113901000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfNi0xLTEtMS0zMzczNg_87ca0e84-a5f0-49fe-961e-1cc9b8f16740"
      unitRef="usd">22342000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfNi0zLTEtMS0zMzczNg_bb5081fe-0d6d-42b3-8a57-4dcf19d8fec4"
      unitRef="usd">23304000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfNy0xLTEtMS0zMzczNg_1cc2543e-ddf5-48db-bd81-bf9caa94a755"
      unitRef="usd">157837000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfNy0zLTEtMS0zMzczNg_c51b5a7e-d5b4-4f33-ad6b-f8dee6e8b833"
      unitRef="usd">184584000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfOC0xLTEtMS0zMzczNg_2a81b2e7-711a-4b05-ac8d-f2a4ab22f1fb"
      unitRef="usd">16887000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfOC0zLTEtMS0zMzczNg_c4037c96-8a55-4673-8a33-ee32e570b9e4"
      unitRef="usd">17671000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfOS0xLTEtMS0zMzczNg_ee5cda7d-038b-4113-9960-b7ed868eb95b"
      unitRef="usd">2953000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfOS0zLTEtMS0zMzczNg_0039a3b4-d1e3-4909-a121-d290b172995e"
      unitRef="usd">3069000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTAtMS0xLTEtMzM3MzY_ca258f9a-a669-4f46-9ca0-c63e1383ec17"
      unitRef="usd">177677000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTAtMy0xLTEtMzM3MzY_ff43bf6a-7374-4a27-a582-4dbb5f9dd99d"
      unitRef="usd">205324000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTQtMS0xLTEtMzM3MzY_b03bab96-b3c6-458f-b48a-fd614a41efbb"
      unitRef="usd">5128000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTQtMy0xLTEtMzM3MzY_b6cf2a02-e79a-4078-ab02-84bdaff8ff34"
      unitRef="usd">7170000</us-gaap:AccountsPayableCurrent>
    <sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTUtMS0xLTEtMzM3MzY_b175cec7-2c79-4fd5-aebb-15373bcb3228"
      unitRef="usd">10881000</sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTUtMy0xLTEtMzM3MzY_0a4e1e89-9511-45f3-ab98-b844be682fa9"
      unitRef="usd">17795000</sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTYtMS0xLTEtMzM3MzY_d7e1ed6e-469f-4ad9-8f34-2a89e7313c96"
      unitRef="usd">16009000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTYtMy0xLTEtMzM3MzY_0972ded4-45d2-4a5e-bc99-b9839d09ebb7"
      unitRef="usd">24965000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTctMS0xLTEtMzM3MzY_484ce57e-0c62-4398-a08c-d6dd94e16d7c"
      unitRef="usd">4014000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTctMy0xLTEtMzM3MzY_e43ebdd1-d2d5-4fd3-b234-9cd0ab8f9abb"
      unitRef="usd">4202000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTktMS0xLTEtMzM3MzY_3648d50a-c9af-46ec-9360-b4d4b31b62d6"
      unitRef="usd">20023000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMTktMy0xLTEtMzM3MzY_afdaa043-5d47-43e0-83da-e2ba2c3f7393"
      unitRef="usd">29167000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjAtMS0xLTEtMzM3MzY_ec3b6e68-283c-49d3-8f24-0826041cdb67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjAtMy0xLTEtMzM3MzY_8cc17813-75c3-4ff6-94d5-bd310f4efc79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMC0xLTEtMzM3MzYvdGV4dHJlZ2lvbjo5OWRmOTM0NGU3NzQ0ZDc5YWIxYTliZjRmZGFhNGQxM18xOQ_3bca0351-96bb-453b-9564-d80a3cfc2ac4"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMC0xLTEtMzM3MzYvdGV4dHJlZ2lvbjo5OWRmOTM0NGU3NzQ0ZDc5YWIxYTliZjRmZGFhNGQxM18xOQ_45dcab6c-9980-47d8-9ea7-a53569171752"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMC0xLTEtMzM3MzYvdGV4dHJlZ2lvbjo5OWRmOTM0NGU3NzQ0ZDc5YWIxYTliZjRmZGFhNGQxM18zMw_5fafc705-1198-4bc4-aa78-e81ca9ca9a8d"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMC0xLTEtMzM3MzYvdGV4dHJlZ2lvbjo5OWRmOTM0NGU3NzQ0ZDc5YWIxYTliZjRmZGFhNGQxM18zMw_a5c00b2d-0821-401d-8f3d-e80c8263d220"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMC0xLTEtMzM3MzYvdGV4dHJlZ2lvbjo5OWRmOTM0NGU3NzQ0ZDc5YWIxYTliZjRmZGFhNGQxM181NQ_9f844b9f-c871-4dd9-b690-d54a521694ce"
      unitRef="shares">42460258</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMC0xLTEtMzM3MzYvdGV4dHJlZ2lvbjo5OWRmOTM0NGU3NzQ0ZDc5YWIxYTliZjRmZGFhNGQxM181NQ_b6902f65-505e-4a73-a470-1f744140cd79"
      unitRef="shares">42460258</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMC0xLTEtMzM3MzYvdGV4dHJlZ2lvbjo5OWRmOTM0NGU3NzQ0ZDc5YWIxYTliZjRmZGFhNGQxM185OA_2a2c2970-abdd-4d13-83cc-e6b990e8f2ca"
      unitRef="shares">42390586</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMC0xLTEtMzM3MzYvdGV4dHJlZ2lvbjo5OWRmOTM0NGU3NzQ0ZDc5YWIxYTliZjRmZGFhNGQxM185OA_7af6b9ff-6bd5-44e5-8d90-a380bddf78ed"
      unitRef="shares">42390586</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMS0xLTEtMzM3MzY_16cfeb55-6b91-4ed0-afb3-694542685a36"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjItMy0xLTEtMzM3MzY_f08e9d9e-e825-4299-a7b9-166b211bdb68"
      unitRef="usd">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjMtMS0xLTEtMzM3MzY_3ed59645-a525-4fc4-a7b4-2bc297c00483"
      unitRef="usd">397724000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjMtMy0xLTEtMzM3MzY_a9edc6dc-c0c4-49d3-9934-c7a52a5cb779"
      unitRef="usd">396041000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjQtMS0xLTEtMzM3MzY_8ca53fd0-be84-4592-8513-68f67e2f82c7"
      unitRef="usd">-339000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjQtMy0xLTEtMzM3MzY_0da4dab3-1649-4bc8-be4c-90adab2b2170"
      unitRef="usd">-877000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjUtMS0xLTEtMzM3MzY_b09d679c-6f70-4248-81ad-0e12c15ab712"
      unitRef="usd">-239736000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjUtMy0xLTEtMzM3MzY_8eaf2be9-c518-4d21-b924-287c8b946a67"
      unitRef="usd">-219012000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjYtMS0xLTEtMzM3MzY_c18950c5-3879-4a55-887d-031f00152b96"
      unitRef="usd">157654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjYtMy0xLTEtMzM3MzY_55f2b5a4-8cde-42c4-9ace-a88da2593c53"
      unitRef="usd">176157000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjctMS0xLTEtMzM3MzY_3e2ff8d6-1fa0-43d0-9afb-3ace42aa1f43"
      unitRef="usd">177677000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xNi9mcmFnOjBmOTA2ZDBmZDkxZTQ3YmE4NzEyYzdiNzJhYWM0NmU3L3RhYmxlOmQ3NjkzYTVlZjNhZDRiMjQ5MGJhMmY3Nzg2OWE0OTExL3RhYmxlcmFuZ2U6ZDc2OTNhNWVmM2FkNGIyNDkwYmEyZjc3ODY5YTQ5MTFfMjctMy0xLTEtMzM3MzY_8b0a2614-d8b7-48ef-b082-42c269fe867a"
      unitRef="usd">205324000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMi0yLTEtMS0zMzczNg_f257f7e5-abd1-4af1-b3f6-0389cba8b07f"
      unitRef="usd">57000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMi00LTEtMS0zMzczNg_b14c9079-cd0f-4742-a3fe-74b8b5faf39c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfNC0yLTEtMS0zMzczNg_2f96e42d-04f5-4775-a44f-60151c9e1ed1"
      unitRef="usd">16667000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfNC00LTEtMS0zMzczNg_460e56b3-2711-419a-a8ba-d924d038c7b6"
      unitRef="usd">19187000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfNS0yLTEtMS0zMzczNg_08fbf16d-2328-404f-9cd5-134547ca84d7"
      unitRef="usd">5051000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfNS00LTEtMS0zMzczNg_f1a74708-cd7f-4518-9598-fc82c9c33b7c"
      unitRef="usd">4979000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfNi0yLTEtMS0zMzczNg_23fc5e54-79cb-4f06-a902-51b6d2f4df8f"
      unitRef="usd">21718000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfNi00LTEtMS0zMzczNg_77a73cc3-2a81-4ae2-a37d-0f0039b825f9"
      unitRef="usd">24166000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfNy0yLTEtMS0zMzczNg_2e2953f8-30b6-4000-95ca-736cf4e02e5f"
      unitRef="usd">-21661000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfNy00LTEtMS0zMzczNg_134f54d8-020a-43b1-8036-03e02aa4b29d"
      unitRef="usd">-24166000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTAtMi0xLTEtMzM3MzY_f7913632-8e41-43c1-aa6d-540fb5879dab"
      unitRef="usd">937000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTAtNC0xLTEtMzM3MzY_11ec1123-0a88-4f1e-a9b5-2ecc54992625"
      unitRef="usd">-362000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTEtMi0xLTEtMzM3MzY_b20b6f10-33cc-4fd0-b7c0-f2d8a202d8c6"
      unitRef="usd">-20724000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTEtNC0xLTEtMzM3MzY_f280e7ca-0a50-4fcf-92d1-98deafa4bdc3"
      unitRef="usd">-24528000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTItMi0xLTEtMzM3MzY_1927a08a-cba4-46ab-b2e0-b21271d50133"
      unitRef="usd">538000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTItNC0xLTEtMzM3MzY_34dd05c8-a87f-4c4e-8a5a-c7de306da53b"
      unitRef="usd">33000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTMtMi0xLTEtMzM3MzY_b4da82e2-e014-4d56-88d0-2a23afc506b1"
      unitRef="usd">-20186000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTMtNC0xLTEtMzM3MzY_6495abd7-d6ff-420c-b3fc-40c82947b02f"
      unitRef="usd">-24495000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTUtMi0xLTEtMzM3MzY_4483fe48-7a08-4149-ab27-62fe4a6969c6"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTUtMi0xLTEtMzM3MzY_b012c392-99f5-4a1b-953b-b3be28bca6c6"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTUtNC0xLTEtMzM3MzY_5b5cd1a1-d5f4-43ec-b891-ab9a53f8b559"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTUtNC0xLTEtMzM3MzY_cfb04c5d-2544-499f-97b0-76ddb8a70229"
      unitRef="usdPerShare">-0.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTYtMi0xLTEtMzM3MzY_4e7622c2-a8af-456c-b189-409a97baca7d"
      unitRef="shares">42439204</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTYtMi0xLTEtMzM3MzY_6061c39d-c80b-4489-9032-a679050ccca8"
      unitRef="shares">42439204</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTYtNC0xLTEtMzM3MzY_15bccd75-727f-449b-a31c-12de28141796"
      unitRef="shares">42357625</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8xOS9mcmFnOmUyNDkwZTQ3NzVhNjQ0MTJiYzBhNGRkMzY2ZDg3ZTYwL3RhYmxlOmQwNzA2ZjhiNGNhMTRhZmI5NTRiODQxNjRiY2M0MTBlL3RhYmxlcmFuZ2U6ZDA3MDZmOGI0Y2ExNGFmYjk1NGI4NDE2NGJjYzQxMGVfMTYtNC0xLTEtMzM3MzY_40108573-1a8c-4d30-ae38-dba4e60437a9"
      unitRef="shares">42357625</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="ic79fdedfe69a4831bd0c813659e24620_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfMy0xLTEtMS0zMzczNg_1073fd58-12f8-4abb-a74e-09ed897af650"
      unitRef="shares">42390586</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic79fdedfe69a4831bd0c813659e24620_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfMy0zLTEtMS0zMzczNg_c83479eb-e669-4787-9801-faa3257cd2f7"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6329837530214020b3ca9fff657cea9b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfMy01LTEtMS0zMzczNg_8ad9201f-78b0-48fe-bd10-80bdf2de62cc"
      unitRef="usd">396041000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic22a2288c5fa4a87bdc2dc2f63c68bee_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfMy03LTEtMS0zMzczNg_7933a245-8cbb-45e4-8227-968eec1ba190"
      unitRef="usd">-877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i237ffce164a14b11b3d4a56d948a6d2d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfMy05LTEtMS0zMzczNg_36b256e2-b128-4099-938f-f642e5f33ab0"
      unitRef="usd">-219012000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfMy0xMS0xLTEtMzM3MzY_40978487-dd02-47e4-838e-9d28116bde07"
      unitRef="usd">176157000</us-gaap:StockholdersEquity>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod
      contextRef="ib31390f36c5a45249b07c710d4824091_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNC0xLTEtMS0zMzczNg_c092920b-cdb4-4735-9c6c-16b8dedb9896"
      unitRef="shares">11888</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod>
    <sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased
      contextRef="i2e92a7048fc84c1aa85deddf715d1c18_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNC01LTEtMS0zMzczNg_99e9d24b-11c2-49b9-b9c4-f4e437833a02"
      unitRef="usd">39000</sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased>
    <sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNC0xMS0xLTEtMzM3MzY_68829bd0-2d5f-4feb-9c78-3f8c6c144bbd"
      unitRef="usd">39000</sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ib31390f36c5a45249b07c710d4824091_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNS0xLTEtMS0zMzkyMg_8ff78dcd-8085-410d-aaea-5a8972204e55"
      unitRef="shares">73937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNi0xLTEtMS01MDAxMQ_9a80c4d9-53aa-40b7-97af-08921bd38300"
      unitRef="shares">16153</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i2e92a7048fc84c1aa85deddf715d1c18_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNi01LTEtMS01MDAxMQ_c055ee79-0af7-469d-82f3-c434243ba38f"
      unitRef="usd">39000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNi0xMS0xLTEtNTAwMTE_ab9d0e19-8a37-4b59-8ce3-ea5b8933ba3e"
      unitRef="usd">39000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2e92a7048fc84c1aa85deddf715d1c18_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNS01LTEtMS0zMzczNg_ecbc8fba-f8ca-46b4-8d23-5e2f4996fd6c"
      unitRef="usd">1683000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNS0xMS0xLTEtMzM3MzY_12653934-1fe1-4f2b-8195-bb457d28cdc1"
      unitRef="usd">1683000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i70b47fdbe5a84c6e8cf8ce134ab56bdb_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNi03LTEtMS0zMzczNg_bd122c86-e90c-49c6-a75a-6122982427dd"
      unitRef="usd">538000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNi0xMS0xLTEtMzM3MzY_e02c0030-a4f4-4966-b428-d3d48005c286"
      unitRef="usd">538000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="id186272227244ec3b82b3b87eabc97f9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNy05LTEtMS0zMzczNg_fc0675b7-9ab1-48a0-a8d9-bc56d05dd57c"
      unitRef="usd">-20724000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfNy0xMS0xLTEtMzM3MzY_380ecf61-5a9a-45a3-bce2-9bee77701c8f"
      unitRef="usd">-20724000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i9b3ef141d1cc4f10aa5bcdaa504aa1a2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfOC0xLTEtMS0zMzczNg_d1e2e4cb-cdc4-48ef-83f2-8080565a736b"
      unitRef="shares">42460258</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9b3ef141d1cc4f10aa5bcdaa504aa1a2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfOC0zLTEtMS0zMzczNg_7d68f6bd-66cf-4fd8-933f-9fd07b5db8be"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7da54cb1c2b04054814e3dfed37c7947_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfOC01LTEtMS0zMzczNg_a80ece90-b4f2-4bb0-beea-ff3194c7288c"
      unitRef="usd">397724000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i104d8a78724041988c7e63d9c8bd9624_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfOC03LTEtMS0zMzczNg_9738d55c-0378-4434-8853-962c80949414"
      unitRef="usd">-339000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i465bbee7d341453dbf57ff22cf4c2c7f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfOC05LTEtMS0zMzczNg_4beee9ba-c46f-4e37-840f-6245ccc42654"
      unitRef="usd">-239736000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOmRlYWMwMmU1MDk5NjQxMGE5NmJhZTQyZDA4MTk2MjNlL3RhYmxlcmFuZ2U6ZGVhYzAyZTUwOTk2NDEwYTk2YmFlNDJkMDgxOTYyM2VfOC0xMS0xLTEtMzM3MzY_55e6b349-be03-40c7-87f4-90b501527ffa"
      unitRef="usd">157654000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ibf15edfb0127444c8297ddfefadc5003_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfMy0xLTEtMS00OTY4NQ_88e45f94-c0c8-425a-8cdf-fa584e50b2fb"
      unitRef="shares">42338898</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ibf15edfb0127444c8297ddfefadc5003_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfMy0zLTEtMS00OTY4NQ_aa09f6da-717a-4411-a218-b16512c05976"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icbe46f015ce244558ede3196621fd998_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfMy01LTEtMS00OTY4NQ_19ca5281-124c-4aa1-92e1-5c611938716d"
      unitRef="usd">389408000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6675d59e3920448683346ca6b09615ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfMy03LTEtMS00OTY4NQ_177315c5-3993-49e8-a95e-8d6a00e5bcea"
      unitRef="usd">-560000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a0210c92623410b817e1521f5ad2f4b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfMy05LTEtMS00OTY4NQ_e7e9f585-448b-4194-925a-b04c1848105a"
      unitRef="usd">-117067000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9126dbe3941542e6958b2493b197a481_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfMy0xMS0xLTEtNDk2ODU_595baa56-cc55-4aeb-85ce-ca7e59e29525"
      unitRef="usd">271786000</us-gaap:StockholdersEquity>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod
      contextRef="i070803840450402f8ea63b2237086a3e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNC0xLTEtMS00OTY4NQ_8cff6e82-e2ac-4efe-a5f5-9d4360ab880d"
      unitRef="shares">39616</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod>
    <sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased
      contextRef="i321f3e6305f148e49074f9fc1dca1b0c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNC01LTEtMS00OTY4NQ_037014e3-19e9-40e0-9565-876f56233b68"
      unitRef="usd">134000</sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased>
    <sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNC0xMS0xLTEtNDk2ODU_cd434fe7-4157-467a-af9a-2c8017e9b017"
      unitRef="usd">134000</sttk:StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i321f3e6305f148e49074f9fc1dca1b0c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNS01LTEtMS00OTY4NQ_bd8f30c7-d722-4fd3-a7fd-832cb0ada995"
      unitRef="usd">1513000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNS0xMS0xLTEtNDk2ODU_01db15d2-fb2a-442b-b008-ec43d12cc359"
      unitRef="usd">1513000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i64ca7813e54547a1b035602b2d224a95_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNi03LTEtMS00OTY4NQ_3401a02f-b0bd-41d6-a8d0-bc248af42682"
      unitRef="usd">33000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNi0xMS0xLTEtNDk2ODU_af567561-a10c-42ea-8204-96e89aaf5351"
      unitRef="usd">33000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i5137177e56c046f79cf0cea692f9f5bf_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNy05LTEtMS00OTY4NQ_b9b35ad8-2c27-4cbf-b7ed-ff58f639492b"
      unitRef="usd">-24528000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfNy0xMS0xLTEtNDk2ODU_d557400f-0c92-4c3d-b034-9eb4e4190d5d"
      unitRef="usd">-24528000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i88a5936fb32b4acfa2716e68e93e1c09_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfOC0xLTEtMS00OTY4NQ_bfe3b15a-12b8-429e-a655-bef0a12e8c61"
      unitRef="shares">42378514</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i88a5936fb32b4acfa2716e68e93e1c09_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfOC0zLTEtMS00OTY4NQ_23f7286e-7f98-408c-800b-901da6aacdc3"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idc6431ddab1f47ae881d4c7214c8921b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfOC01LTEtMS00OTY4NQ_3b7af036-7ed2-46d7-ab8f-ee8f4ca42bda"
      unitRef="usd">391055000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic8199b2a3360472d9aaf8cec50d6e134_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfOC03LTEtMS00OTY4NQ_4b55af49-a112-4cb5-b040-a60de235d569"
      unitRef="usd">-527000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie23479f9e8944779858f19140c19a37f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfOC05LTEtMS00OTY4NQ_aa2f5bbe-5215-460f-b56b-c05c88b290d7"
      unitRef="usd">-141595000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib8acaafaf90b4af786b67f9282de530a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yMi9mcmFnOjAxYTc4MzE4MDJiZDQ0ZjBhNjUwOTk1ODIxMDkxMWFjL3RhYmxlOjM2MjhmNmMzNWZjMDQ2Yzc5NjhiMGEzNWZhYWZiNzljL3RhYmxlcmFuZ2U6MzYyOGY2YzM1ZmMwNDZjNzk2OGIwYTM1ZmFhZmI3OWNfOC0xMS0xLTEtNDk2ODU_a322def6-8433-4dda-9bba-7ab2569f72d9"
      unitRef="usd">248938000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMy0xLTEtMS0zMzczNg_b20b6f10-33cc-4fd0-b7c0-f2d8a202d8c6"
      unitRef="usd">-20724000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMy0zLTEtMS0zMzczNg_f280e7ca-0a50-4fcf-92d1-98deafa4bdc3"
      unitRef="usd">-24528000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfNS0xLTEtMS0zMzczNg_f2e11829-75a5-4eec-b74e-2178549f27fe"
      unitRef="usd">1683000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfNS0zLTEtMS0zMzczNg_84c52ed6-b909-4522-bf90-34c1f2e3de76"
      unitRef="usd">1513000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfNi0xLTEtMS00ODkwMA_0059c574-992d-45f5-94cf-0de08fa0a55d"
      unitRef="usd">1014000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfNi0zLTEtMS00ODkwMA_ac5ec480-4350-43e3-96a5-92dcb1843195"
      unitRef="usd">472000</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfOC0xLTEtMS0zMzczNg_b06c3a23-3b5c-46be-b185-a712ee7963ea"
      unitRef="usd">85000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfOC0zLTEtMS0zMzczNg_8b8d7b44-0922-4e09-9f20-aa4655f719b8"
      unitRef="usd">65000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfOS0xLTEtMS01MDI2NA_73687801-690b-4794-813f-03a65cc85638"
      unitRef="usd">213000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfOS0zLTEtMS01MDI2NA_bfea9a1d-c9da-42c3-8ee1-5a96dace8b47"
      unitRef="usd">-981000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTAtMS0xLTEtMzM3MzY_466868e0-0c01-4e2f-a841-33149de6f3dd"
      unitRef="usd">-1462000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTAtMy0xLTEtMzM3MzY_9f30c1e0-1a05-442f-b67c-6b4758516957"
      unitRef="usd">-3699000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTEtMS0xLTEtMzM3MzY_d096bd08-977f-4e49-8288-1e21e5c377c9"
      unitRef="usd">-30000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTEtMy0xLTEtMzM3MzY_555bad36-0e22-40b8-ac13-67091ed568f1"
      unitRef="usd">-25000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTItMS0xLTEtMzM3MzY_0e5a2f1e-f2db-4d55-af2a-567126f2a08f"
      unitRef="usd">-2197000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTItMy0xLTEtMzM3MzY_45acc39e-9ffb-48f6-aed7-95920971225b"
      unitRef="usd">-7738000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTMtMS0xLTEtMzM3MzY_7d1728c1-6105-42fd-b9b2-71f4ef1d1aec"
      unitRef="usd">-7356000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTMtMy0xLTEtMzM3MzY_124f5e54-7aa6-4f84-a678-605eb994d557"
      unitRef="usd">-601000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTQtMS0xLTEtMzM3MzY_b550b8db-9a9f-4f63-a80b-7f0cd0939fc2"
      unitRef="usd">-188000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTQtMy0xLTEtMzM3MzY_63349e5f-6767-426a-bd17-cf1f658d187a"
      unitRef="usd">-165000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTYtMS0xLTEtMzM3MzY_1196d528-3207-4af2-92bf-f1a3e496bd9e"
      unitRef="usd">-57000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTYtMy0xLTEtMzM3MzY_17d07f02-160b-4f14-af43-b7fcac0ada1f"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTctMS0xLTEtMzM3MzY_dbab6682-c95d-42fa-a766-7d5ab440f4c1"
      unitRef="usd">-26461000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMTctMy0xLTEtMzM3MzY_094adf4d-86f0-4023-a4f7-587bf0f5330f"
      unitRef="usd">-26277000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjAtMS0xLTEtMzM3MzY_086e000d-e320-4a39-b92f-1fabd7354ebe"
      unitRef="usd">75000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjAtMy0xLTEtMzM3MzY_b7f3ea90-bb54-4206-9cd4-0764929af7eb"
      unitRef="usd">2488000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjEtMS0xLTEtMzM3MzY_08e13fa8-231e-4271-a81e-c3843bedf1d9"
      unitRef="usd">-45200000</us-gaap:PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm>
    <us-gaap:PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjEtMy0xLTEtMzM3MzY_d71d473c-3a38-4ee9-a27e-55d60977f4df"
      unitRef="usd">12894000</us-gaap:PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjItMS0xLTEtMzM3MzY_2f293142-80d9-46c1-9ed3-ad651d26f5b6"
      unitRef="usd">45125000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjItMy0xLTEtMzM3MzY_560e22f9-4c61-4102-9f87-ac8e1a4eab46"
      unitRef="usd">-15382000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjUtMS0xLTEtMzM3MzY_bce3b2f6-5a7f-4108-8ee5-7a2aae6df4b8"
      unitRef="usd">39000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjUtMy0xLTEtMzM3MzY_8941b29b-a9ab-49d5-ba17-a3be5f26a949"
      unitRef="usd">134000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjUtMS0xLTEtNTAxNjU_8ee80395-8848-4d52-883e-4e1fd7e3aa55"
      unitRef="usd">39000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjUtMy0xLTEtNTAxNTg_6ddafbc9-bd7a-465c-9b15-74a2ec01ff71"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjYtMS0xLTEtMzM3MzY_9d0dab1c-ac4b-4e89-8562-84c07f35b977"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjYtMy0xLTEtMzM3MzY_7c1160b9-63a5-43f5-8eee-6b6c5b556818"
      unitRef="usd">134000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjctMS0xLTEtMzM3MzY_3e04f10e-6dfb-49c6-b4fb-de27af6feabf"
      unitRef="usd">18664000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjctMy0xLTEtMzM3MzY_d484976b-590a-4273-bed2-4b3c9ef63845"
      unitRef="usd">-41525000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjgtMS0xLTEtMzM3MzY_494db93a-977b-4970-bb94-546e7956a3ab"
      unitRef="usd">47379000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9126dbe3941542e6958b2493b197a481_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjgtMy0xLTEtMzM3MzY_42630e59-6cbd-4405-8b98-dcdc0226bc23"
      unitRef="usd">92268000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjktMS0xLTEtMzM3MzY_bc2b6ae6-d3d7-40eb-a206-b26887f5ed8e"
      unitRef="usd">66043000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib8acaafaf90b4af786b67f9282de530a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMjktMy0xLTEtMzM3MzY_8beaecfd-ab0f-494d-bafb-85a05fcbcbe3"
      unitRef="usd">50743000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sttk:OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMzItMS0xLTEtMzM3MzY_65986f17-0a3f-494f-b39f-8e1b0026c13d"
      unitRef="usd">0</sttk:OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets>
    <sttk:OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMzItMy0xLTEtMzM3MzY_a77a2783-a48a-41f6-87bd-5483eb71e385"
      unitRef="usd">5447000</sttk:OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMzMtMS0xLTEtMzM3MzY_2971d8fe-c772-4bd6-92cb-94d40844fac1"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMzMtMy0xLTEtMzM3MzY_4917e305-c89e-4919-9bbf-d561bdadd945"
      unitRef="usd">2945000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <sttk:RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMzQtMS0xLTEtNTA2MzA_294a02da-12c2-4719-982d-2ffd67093f4c"
      unitRef="usd">500000</sttk:RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived>
    <sttk:RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMzQtMy0xLTEtNTA2MjM_31ab2efd-5aaf-41b6-a844-a84ffea3c069"
      unitRef="usd">0</sttk:RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMzUtMS0xLTEtMzM3MzY_ef87995f-4dd9-41c6-97d3-eb3491a958e1"
      unitRef="usd">155000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8yOC9mcmFnOjljYWUxOWRhYmU4ODQzMTRiYjc2ZGQ0ZDg3OTAzZWQ0L3RhYmxlOjJiODQxZDYzM2UxZjQ5Mjg5ODQyZGRlNDI4ODYwYjg1L3RhYmxlcmFuZ2U6MmI4NDFkNjMzZTFmNDkyODk4NDJkZGU0Mjg4NjBiODVfMzUtMy0xLTEtMzM3MzY_c406b206-61b3-40ac-b8c3-c397226b74d8"
      unitRef="usd">319000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNC9mcmFnOjEyZWQ5YzM2ZmUxNTQyZTRhYTkwMGEzYmE2ODZmYTQyL3RleHRyZWdpb246MTJlZDljMzZmZTE1NDJlNGFhOTAwYTNiYTY4NmZhNDJfMzE5Mg_f9746e4e-5e0d-41a9-a5b5-6f0695f1404b">Organization and Description of Business &lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shattuck Labs, Inc. (the &#x201c;Company&#x201d;) was incorporated in 2016 in the State of Delaware and is a clinical-stage biopharmaceutical company developing dual-sided fusion proteins, including its Agonist Redirected Checkpoint (&#x201c;ARC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) and gamma delta T cell engager (&#x201c;GADLEN&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) platforms, as novel classes of biologic medicines capable of multifunctional activity with potential applications in oncology and inflammatory diseases. Using its proprietary technology, the Company is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic malignancies. The Company has one clinical-stage product candidate, SL-172154, and has several compounds in preclinical development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $239.7 million as of March&#160;31, 2023. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company&#x2019;s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company&#x2019;s cash and cash equivalents and investments of $135.5 million as of March&#160;31, 2023 are sufficient to fund projected operations of the Company for at least the next twelve months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Global Economic Considerations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine and other political tensions, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on our future operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <sttk:NumberOfClinicalStageProductCandidates
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNC9mcmFnOjEyZWQ5YzM2ZmUxNTQyZTRhYTkwMGEzYmE2ODZmYTQyL3RleHRyZWdpb246MTJlZDljMzZmZTE1NDJlNGFhOTAwYTNiYTY4NmZhNDJfMjc0ODc3OTA3NjY1Nw_35b96464-3c60-4434-bac8-e7e4c534986c"
      unitRef="candidate">1</sttk:NumberOfClinicalStageProductCandidates>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNC9mcmFnOjEyZWQ5YzM2ZmUxNTQyZTRhYTkwMGEzYmE2ODZmYTQyL3RleHRyZWdpb246MTJlZDljMzZmZTE1NDJlNGFhOTAwYTNiYTY4NmZhNDJfOTA4_8782d07e-dfc3-409f-9b9e-cfef9e05bc0f"
      unitRef="usd">-239700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNC9mcmFnOjEyZWQ5YzM2ZmUxNTQyZTRhYTkwMGEzYmE2ODZmYTQyL3RleHRyZWdpb246MTJlZDljMzZmZTE1NDJlNGFhOTAwYTNiYTY4NmZhNDJfMTc0Mw_b605bea7-7f9e-4fbe-a714-e085617d8960"
      unitRef="usd">135500000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMjc_82317780-c497-4cdd-901b-d06db6fd98bb">Basis of Presentation and Summary of Significant Accounting Policies &lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Condensed Financial Statements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#x2019;s financial position, its results of operations, statements of changes in stockholders&#x2019; equity and cash flows for the interim periods presented. Operating results for interim periods presented are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023. The interim financial statements presented herein do not contain all required disclosures under GAAP for annual financial statements. The accompanying unaudited interim condensed financial statements should be read in conjunction with the annual audited financial statements and related notes in our Annual Report on Form 10-K for the year ended December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including investments and accounts payable, approximate fair value due to the short-term nature of those instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. While the Company has not experienced any losses, the recent failure of Silicon Valley Bank (&#x201c;SVB&#x201d;), at which the Company held cash, exposed the Company to significant credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors. The Company is in the process of transferring its cash to an alternate depository institution, the financial position of which management believes does not expose the Company to significant credit risk. Where possible, the Company will also continue to hold its excess cash in investments and money market accounts to further limit exposure. The Company does not believe that it is subject to other unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only U.S. Treasury securities that management believes protects the Company from risk of default and impairment of value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is highly dependent on a limited number of contract manufacturing organizations (&#x201c;CMOs&#x201d;) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is highly dependent on a limited number of contract research organizations (&#x201c;CROs&#x201d;) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents consisted of $0.8 million held in operating accounts and $65.2 million held in money market funds as of March&#160;31, 2023, and $3.5 million held in operating accounts and $43.9 million held in money market funds as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income (loss), a component of stockholders&#x2019; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. As of March&#160;31, 2023 and December 31, 2022, there were no impairments related to credit losses of investments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets. There were no impairments of long-lived assets for the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The classification of the Company&#x2019;s leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirement of Accounting Standards Codification (&#x201c;ASC&#x201d;) 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) to leases with a term of 12 months or less for all classes of assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 450-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the FASB to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#x2019;s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration revenue is recognized in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;identify the contract(s) with a customer;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;identify the performance obligations in the contract; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt"&gt;determine the transaction price; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"&gt;allocate the transaction price to the performance obligations within the contract; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;v.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#x2019;s arrangements may consist of a license of, or options to license, the Company&#x2019;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#x2019;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaboration revenue arrangements may include the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company considered the guidance in ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and will recognize the payments received from these agreements as revenue when the related costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A substantial portion of the Company&#x2019;s ongoing research and development activities are conducted by third-party service providers, including CROs and CMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO or outside service provider, the payments will be recorded as a prepaid asset, which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#x2019;s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#x2019;s accruals that could materially affect the Company&#x2019;s results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock or convertible notes, if any, stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as of March&#160;31, 2023 and 2022, as they would be anti-dilutive:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,261,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,460,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;652,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;313,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,914,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,774,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Comprehensive Income (Loss) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on investments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMTc_990544fc-5d5c-4453-9f2d-0522d6ced590">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Condensed Financial Statements &lt;/span&gt;&lt;/div&gt;In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#x2019;s financial position, its results of operations, statements of changes in stockholders&#x2019; equity and cash flows for the interim periods presented. Operating results for interim periods presented are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023. The interim financial statements presented herein do not contain all required disclosures under GAAP for annual financial statements. The accompanying unaudited interim condensed financial statements should be read in conjunction with the annual audited financial statements and related notes in our Annual Report on Form 10-K for the year ended December&#160;31, 2022.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMTg_f9fa89d1-3ac6-4488-86bb-855c1977bad9">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, &lt;/span&gt;&lt;/div&gt;the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management&#x2019;s estimates.</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjc0ODc3OTExMTE1Mg_375fa0dd-dda2-4a3d-b286-cd0aae9fe66f">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMzM_51849944-3b01-424c-b6cf-9f1d758016b2">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Level&#160;3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including investments and accounts payable, approximate fair value due to the short-term nature of those instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMTk_38aca953-201a-4fab-8d6f-71532026e1c4">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. While the Company has not experienced any losses, the recent failure of Silicon Valley Bank (&#x201c;SVB&#x201d;), at which the Company held cash, exposed the Company to significant credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors. The Company is in the process of transferring its cash to an alternate depository institution, the financial position of which management believes does not expose the Company to significant credit risk. Where possible, the Company will also continue to hold its excess cash in investments and money market accounts to further limit exposure. The Company does not believe that it is subject to other unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only U.S. Treasury securities that management believes protects the Company from risk of default and impairment of value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is highly dependent on a limited number of contract manufacturing organizations (&#x201c;CMOs&#x201d;) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. &lt;/span&gt;&lt;/div&gt;The Company is highly dependent on a limited number of contract research organizations (&#x201c;CROs&#x201d;) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMzk_4e070a5d-0580-4435-9a6a-f51c68cd660f">Cash and Cash Equivalents The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents.</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia5a069be2f114474a16ab65a58e0073c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfNTQ4Mg_74dcb47f-af83-459b-a573-4d218ddff916"
      unitRef="usd">800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idb23ff2081e748fd9ff374eb3980514e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfNTUxNg_82a11ae0-4708-4270-a98b-a214e96e4bda"
      unitRef="usd">65200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i24b4d1c38b1242aca9f89fabfca382b8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfNTU2MA_3ea15295-b299-49bd-9589-93d97c3d58cf"
      unitRef="usd">3500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia5862eb6343f4314b9960014696b7d5e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfNTU5NA_46a79009-2728-439c-a17f-6207ff5fe931"
      unitRef="usd">43900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMjg_43537574-0b3c-4fca-b32e-172b7a32b323">Investments The Company&#x2019;s investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income (loss), a component of stockholders&#x2019; equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjc0ODc3OTEwNTAxNQ_07477853-a45a-4697-a2c2-27caa1aedcfd">Impairment of Long-Lived AssetsLong-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjc0ODc3OTEwNTY2NA_79a55d43-c18f-4a69-bfbd-ff0a68a40836"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjc0ODc3OTEwNTY2NA_a6543420-3124-4f82-88b5-37bf021dd72d"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMjE_aafbb9ed-569c-4fec-9501-c29ffca3e517">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. The classification of the Company&#x2019;s leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirement of Accounting Standards Codification (&#x201c;ASC&#x201d;) 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) to leases with a term of 12 months or less for all classes of assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjc0ODc3OTEwNTAzMg_7c98c7a4-d863-4977-8b8c-1483f93dad99">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 450-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the FASB to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company&#x2019;s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMjQ_64f8515f-5aac-4bf6-97bf-eca904b80cb2">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration revenue is recognized in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;i.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt"&gt;identify the contract(s) with a customer;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt"&gt;identify the performance obligations in the contract; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iii.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt"&gt;determine the transaction price; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;iv.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt"&gt;allocate the transaction price to the performance obligations within the contract; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;v.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#x2019;s arrangements may consist of a license of, or options to license, the Company&#x2019;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&#160;the customer can benefit from on its own or together with other readily available resources and (ii)&#160;are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#x2019;s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaboration revenue arrangements may include the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company considered the guidance in ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt; and will recognize the payments received from these agreements as revenue when the related costs are incurred.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMjU_8509accc-5877-4a6b-821a-1c88a4a7ddad">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. &lt;/span&gt;&lt;/div&gt;A substantial portion of the Company&#x2019;s ongoing research and development activities are conducted by third-party service providers, including CROs and CMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO or outside service provider, the payments will be recorded as a prepaid asset, which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company&#x2019;s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company&#x2019;s accruals that could materially affect the Company&#x2019;s results of operations.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMjY_e8962ee7-3a35-41e5-a52f-b2c517d35bc7">Net Loss Per Share Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock or convertible notes, if any, stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwMjI_1c88a304-043c-4844-b655-a9870cb4fe24">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as of March&#160;31, 2023 and 2022, as they would be anti-dilutive:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.092%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,261,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,460,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;652,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;313,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,914,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,774,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i66202690cd934e39a5b02adc401092ec_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RhYmxlOmFiMDBhZDZmOTQwNjRkZmM4ODM2MzA1Njk0OTU0ZmUyL3RhYmxlcmFuZ2U6YWIwMGFkNmY5NDA2NGRmYzg4MzYzMDU2OTQ5NTRmZTJfMi01LTEtMS0zMzczNg_2947016e-eec6-4f9c-bd02-cdc88834eb43"
      unitRef="shares">5261439</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2c8063b21bdd42d6a8b2bd6b8a659fe6_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RhYmxlOmFiMDBhZDZmOTQwNjRkZmM4ODM2MzA1Njk0OTU0ZmUyL3RhYmxlcmFuZ2U6YWIwMGFkNmY5NDA2NGRmYzg4MzYzMDU2OTQ5NTRmZTJfMi03LTEtMS0zMzczNg_39108d47-e3b7-4db2-8436-75b337cc7782"
      unitRef="shares">3460911</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1634b5c2ee444f55945905fb30149f97_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RhYmxlOmFiMDBhZDZmOTQwNjRkZmM4ODM2MzA1Njk0OTU0ZmUyL3RhYmxlcmFuZ2U6YWIwMGFkNmY5NDA2NGRmYzg4MzYzMDU2OTQ5NTRmZTJfMy01LTEtMS0zMzczNg_8979cadf-fecc-463c-bb58-77b671256214"
      unitRef="shares">652598</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i64b931a9bad34aaf9918cffa88232c5e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RhYmxlOmFiMDBhZDZmOTQwNjRkZmM4ODM2MzA1Njk0OTU0ZmUyL3RhYmxlcmFuZ2U6YWIwMGFkNmY5NDA2NGRmYzg4MzYzMDU2OTQ5NTRmZTJfMy03LTEtMS0zMzczNg_ea5fb3f8-157e-447d-9848-43fc179543c1"
      unitRef="shares">313390</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RhYmxlOmFiMDBhZDZmOTQwNjRkZmM4ODM2MzA1Njk0OTU0ZmUyL3RhYmxlcmFuZ2U6YWIwMGFkNmY5NDA2NGRmYzg4MzYzMDU2OTQ5NTRmZTJfNC01LTEtMS0zMzczNg_2a63b7b7-d3c5-408c-9f9a-9922b81e02e3"
      unitRef="shares">5914037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RhYmxlOmFiMDBhZDZmOTQwNjRkZmM4ODM2MzA1Njk0OTU0ZmUyL3RhYmxlcmFuZ2U6YWIwMGFkNmY5NDA2NGRmYzg4MzYzMDU2OTQ5NTRmZTJfNC03LTEtMS0zMzczNg_f3657787-5446-4e49-a83a-bd881ab88959"
      unitRef="shares">3774301</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwNDU_2a38f860-ef16-4b89-8dd0-387eedfc9277">Other Comprehensive Income (Loss) Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on investments.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNy9mcmFnOjc1OTEwZTI4MDMxYjQ5NDViNjNmNzAzNTUyYzI2NWZkL3RleHRyZWdpb246NzU5MTBlMjgwMzFiNDk0NWI2M2Y3MDM1NTJjMjY1ZmRfMjMwNDY_e53b8023-658d-4cd2-bf41-a43f3a6cc1f1">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RleHRyZWdpb246MjIzNmJiNmI2N2RlNDBmM2JmYmNmMDlhYmZkMDg4NWJfNDk3_17b35726-b5c9-4f21-a5dd-b3453764c319">Investments &lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s available for sale investments by major security type (amounts in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-indent:24.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investment instruments and cash and cash equivalents are classified using Level&#160;1 inputs within the fair value hierarchy and are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Debt securities have a weighted-average maturity of 0.24 years as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RleHRyZWdpb246MjIzNmJiNmI2N2RlNDBmM2JmYmNmMDlhYmZkMDg4NWJfNDk4_7f5788a6-554b-4af4-af91-bec75fd89e6c">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the Company&#x2019;s available for sale investments by major security type (amounts in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;69,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;114,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(877)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;113,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1f7e7bca8d6041f39e4dc1a03ecdaf39_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjdlNWE2NzEyMDgxZjQxZTFhY2VmNzEzNTQyNDdlYTNmL3RhYmxlcmFuZ2U6N2U1YTY3MTIwODFmNDFlMWFjZWY3MTM1NDI0N2VhM2ZfNC0xLTEtMS0zMzczNg_4357d1d5-a9ed-4d33-9535-dde0f612dded"
      unitRef="usd">69791000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="i1f7e7bca8d6041f39e4dc1a03ecdaf39_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjdlNWE2NzEyMDgxZjQxZTFhY2VmNzEzNTQyNDdlYTNmL3RhYmxlcmFuZ2U6N2U1YTY3MTIwODFmNDFlMWFjZWY3MTM1NDI0N2VhM2ZfNC0zLTEtMS0zMzczNg_514c553c-4304-48ba-a6d5-fd1b36c5106d"
      unitRef="usd">-339000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1f7e7bca8d6041f39e4dc1a03ecdaf39_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjdlNWE2NzEyMDgxZjQxZTFhY2VmNzEzNTQyNDdlYTNmL3RhYmxlcmFuZ2U6N2U1YTY3MTIwODFmNDFlMWFjZWY3MTM1NDI0N2VhM2ZfNC01LTEtMS0zMzczNg_1a6f2092-c313-4d69-a484-3f46d68bdef0"
      unitRef="usd">69452000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjdlNWE2NzEyMDgxZjQxZTFhY2VmNzEzNTQyNDdlYTNmL3RhYmxlcmFuZ2U6N2U1YTY3MTIwODFmNDFlMWFjZWY3MTM1NDI0N2VhM2ZfNS0xLTEtMS0zMzczNg_3217f0e8-f721-4454-945d-7ffb8c6c357e"
      unitRef="usd">69791000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjdlNWE2NzEyMDgxZjQxZTFhY2VmNzEzNTQyNDdlYTNmL3RhYmxlcmFuZ2U6N2U1YTY3MTIwODFmNDFlMWFjZWY3MTM1NDI0N2VhM2ZfNS0zLTEtMS0zMzczNg_33bfbcf0-d3c4-4f82-82f8-9aa25c555e25"
      unitRef="usd">-339000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjdlNWE2NzEyMDgxZjQxZTFhY2VmNzEzNTQyNDdlYTNmL3RhYmxlcmFuZ2U6N2U1YTY3MTIwODFmNDFlMWFjZWY3MTM1NDI0N2VhM2ZfNS01LTEtMS0zMzczNg_09c58aed-494e-4281-a024-dbe3811bce3e"
      unitRef="usd">69452000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i56b2909098264559bde53509e6f16d96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjljOWFjNGI3OGNjODQwNGNhYzE0ODcxZDYxNmI3OTg0L3RhYmxlcmFuZ2U6OWM5YWM0Yjc4Y2M4NDA0Y2FjMTQ4NzFkNjE2Yjc5ODRfNC0xLTEtMS0zMzczNg_8a7a4ebd-6d81-446e-b4eb-585bd7e2d14d"
      unitRef="usd">114778000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="i56b2909098264559bde53509e6f16d96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjljOWFjNGI3OGNjODQwNGNhYzE0ODcxZDYxNmI3OTg0L3RhYmxlcmFuZ2U6OWM5YWM0Yjc4Y2M4NDA0Y2FjMTQ4NzFkNjE2Yjc5ODRfNC0zLTEtMS0zMzczNg_3f8a87df-45d4-49b1-aa82-96390a3bd2d6"
      unitRef="usd">-877000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i56b2909098264559bde53509e6f16d96_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjljOWFjNGI3OGNjODQwNGNhYzE0ODcxZDYxNmI3OTg0L3RhYmxlcmFuZ2U6OWM5YWM0Yjc4Y2M4NDA0Y2FjMTQ4NzFkNjE2Yjc5ODRfNC01LTEtMS0zMzczNg_37a50f25-839b-482f-8510-360d0a75d72c"
      unitRef="usd">113901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjljOWFjNGI3OGNjODQwNGNhYzE0ODcxZDYxNmI3OTg0L3RhYmxlcmFuZ2U6OWM5YWM0Yjc4Y2M4NDA0Y2FjMTQ4NzFkNjE2Yjc5ODRfNS0xLTEtMS0zMzczNg_84abe972-f127-4ead-be92-7f86b019bbe5"
      unitRef="usd">114778000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjljOWFjNGI3OGNjODQwNGNhYzE0ODcxZDYxNmI3OTg0L3RhYmxlcmFuZ2U6OWM5YWM0Yjc4Y2M4NDA0Y2FjMTQ4NzFkNjE2Yjc5ODRfNS0zLTEtMS0zMzczNg_2461beef-8e65-41fc-bac9-44d488d69ea6"
      unitRef="usd">-877000</us-gaap:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RhYmxlOjljOWFjNGI3OGNjODQwNGNhYzE0ODcxZDYxNmI3OTg0L3RhYmxlcmFuZ2U6OWM5YWM0Yjc4Y2M4NDA0Y2FjMTQ4NzFkNjE2Yjc5ODRfNS01LTEtMS0zMzczNg_9f1d16b2-4dbc-416a-a060-da221d63c5b2"
      unitRef="usd">113901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80MC9mcmFnOjIyMzZiYjZiNjdkZTQwZjNiZmJjZjA5YWJmZDA4ODViL3RleHRyZWdpb246MjIzNmJiNmI2N2RlNDBmM2JmYmNmMDlhYmZkMDg4NWJfNDc5_66c255bd-320e-4951-bdf3-a297cbecb4d2">P0Y2M26D</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RleHRyZWdpb246N2JmOTllODE3Y2JjNDY0Yjg5ZGNiM2EwY2JmZGJkMmNfOTQ_a02d0939-b640-46b6-805e-7ec18c947090">Accrued Expenses and Other Current Liabilities&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development contract costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RleHRyZWdpb246N2JmOTllODE3Y2JjNDY0Yjg5ZGNiM2EwY2JmZGJkMmNfOTY_db9bd4de-621a-4138-ac9b-24af38e3d853">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following (amounts in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.401%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development contract costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <sttk:AccruedResearchAndContractCostsCurrent
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfMS0xLTEtMS0zMzczNg_5346ffe6-6a29-44d7-a572-785c80c413de"
      unitRef="usd">6650000</sttk:AccruedResearchAndContractCostsCurrent>
    <sttk:AccruedResearchAndContractCostsCurrent
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfMS0zLTEtMS0zMzczNg_12c6208c-39e0-44ba-b6c3-88aee6b03f23"
      unitRef="usd">11256000</sttk:AccruedResearchAndContractCostsCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfMy0xLTEtMS01MDMwOQ_71d3887c-fc6c-449c-b290-55616e55560f"
      unitRef="usd">1400000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfMy0zLTEtMS01MDMwOQ_1098c51d-9ef3-489f-be29-f706d35cdc57"
      unitRef="usd">1400000</us-gaap:LitigationReserveCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfMi0xLTEtMS0zMzczNg_6c60ff0e-d60c-4842-879c-0f29282e0d9e"
      unitRef="usd">1203000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfMi0zLTEtMS0zMzczNg_b5e9ae87-4087-4bcd-8041-ff3e8a2794dd"
      unitRef="usd">3967000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfNS0xLTEtMS01MDQ1Mg_d8b9e738-486f-48e8-bdb5-9698549da6c9"
      unitRef="usd">1628000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfNS0zLTEtMS01MDQ1Mg_d36dc6c9-29a7-4e99-8b41-a24f056d497c"
      unitRef="usd">1172000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfNC0xLTEtMS0zMzczNg_599fa443-4d4e-4096-ae18-2f37105bac08"
      unitRef="usd">10881000</sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80My9mcmFnOjdiZjk5ZTgxN2NiYzQ2NGI4OWRjYjNhMGNiZmRiZDJjL3RhYmxlOjNlNzlmMGUxZDc0ZjQ2NDA4MDVmNzM2NjRkYjdmZjMyL3RhYmxlcmFuZ2U6M2U3OWYwZTFkNzRmNDY0MDgwNWY3MzY2NGRiN2ZmMzJfNC0zLTEtMS0zMzczNg_73bdcfd2-daa1-40aa-add7-d27d2f460ff6"
      unitRef="usd">17795000</sttk:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80Ni9mcmFnOmM3MTAxNzMyZTk5MDRhYWViNzEzMzVmMWRkYjRjZGZmL3RleHRyZWdpb246YzcxMDE3MzJlOTkwNGFhZWI3MTMzNWYxZGRiNGNkZmZfNDI0MA_5490f315-7e3f-4dfa-8dbf-2910de2e81f9">Commitments and Contingencies &lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain office space, laboratory facilities, and equipment. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has operating leases. There have been no material changes in our operating leases as compared to operating leases disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nighthawk Biosciences, Inc. License Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with a license agreement with Nighthawk Biosciences, Inc. (&#x201c;Nighthawk&#x201d;), the Company is required to make payments of up to $20.6&#160;million in aggregate for the achievement of specified development, regulatory and commercial sales milestones for certain licensed products. The Company paid $0.1&#160;million to Nighthawk in the three months ended March 31, 2023 as a milestone payment for the Company&#x2019;s completion of a Phase 1 clinical trial for SL-172154.&#160;The Company is required to pay Nighthawk a percentage of upfront fees or other non-royalty payments not tied to milestone events that it receives in connection with certain sublicenses of the licensed patents.&#160;The Company is also required to pay Nighthawk a royalty on all of its worldwide net sales, those of its affiliates, and sublicenses of certain licensed patents in the low single digits. The Company has not recorded a liability for the aforementioned payments given the achievement of specified development, regulatory and commercial sales milestones for certain licensed products is not probable as of the balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. On January 31, 2022 and February 11, 2022, putative class action lawsuits were filed in the U.S. District Court for the Eastern District of New York against us and certain of the Company&#x2019;s officers and directors. The cases were consolidated on June 2, 2022, and the plaintiffs filed an amended complaint on July 1, 2022. The amended complaint cites the volatility in the Company&#x2019;s common stock and alleges that the defendants made or are responsible for misleading omissions regarding the Company&#x2019;s clinical trial results and the collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company, Ltd. The parties reached a settlement in principle of the plaintiffs&#x2019; claims in the amount of $1.4&#160;million on November 2, 2022. The settlement is subject to a definitive settlement agreement, notice to stockholders and court approval. The parties filed their motion for preliminary approval of the settlement agreement with the court on December 14, 2022, and, as of May 8, 2023, that motion is pending. The Company has accrued the settlement amount in accrued expenses and other current liabilities as of March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations &lt;/span&gt;&lt;/div&gt;Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which the Company cannot reasonably predict future payment. The Company&#x2019;s contractual obligations result primarily from obligations for various CMOs and CROs, which include potential payments that may be required under its agreements. The contracts also contain variable costs and milestones that are hard to predict, as they are based on such things as patients enrolled and clinical trial sites. The timing of payments and actual amounts paid under CMO and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Such agreements are cancellable upon written notice by the Company and, therefore, are not long-term liabilities.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sttk:LicenseAgreementRoyaltyPaymentsMaximum
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80Ni9mcmFnOmM3MTAxNzMyZTk5MDRhYWViNzEzMzVmMWRkYjRjZGZmL3RleHRyZWdpb246YzcxMDE3MzJlOTkwNGFhZWI3MTMzNWYxZGRiNGNkZmZfMTcwMA_019f9805-af27-4b87-ad37-2041637d55b7"
      unitRef="usd">20600000</sttk:LicenseAgreementRoyaltyPaymentsMaximum>
    <us-gaap:PaymentsForRoyalties
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80Ni9mcmFnOmM3MTAxNzMyZTk5MDRhYWViNzEzMzVmMWRkYjRjZGZmL3RleHRyZWdpb246YzcxMDE3MzJlOTkwNGFhZWI3MTMzNWYxZGRiNGNkZmZfMjc0ODc3OTA4MzAzOQ_65ed027d-5e12-46ba-b8a5-eb0a67177535"
      unitRef="usd">100000</us-gaap:PaymentsForRoyalties>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80Ni9mcmFnOmM3MTAxNzMyZTk5MDRhYWViNzEzMzVmMWRkYjRjZGZmL3RleHRyZWdpb246YzcxMDE3MzJlOTkwNGFhZWI3MTMzNWYxZGRiNGNkZmZfMjIzOA_9d0b93c4-494e-4995-b874-cd109ad41a8f"
      unitRef="usd">0</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ie0fe0931d7fd474e9944465230cae621_D20221102-20221102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV80Ni9mcmFnOmM3MTAxNzMyZTk5MDRhYWViNzEzMzVmMWRkYjRjZGZmL3RleHRyZWdpb246YzcxMDE3MzJlOTkwNGFhZWI3MTMzNWYxZGRiNGNkZmZfMjc0ODc3OTA4MjY0OA_793e9a20-c2b0-4a7d-8f3c-7659a62a3e98"
      unitRef="usd">1400000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNzQvZnJhZzphYWEwNmRmZGJlMWQ0NGQyODA4MzA4NzQzNTNkMmU3ZS90ZXh0cmVnaW9uOmFhYTA2ZGZkYmUxZDQ0ZDI4MDgzMDg3NDM1M2QyZTdlXzI3NDg3NzkwNzI2MDk_e7788f84-fbbc-46db-bc8c-967903b78a24">EquityThe Company is authorized to issue up to 300,000,000 shares of common stock and 10,000,000 shares of preferred stock, all with a par value of $0.0001 per share. The holders of the Company&#x2019;s common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. The Company&#x2019;s common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of the Company&#x2019;s common stock will receive ratably any dividends declared by the Company&#x2019;s board of directors (&#x201c;Board&#x201d;) out of funds legally available. In the event of the Company&#x2019;s liquidation, dissolution or winding-up, the holders of the Company&#x2019;s common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. As of the periods presented, no common stock dividends had been declared by the Board. At March 31, 2023, none of the 10,000,000 shares of preferred stock were outstanding, and the Company has no present plans to issue any shares of preferred stock.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNzQvZnJhZzphYWEwNmRmZGJlMWQ0NGQyODA4MzA4NzQzNTNkMmU3ZS90ZXh0cmVnaW9uOmFhYTA2ZGZkYmUxZDQ0ZDI4MDgzMDg3NDM1M2QyZTdlXzI3NDg3NzkwNzI1MDM_1dbbb9a4-33b3-42f0-b621-ef7c74f52902"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNzQvZnJhZzphYWEwNmRmZGJlMWQ0NGQyODA4MzA4NzQzNTNkMmU3ZS90ZXh0cmVnaW9uOmFhYTA2ZGZkYmUxZDQ0ZDI4MDgzMDg3NDM1M2QyZTdlXzI3NDg3NzkwNzI1MTY_b3be3495-8d3b-4ce3-ad57-dd4551955196"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNzQvZnJhZzphYWEwNmRmZGJlMWQ0NGQyODA4MzA4NzQzNTNkMmU3ZS90ZXh0cmVnaW9uOmFhYTA2ZGZkYmUxZDQ0ZDI4MDgzMDg3NDM1M2QyZTdlXzI3NDg3NzkwNzI1Mjg_b619f618-012d-42db-8a04-a30a444f9b6e"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNzQvZnJhZzphYWEwNmRmZGJlMWQ0NGQyODA4MzA4NzQzNTNkMmU3ZS90ZXh0cmVnaW9uOmFhYTA2ZGZkYmUxZDQ0ZDI4MDgzMDg3NDM1M2QyZTdlXzI3NDg3NzkwNzI1Mjg_ea1deb87-b4e7-41ad-bdd6-8a4daf90b514"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNzQvZnJhZzphYWEwNmRmZGJlMWQ0NGQyODA4MzA4NzQzNTNkMmU3ZS90ZXh0cmVnaW9uOmFhYTA2ZGZkYmUxZDQ0ZDI4MDgzMDg3NDM1M2QyZTdlXzI3NDg3NzkwNzI1NTI_83caf03b-dc11-4346-8eb0-26760c3ffed9"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNzQvZnJhZzphYWEwNmRmZGJlMWQ0NGQyODA4MzA4NzQzNTNkMmU3ZS90ZXh0cmVnaW9uOmFhYTA2ZGZkYmUxZDQ0ZDI4MDgzMDg3NDM1M2QyZTdlXzM4NDgyOTA3MDA1MDc_61209e55-b65d-4d68-b288-481f2664677a"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE1OTQ_d400abba-cdce-458f-8763-1512abbedb8e">Stock-Based Compensation&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company adopted the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;) which, as of the adoption date, replaced the 2016 Stock Incentive Plan. Under the 2020 Plan, the share reserve automatically &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;increases on January 1st of each year beginning in 2021 and ending with a final increase on January 1, 2030 in an amount equal to 4% of the Company&#x2019;s outstanding common shares on December 31st of the preceding calendar year. The Board may provide that there will be no increase in the share reserve for any such year or that the increase in the share reserve may be smaller than would otherwise occur. On January 1, 2023, the share reserve automatically increased by 1,695,623 shares. As of March&#160;31, 2023, there were 3,739,124 shares available for future grants. The 2020 Plan permits the granting of options, stock appreciation rights, restricted stock units (&#x201c;RSUs&#x201d;), performance stock and performance cash awards. The terms of the agreements under the 2020 Plan are determined by the Board. The Company&#x2019;s awards generally vest over four years and have a term of 10 years. In 2023, the Company granted 165,050 awards that vest in three equal tranches based on the Company achieving a certain closing share price for each tranche for 30 consecutive trading days on or before the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE4MDA_cc775207-fe02-4c9b-8e4e-2107d58e985d"&gt;four&lt;/span&gt;th anniversary of the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2020 Employee Stock Purchase Plan (&#x201c;2020 ESPP&#x201d;) became effective in October 2020. A total of 395,795 shares of common stock were reserved for issuance under the 2020 ESPP. Eligible employees may purchase shares of common stock under the 2020 ESPP at 85% of the lower of the fair market value of the Company&#x2019;s common stock as of the first or the last day of each offering period. Employees are limited to contributing 15% of the employee&#x2019;s eligible compensation and may not purchase more than $25,000 of stock during any calendar year or more than 600 shares during any one purchase period. The 2020 ESPP share reserve automatically increases on January 1st of each calendar year, for ten years, commencing on January 1, 2021, in an amount equal to 1% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Board may act prior to January 1st of a given year to provide that there will be no January 1st increase of the share reserve for such year or that the increase in the share reserve for such year will be a smaller number of shares of common stock than would otherwise occur pursuant to the preceding sentence. On January 1, 2023, the share reserve increased by 423,905 shares. As of March&#160;31, 2023, there were 1,216,723 shares available for future grants. During the three months ended March 31, 2023 and 2022, the Company issued 11,171 and 5,227 shares of common stock for aggregate cash proceeds of $0.1&#160;million and $0.1&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories of its accompanying unaudited interim condensed statements of operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes option activity under the 2020 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,209,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,181,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(128,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,261,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,174,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.05&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,122,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted during the three months ended March 31, 2023 and 2022 had weighted-average grant-date fair values of $2.46 and $5.13 per share, respectively. As of March 31, 2023, the unrecognized compensation cost for options issued was $14.1 million and will be recognized over an estimated weighted-average amortization period of 2.49 years. The total intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was $0.1 million and $0.1 million, respectively. The aggregate intrinsic value of options outstanding and exercisable as of March 31, 2023 was $0.2 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes employee RSU activity for the three months ended March 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.455%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.080%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested RSUs as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;309,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;445,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(73,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(27,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;652,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized $0.2 million of stock-based compensation related to RSUs as of March 31, 2023. As of March 31, 2023, the unrecognized compensation cost for RSUs issued was $3.1 million and will be recognized over an estimated weighted-average amortization period of 3.47 years. The fair values of RSUs are based on the fair value of the Company&#x2019;s common stock on the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Stock Options and Shares Issued&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation by measuring and recognizing as compensation expense the fair value of all share-based payment awards made to employees, including employee stock options and restricted stock awards. The Company uses the Black-Scholes option pricing model to estimate the fair value of employee stock options that only have service or performance conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The inputs to both pricing models require a number of management estimates such as the expected term, volatility, risk-free interest rate and dividend yield. The fair value of stock options was determined using the methods and assumptions discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;The expected term of employee stock options with service-based vesting is determined using the &#x201c;simplified&#x201d; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#x2019;s lack of sufficient historical data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;The expected stock price volatility assumption is based on the historical volatilities of the common stock of a peer group of publicly traded companies as well as the historical volatility of the Company&#x2019;s common stock since the Company began trading subsequent to the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) in October 2020 over the period corresponding to the expected life as of the grant date. The historical volatility data was computed using the daily closing prices during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of the Company&#x2019;s stock price becomes available, or until circumstances change, such that the identified entities are no longer comparable companies. In the latter case, other suitable, similar entities whose share prices are publicly available would be utilized in the calculation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay dividends on its common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Prior to the Company&#x2019;s IPO, the Board periodically estimated the fair value of the Company&#x2019;s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. Subsequent to the Company&#x2019;s IPO, options are issued with a strike price no less than the market price on date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company&#x2019;s 2020 Plan were estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.797%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of options calculated using the Monte Carlo option pricing model granted under the Company&#x2019;s 2020 Plan were estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.797%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company&#x2019;s 2020 ESPP were estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.797%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage
      contextRef="i5c388e0f89f34e2c831691fb79c15cb8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE1OTY_574c653f-d905-442f-a2d8-27000cca54f2"
      unitRef="number">0.04</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage>
    <sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="ifdcd40cea1904365b4a1a01161642a02_D20230101-20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2MDA_e61adc77-6d7c-4659-b1b7-567b3f8615d9"
      unitRef="shares">1695623</sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6fb1051978f94abc950815f2d8001c2f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDYzNzU_f44cc9b1-05fa-476a-a52b-6613b76f0e09"
      unitRef="shares">3739124</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i991dfc7ff32043179c7e3f86c543184b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3Njg_babba7e2-6704-4e85-8573-dbf207e53bbc">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i991dfc7ff32043179c7e3f86c543184b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3ODc_47ab6ba8-72a8-4934-bad4-29b5345c41c3">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod
      contextRef="i991dfc7ff32043179c7e3f86c543184b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2MTE_e9c8905f-d33d-4399-a91f-0c023e85c5ab"
      unitRef="shares">165050</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches
      contextRef="i6fb1051978f94abc950815f2d8001c2f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTIwMzI_6b659843-1d23-4db6-97d3-d432c0cfab34"
      unitRef="tranch">3</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays
      contextRef="i991dfc7ff32043179c7e3f86c543184b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2NDE_5c1d3df8-0cdd-4b9a-bdaa-33ad91be2689">P30D</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i0e6401db080843d78c401499533d1dc2_I20201014"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2NDk_6d046ce5-3904-4ab7-8444-23b6b73a9841"
      unitRef="shares">395795</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ieb1b33d499ae4e9d975505ddf2b6a145_D20201014-20201014"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2NTg_51155463-7f4a-4bbd-ac5c-8c70d239ef0a"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i0e6401db080843d78c401499533d1dc2_I20201014"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2NzY_048d311a-c2f4-4eed-a3dd-52eb054b1d24"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue
      contextRef="ieb1b33d499ae4e9d975505ddf2b6a145_D20201014-20201014"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2NjM_fe983e5e-19d7-4217-a076-48f10f38a862"
      unitRef="usd">25000</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="ieb1b33d499ae4e9d975505ddf2b6a145_D20201014-20201014"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2ODE_77c9c76e-4674-4fdb-bd7a-de20ebb256c3"
      unitRef="shares">600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm
      contextRef="i76febd49246745a9a7bb5f9df44806a6_D20210101-20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3NDg_4ce2c134-8283-4fc3-bc1e-aa234a385957">P10Y</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm>
    <sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage
      contextRef="i0e6401db080843d78c401499533d1dc2_I20201014"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2NzI_08f5d8a1-9d26-44db-94b4-792257441005"
      unitRef="number">0.01</sttk:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage>
    <sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="i9a2cffc815b14f15ba52b9eacfa7e4a7_D20230101-20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2ODY_16364e67-5623-4452-b366-93d112331654"
      unitRef="shares">423905</sttk:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9cbaef79f5984155995efe7d1dfec7e6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDcyNjY_1410bebe-4955-4ef6-a018-6f4e1b56a22e"
      unitRef="shares">1216723</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic07dbdc8b50c460b91220dd5d8950518_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY2ODY_fafd05b7-4151-4f24-a1df-fcdef1e2a1f0"
      unitRef="shares">11171</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i9f423208f22d42beb3d0027d59f5a13a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3NDI_86698d15-4db0-474b-bd63-cd3765f8c885"
      unitRef="shares">5227</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ic07dbdc8b50c460b91220dd5d8950518_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE2OTU_e0a7e1d4-dae8-43c1-bf6a-57dba8a1cf49"
      unitRef="usd">100000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i9f423208f22d42beb3d0027d59f5a13a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3MDk_c91f9956-db07-4bc8-8a2f-9f853c919f25"
      unitRef="usd">100000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3MjI_dd0df584-106f-43c8-bd0a-e26f89c8d22b">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation expense in the following expense categories of its accompanying unaudited interim condensed statements of operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i553413b499654651890bbd3c2a30bad5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZGZlODhkODhkOWQ0YjM0ODMyNGViNjgzODlhMzAxMy90YWJsZXJhbmdlOjdkZmU4OGQ4OGQ5ZDRiMzQ4MzI0ZWI2ODM4OWEzMDEzXzItMS0xLTEtNTA5MTU_aea4c0b2-45d9-41df-9ec6-120b6227cba6"
      unitRef="usd">814000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0696e705fa644b0eb1e32b0abcf24c9a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZGZlODhkODhkOWQ0YjM0ODMyNGViNjgzODlhMzAxMy90YWJsZXJhbmdlOjdkZmU4OGQ4OGQ5ZDRiMzQ4MzI0ZWI2ODM4OWEzMDEzXzItMy0xLTEtNTA5MTU_41858434-2c50-4b32-8909-c0a499463718"
      unitRef="usd">827000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i26ed59b30fb3417b8f0372f4e8d87f2a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZGZlODhkODhkOWQ0YjM0ODMyNGViNjgzODlhMzAxMy90YWJsZXJhbmdlOjdkZmU4OGQ4OGQ5ZDRiMzQ4MzI0ZWI2ODM4OWEzMDEzXzMtMS0xLTEtNTA5MTU_974b48fe-3a68-4103-9530-2b53cf834baa"
      unitRef="usd">869000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i24d5ba980a4546dd9c94c7d3d055e5dc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZGZlODhkODhkOWQ0YjM0ODMyNGViNjgzODlhMzAxMy90YWJsZXJhbmdlOjdkZmU4OGQ4OGQ5ZDRiMzQ4MzI0ZWI2ODM4OWEzMDEzXzMtMy0xLTEtNTA5MTU_164e55ab-9a10-4dd4-8cb7-4485dae86b7c"
      unitRef="usd">686000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZGZlODhkODhkOWQ0YjM0ODMyNGViNjgzODlhMzAxMy90YWJsZXJhbmdlOjdkZmU4OGQ4OGQ5ZDRiMzQ4MzI0ZWI2ODM4OWEzMDEzXzQtMS0xLTEtNTA5MTU_dd321e00-3c04-4ebb-b27a-0e3dd6e7845e"
      unitRef="usd">1683000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZGZlODhkODhkOWQ0YjM0ODMyNGViNjgzODlhMzAxMy90YWJsZXJhbmdlOjdkZmU4OGQ4OGQ5ZDRiMzQ4MzI0ZWI2ODM4OWEzMDEzXzQtMy0xLTEtNTA5MTU_1510930e-8b55-42a0-acc4-ca498937a897"
      unitRef="usd">1513000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3MjM_e624f59b-e267-459e-9ee1-9434922ba21c">&lt;div style="margin-top:4pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes option activity under the 2020 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.375%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.886%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Remaining&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,209,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,181,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(717)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(128,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,261,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,174,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.05&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,122,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzEtMS0xLTEtNTA5MTU_d45c03f1-7e8d-4387-bc20-f2f438f24d7a"
      unitRef="shares">4209255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzEtMy0xLTEtNTA5MTU_0d1dee9c-762f-4cf8-91a4-e865cca21b6a"
      unitRef="usdPerShare">8.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i2b0c733727b44be5a7356b37de831391_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzEtNS0xLTEtNTA5MTU_ad76bb28-90fe-4eba-b368-4a4cc3cb974f">P8Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzItMS0xLTEtNTA5MTU_a77478c8-e2d3-425b-9171-75be8cc35878"
      unitRef="shares">1181087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzItMy0xLTEtNTA5MTU_38f9f7f1-fa9b-4e1a-bf02-8eb3fc4817f6"
      unitRef="usdPerShare">3.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzMtMS0xLTEtNTA5MTU_cdf2e14d-034a-4aef-8cff-51e8f00796d7"
      unitRef="shares">717</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzMtMy0xLTEtNTA5MTU_689a6faa-fe67-44d3-9786-76a601d22ee9"
      unitRef="usdPerShare">2.95</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzQtMS0xLTEtNTA5MTU_d65dbd9a-3e7b-4559-b42e-2fb296230aae"
      unitRef="shares">128186</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzQtMy0xLTEtNTA5MTU_4c52f847-fa4a-4659-8312-075bee605354"
      unitRef="usdPerShare">7.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzUtMS0xLTEtNTA5MTU_fd562a4a-9236-49bd-89e7-4a911eedee8f"
      unitRef="shares">5261439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzUtMy0xLTEtNTA5MTU_5a4e14c8-a7ec-445c-8c82-8c13d0f3fdfc"
      unitRef="usdPerShare">7.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzUtNS0xLTEtNTA5MTU_c93b6554-ba43-44a9-844a-7efd14b76bb9">P8Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzYtMS0xLTEtNTA5MTU_3de45eac-fd6b-45bd-8995-076862c5a042"
      unitRef="shares">5174691</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzYtMy0xLTEtNTA5MTU_82f440d7-fb32-41f6-8a3e-528a9e6c283b"
      unitRef="usdPerShare">7.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzYtNS0xLTEtNTA5MTU_f8441e3c-212b-43ff-bf03-1637028f0f51">P8Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzctMS0xLTEtNTA5MTU_2cb08b35-58d3-422b-b015-540e051cb9e1"
      unitRef="shares">2122655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzctMy0xLTEtNTA5MTU_2343a1cc-7b94-4328-9d0f-5cecb6c1b9ee"
      unitRef="usdPerShare">8.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTozZDRmODFjNzkwMDk0ZTY0YmU1N2U4MzdiNzMzNzVlYi90YWJsZXJhbmdlOjNkNGY4MWM3OTAwOTRlNjRiZTU3ZTgzN2I3MzM3NWViXzctNS0xLTEtNTA5MTU_61c3b53f-25c5-4720-9b79-8731d5227c6b">P6Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY4MDU_c407f881-c575-4acf-b987-1492a0e5c443"
      unitRef="usdPerShare">2.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3MjU_0bd588f1-60f8-4221-96b8-fe851f9b50b1"
      unitRef="usdPerShare">5.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY4MzI_af14a00e-fce8-4168-b3e4-7d331f3c77e5"
      unitRef="usd">14100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i428ae4dc142344e4867b47e344b894fe_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY4NDc_7f3f88ee-a3b1-48e1-a7b5-b5243aef7ce1">P2Y5M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY4OTA_4f4709e9-d786-4298-9c55-0cb8c342fdc3"
      unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="iae7a916c76964d90b33a0120be3e3db1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY4OTU_4bd039a7-dd58-44e1-8be9-70999632e393"
      unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY5MjQ_41f1c547-c261-47bf-83c2-49263bfc0fa8"
      unitRef="usd">200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i54a9b5c3ecd3444eb11bc87522cd5887_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY5MjQ_87468520-b504-4628-8b78-c662b09b2533"
      unitRef="usd">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3MzE_4d2008ca-8b7c-4ab6-bf7e-40011dc9d405">&lt;div style="margin-top:7pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes employee RSU activity for the three months ended March 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.455%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.080%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested RSUs as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;309,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;445,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(73,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(27,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;652,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iaf0a0042588b4fd2ac8a83479b491708_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzEtMS0xLTEtNTExOTQ_93e5ed28-8383-402c-a597-e2960dcbafe7"
      unitRef="shares">309477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iaf0a0042588b4fd2ac8a83479b491708_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzEtMy0xLTEtNTEyMDE_cafedfbe-2507-41c7-a9a0-a94705524998"
      unitRef="usdPerShare">7.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzItMS0xLTEtNTExOTQ_b951dfd9-aab1-40d3-9ea0-bfe482cd67c0"
      unitRef="shares">445025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzItMy0xLTEtNTEyMDE_deebc632-9162-4c09-a94d-ea939303d6fa"
      unitRef="usdPerShare">3.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzMtMS0xLTEtNTExOTQ_cb3464ff-2562-4123-89cb-bd38b9c8c3f6"
      unitRef="shares">73937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzMtMy0xLTEtNTEyMDE_ba5cdf02-8b4e-46af-9df6-b8ed6f9ccbba"
      unitRef="usdPerShare">7.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzQtMS0xLTEtNTExOTQ_2bf3bf50-0552-443e-a95f-65594843f4cb"
      unitRef="shares">27967</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzQtMy0xLTEtNTEyMDE_44c66440-30f4-4f2f-a118-9204de9e7080"
      unitRef="usdPerShare">4.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4d4b4c0ce8c04ddbaf55caff9825c696_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzUtMS0xLTEtNTE2NDg_98dcc731-175b-4b84-b974-b805e0942315"
      unitRef="shares">652598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4d4b4c0ce8c04ddbaf55caff9825c696_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo3ZDRmYmY2NWZkMmI0ODFmYWYxODBmZmNhYjg0YTIzOS90YWJsZXJhbmdlOjdkNGZiZjY1ZmQyYjQ4MWZhZjE4MGZmY2FiODRhMjM5XzUtMy0xLTEtNTEyMDc_60205d22-f300-462a-8f84-a400f24223b0"
      unitRef="usdPerShare">4.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDY5Nzc_720b7f66-8c02-4e41-b929-e5d41927113a"
      unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i4d4b4c0ce8c04ddbaf55caff9825c696_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDcwMjY_3a4780f4-83c0-44ab-9c9c-03738b82a8f3"
      unitRef="usd">3100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i108e21ef28fe49d1ba042381b84ef878_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzEwOTk1MTE2NDcwMzk_3d18bc6d-b506-4d90-b4d1-938b4766239e">P3Y5M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i428ae4dc142344e4867b47e344b894fe_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3MzM_599cb1d3-6c66-4569-8b3b-84e376e9a091"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE3NDA_b843a776-b9eb-4528-b2f8-638c6a64a82e">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company&#x2019;s 2020 Plan were estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.797%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of options calculated using the Monte Carlo option pricing model granted under the Company&#x2019;s 2020 Plan were estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.797%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;80.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company&#x2019;s 2020 ESPP were estimated using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.797%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.800%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2020 ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term - years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia3286ad000a74fb2b534f75b6f23f669_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NGQ1ZjU5OWJkODM0MGI5YTQwMThiYzc0MWM3MWVmYS90YWJsZXJhbmdlOjY0ZDVmNTk5YmQ4MzQwYjlhNDAxOGJjNzQxYzcxZWZhXzMtMS0xLTEtNTEzMDQ_f0b604bd-0f71-4980-9927-9ccb5ada0ab4">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8c88b5d9b1e14fc3b353ec2bed09c97d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NGQ1ZjU5OWJkODM0MGI5YTQwMThiYzc0MWM3MWVmYS90YWJsZXJhbmdlOjY0ZDVmNTk5YmQ4MzQwYjlhNDAxOGJjNzQxYzcxZWZhXzMtMy0xLTEtNTEzMTE_a2a02fcc-0bce-4918-b6dc-deba3de06aa9">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia3286ad000a74fb2b534f75b6f23f669_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NGQ1ZjU5OWJkODM0MGI5YTQwMThiYzc0MWM3MWVmYS90YWJsZXJhbmdlOjY0ZDVmNTk5YmQ4MzQwYjlhNDAxOGJjNzQxYzcxZWZhXzQtMS0xLTEtNTEzMDQ_329bdd4f-6762-4e18-9462-a5e326ec34dd"
      unitRef="number">0.848</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8c88b5d9b1e14fc3b353ec2bed09c97d_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NGQ1ZjU5OWJkODM0MGI5YTQwMThiYzc0MWM3MWVmYS90YWJsZXJhbmdlOjY0ZDVmNTk5YmQ4MzQwYjlhNDAxOGJjNzQxYzcxZWZhXzQtMy0xLTEtNTEzMTE_296e1e77-126f-47e1-8125-f97e976c0c9f"
      unitRef="number">0.819</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia3286ad000a74fb2b534f75b6f23f669_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NGQ1ZjU5OWJkODM0MGI5YTQwMThiYzc0MWM3MWVmYS90YWJsZXJhbmdlOjY0ZDVmNTk5YmQ4MzQwYjlhNDAxOGJjNzQxYzcxZWZhXzUtMS0xLTEtNTEzMDQ_bdb27af3-b222-45a3-9e4c-60bdb0a0bc44"
      unitRef="number">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8c88b5d9b1e14fc3b353ec2bed09c97d_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NGQ1ZjU5OWJkODM0MGI5YTQwMThiYzc0MWM3MWVmYS90YWJsZXJhbmdlOjY0ZDVmNTk5YmQ4MzQwYjlhNDAxOGJjNzQxYzcxZWZhXzUtMy0xLTEtNTEzMTE_82e9dc0a-6937-4348-a1f6-d2dbc9e20ee0"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia3286ad000a74fb2b534f75b6f23f669_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NGQ1ZjU5OWJkODM0MGI5YTQwMThiYzc0MWM3MWVmYS90YWJsZXJhbmdlOjY0ZDVmNTk5YmQ4MzQwYjlhNDAxOGJjNzQxYzcxZWZhXzYtMS0xLTEtNTEzMDQ_bd0a029b-0caf-4a19-81b0-b1f7c1b0459f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8c88b5d9b1e14fc3b353ec2bed09c97d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NGQ1ZjU5OWJkODM0MGI5YTQwMThiYzc0MWM3MWVmYS90YWJsZXJhbmdlOjY0ZDVmNTk5YmQ4MzQwYjlhNDAxOGJjNzQxYzcxZWZhXzYtMy0xLTEtNTEzMTE_602199d4-15ad-4948-880b-0003b819e055"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie3ea58e597ec4bc9b179b6cbe88d9b32_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTphY2I3MWE5M2U3YTQ0M2VmYjk4NmIxYWQ4N2U1MzMwOC90YWJsZXJhbmdlOmFjYjcxYTkzZTdhNDQzZWZiOTg2YjFhZDg3ZTUzMzA4XzMtMS0xLTEtNTE2NDA_eb2ddc12-5864-4c93-9c7a-809e97fbb9c6">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iafe592e811e24849a2a391b482b2fa73_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTphY2I3MWE5M2U3YTQ0M2VmYjk4NmIxYWQ4N2U1MzMwOC90YWJsZXJhbmdlOmFjYjcxYTkzZTdhNDQzZWZiOTg2YjFhZDg3ZTUzMzA4XzMtMy0xLTEtNTE2NDM_80a50385-374b-4d00-a5f5-bc71ad159af3">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie3ea58e597ec4bc9b179b6cbe88d9b32_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTphY2I3MWE5M2U3YTQ0M2VmYjk4NmIxYWQ4N2U1MzMwOC90YWJsZXJhbmdlOmFjYjcxYTkzZTdhNDQzZWZiOTg2YjFhZDg3ZTUzMzA4XzQtMS0xLTEtNTE2NDA_0d36b5c2-7e93-4ac2-8535-aeb97f3252ee"
      unitRef="number">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iafe592e811e24849a2a391b482b2fa73_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTphY2I3MWE5M2U3YTQ0M2VmYjk4NmIxYWQ4N2U1MzMwOC90YWJsZXJhbmdlOmFjYjcxYTkzZTdhNDQzZWZiOTg2YjFhZDg3ZTUzMzA4XzQtMy0xLTEtNTE2NDM_bcc9e5e4-70e8-4be5-9f66-1da47d139c22"
      unitRef="number">0.800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie3ea58e597ec4bc9b179b6cbe88d9b32_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTphY2I3MWE5M2U3YTQ0M2VmYjk4NmIxYWQ4N2U1MzMwOC90YWJsZXJhbmdlOmFjYjcxYTkzZTdhNDQzZWZiOTg2YjFhZDg3ZTUzMzA4XzUtMS0xLTEtNTE2NDA_7e17376e-f306-4080-8f86-09f082ae1925"
      unitRef="number">0.036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iafe592e811e24849a2a391b482b2fa73_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTphY2I3MWE5M2U3YTQ0M2VmYjk4NmIxYWQ4N2U1MzMwOC90YWJsZXJhbmdlOmFjYjcxYTkzZTdhNDQzZWZiOTg2YjFhZDg3ZTUzMzA4XzUtMy0xLTEtNTE2NDM_f73c351a-575e-4d9a-9e64-099a989c1058"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie3ea58e597ec4bc9b179b6cbe88d9b32_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTphY2I3MWE5M2U3YTQ0M2VmYjk4NmIxYWQ4N2U1MzMwOC90YWJsZXJhbmdlOmFjYjcxYTkzZTdhNDQzZWZiOTg2YjFhZDg3ZTUzMzA4XzYtMS0xLTEtNTE2NDA_be3df753-653b-48f7-98bc-7cc8970a59ea"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iafe592e811e24849a2a391b482b2fa73_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTphY2I3MWE5M2U3YTQ0M2VmYjk4NmIxYWQ4N2U1MzMwOC90YWJsZXJhbmdlOmFjYjcxYTkzZTdhNDQzZWZiOTg2YjFhZDg3ZTUzMzA4XzYtMy0xLTEtNTE2NDM_b8a09ad0-6e67-4161-bad8-603560091dd5"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i4634c39261264b90ac1a96707bd46a0b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NTg1M2I0NGM4ODg0ZjQ5ODI3Nzc4ZjM4NzJhZGE3MC90YWJsZXJhbmdlOjY1ODUzYjQ0Yzg4ODRmNDk4Mjc3NzhmMzg3MmFkYTcwXzMtMS0xLTEtNTEzMTg_02d8dacc-4b28-4d72-a2a6-acebf2c797ec">P0Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i58eae8a702644e09b9d6eafabc8fd6fd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NTg1M2I0NGM4ODg0ZjQ5ODI3Nzc4ZjM4NzJhZGE3MC90YWJsZXJhbmdlOjY1ODUzYjQ0Yzg4ODRmNDk4Mjc3NzhmMzg3MmFkYTcwXzMtMy0xLTEtNTEzMjU_19b569fd-4618-4424-b470-f4e494fc8c9f">P0Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4634c39261264b90ac1a96707bd46a0b_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NTg1M2I0NGM4ODg0ZjQ5ODI3Nzc4ZjM4NzJhZGE3MC90YWJsZXJhbmdlOjY1ODUzYjQ0Yzg4ODRmNDk4Mjc3NzhmMzg3MmFkYTcwXzQtMS0xLTEtNTEzMTg_95bfbe35-4f98-4315-8da7-a6000459d780"
      unitRef="number">0.848</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i58eae8a702644e09b9d6eafabc8fd6fd_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NTg1M2I0NGM4ODg0ZjQ5ODI3Nzc4ZjM4NzJhZGE3MC90YWJsZXJhbmdlOjY1ODUzYjQ0Yzg4ODRmNDk4Mjc3NzhmMzg3MmFkYTcwXzQtMy0xLTEtNTEzMjU_cc630217-5967-4115-95ac-a5e369363eda"
      unitRef="number">0.818</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4634c39261264b90ac1a96707bd46a0b_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NTg1M2I0NGM4ODg0ZjQ5ODI3Nzc4ZjM4NzJhZGE3MC90YWJsZXJhbmdlOjY1ODUzYjQ0Yzg4ODRmNDk4Mjc3NzhmMzg3MmFkYTcwXzUtMS0xLTEtNTEzMTg_782aef07-7d96-471f-93e6-75bc01bedde7"
      unitRef="number">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i58eae8a702644e09b9d6eafabc8fd6fd_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NTg1M2I0NGM4ODg0ZjQ5ODI3Nzc4ZjM4NzJhZGE3MC90YWJsZXJhbmdlOjY1ODUzYjQ0Yzg4ODRmNDk4Mjc3NzhmMzg3MmFkYTcwXzUtMy0xLTEtNTEzMjU_ac44d9fd-8843-4a75-a1a8-638e598a54a3"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4634c39261264b90ac1a96707bd46a0b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NTg1M2I0NGM4ODg0ZjQ5ODI3Nzc4ZjM4NzJhZGE3MC90YWJsZXJhbmdlOjY1ODUzYjQ0Yzg4ODRmNDk4Mjc3NzhmMzg3MmFkYTcwXzYtMS0xLTEtNTEzMTg_3b4c2f49-5d89-45f7-a02f-a1d3bbf4d7e0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i58eae8a702644e09b9d6eafabc8fd6fd_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90YWJsZTo2NTg1M2I0NGM4ODg0ZjQ5ODI3Nzc4ZjM4NzJhZGE3MC90YWJsZXJhbmdlOjY1ODUzYjQ0Yzg4ODRmNDk4Mjc3NzhmMzg3MmFkYTcwXzYtMy0xLTEtNTEzMjU_a73b1a6d-a488-4642-a123-64f7ee1df906"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>42
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M  !G!P  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;*U576_3,!3]*U9
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MK.B&FRNYNX#&3VSY,LFU^R>[.C<>>"3;:"/+!HP*2B;J)[UISF$/T+\/$#:
M\*F J %$SFBMS-F:4D/3H9([HFPVLMF!.QN'1C=,V+>X, I7&>),.OE\.9U=
M+F93<C;^.+Z<S,CB8C;[LB!OR9PJ$*8 PS+*,7Y)?*(+G-1#W^#6EL#/FFW.
MZFW">[;Y1%6/1/TC$@9AU &?/ R?0M;"PT.XCX9;UV'K.G1\T3U\"T,-8"T:
M(E?DG DJ,H8>YU(S5UP_QDMM%);8SRZK-?>@F]M^=J>ZHAF,//RN-*@M>.FK
M%_TD>-]E_#^1'1Q#U!Y#]!![.I%EB6ZQR++K(U)11;:4;X"\9H+DDG.J-*E
MU6_]3==1U/S'CM\VC&T:]((@Z _][;[)1],.Y ]:^8-GR*]+D]"-*:1B?R!W
M-NK93NTU>;PG*@J:WQWY3\D\<!"W#N+G.V!:;QY7'_^C:1 .DB",3^Z([TJ,
MW@7Q2=*M/6FU)\_7CO>$-E3D3*P?,Y \U4!78J<!?Z\-VBL(F\Z:"4TXK! :
M](Z10]5MO0Z,K%QG7$J#?=8-"[P)0=D$7%]):6X#VVS;NS7]"U!+ P04
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M"6MLU"NC:J6N+KO%&'E3%)Q-=OOP;6)!B&:MV &PL 46.K?F(OE')9.J/U(
MR50!BED>TY2 O$&LG^KK6.]A*4BB8[W90);;MRT\YK8=2=F!=Z+6.Y%SVU:2
MQ3_&NAPF(&:9X@A1F6TSNM84[NT/C&9^;Q,M0B'T[5LX;4%.G2 OB;(\IH/
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MU\G7@(<F(CB;]7';I(8J)NR($;J9\9*LB4*=J(YA1_+2'AHFVXU#(S!,(6\
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M*)BIKN*E5%$L]781NNL?Z#>HS7D]-/H_B]  Z?A[1_'N;N%;7A$GSNK)?H]
MB__7=3?OVS^8AF&_!;0(^;!_<#+9^UR3$;ZIOF()4)U!U-\^VJ?ME[*+ZOM0
M[_DG>+JLOW=U:NK/;]>8J](N5&2ME4KOXU3YEM=?M.H;R8KJH] #DY)EU>66
MX(1P+:!^7S,F7V[T"]KOBHO_ %!+ P04    "  ;@:E601+2N/D&  !K#P
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MTMA-E^\26U+45<-N;]\1&82%&@K(_'/;TX=&2&&-GT.#58ID*"0@*VUJY^'
MGZ"?$][G/%$W["5TU'A'=H60'GYZLKM_'L\>+4=0_"%"L;A955>>P=\#*W5W
MB-C4_'=6TC;@)_X6D"/)Q!HFQ=\_AR:*@"(D*1C6P5&JWJ7I 7X 6]Q4T.C&
M&3G^X2^1D3OB6K&&W0GKL,:S(IE'+"![&S1&R5%7M$)B@64TA6@;FJ FI/5.
M*(DX+\XIACB(3\8QDW@&''72ZSV%]60?6=NMS'&#'6US8LO594#<L,Z^.5\^
MSW:D38%0MH)0'3X?X94C9OKFV=/EY>3C1)FNAZ9T@=Y/S%LN4RNIJF^NED^_
M>KDG5\L77[_<3+KR783TN? F)DKD2 GESCI6PD<U*$ ,M9<X3H_2/F>D@LXX
M:\%LT8F'RU^%+&,9^Y^Y]2&)C^\XNZ'1KTM3<!"<>--^F,;?\&_I,W".@Z[P
M[D;5Q]M/]B4<1Z E'#?V&P]B;:.!$C%(M!0Q]89PU[L0'BD+I)B7V34,^!1-
M,2# 5JBCA%2:JGNH%U1X6-6E.:MQYL3Z#R7D(?$0DQOLEUB++T/DLYC]MFN'
MS5;\)HH-V:DC('RZ(M>D0W9/P\U9B1C?1=$RY\$#.YT5"=AN$V*1I,P3MHO2
M&R&XKOZ@P1OVY*$ZV%5F+\45 A!33/<\SLN2  Z[04:(!P.7MC-;=#/<(>[A
M].Q#+ !?.F1*?=YYMN2TR%!\1!I70$VY21+0LV)3FE7"G6S2HPU,MZ=[GX;1
M)B=U]/M =L" _V9T% ^:Z)&%IGSN#:?QOVYY3K]$0=>[Q%'ZD6+BLQ\YMWDM
M,3@_J?F)RQDP:30SO]:T51'B0><8QS[8/=&)W!MDFH55NF-Y?#>;.1I[)WE6
MR+OXO,PNM 3(M,P^N%\TRVI=KH<-,1=9R&T,$<XDOG?)HH'C:U+GE6438)(*
M9=Z3Z[ :>B?^8N&=+%\W,0Y   "BA94_A#I8Q'SN606X37$F'9^*G/AM^:+*
M&",2S+J$=?N;N"@1R+J-&'+:/F9@#SH%^Y>C7$7(JB?\X)(VI"&,@1E$&XI4
MZF:X6 S@CT0,DSHVD96HA,!=!PYAW*%B07X'' S$- UZ HC?B,XH"YVUZ[.!
M7CD'\<//'X-_*$!VQE6XY[(V'1>7B!J8A9;F"FLM&&:*N#T*")QYX=09_QKG
MJ$ZOTZ[J:B.FSA4398I]?G!Z+R6+O!>M-#66<VO4@MK<1NX+02].H<Z'^AP(
M&<JW%2I]</JBC*CV*K@J8)3O=($@(3K))([1L7 U/:3>Q+<(6.0 LBE"LEUV
M&4, ?IN@F'@AR2X[A-^Y*H\R^PBS$*(1#5G9GL"A%N1=)C%G<4;73 ][.HK\
M!ZNU*.). 1^1<=MU4O[@:EP"=YR0##[$:11)=4T$!;-^_?X%N9Y@$RR.T!Y@
M"*4J"2!LZVK(5K)?*9IWN>1<)?=$_]+\,YN1*JU.(^\K3BQ6=[XZ*!RIODK1
M2OJ _:5RP<[L'L00??]+0EC+=L&UW[2N.M^*IBT!EDNNFVBKL%*:,(%?W38T
M-QD+TW$_QB3-8SXC_\$:XR!Q<.NJ)!^B8KA7'A-MX.53^2TU#APEH]V-51Q:
MOR13/<_)L2I%HM)H-T O/)QSO*X92B_1FKUW1(^ZPV[)&)<HT-.D9= Y3L->
MW]YX#?O\"7DBJM"5<T**>7;*-RW]Y^=Z>WW[)LZ8*#*D.TQT+4U[<>E,BXM
MV2TF,K!:E+6]$TVL5D5YM1O.Q6V(^ZJ1U9'ZI,UH0]F3I^=GE^>+T==N2P0E
MH)."6=RV!CB*> BMKRR#UII*F \,:3XCD O5QM*QWQ=:<'*NZ]D!?!]J4M)Y
M()E8]BW4FW!;6_EN .963KNM-)<+\\W<SJ5:U(<[[^LX%XVK+; <I)I8EO$@
M930IPQFMUGHD]",;P&D7+N?ZJEW5P,EH>FZ_N@- EML9G$@1AEP=#N%RU"C
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MM=&91(.L*_K^CU$YQ?J.<.![E)R3("TMKDTI=I.<S&E^.KAD8*]JMQHZJPU
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M1(E4:/*HY] 69 PXT'<^#_.U;]$%A\,!V-LT;_<RJY9.]1P2K?/0/G*!NL/
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MB%-1<"*O/A/"4?5<4)U$2WIJ19 Q34O/P*+'E!S,OFN#]@=NPM)'X$P<1Q<
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MID G;'=P1GPN"O=)8]>GZ'(ETY6.!@;Q4?]57C,S\+5#R^R'T1QVQG)%2_I
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M<>IQE<6.LQ%Z4T#\O5,BQSS[E CKJCL6H$PF5]BG65XYF^0C*SL*H;Q>UJ[
MHX$5LR,A( 4QG.,=7/;MQ%CI4<FC!U5\A1=?/K%'%[IXRV#L*75<'AFA+2XN
M&WIT])\,S7R=%Q"#85V3:G*&18%-3T&>B&-"L)<]5.=_X9>:;X&9C<;FXR^I
MBH6HBX_0I.=K1S'8HQ0'P[[T7!,W?1P--IDUR^-1)Y"5"CV;7\GF>3GC99VU
MGEZ_D#+&)!_@>X"D93/>:81N3A5PW<8[(.%.G^2RGV7VH3WD=<^WB;P]F>3
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M3"]=X>^)N+=;\!^ND2[$HZ /,\L/1=QVK=[Z"V\9XC>H$>#*,E]U:O1\[/A
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M^D#*F.Z7OMWS7]]8M7W?[OC'K2&OK,,']'[=DJ3I+UC _SF6U_\%4$L#!!0
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M:#0<GP:@NSG3;:RJ?6_/E*5)X9<EC6;43H'.EXIBOMVX"_IAO_@-4$L#!!0
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M7DS''E&=V743(QMG,)DT:%=N6.'_ 90-P/U22G.8V 3#'R?] U!+ P04
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M#(6.0H1<?O/"BSHC,@GETBPU2Z((S- J%Q;DR3>S.TCF^]>A(9T6T+57Q]Q
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MV48..6P?9R#OL0![B4^O$I]>+7+53X#M^2+:%PTLG?ID90R3WCGD'<(J%C_
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M='05[Q<#A@5C%]R,.VQ.P[^!K21JE+VXXC7=LYB@D&\.22L-=)P:AT?<P#^
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M7LSI$X+:!9!_II3=**Y \U$:_P%02P,$%     @ &X&I5F<&O3+6 @  8P8
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M-'C[LJ\+O.Z"H@VX/I/2/'R0@O8"/?P74$L#!!0    ( !N!J59@+X\TP0(
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M"_R7@78!N+]0RFXFKEUV?\?L)U!+ P04    "  ;@:E6[L&Q5&T#  #U#@
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M92>G,RR(0&R%%AP$4(GSTZ 16N9O@GZV)&M*5B3$5*+K,&0;*@E=HP5+2$A
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M#/3#:BJQYS8N&2N@5$R41,)BY(S]JTELXFW -P9;U6H3D\E<B$?3^9R-',\
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ME"_7C(J!0AX@_OZ89<7;&]G!;OO@Y;\!4$L#!!0    ( !N!J59$=52X&0,
M *H+   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;,5676_:,!3]*U96
M3:VT-A] @ XB =U'I55"I=T>ICV8Y$*B)G%F&VC__:Z=D"8HH%6*U!>PG7N/
MSSF^<>YHQ_B3" $D>4[B5(R-4,KLVC2%'T)"Q17+(,4G*\83*G'*UZ;(.-!
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M3 -7 ?A\Q9C<3]0&97ON_0-02P,$%     @ &X&I5E.\?234!   11@  !D
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MMP;-1@X<]$=GT.KKSM^_DZQ'1=:C;EGO"%>%D"-1=EHBA86\$31]W 9A5(<
MAP-G!,\@:#.YLCK0*C=WZTTO$EZ&K<7)75:A(8B04YMZ^MC78JL(%_A_[(PW
MX'LJ_>3JV8XP*67!UWP*@04+9'/_F"VY8%(*-6Z;>=;OM&^^E[=3CE'),=+V
M3T$%SJDX#F20*"HN;:F^U!:8<9 0EG5:<Z-EL=U*H[D]Y(ZJ?^<MITWW6CI*
M+0:U.J6=CNH>W)&$+*)ZEPH6^CW[?.O2)W8M\%)!0;V$:@5^NE%WA#ZH0T>]
M46W,?(2Z@J6\@GI]U0K]=$/O"-VN0Q\V5/TC1!@L51C4R[#VJM=W_8[XG2;\
MJ%9ZYPT3XA1DJ<N@7IBU@FP3"1T1#QL1URK^$6H.EG(.ZO5<U_>\T!$=P;M-
M=1QJ)[TVT6N)*!4B'/UGXF+F^X&ZQ"%X"+@74KZ5*;?)B'<2CCF;'R%#42E#
MD5Z&'MLJ<WGL+4;4,:,:(!Z-4R9 &*QDD]%2C351TQ+,!0>B6A+9P,>'IC.I
M^;_Q<$I!J5:15JF]E0+-T&FD1!_\" BZERGY"*&)2J&)N@G-CO14QE C'?I@
M3DZ' Z+L[%#'R[LJ3K-R4!L1MD[/K[E$MXU%=F9;/"W.R&?IR;!9+L\.V!\Q
MD]*;@Y"LI*G5&TJMP+(SZ^Q&T"0]]EU2(6B47FX(]@E3"^3W*TK%\48%*'XY
MF/X#4$L#!!0    ( !N!J59^ZE9<H@,  &L+   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;+66WV_B.!#'_Y51;G5JI9;\)M #).AV]_9A=RM0NP^G
M>S")(5$3F[4=V$KWQ^_820.WA(A#NA>('<_X,U][)C/:<?$B4TH5_"AR)L=6
MJM3FSK9EG-*"R![?4(9O5EP41.%0K&VY$90DQJC(;<]Q^G9!,F9-1F;N44Q&
MO%1YQNBC %D6!1&O,YKSW=ARK;>)>;9.E9ZP)Z,-6=,%54^;1X$CN_&29 5E
M,N,,!%V-K:E[-W,#;6!6/&=T)P^>08>RY/Q%#SXE8\O11#2GL=(N"/YMZ3W-
M<^T).;[73JUF3VUX^/SF_8,)'H-9$DGO>?XM2U0ZM@86)'1%RES-^>Y/6@<4
M:G\QSZ7YA5V]UK$@+J7B16V,!$7&JG_RHQ;BP,#W3AAXM8%GN*N-#.5[HLAD
M)/@.A%Z-WO2#"=58(US&]*DLE,"W&=JIR4+Q^.5VAG$E<,\+/&Q)C%RWL, ;
MD)0Y!;Y"_:426:QPE=06E9J9>H6K]U21+)?7:#'?KS)^X8EE2L+5?/$DKT>V
M0EZ]JQW7;+.*S3O!YL-GSE0JX8$E-/FWO8UQ-L%Z;\'.O$Z'GXGH@>_>@.=X
M/KP#&V1*,+3ZKV,'OY'3-SOXI^34CMKDG I!V)KB?5:P?(7#=8_DU4Q/=T0D
M-_#PO=2Z?F*H9:E?2/BJ4BI I83!UXUV)V_@"V=;E)NBQ9>R6.)[/*9%%<Y?
M<Y[G@+=6>_R[3?@JBJ ]"ET)[N2&Q'1L8:I+*K;4FOS^F]MW_NC0*&@T"KJ\
M3TR<&,&2KC/&,K;&M,H)BRE<9:P^BFOXI_50*OK*?VC\Z[*SG?C.,(BBD;UM
MX0H;KK"3ZR.>D+ZZYU*$1Q1!$#I>V$[1;RCZ9ZE3'>[9,/TCF-O('_HG)(D:
MF*@3!J_0BF;_A2,ZYO"B8?\$QZ#A&)PE"F7))?=E< 35#[UP.&B'&C90P\Y<
M_V8J/FHSW5*!7S P%PBP#%/X0#(!SR0O:1O/\'_(/M?95WRG4\Q9:]XE6#*(
MD+#!2F*4U)+N2V1K]:[V&1SH&O4\KUU5]^"+Y)Z=AY=0U1\\Y[ \],(3-]#U
M]EA>)];S/B$OH?*.J:)>X)^@VG]OW,Y2_4N&7@+F'X,%O<'P!-B^R+O=5?[A
M.%4OH0N.KAC"N;_ V0?]3T'%VG1Y$F)>,E6U0LULTTE.J_YIO[QJ0[%%P.R0
MD-,5FCJ]"*N&J#J[:J#XQG132ZZP-S./*7;#5.@%^'[%N7H;Z V:_GKR$U!+
M P04    "  ;@:E6FGF\P%T$  !<%@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S,2YX;6S%6&UOZC84_BM6)DV;M)+8O'> 5+B=;J550T7;/DS[X"8'B.K$
MF6V@2/OQ<UY("$M,N(W4?F@3YYS'YQS[/'[JR8&+-[D%4.@]8*&<6ENEHGO;
MENX6 BH[/()0?UES$5"E7\7&EI$ ZB5. ;.)XPSL@/JA-9LD8TLQF_"=8GX(
M2X'D+@BH.,Z!\</4PM9IX,7?;%4\8,\F$=W "M3OT5+H-SM'\?P 0NGS$ E8
M3ZT'?+\@W=@AL?C#AX,\>T9Q*J^<O\4O3][4<N*(@(&K8@BJ_^QA 8S%2#J.
M?S)0*Y\S=CQ_/J'_DB2ODWFE$A:<_>E[:CNU1A;R8$UW3+WPPU?($NK'>"YG
M,OF-#JGM<&PA=R<5#S)G'4'@A^E?^IX5XLP!#VL<2.9 FCIT,X>D<G8:69+6
M%ZKH;"+X 8G86J/%#TEM$F^=C1_&R[A20G_UM9^:K11WW^[FNA >6O! [PY)
MD_K>H97>,MZ. >)KM*=LEXY3J5<\BA\E^N$+*.HS^>/$5CJ6&-%VLWGGZ;RD
M9MXN>N:AVDKT&'K@E?UMG4.>"#DE,B=&P&<J.JB+?T+$(=V*>!;-W8DAG&Y>
MUVZ"US/5%?&T4%7E,;K'S7LO(^K"U-+=*4'LP9I]_QT>.#]7Y=826"G37IYI
M+T'OUF6ZI0+N7O^_@QZ$H.$&=,\K]'I$YW9+>DR&'PY4>.BO7S4D>E(0R+^K
M2M5KLU0M@95*U<]+U3=NBL?W2+.7SM_S][X'H5>Y,U*,<8(1L_!^YDSL_7D.
MQEF^,8=!GL.@^<9&_\;]XJ!T\"ET]:)J5D9+1D/];<ZH)A?-(YR!1+\E/F@I
M?-</-[K_/6!5^1OGOW6Y6P(KE6J8EVKXR9TQ;+-4+8&52C7*2S5JUAD*1*#/
MGB-04=D<9IA!ZHC(&'GT6 6P^ ! *;-QGMFX669[SO3J,U\=J_)*03 ^[_K.
MJ#>ZZ/QJ,SS.S4HQ8J=0 8XQRA=?OMVM!0#R0[T$(!425$'EN>Y4Q>!T^Q>A
MUMCA04VL9XH%M\"B&8B)1HTFY>!($1QIC1YC!01H007CC<G1//VM+=\66KE8
MA4;"W4\F2-RJS&H+K5RN0FAAHSAI3I)7<'JUGHMO\2QG4V@AW% ,F8D15\BA
MSB4M7C$J1U@H'6R6.K>0XJ":% >7@5;;X5Y-K(74P,;CN2DI#J^3HLFD'%QQ
MN.,KI_MJN3QQX6,0,7[4-4U)<;D3[E8W]L<DHWG^F]N\);1RM0K!@,>?S8I&
MR7)SN5I"*__;7T@78I8NC5GQ"DX?!>F-!!G4BL</093S*^0.:2AWS#R9H5Q5
MD#5V>#@^_ZGN>%+((&*603=09X9T54]F=F6.=TA-I(4&(>:+FF;$F8&8B--H
MD@9GG]W3!2 VR?6E1"[?A2J]Z<I'\RO2A^1B\&)\CN\7Z45G 9/>NSY3L?&U
M\F2PUI!.9ZA/1I%>9:8OBD?);> K5XH'R>,6J <B-M#?UYRKTTL\07ZA//L/
M4$L#!!0    ( !N!J59!'B>>,0,  / 2   -    >&PO<W1Y;&5S+GAM;-U8
M76O;,!3]*T9=1PNC3N+%C=<DL 4*@VT4VH>]%266$X$L>;+2)?OUTY4<YZ.Z
MI>O#ELXAM72/SKE'TG4M,JS-6K#;!6,F6I5"UB.R,*;Z$,?U;,%*6E^HBDF+
M%$J7U-BNGL=UI1G-:R"5(NYU.FE<4B[)>"B7Y75IZFBFEM*,2+\-1?[V.1^1
M;OJ>1%YNHG(V(O=G;W\LE;EZ$_G[R;N3D\[]^=5A_,P!YR0.BO:?(7K1L1>J
M[%!,/GV>_%/BF/3EOK0;?FJ%//$4HPT"-)MERX2.(\?-MHR'A9+;W4F(#UAU
M6K+H@8H1F5#!IYH#JZ E%VL?[D%@IH32D;%E8=-U(5+_\G#7]Z!B&IV22Z5=
M;I_!_YTVPP^ 30\,<B%:@SWB ^-A18UA6E[;CAOL@H^@J&G?K2OK<*[INMOK
MDRW!W6R2J=(YTVV:+MF$QD/!"K"C^7P!=Z.J&$!C5&D;.:=S):GSL&$T#2L[
M8T+<PN/TO=C37A4[^]:!79-MTQIJFE[&=T!_5\UK[\KV7J0;5?Q!F4]+.QWI
M^E"@[$:S@J]<?U6T!C#U+JY.JTJL/PH^ER7SDW]VPO&0;GC10FG^RV:#4IG9
M -,D>F#:\-ENY*>FU1U;F4TYK0K<<^\5>OZ[ZSQGDFDJ=DW;VC_F57ZQX^3R
M7UEV_U4.#0<]-N_(8S?9?PTFT]=@\A749)(=O\?F5'1T)N/F_;US2-@[(K31
M"(YB(_(-#G9BFS2:+KDP7#:]!<]S)A^=%*R\H5-[G-_3M^-S5M"E,'<M."+;
M]E>6\V69M:-N8"&:4=OV%YA>-VW/@387ESE;L7S2=/5\ZIJ1;=BLS06$0^3:
M76$$XW@LC "&Y<$<8!S/PO+\3_,9H//Q&.9M$$0&*&> <CPKA$S<!\L3YF3V
M"L\TRY(D3;$5G4R"#B;8NJ4I?,-JF#=@8'D@TY^M-;[;>(4\70?8GCY5(=A,
M\4K$9HJO-2#A=0-&EH5W&\L##&P7L-J!_.$\4%-A3I+ KF+>L"<81[(,0Z 6
MPS6:ILCJI/ )[P_VE"1)EH41P,(.D@1#X&G$$<P!>,"0)''OP8/W4;QY3\7;
MW[C&OP%02P,$%     @ &X&I5I>*NQS     $P(   L   !?<F5L<R\N<F5L
M<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\
M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M2>9I,B&WHX?1?)R0=)HDJ]2CHP@=/0T=:9$ET^!!=A'([O^"3%>C5?(MF3O
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MXO!!!H),^* U!*W#!VT@:!,^*(&@)'S0%H*VX8-V$+0+'[2'H'WX((I1QEA
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M;W!S+V%P<"YX;6Q02P$"% ,4    "  ;@:E6#!U[@.\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  ;@:E6
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( !N!J59/Q:&H  8  )4@   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  ;@:E6
MVAEI/2(%  #\$P  &               @(%$#@  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ &X&I5CK.>ORF @  9P<  !@
M     ("!G!,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M !N!J5;%H-5:G00  #$0   8              " @7@6  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    "  ;@:E6]][B%)<&   T*P  &
M            @(%+&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ &X&I5FZ2! RZ!@  8QP  !@              ("!&"(  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( !N!J59!$M*X^08  &L/
M   8              " @0@I  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    "  ;@:E6B<=O62X?  ":90  &               @($W,
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ &X&I5OU0)N1[
M P  ^ <  !@              ("!FT\  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( !N!J5;]$?I.Q (  'T&   9              "
M@4Q3  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ &X&I
M5D)J*G%J!P  ZQ$  !D              ("!1U8  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    "  ;@:E653BOULX#   G"0  &0
M        @('H70  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( !N!J5;;_CK%:PT  #$H   9              " @>UA  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ &X&I5K71S+BL&P  >ET
M !D              ("!CV\  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    "  ;@:E6!A-O"14#  "M!@  &0              @(%RBP
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( !N!J58&JA8Q
MV (  * &   9              " @;Z.  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ &X&I5F<&O3+6 @  8P8  !D
M ("!S9$  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  ;
M@:E6&V5;H5T%  !,#P  &0              @(':E   >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( !N!J59@+X\TP0(  "D'   9
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M970R,RYX;6Q02P$"% ,4    "  ;@:E6C7I=)>0"   @"   &0
M    @('CJ0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M !N!J59\,PO/U0(  %L(   9              " @?ZL  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ &X&I5FV$<AV+ @  :0@  !D
M             ("!"K   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    "  ;@:E6UX[0:K()  !*6   &0              @(',L@  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( !N!J59$=52X&0,
M *H+   9              " @;6\  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ &X&I5E.\?234!   11@  !D              ("!
M!<   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  ;@:E6
M?NI67*(#  !K"P  &0              @($0Q0  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( !N!J5::>;S 700  %P6   9
M      " @>G(  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ &X&I5D$>)YXQ P  \!(   T              ( !?<T  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    "  ;@:E6EXJ[',     3 @  "P
M@ '9T   7W)E;',O+G)E;'-02P$"% ,4    "  ;@:E6E'?U?R(#  !-%0
M#P              @ '"T0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M&X&I5H]ZM&%= 0  )!,  !H              ( !$=4  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ &X&I5N];R@F& 0  U1,  !,
M             ( !IM8  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "<
,)P"("@  7=@

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>68</ContextCount>
  <ElementCount>195</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>18</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - COVER</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/COVER</Role>
      <ShortName>COVER</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED BALANCE SHEETS - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/Investments</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/StockBasedCompensation</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Investments - Schedule of available for sale investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails</Role>
      <ShortName>Investments - Schedule of available for sale investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of accrued expenses and other current liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities - Schedule of accrued expenses and other current liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.shattucklabs.com/role/Equity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Stock-Based Compensation - Schedule of stock-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of stock-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Stock-Based Compensation - Schedule of option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Stock-Based Compensation - Schedule of restricted stock activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of restricted stock activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sttk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Stock-Based Compensation - Schedule of valuation assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of valuation assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  sttk-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="sttk-20230331.htm">sttk-20230331.htm</File>
    <File>sttk-20230331.xsd</File>
    <File>sttk-20230331_cal.xml</File>
    <File>sttk-20230331_def.xml</File>
    <File>sttk-20230331_lab.xml</File>
    <File>sttk-20230331_pre.xml</File>
    <File>sub-certxsection302xceoxq1.htm</File>
    <File>sub-certxsection302xcfoxq1.htm</File>
    <File>sub-certxsection906ofthesa.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="312">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>48
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sttk-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 312,
    "http://xbrl.sec.gov/dei/2022": 31
   },
   "contextCount": 68,
   "dts": {
    "calculationLink": {
     "local": [
      "sttk-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sttk-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sttk-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sttk-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sttk-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sttk-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 268,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 3,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 8
   },
   "keyCustom": 15,
   "keyStandard": 180,
   "memberCustom": 5,
   "memberStandard": 12,
   "nsprefix": "sttk",
   "nsuri": "http://www.shattucklabs.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - COVER",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.shattucklabs.com/role/COVER",
     "shortName": "COVER",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.shattucklabs.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Equity",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.shattucklabs.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.shattucklabs.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "14",
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "15",
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Investments (Tables)",
     "menuCat": "Tables",
     "order": "16",
     "role": "http://www.shattucklabs.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "17",
     "role": "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "18",
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sttk:NumberOfClinicalStageProductCandidates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "candidate",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Organization and Description of Business (Details)",
     "menuCat": "Details",
     "order": "19",
     "role": "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails",
     "shortName": "Organization and Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sttk:NumberOfClinicalStageProductCandidates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "candidate",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "20",
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)",
     "menuCat": "Details",
     "order": "21",
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Investments - Schedule of available for sale investments (Details)",
     "menuCat": "Details",
     "order": "22",
     "role": "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails",
     "shortName": "Investments - Schedule of available for sale investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Investments - Narrative (Details)",
     "menuCat": "Details",
     "order": "23",
     "role": "http://www.shattucklabs.com/role/InvestmentsNarrativeDetails",
     "shortName": "Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sttk:AccruedResearchAndContractCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of accrued expenses and other current liabilities (Details)",
     "menuCat": "Details",
     "order": "24",
     "role": "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of accrued expenses and other current liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sttk:AccruedResearchAndContractCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sttk:LicenseAgreementRoyaltyPaymentsMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sttk:LicenseAgreementRoyaltyPaymentsMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Equity (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://www.shattucklabs.com/role/EquityDetails",
     "shortName": "Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Stock-Based Compensation - Schedule of stock-based compensation expense (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails",
     "shortName": "Stock-Based Compensation - Schedule of stock-based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i553413b499654651890bbd3c2a30bad5_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Stock-Based Compensation - Schedule of option activity (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED BALANCE SHEETS - Parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED BALANCE SHEETS - Parenthetical",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "iaf0a0042588b4fd2ac8a83479b491708_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Stock-Based Compensation - Schedule of restricted stock activity (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of restricted stock activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "iaf0a0042588b4fd2ac8a83479b491708_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i428ae4dc142344e4867b47e344b894fe_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Stock-Based Compensation - Schedule of valuation assumptions (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails",
     "shortName": "Stock-Based Compensation - Schedule of valuation assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "ia3286ad000a74fb2b534f75b6f23f669_D20230101-20230331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "ibf15edfb0127444c8297ddfefadc5003_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "ibf15edfb0127444c8297ddfefadc5003_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Organization and Description of Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Investments",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.shattucklabs.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sttk-20230331.htm",
      "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 18,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/COVER"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sttk_A2020EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Employee Stock Purchase Plan",
        "label": "2020 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2020 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2020EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sttk_A2020StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Stock Incentive Plan",
        "label": "2020 Stock Incentive Plan [Member]",
        "terseLabel": "2020 Stock Incentive Plan"
       }
      }
     },
     "localname": "A2020StockIncentivePlanMember",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities and Other Liabilities, Current",
        "label": "Accrued Liabilities and Other Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails",
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sttk_AccruedResearchAndContractCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails": {
       "order": 2.0,
       "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Research And Contract Costs, Current",
        "label": "Accrued Research And Contract Costs, Current",
        "terseLabel": "Research and development contract costs"
       }
      }
     },
     "localname": "AccruedResearchAndContractCostsCurrent",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sttk_BlackScholesOptionPricingModelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Black-Scholes Option Pricing Model",
        "label": "Black-Scholes Option Pricing Model [Member]",
        "terseLabel": "Black-Scholes Option Pricing Model"
       }
      }
     },
     "localname": "BlackScholesOptionPricingModelMember",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock, additional capital shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockAdditionalCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sttk_LicenseAgreementRoyaltyPaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Royalty Payments, Maximum",
        "label": "License Agreement, Royalty Payments, Maximum",
        "terseLabel": "License agreement, maximum payment"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyPaymentsMaximum",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sttk_MonteCarloOptionPricingModelMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monte Carlo Option Pricing Model",
        "label": "Monte Carlo Option Pricing Model [Member]",
        "terseLabel": "Monte Carlo Option Pricing Model"
       }
      }
     },
     "localname": "MonteCarloOptionPricingModelMember",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sttk_NumberOfClinicalStageProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Clinical-stage Product Candidates",
        "label": "Number Of Clinical-stage Product Candidates",
        "terseLabel": "Number of clinical-stage product candidate"
       }
      }
     },
     "localname": "NumberOfClinicalStageProductCandidates",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sttk_OperatingAccountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Account",
        "label": "Operating Account [Member]",
        "terseLabel": "Operating Account"
       }
      }
     },
     "localname": "OperatingAccountMember",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liabilities Recognized For Operating Lease Right-of-Use Assets",
        "label": "Operating Lease Liabilities Recognized For Operating Lease Right-of-Use Assets",
        "terseLabel": "Operating lease liabilities recognized for operating right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer, Deferred Revenue Billed Not Received",
        "label": "Revenue From Contract With Customer, Deferred Revenue Billed Not Received",
        "terseLabel": "Deferred revenue billed but not received"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term",
        "terseLabel": "Annual increase in number of shares authorized, term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period",
        "terseLabel": "Share-based payment award, grants in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage",
        "terseLabel": "Increase in number of shares authorized, percentage of capital stock outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value",
        "terseLabel": "Maximum value of shares per employee during any calendar year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number Of Tranches",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number Of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options Exercised And ESPP Purchased in Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Exercises And ESPP Purchases in Period",
        "terseLabel": "Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Consecutive Trading Days",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased",
        "label": "Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased",
        "terseLabel": "Exercise of stock options and purchases pursuant to employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased",
     "nsuri": "http://www.shattucklabs.com/20230331",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r9",
      "r346"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Net amortization (accretion) of investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r81",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.",
        "label": "Accrued Royalties",
        "terseLabel": "Accrued royalty"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r102",
      "r321",
      "r328",
      "r329"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r17",
      "r20",
      "r74",
      "r284",
      "r324",
      "r325",
      "r355",
      "r356",
      "r357",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r4",
      "r346"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r364",
      "r365",
      "r366",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares withheld related to net share settlement"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r68",
      "r69",
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r254"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r79",
      "r86",
      "r101",
      "r116",
      "r149",
      "r158",
      "r162",
      "r173",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r265",
      "r267",
      "r274",
      "r346",
      "r374",
      "r375",
      "r408"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r97",
      "r103",
      "r116",
      "r173",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r265",
      "r267",
      "r274",
      "r346",
      "r374",
      "r375",
      "r408"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r168",
      "r180"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r49",
      "r167",
      "r180",
      "r317"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Total Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r48",
      "r180"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Unaudited Interim Condensed Financial Statements"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid amounts related to purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r34",
      "r99",
      "r333"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r28",
      "r34",
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r28",
      "r77"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r14",
      "r82",
      "r90"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r54",
      "r186",
      "r187",
      "r330",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r55",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r364",
      "r365",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical",
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r346"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value: 300,000,000 shares authorized; 42,460,258 shares issued and outstanding at March\u00a031, 2023 and 42,390,586 shares issued and outstanding at December\u00a031, 2022"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r21",
      "r105",
      "r107",
      "r111",
      "r318",
      "r322"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r85",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities [Abstract]",
        "terseLabel": "Investments:"
       }
      }
     },
     "localname": "DebtSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax",
        "terseLabel": "Gross Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-Sale, Term",
        "terseLabel": "Debt securities, average maturity term"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r32",
      "r51"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r227",
      "r255",
      "r256",
      "r258",
      "r262",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r112",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r130",
      "r132",
      "r134",
      "r135",
      "r136",
      "r138",
      "r272",
      "r273",
      "r319",
      "r323",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share \u2013 basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r112",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r132",
      "r134",
      "r135",
      "r136",
      "r138",
      "r272",
      "r273",
      "r319",
      "r323",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share \u2013 diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r41",
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails": {
       "order": 3.0,
       "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and related benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average amortization period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost for RSU"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r56",
      "r95",
      "r108",
      "r109",
      "r110",
      "r117",
      "r118",
      "r119",
      "r121",
      "r127",
      "r129",
      "r139",
      "r174",
      "r212",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r271",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r284",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r183",
      "r197",
      "r210",
      "r269",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r339",
      "r368",
      "r369",
      "r370",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r315",
      "r360"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r360",
      "r407"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r172",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r50",
      "r78",
      "r84",
      "r93",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r116",
      "r173",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r266",
      "r267",
      "r268",
      "r274",
      "r337",
      "r374",
      "r408",
      "r409"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r80",
      "r88",
      "r346",
      "r363",
      "r371",
      "r406"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r98",
      "r116",
      "r173",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r266",
      "r267",
      "r268",
      "r274",
      "r346",
      "r374",
      "r408",
      "r409"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r14",
      "r372"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails": {
       "order": 4.0,
       "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Litigation settlement"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Litigation settlement, amount awarded to other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r140",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r28",
      "r30",
      "r33"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r22",
      "r33",
      "r83",
      "r92",
      "r96",
      "r104",
      "r106",
      "r110",
      "r116",
      "r120",
      "r122",
      "r123",
      "r124",
      "r125",
      "r128",
      "r129",
      "r133",
      "r149",
      "r157",
      "r161",
      "r163",
      "r173",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r273",
      "r274",
      "r338",
      "r374"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Expense from operations"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r149",
      "r157",
      "r161",
      "r163",
      "r338"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r1",
      "r40",
      "r46",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails": {
       "order": 1.0,
       "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized gain on investments",
        "verboseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm": {
     "auth_ref": [
      "r358",
      "r359",
      "r362"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow (inflow) through acquisition (sale) of short-term available-for-sale securities.",
        "label": "Payments for (Proceeds from) Available-for-Sale Securities, Short-Term",
        "negatedTerseLabel": "Net change in investments"
       }
      }
     },
     "localname": "PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "terseLabel": "Payments for royalties"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r27",
      "r67"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from the exercises of stock options and purchases pursuant to employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r52",
      "r89",
      "r320",
      "r346"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r70",
      "r94",
      "r410"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Unvested restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r57",
      "r87",
      "r327",
      "r329",
      "r346"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS",
      "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r95",
      "r117",
      "r118",
      "r119",
      "r121",
      "r127",
      "r129",
      "r174",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r271",
      "r324",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r147",
      "r148",
      "r156",
      "r159",
      "r160",
      "r164",
      "r165",
      "r166",
      "r221",
      "r222",
      "r316"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r223",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible List]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r283",
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating right-of-use assets exchanged for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities excluded from computation of net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.",
        "label": "Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]",
        "terseLabel": "Schedule of RSU activity"
       }
      }
     },
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r224",
      "r226",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r59",
      "r61",
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of valuation assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Stock-based compensation, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Awards, ending balance (in shares)",
        "periodStartLabel": "Awards, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Awards, vested (in shares)",
        "verboseLabel": "Issuance of common stock upon settlement of restricted stock units (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Contribution limit in percentage of employee's eligible compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Maximum number of shares per employee during any one purchase period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options, exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options, forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options, ending balance (in shares)",
        "periodStartLabel": "Options, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted average exercise price, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options, vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails",
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Share-based compensation, expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term - years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted\u00a0average remaining contract life, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted\u00a0average remaining contract life, outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted\u00a0average remaining contract life, vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock in percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Shares withheld related to net share settlement (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r16",
      "r56",
      "r95",
      "r108",
      "r109",
      "r110",
      "r117",
      "r118",
      "r119",
      "r121",
      "r127",
      "r129",
      "r139",
      "r174",
      "r212",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r271",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r284",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r139",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r2",
      "r3",
      "r56",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Stock issued under ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r2",
      "r3",
      "r56",
      "r57",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options, exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r47",
      "r346",
      "r363",
      "r371",
      "r406"
     ],
     "calculation": {
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS",
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r58",
      "r115",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash financial activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r0",
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r169",
      "r170",
      "r197",
      "r210",
      "r269",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r368",
      "r369",
      "r370",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r335",
      "r341",
      "r342",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r43",
      "r44",
      "r45",
      "r141",
      "r142",
      "r144",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r131",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r130",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r347": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r348": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r349": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r351": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r352": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r353": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3098-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r413": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r414": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r415": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r416": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r417": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r418": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r419": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>49
<FILENAME>0001680367-23-000035-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001680367-23-000035-xbrl.zip
M4$L#!!0    ( !N!J5:0E_C* AX! *.,"@ 1    <W1T:RTR,#(S,#,S,2YH
M=&WLO6M7V\JR+OS]_ J][//N,^<8-.F;I&XR%V<XF#"9*[83,,F&+QE]$Q;X
MMBR;VZ\_U9+-S9! ,-@F6BL3L"6UNKNJGKIT=?5?__>\TPY.W2!+>]U_K9 U
MO!+\WXV__C^$_N?#[J>@VC.CCNL.@\V!4T-G@[-TV J^69>=!,F@UPF^]08G
MZ:E"*']FL]>_&*1'K6% ,65W+@[6C1-&10PC9KE#G-$0B<0HY)*8Q)%3(<?Q
MZM$Z-K'@B> HQJ%$G#J,9.0T"B/*G4P$I219M>M*QZ&-F;+"A=PF3##X+7!B
MK8VLT:%_;6L(HX,1=K-_K;2&P_[ZNW=G9V=K9VRM-SAZ1Z24[\[]/2O%3>O6
MI5<WGNM!>RUS9NVH=_H.+KR#,=')C>?MM'OR<)O^ZN36]'QXZ\:\77]KVH7;
MG)_G=\.!ZF9);]!10Z"#?Q-&F")R];Y1AHZ4ZE\UE*A,YXV,+]SN7);>US6*
M,7GW/[5/>Z;E.@JEW6RHNL9=/07]2N_O*3S)WMUWO[TS7>.;HW?%Q:LIR'J<
MDOA'C1=W7,_90_<2=F/>)K=/$>-VX_ZR5ME5S[/A\/;M64L-AR-STE8Z6S.]
MCI]-AADC-VB(@!5N/S1FC1^1D80("S1N9[VMND?_6G%=M+^W KSIE-WXJ^.&
M*O"M(O>?47KZKY7-7G<($H>:%WWHL"D^_6MEZ,Z'[W)6?;?QO_[7__IKF [;
M;L./!$TZ^]>[XLN_WA5-ZYZ]V/C+IJ=!-KQHNW^MV#3KM]7%>K?7=="!]'S=
MW^@&Q9^IM:Z;_PG7ZR#V@]04[S\?[KKD7RLI%221AL CD>6)HHK!Y\1$*E&1
M%MQ]K^9=(9B@ZPGLJHY_M4O7M[K0OXM-&,Y M7>ZUIW_VUVL!*F%IBW[>J&K
MO=-/=/?T@-5&]GCK]'!;'C<Z']/ZY=>3^F6]=5AMM>O-W9/#XQJOT7U2KQZ=
M'7;@<_7PY(#ND$^LWCZX[+<.C@TYK)K+@V]?^&%S'Q]N'UPVJG5X]@NO;1^>
M'&Y_H8?;];3^5>!/]/#BX)N)H%UHW_!ZLW)Q6-VG]:H];GS;.C\\_A(>'._P
M>N<+.6A^;-4O]T_M]L=4;^]'A]7*V4%S*VQ\^X(/CD_">K5V7H/?!_1KN]$\
MNJQ7*QSZ>%&G7\;/?(5WA=W#9O^D5OW0JC5/PL/J;MIHGN#:Y=9%H]D^/ORV
M'S:J-5RK'N%&=8<=?A07GYI;P]H>/O_4K%W6+VOTNU4)94H+I"0#@&1AA#23
M"5*&",& &@Z3E0T,XAX)S*+XKW>WB/J2-*Z MK!>8WQLJZ.5H) %:/9\N)ZD
MY\ZB1+6]()9$_S'1\13152((BVB$8E"CH!4I1<)%!A%K&),VC)P4*QL?*Y_V
MMEZ1WA,#X6.:&=4^<&KP$;[)2@+_C,!DBL"2&6K @$$V-@QQ13A23 B4"$M"
M$2J;A&9EPQ-A;O3]#.WW;$GA1U&83N,V)=H)#*9=8A*@<!PAE4B+0D-CZ9(D
MXI%:V?A"7I&^FZ/!X);X;G5M%2S]V]!MX1O4@=>V_)/(J@ODNB4'_(P#V+2,
M2V5BKA)D)?S@6CLDG<* Z882'$:2:]#<56=<1[M!P)[$"LK%2I+(Q)&,N)58
M,Z8PH5@[YIC5)&<%.F$%>I,5QE[$^JX[==V1^PBNG;=#!\H,OX''MSG*ACUX
MX^=!SX[,L-*U>VYPFAJW=0[6:9;JMON49L/Y<L1Y8T]V3.=CM]'9OZA73\X.
MFU\8O*]5/_Z":\U_TH/+#ZWZ]NY)[?* 'E:/V&'SX.P3VVT==,[;C<Z7L_IE
MA1X>M]+Z=ATH#%S5V0FACVFC^N6\?KR;'E"@;O-#>_(,O&MT2'-N8K7J8:>Q
MO8,/Z-9Y??MC![B*U+>!^ZI;M+[]S_'!Y9?SVO;7I);BLS%77-8NS67]Z#NV
MVE)#&!*2@&+7$4/:)A0QC"7%BB:&@K7^([_OOSX!*;J9J^5<\TKH4;+,_%A&
MB]@*E7# #6 4L 4),$^H$;,84T !RHA\*9:1DMC$Q$G"*.:,Q-+$CB4B,B%\
M$EP_@F7V6FK@/H!#;C=[G3YT(W>7*P/PGH^<MS8^7%S?\EE=^*\J9VI@\Q]?
M739,NT>%+4+FRT"7]>/]T\/N/ZW#RWY:J_[3KM-ZI_8-[@%-<'A\0N&Y3JVZ
M#X3;"6O5>GK8_-BI[TE\^#\M;#I?N^J;'#4Z.V>USCX[H ?GOC^UR]U.HWD
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ME:4)UV^&9*^JE&9''TEH9#5(%"<AIRZ2H="42Z:)C!48YZ]'GWG- (XQ]$F
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M5QWE@# V";.@FF9F5!S2[!5@I:O:%UF::]%K'/'84F0=^GMV739JWW6ZWC#
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MB-EOBQ6SS\LJL6*AL.*N?<2XM3@T BGA,\X-=TBH$* CMH[AR*J0:7\0^7)
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MJ5VE=I7:5=JD5;I/[0(6IWF<YY9E.J*9RX5VD;8R$XD3CBEW!P*]HH@!<()
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M@SA&>33J#(85T,.YD[OE%TM;XO(##0>XM!\$GGHU:)KU[AXGNGG"_5LR+%A
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M+"+ P?AE:>;T\1-;4DSE!R.&'\/YQYP:K6CN@(WQE% F%)$LAU<FB;DQ#CA
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MUS9J5E;V< \"?ZZ->Y;!ULE$I(U(J4V%9"I*I-$4^*E(K%Y*5J=MW*-YYOI
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M6]5^LY!U7K5/4^64=A$F>H)J[WA">.(X$5(F#)1^9A/V4-6^1=0649\#HFX
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MH^4P"V]MS)VCLHJ* 99'TYB;Y!G.22FM6IO+1=@(DAL8G" TZLRCM,3N>E'
M@K6%HA5IH4";TPKJK&RI6 XLF)+KBDJ_GW A,#Z,MWA9VE:Y;FW5G#'PN]>K
M-/"++.])T)? [% C@P8HF+)"54]PL-]Z:#Z49MK,#.>QPLRRHH1>=F%A7;P>
M6"_I:3J+(:CE/[A0VSMXOZ"4ETY"K5"C] ?O#.1!-A"+G,-)^DM)<J7RK 81
M^\6!R-[5X<Y)).TX<@4KN[)'D0? $3 BI&-'7#*'A\FK-X-L#C<T"Z /5FI=
MRIBHEQ-9AF6MD9_@64U()7.= M,,GD#:(5LA8\/OL2Z%Q&N>C'F/#]"K<::
M;220?'=5_79S]?E&CNF6*>OO\ZP/^-M7"'SXWVGEVGB'@ X4%@S->C^-B?^3
MYVDV+L#\/]7Q)*5?)T]U'<\2OX!<TP$'4A+9.#>H&&.A3U4 DAT.K#\YV(;P
M<67T:Y)[K^)<_]4I_]JQAN.1J>ZI*X^6;[-Z_*(8:QQ&MP8 [<37HUN@[J8%
M"#8Q@J6,\XET?,<++!<Z^1AFA5MYG.4 ]:<<:Z%:X[(.ZI1S:TZP&O=<7GI@
M0'@(8)P2I(5VB^BIH4,(KTNT&PDF_N<8Y!NM%L=+[]:P!V\:I4E2E&L!4@#8
MU?)?2W#\V'R]!YM3NDGTN^8?$^E(&>\4'!GLG<:*<G,6J =]3(T>9>+<E&7M
MP:FJ4O8:UUD"+^"()WU00'7-U1R]>L40?5W(WKB[_;3H*8X,:F7P<Z%) G7N
M7/]MX;NG51 8<=PK/5KXN"Z4IIV>.N=JVG+<!QU*#0;IN(\:#0@;H<;ZAJDT
M'SM8N?4,1K@DV06"(DC?(I4ITA8<Z!&8B9+/?+6:8,?Z:R3-Y@YYKEV!N>)8
M4A &G221XY8.\W0@4E"P*BJ9'&2Y3"3;M%]+=5-;#I^^C?ZO[$39D>O(()$L
MP, ZD.&^!P);<.531^O_U'%L2JH?KM?_)XCUI5[/CI[:S@5'.7.4Z8O?C[#^
MR]8PN-$P^'%L@WP/(E=%G-I$T-@FC(.)$":N(('O1=P'JTU%& 3393<8!O#_
M#[*?QB=*F[S>)+YBRFF/; K<I(&R\53--1T4R+KF<6:8'7A#5N@E-$;R(<CK
MG[PW3?D&CH 64N#Q3!,JLOLP5[VT;P"^^F+% XO>7WO0RY?!,+7;UV$-..S4
MU7@OK="8/)WRJL*\'18^!$ "4)E7B*O0QME9&*9#/\#MJD0V"@-;2VH";Z.^
M4I6-01_](1@EI^7EPBW<[INISBQV.]_L1FYN2-;8D%P!G1?:O!Z/QKDR)='%
MS%UNDV+& [S\J<F^J.@^S67%4N6EW2]S.R:JB^!IRD,>NSA+Q=F4/B;X /7J
MQL42S$^B'E/.KU3]ISBC(>N7K1(%+\HR.%4X%"M!K;#Y!,ZF4OK>[A^65]B?
M#V$M9I+57=\P0QL6I?G":\;:S#;;I*WD>JM*U6ERLX6&.?[*2Y53FQ*ZKJ!^
M?\,:T>_@^GXK-S:\V99.>4UWJ3^,>6%TL&*L]Q6V7;,X&-ZIGJH:Y* Q:.U+
MSFHG!2I59HHC!+Y374:^6J36G,S.5M5CM9//K!.VK-JQ)FF4FR)!6U :>J0J
MD0TG.9IZDW:!#+7B<)KAC2><"-9DP"+Y^'-UA8>R -\@R7B(@ZB\KS^O9H4G
M6: ^WSC>KO4%-Z0Q,UWH'^VTGBX\;^FQ+O)T--(WAUJ0Q)=3I*FA&X%4]UCJ
MZ"&05GL90"!.HTG>W7EP66 YK1;>XP9L8^-[_ >/[_G2D.7O@+E&EP? @AL7
MVG-U</7IY_?!GV??\7O?WET<]#]C4>K>_K=/]L&'3Y>'N]J]RN"YJX.C@_/]
M_E?W^Y?(_OZ_9[;H_SW@WZ(QS/'L^&@'QH1Y]#$J[Y/]?7>/[>^>7L'_W(/=
M?6>??@*M3_;^]VH/?H>_78$6=[5']W?/3U00A&$2,I+$V''%ES&)12A(Y >1
M[<9!R"F;O8)4K@UJ-F>,TX2Y0L4)50D+0,L3G+EA,!OG8\[@^GB>+16C-V[%
M5# +>E;'H[,LQP9L"$M@$XY5>1VWU/0I ,#Q)N)A?)=OM;&K6>:+?M%./</5
M;)PG]EL^-1=AC9H31\9Q''%&7#=V":.)36(P08E* A&PQ*,1&)]O7-ONV.9_
M<\:.94Y9.\%GW0]/1!D?06PIT/]E2QQW)XZCXY/8C97+(H^$THT)$\HE7'H!
MD9)YGA/A_WR=!K(";0RK,S'DT=&W+V4\ :C295.AFSPI'U6NC_,1,.4CSP_S
M+R/T]/V-<YN\NJ400R$_3D]BWXD2WPF)[5 )\ %"..0V(]RU0;2P)(I]=7WJ
MPT.?Z#06M(>ZPJ$J[DB% 1HQ4P%A#K9:!OT<3I9)GD1V[#D,;\2!X^<OQ><Q
M8 @VD\8!8V]5KJHECOAI&0)F!UJ@HUX9JSA +_A(3<:L[G$!ST<X:C&.^VC8
M2.-'TP_C%5E#L5YF3C?>6]YX-5\]1'-JJ#UR.@FB-/S+)QO..R#CG_ 66#I>
MP4G])?0"YGC_>XX&8 )V)-ZF_4R+RF"KOVU@4D=.36QM/ASV+DTT[^5R2+6R
M\:@8<6-REN[^R270;;;](NWUJFMZ*^<C[9LP<;$_4U!GP6 %GNOI"-)IP[$>
M+\[0=H>7U7<I=0C8O_&C*OP+)XV/X9Z45U#XKJI)6M?:,[:SCB%8-OE>"GJZ
MU,IM!\-7=>QGN>D7J=X0,*#ON _Q- D:JJLV)3745\8=YZK/TX'>?HS2K*,Y
MX%W:R5J>N#;;=8AXPX:V=NHY56'0I;=*273W3L]L<A!G7)H0X-D3T=L,PXYF
M/)Z=3=+*#B<DN^EA!D\.S0='>R>A*W@"UBV1PG$(<QF@LHIM0OW MX6;)$I&
M&',P4/,X7%+7!IU^JY/?1 '8A_;T\O!HQ]W?W0&#39SX8-1'RO/ 3/- XY)^
M2&(:8KD=)Z&^S_P@X'?4R<T5=T.*3&ZTF]<R@ZQ")KP?'103=\"UXFF!E_#.
M3D+?VU@G8?#@3L*)._ P:18R+8OOZ>X!FK_^C1[R*C9T8UR'/[Y6/)3N[_[9
M.Z '_?UO\,SNOOW]QSF%[_7W=[]>[5_M>?N[!^GWH_?]@SD>VKM WCJFQ[]P
M/OM7G_N'1\<PQ^.+@Z/]J_T?YQ?[%/GRV&FBZ.'1.P?;,DIFVSR..1%2*,*\
M,"%AX+O$\1P*?U<R#M6LZS!180#/!$D<),R7=N0Q+PIBF2CXW?'G7(<:YH@^
M JMY2G=(#KSYU=-3E2$52OD)0+?-(IZ$G@H\)Q'"BQQ&0W=+DP.!'VS+>&0Q
M* 25,E!//P($;9E#%E3:+VHX*B,"8%7385I<9L-1>>VMUZQ):6;)UN_X<:E1
MZZ?PK[56K>_Q.HU(/3TH4A2&+J%A M MZI<X_L*7=*VO^L:KG@G^T4RV5(--
M)7'T#<.VZ+ ;4(K;?*]K\KWHUN9[W0@K,S 4,B$3K@)7A(HY"8 J8)A-A4<]
MVW%C^SH8>J+3F:3)9I.01J?0%AS&C)D\QUC!3 =E<"3PA6-" (SA7;HTDW30
M2+N=&@[-,-?6IN.@"F91_\'+YNON4D G!KB8U<Z%&X;*3L(H<9FB(G0=/W)
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MMYW]GI$>9,K4M'K0^L%M?TX/$K'+?)9@YA^"&UC\)(Q$3&+IAG$D0N%B_]3
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M7";EJS<AZ\YG8/]C'8RT#@/G.3+CG81ZRXQ;QHPSPIU&OG)4$!"'^@EA 79
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M)/#&G3*O+2LPEO2--=ITJ]U9C<[R;'QZIK\] $,*J%4H52D#A@=3H]>CDTO
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M<V.;M*K6<7- 4[FZL,Y4SU@&V(9.79;$H<O@&I(<3:J:Z97"LZ=XT63*CV:
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MP8^LE5VSFU98O@]X+;',7#KK(Q251-$CO%[!\W8\EKH:(RMR]2*%";"Q43K
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M>1"L1=$Y+$)_!Q86^[O?"$'<"VH/7Z<<M+SW/T91+YJNS65A/=N>DI%2>GM
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M-)F068_K5/+WFD(?0%O2Q-QA?5T-#^"B!"@^,(LXN[-'%LKWD$GN'&P^PB4
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MB3F:I LO']4N>/*5,R07CN97!R<=O _AX^#=C$;#.C"27O E_=@->+ ^*!;
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MIUY6?0_PRKI7X^^_?'Q:KK\+4?M^J:_VB[Y15)]@&T 8$1DA9<K2((ET#%8
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MWA\H=?ZU843S#Z%S'0I^_U7DY$&TOK^_9,N-^NWQY(\8BF0:)T#ZD"KSCB>
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M<!L_:.E4YW,)7.H!QB)XJ:^58037\>]NKE2WMYM8<5E*L00A@B& S&> 4)H
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ML^A^FXQQX<=AP+F ()9<*K)("5#+NL[JEB8(B302(EJ4.GC*C"S,N[:BCZT
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MD6\+Q822)3%3]H]$:F<J": 13D&0B 2F H9!;+4SM>Q_;ES8$=];5UY"K*N
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MZ,-EZM$.&G=>BX?7 .*UB'@5)"9^?7.9=6:6U[SGTLA$/.=I-'F.V^$C>>N
MF^$*/(\ G:L'R'4"W2LD&>HJ]O&1+)<_;XIL)8IB(4B:$%]2P"5# !(DU&X^
M30&CE%,4$C_V SO?L+WVY[;<-9Y,E8Q>*Z2MZ]<^@I>-YRMQ&9FZ[2 9X,IU
M4O$K?+?VVYO86>ND,L?>6:<?FUM*[+?KZO!*<,TOKQIK)TD2G/@^ 22I_+IB
M";!(0R C',(DX('/C#;.MQ%_;H0S7?[D+1KJQXVN9ZC=QALGS=\T0EX#T50&
M][#I-[*Q/?JDFK^A/=U\FE&:[KYAO;75/4SXYV%Q7S4PT^7K[I7BBF5[+RH
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MA%ZRU?[LQ7I5Q71MR/*3R!^#A: 0$2D$H)1C &E" 260 5^R-$6$$&:W,-Y
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M&1"4=%KU*Z*2#AJ<."SIM#K'<4EGGAO)0?]"<;M.O$!O.<TH#6(,%1-P(A(
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M[2#[>[^ER:SNDPIT;>W3#PQ;7M[HK;BHJET5[]?+C'W?U=>%,HUQ&$0 ^DD
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MCM4X=H8Z\<S@#)-"O?1%K;*_B*]BN7[21G];F)UP!0Q%*1"^3C '$Q\@D7+
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MLJ\DBD-(>0+B2*@-6N!+@+A(%7Z2PQ2%,I)657>?2YU=5W5U3T J9!ISQE-
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M_''>YECB!L\?/JZJP5G#3N0,SE_5==QVNHI:-1H)M:-7$&<FQ1@(A14@@G+
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M;IM\6N(1[#](XN'YSA@OM?!"^]TBIO-KUV_F2_UZJQ\V,Y1EBB#D2I3;(8M
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M8/K9J[KO<1[M;=POU2]?5NOM1[U^>%T>62NW6F>802)0(4'*,P$(4CD0J<"
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MX0FJMDM[3  V[_E<O5JM/_+O3GO7%9B;+S_;7YQW8+.B*+!R!2)R R4@7"+
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M'%_1@';SM!IVTN"^2TKD=]6$KI7EX+E9.&&1YE$!#8\ZYPDGY'A^TN$)PY2
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M"[:SZ+5[WDM=_?UZ^7ZMO_*Y#7J-7J^UJB->&P97Q;%*)S*#A18"90880U)
M.&% (.4BTS3%*2LDU*C#5FHW-%/=5JV@ER>!EVYWU4W]5L\JYO$.6K0=>\S/
MQP[8 >.XU\: Y*?&A+^4Z2UU7S2S;=<5=1V^ZUT0[%#[,1C)EW8$,:H;[4?4
ML0?M^;2N)88?'NHMB')W8G-PV'0&L9&,&PQR0PM =&X#5"5S8#AF*DT%PAB'
MU1B^W-C4(M *:[)Q8.]J@=-DM<?;7??T*N5^/BX6D0-[LIK#7RH.*Z3/COK'
MK#'<SDBT(L-7FAJYRG"[T:=EACWNZ>9+WLQE\!+XLWLF].K6N 98TSYK<:17
M\_FS1WT7SYIU_/*=O^C2VW;(^1O[TU__U/S&_N$$+_[ZI_\#4$L#!!0    (
M !N!J59#:C!$CT<  -)1 P 5    <W1T:RTR,#(S,#,S,5]P<F4N>&UL[;UI
M=YM)CB;ZO7]%WKI?!Y6Q+WVZ>X[22Y7/.&V/[:R:GB\\L2!LWI1(-TDY[?[U
M%T%JW\PE7C*DJCQ5LD11?+$\@0 0 >#?_N>WD^.?ON)L/IY._OU/_,_L3S_A
M)$WS>/+IW__TV\>7X/[T/__C7_[EW_X?@/_SR_O7/SV?IM,3G"Q^>C;#L,#\
MTQ_CQ>>?_IYQ_OM/938]^>GOT]GOXZ\!X#^6?_1L^N7[;/SI\^(GP82\^=O9
MOR9T*1C)0&:%H*30X$H*@,5R:S!HQ>S_^/2O+%FGBE-@F?:@!#+P!B-H(Q3Z
MXH3@9?FAQ^/)[_]:O\0PQY^(N<E\^>.__^GS8O'E7W_^^8\__OCSMS@[_O-T
M]NEGP9C\^?S=?SI[^[=;[_]#+M_-O?<_+W][\=;Y^*XWTL?RG__/KZ\_I,]X
M$F \F2_")-4'S,?_.E^^^'J:PF(I\Q_2]=.][Z@_P?G;H+X$7(#D?_XVSW_Z
MCW_YZ:>5.&;38WR/Y:?Z[V_O7UU[Y/QS6"Q.T^_'(<[_G*8G/]<W_?SL[=]>
MO"=REW^^^/X%__U/\_')EV,\?^WS# N]MEC\#E6O3*X>^O^N_O#GRV=_F>&<
MX++D]36]</;W]2G;T8'?%CC)N.+O_"G'TW3M3<=5NM/9^5_2A^+Q\M51QO'H
MV90 ?Q3GBUE(BQ$WI6"6'*)##DI[#0&E!*V9<%S$G(RZSG8E>TYT+Y4QQ_3G
M3].O/],'DU*$J-]4F8BE/&X];B6;[>@^7WL?Z;TC9C*/@5>-:P8JF@ ^A "9
M>Y.#==D&OQ/95Y]VG>JK.CV:I9^FLXPS,A[GCPNS=$N_UX%[]HZ?OX09?1"D
MS^/C?/[7U8JTT-5BVD!R*[40N7_ZB;@N.)MA?KW2RKW,+3E;D$G%Y3M;:/Q_
MGX89?>+Q]_?X93I;C&)B23C4D(,@JQEUA*!"@I)3PA@+3\(T4?Z-!Z^% ]$_
M#G:19R>0>(>S\32_F.3GM V/-.,\J)R) 4>8+D6"DR:35(+C+N60HFP"B&N/
M70L.LG\X;"_+3L#P<18F\W$5_!F@K9/)6^- .*U!>3)TT0D#0>=@8F8DES8&
MXN:3UX*$ZA\2.TGTP*AX,5F,%]]?CH_QS>E)Q-G(:N:Q&"2*I0'%HX.0<P&.
MEEFF7%1\-Q?GYA/70H'N%P4[2; +[;_'3^,JA,GB33@AGZ>0PR,)O<BM!-K:
M$'R1$60H9-!85,SI!@BX_M2U4&!Z1\$.DNP"":\HG)^1"5L*_@/)'Y]-3R>+
MV?=GTXRC&)%"9Y*(E6BK6>.TV64#W+M _S<R"VP C >)6 LGMG><M)-S%[#Y
M&+Z]RB2^<1FO,A5GEC @FB"9 1(*,:*DINC)D"6TFLN2O$F*-0#,/8]?"RJN
M=ZBTD&T7(#G*F50P/_OG]7B"?!1E8"RX0F&45:",3A!X]&",30X3RTF(!@"Y
MX]%K@</W#HY=9=HI,,0H*RMB*0)$,@&477K02H/+468F @7:+2S''8]>+WW%
M'A\R-A-J3\AX1M^^G7V<_C$9"6:-*=P 9C)]"ID#IP0'6YA.)2D*PTL[7%P^
M>#U4=)S5;"'0GC"Q=)K>SM[-IE_'DX2C0JY25%X :IF)#Q).M*F =%)IRYQ*
M);<#QHVGKX>.CG.=S43;$T3>3>>+</Q_QU^63G719/70)F#(B8ND+3AN%"3Z
M,2<7.1<M\AIW/7L]>'2<^VPDU@.#HUJ]HQF&)=W,DP,MI2!1Q A*Q !!D/%+
MQJ',B4N7=HMEKSYM/0!TG.G<6G0'5GD].3]^]WDZ.<_-91]XD%$#14Y$>RX!
MG'42;$1F@O/>B-W\AYM/7$_U':<W=Q+A@=7_ =/IC*!+['T<+XYQI'42(=%6
MYHUVY $S"U%:!D(DA:4D*W+82?TWG[B>^CO.:^XDP@.K_^,LU+M)'[Z?Q.GQ
M2*J"O*@"V28!BBD+/ED)(C,O752.A=V./:\];CW%=YRHW%YXG2SZ%]_2YS#Y
MA,M,?+ A)DP2)"$6E(H2G"\%>+':HBS9Y]V4?]=3U\- QQG(G47913CP['16
MQ;4ZFZV0)AV<SD>6PEP?K(=<D"!M5+W'P37M:-D7$H_POL4QU]U/7P\:W><?
M&XBV"XB\FM"GD3C&7_%Y6(0SMNI>QPC2#B37AJ N/$2C%.A4F"F).REWNQGQ
MT-/7NS_5?2*R@6B[@$@]X)\]"PO\-)U]'VG/9.(A0;2BW@M,&KS2 ;Q$3A%Q
M]B[MMI_<\=#U -%]#G)[07:!@P\GX?CXE]/Y>(+S^8C;+$- #9%\(K)TCBR=
M%P50!J=0.UY8BTWDVD/7PT'WV<;M!=D%#EZ<X.P3;7E_F4W_6'Q^-CWY$B;?
M1YX%X6PQ(+S(9-94AL@Q@+$:C5/D+O,6:>@['[X>+KI/,^XNV#[P\>WR6N#J
MSNC(!!)%TAQ\M@$428'<(J0O)N10DK:ER>'5[2>OAXR.\X]-1-H%+#Y\QN/C
M<U G:5*0)0!?4A^R O*/.6 )PG!4)9G=ZC)N/W,]*'2<C]Q1C%V @ @_J?>^
MINGW#Y]);O.WIXM:]E43+O0VRSW%T."#KY9.,PB"^'+>:*4"#Z+$%G'I S2L
M!Y*.LY:-Q=P':$ARLW#\:I+QV_]"0KV3,15K@#PD!(4Y08B.!%1L,B7D8D0+
M5^/&8]>#1L=YS=V%>6 T')W@)->R@Y?'X=-(H,O96@4I2T%BB!E<\@4<9JU#
M)MIWS&)=>]QZVN\XH[F]\#JIWGDYGJ=P_)\89B_IE?E(HN$YD!GCD4EB0=+>
MAQ1&*668-M8)O%3'3L4[-QZ\'A(Z3F"V$&A7F%AYQ"LFR.>Q.BH$:P,QH7*D
M?4U%,$JBE:;(S'8[Y[SWT>N5^76<M6PCU$-?=5EE62^Q?5ZO6(1Q1I.#;,OR
MUGBB?4X5!ZA$M$2_]3L"X[XGKX>+CI.7343:#!;_]O,M.;ZF%W;KX_#F^8LW
M'UX\_^7H]=&;9R\^_/7%BX\?KE.^;F.'.S^I8:>''U.Z8^N'TSE\"N'+:'D7
MLIJ#M^7E>!(F:4PV8;I*05Q 2A>OA',9R$LD!#B=R(VP&C)BX,4S6?)#>9T2
MYG&I[K.'KE86'B_FYZ]<+K%-Z-K6@)P_XV@^Q\7\@LM<5$A%(##NB<N,#H)V
MD8+NA+X(SC)[Z +E-EQ>I^ PC24&0\*Y<6D@[@/N-M>I/S.2%TPPK="4>G78
MD(E5J"-X00:RF"AX<EF6\M !ZO:8N4'(8:&SBV;O!,DN8NX *\_"_//1)-=_
M7OS7Z?AK."9FYD>+9V$V^SZ>?/I;.#[%$3J1M0H1V/*::4@1*$1/H'B(5A4?
M8GK(5=D&.VL1U@.6=@+ =&AM= "QHZ]A3"\?X\OI[ -Q=':3:8SSYQ@7ES^=
M7T= JZPWCLRU*R1 :3U$'P)YA:BYM/2[^% :92M#M1F)AVFG,QSLAM10!P!\
M-\,O89Q??/N"DSG2^GJ[^$Q1R%4QCJP1Z**1('FB4"10:.DRK2FN5#0FA5CR
M0[F;;4"W!EF':=0S'-!::Z(#<%TG/@A?+^!2 &IX 27J\1<3 7@@)\.XPKQJ
M;KLV!DSSP^4!+=/6TMT>&M-%.&YD=Z9?<+;X_NXXD#@FN6[I7VK8\@9K7R+O
M* RI,%<D%18\!)$-*),39]RAQ]8AW$/T]+"E-?'*FPF] ]MRQ3J^F4[2V2KP
M67!AO /+0JH&,D*(0H$P.F@25F0/-A'<!CEW$M+#YM0$,KN+N0.LK.@?>9.5
M)BL)(AA1+WD7B(89<&AX\,Y)X5M':JLG][#S- SK-Q)D!WO-ZW&(X^.EETY&
M;WG/XO/TF(0^KP9P\?UR-V8"BP@(VN4,R@H.OGKQUNAL)=/:!-L8(.O2=M@]
M:/"DXB JZL#R7.'KINL7DXM"T/HIM!Q!\7K48VL3'*-U0*.-U:W=X?NI.6RR
M:!CMWP^Q7531 :B.4JI=V.;OPO>:F#B/ #B%AM)P#UAO%BK./,08,@CD@1PX
M6Z1YJ!?15MO;G91T Z:=]'QSZ]M=Z >$3CW\K"S,3NF1UU;;TL&[+;.1418I
M!G5@DF&@*! %)W*MIHQ<1RTCB^E'!ZP;/_6PNUQCY PK\P[LT!T<2)N\"UX
MA8\(ROM0RZ0<V>LBDXSD!^B'+GNVV=0.&WP-9']V%'8';OC;+U@;B4X^O<9
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MZ)XC/3F-5[2SXE,HLH OV8,JBKZ+Z,$C5\SSK UK/<SYZO,/:_&Z ]C6JND
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MW1.&^(&1T<'B>(W$"R[;+,QOL<)2(0%:R)IV%%4\!9+1(PCDR:(BX38? ?(
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MR]$8*U7KRR$#LM-+1G[_*)WV"9EN5\^;<(+/IR=A/!E1S***51$XN984QJ0
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M7>W)+6![&+5V:%0OA7!=)",1?0[%>/"JR%J%X\![+@')JT9-+(KFK;'7I>W
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M     '-T=&LM,C R,S S,S$N:'1M4$L! A0#%     @ &X&I5GC%%P+-"0
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M,#(S,#,S,5]L86(N>&UL4$L! A0#%     @ &X&I5D-J,$2/1P  TE$# !4
M             ( !CM ! '-T=&LM,C R,S S,S%?<')E+GAM;%!+ 0(4 Q0
M   ( !N!J5:T)>IT\ @  #%#   >              "  5 8 @!S=6(M8V5R
M='AS96-T:6]N,S R>&-E;WAQ,2YH=&U02P$"% ,4    "  ;@:E6J!F.F1$)
M  #U0@  '@              @ %\(0( <W5B+6-E<G1X<V5C=&EO;C,P,GAC
M9F]X<3$N:'1M4$L! A0#%     @ &X&I5HDRB>J=!@  K",  !X
M     ( !R2H" '-U8BUC97)T>'-E8W1I;VXY,#9O9G1H97-A+FAT;5!+!08
1    "0 ) &X"  "B,0(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
